#Patient Identifier	Sample Identifier	Cohort	Used In Manuscript	Center ID	CEBPA bi-allelic	Age at Diagnosis	Relapsed	De Novo	Transformed	Diagnosis MDS, MPN	Diagnosis non AML, MDS, MPN	ELN2017	Cancer Type Detailed	Age At Specimen Acquisition	Time Of Sample Collection, Relative To Inclusion	Specimen Groups	Disease Stage At Specimen Collection	Specimen Type	No. Of Cumulative Regiments	Unique Regiments	No. Of Unique Treatment Stages	Unique Treatment Stages	Response To Induction	Current Regimen	Current Stage	Most Recent Treatment Duration	FAB BLAST morphology	Karyotype	Other Cytogenetics	Surface Antigens Immunohistochemical Stains	FLT3-ITD	FLT3-ITD Allelic Ratio	NPM1	RUNX1	ASXL1	TP53 Pathway	Variant Summary	Cancer Type	Oncotree Code	TMB (nonsynonymous)	Somatic Status
#Identifier to uniquely specify a patient.	A unique sample identifier.	Cohort.	This specimen was used in the manuscript analyses	Unique identifier for each institution that contributed specimens	Was the CEBPA variant biallelic?	Age at Diagnosis	The specimen was obtained at time of relapsed disease	The specimen was obtained at the time of de novo disease	The patient transformed from another heme malignancy before or at the time of specimen collection	Patient's diagnosis at the time of specimen collection was MDS, MPN, or MDS/MPN	Patient's diagnosis at the time of specimen collection was not AML, MDS, MPN, or MDS/MPN	Risk classification assigned to the specimen based on European Leukemia Network 2017 guidelines	Cancer Type Detailed	Difference in years between specimen collection date and patient's date of birth	Difference in days between collection dates of earliest specimen and this specimen	Concatenated list of specimen groups, referring to disease stage at the time point of this specimen collection	Description of the patient's stage of disease at the time of specimen collection.	The broad cancer phenotype and site information values for a sample to be processed.	Number of unique chemotherapy treatment regimens for the disease instance	Concatenated list of unique chemotherapy treatment regimens for the disease instance	Number of unique treatment stages for the disease instance	Concatenated list of unique treatment stages for the disease instance	Treatment response corresponding to the first treatment record found with a stage of induction	The most current treatment	Stage of the most current treatment	Most Recent Treatment Duration (Days)	French-American-British (FAB) morphological classification	Karyotype.	FISH results pulled from cytogenetics report in EMR	Positive surface antigens, as determined by clinical flow	Consensus result from internally run PCR assay and capillary electrophoresis and/or CLIA lab assay and/or whole-exome sequencing	Ratio of FLT3-ITD mutated alleles to wild-type alleles	Consensus result from internally run PCR assay and capillary electrophoresis and/or CLIA lab assay and/or whole-exome sequencing	Manual review of RUNX1 variant results from clinical testing and WES	Manual review of ASXL1 variant results from clinical testing and WES	TP53 Pathway	Clinical gene variant testing result	Cancer Type	Oncotree Code	TMB (nonsynonymous)	Somatic Status
#STRING	STRING	STRING	STRING	NUMBER	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	NUMBER	STRING	STRING	STRING	NUMBER	STRING	NUMBER	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING	STRING	STRING	STRING	STRING	STRING	STRING	NUMBER	STRING
#1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	1	0	1	1	1	1	0	1	0	0	0	0	0	0	0	1	0	1	1	1	1
PATIENT_ID	SAMPLE_ID	COHORT	USED_IN_MANUSCRIPT	CENTER_ID	CEBPA_BIALLELIC	AGE_AT_DIAGNOSIS	IS_RELAPSE	IS_DENOVO	IS_TRANSFORMED	SPECIFIC_DX_AT_ACQUISITION_MDSMPN	NON_AML_MDSMPN_SPECIFIC_DX_AT_ACQUISITION	ELN2017	CANCER_TYPE_DETAILED	AGE_AT_SPECIMEN_ACQUISITION	TIME_OF_SAMPLE_COLLECTION_RELATIVE_TO_INCLUSION	SPECIMEN_GROUPS	DISEASE_STAGE_AT_SPECIMEN_COLLECTION	SPECIMEN_TYPE	CUMULATIVE_TREATMENT_REGIMEN_COUNT	CUMULATIVE_TREATMENT_REGIMENS	CUMULATIVE_TREATMENT_STAGE_COUNT	CUMULATIVE_TREATMENT_STAGES	RESPONSE_TO_INDUCTION_TX	CURRENT_REGIMEN	CURRENT_STAGE	MOST_RECENT_TREATMENT_DURATION	FAB_BLAST_MORPHOLOGY	KARYOTYPE	OTHER_CYTOGENETICS	SURFACE_ANTIGENS_IMMUNOHISTOCHEMICAL_STAINS	FLT3_ITD	ALLELIC_RATIO	NPM1	RUNX1	ASXL1	TP53	VARIANT_SUMMARY	CANCER_TYPE	ONCOTREE_CODE	TMB_NONSYNONYMOUS	SOMATIC_STATUS
aml_ohsu_2022_2476	aml_ohsu_2022_2476_BA2102	Waves1+2	Yes	1	NA	27	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	27	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Sorafenib	Experimental	99	M1	46,XX[20]	Normal	CD7, CD13, CD33, partial CD34, dim CD45, CD117, CD123, HLA-DR and MPO positive	Positive	0.960784314	Positive	NA	NA	NA	CEBPA|FLT3-ITD|NPM1	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2476	aml_ohsu_2022_2476_BA2005	Waves1+2	No	1	NA	27	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	31	1339	Relapse|Post-Transplant|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Sorafenib	Experimental	99	M1	46,XX,del(6)(q13q23)[18]/46,XY[2]	Missing 6q21 signal while having two copies each of the 6 centromere signal and the MYB (6q23) signal (40%)	partial CD7, variable CD13, CD33, partial CD34,CD38, CD58, CD117, CD123, and partial HLA-DR positive	Positive	1.173913043	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2476	aml_ohsu_2022_2476_BA3074	Waves1+2	No	1	NA	27	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	31	1354	Post-Transplant|Residual Disease	Residual	Peripheral Blood	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Sorafenib	Experimental	99	M1	46,XX,del(6)(q13q23)[18]/46,XY[2]	Missing 6q21 signal while having two copies each of the 6 centromere signal and the MYB (6q23) signal (40%)	NA	Positive	2.03030303	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2476	aml_ohsu_2022_2476_BA2555	Waves1+2	No	1	NA	27	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	31	1465	Relapse|Post-Transplant|Post-Chemotherapy	Relapse	Peripheral Blood	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Sorafenib	Experimental	99	M1	46,XX,del(6)(q13q23)[15]/46,XY[5]	6q deletion (79%)	NA	Positive	NA	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2476	aml_ohsu_2022_2476_BA3073	Waves1+2	No	1	NA	27	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	31	1465	Residual Disease|Post-Transplant	Residual	Peripheral Blood	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Sorafenib	Experimental	99	M1	46,XX,del(6)(q13q23)[15]/46,XY[5]	6q deletion (79%)	NA	NA	NA	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2157	aml_ohsu_2022_2157_BA2452	Both	No	1	NA	34	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	36	574	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Salvage|Induction|Re-induction	Complete Response	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	43	M4	46,XY,add(17)(p13)[19]/46,XY[1]	Normal	partial CD7, CD13, CD33, CD38, dim CD45, dimCD58, CD117, CD123, and HLA-DR	Positive	0.960784314	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2053	aml_ohsu_2022_2053_BA2673	Waves1+2	Yes	1	NA	70	FALSE	TRUE	FALSE	FALSE	FALSE	FavorableOrIntermediate	AML with mutated NPM1	70	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	4	7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Cytarabine, Methotrexate	3	Consolidation|Induction|Supportive/Palliative Care	Refractory	Quizartinib	Supportive/Palliative Care	164	M1	46,XX[20]	normal	CD13, CD33, dimCD45, CD56, partial CD117, MPO/positive	Positive	NA	Positive	NA	NA	NA	FLT3-ITD|NPM1	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2053	aml_ohsu_2022_2053_BA2803	Waves1+2	No	1	NA	70	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	71	337	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Cytarabine, Methotrexate	3	Consolidation|Induction|Supportive/Palliative Care	Refractory	Quizartinib	Supportive/Palliative Care	164	M1	46,XX[20]	normal	CD13, CD33, CD38, CD56, CD117, and MPO positive	Positive	NA	Positive	NA	NA	NA	FLT3-ITD|NPM1	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2269	aml_ohsu_2022_2269_BA2922	Waves1+2	Yes	1	NA	11	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with t(6;9)(p23;q34); DEK-NUP214	14	950	Relapse|Post-Transplant|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	13	Cyclophosphamide, TBI|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Cytarabine, Mitoxantrone, Sorafenib|ADE (Cytarabine, Daunorubicin & Etoposide)|Donor Lymphocyte Infusion|Cytarabine|Sorafenib|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)|Methotrexate|Etoposide, Cytarabine	8	Allogeneic - Sibling|Consolidation|Unknown|Induction|Experimental|Intensification|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Sorafenib	Experimental	187	M2	48,X,-Y,+4,t(6;9)(p22;q34),+8,+10,del(15)(q11.2q15)[20]	DEK/NUP probe set; 70/100 (70%) interphasecells scored had a 1 red/ 1 green/ 2 yellow fusion signal pattern,consistent with DEK/NUP fusion and the 6;9 translocation observed in themetaphase karyotype.	CD13, CD33, CD34, CD38, CD117,CD123, dim HLA-DR, partial MPO	Positive	NA	NA	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2295	aml_ohsu_2022_2295_BA2216	Waves1+2	Yes	1	NA	74	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myelomonocytic leukaemia	77	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	3	Decitabine|Quizartinib|Mitoxantrone	3	Induction|Experimental|Supportive/Palliative Care	Refractory	Mitoxantrone	Supportive/Palliative Care	18	M4	46,XY[17]	normal	CD2, dim CD4, partial CD7, partial/dim CD64, CD13, partial CD22, dim CD33, partial CD34, CD117, CD123, HLA-DR, partial cCD79, partial TdT,  partial PAX/5 and partial MPO positive	Positive	0.923076923	Negative	RUNX1 (p.R166*; 40.0%)	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2295	aml_ohsu_2022_2295_BA2859	Waves1+2	No	1	NA	74	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myelomonocytic leukaemia	77	166	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	3	Decitabine|Quizartinib|Mitoxantrone	3	Induction|Experimental|Supportive/Palliative Care	Refractory	Mitoxantrone	Supportive/Palliative Care	18	M4	46,XY[20]	normal	CD2, dim CD4, partial CD7, partial/dim CD64, CD13, partial CD22, dim CD33, partial CD34, CD117, CD123, HLA-DR, partial cCD79, partial TdT,  partial PAX/5 and partial MPO positive	Positive	0.01010101	Negative	RUNX1 (p.R166*; 47.6%)	NA	NA	FLT3-D835|FLT3-ITD	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2030	aml_ohsu_2022_2030_BA2336	Waves1+2	Yes	1	NA	73	FALSE	TRUE	FALSE	FALSE	FALSE	FavorableOrIntermediate	AML with mutated NPM1	73	1	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit)	3	Consolidation|Induction|Experimental	Complete Response	AC220 (Ambit)	Experimental	30	M1	46,XY[20]	normal	CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive, CD34 negative, HLA-DR negative	Positive	NA	Positive	NA	NA	NA	FLT3-ITD (Low Level)|NPM1	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2030	aml_ohsu_2022_2030_BA2708	Waves1+2	No	1	NA	73	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	74	378	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit)	3	Consolidation|Induction|Experimental	Complete Response	AC220 (Ambit)	Experimental	30	M1	46,XY[20]	normal	CD13, dim CD33, CD56, and CD117 positive	Positive	0.923076923	Positive	NA	NA	NA	NPM1	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2551	aml_ohsu_2022_2551_BA2643	Waves1+2	Yes	1	NA	69	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myelomonocytic leukaemia	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	4	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation|Induction|Experimental|Re-induction	Complete Response	Hydroxyurea	Re-induction	3	M4	47,XY,+8[cp9]/46,XY[11]	Signal copy for CEP 8 and ETO	dim CD4, partial CD7, CD13, CD33, CD34, dim CD45, dim CD56, variable CD64, CD117, CD123, HLA-DR and MPO positive	Positive	0.960784314	Negative	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2551	aml_ohsu_2022_2551_BA2265	Waves1+2	No	1	NA	69	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myelomonocytic leukaemia	69	163	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation|Induction|Experimental|Re-induction	Complete Response	Hydroxyurea	Re-induction	3	M4	47,XY,+8[cp20]	trisomy 8	CD7, CD13, CD33, CD34, CD117, CD123, HLA-DR, and MPO-positive	Positive	0.851851852	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2551	aml_ohsu_2022_2551_BA2460	Waves1+2	No	1	NA	69	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myelomonocytic leukaemia	70	333	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation|Induction|Experimental|Re-induction	Complete Response	Hydroxyurea	Re-induction	3	M4	47,XY,+8[cp20]	trisomy 8	CD7, CD13, CD33, CD34, CD117, CD123 and HLA-DR positive	Positive	NA	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2401	aml_ohsu_2022_2401_BA2067	Waves1+2	Yes	1	NA	59	FALSE	TRUE	FALSE	FALSE	FALSE	IntermediateOrAdverse	Acute myelomonocytic leukaemia	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Quizartinib|Busulfan, Cyclophosphamide	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	4	M4	47,XX,+13[18]/46,XX[2]	trisomy 13	Blast immunophenotype: dim CD4, variable CD11b, CD13, CD33, partial CD34, dim CD45, variable CD64, partial CD117, CD123, HLA-DR and MPO positive; Promonocyte immunophenotype: dim CD4, CD11b, CD13, CD33, CD45, bright CD64, CD123, HLA-DR, and dim MPO positive	Positive	NA	Negative	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2302	aml_ohsu_2022_2302_BA2881	Waves1+2	Yes	1	NA	66	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with mutated NPM1	67	386	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Quizartinib	4	Consolidation|Induction|Experimental|Re-induction	Complete Response	Quizartinib	Experimental	57	NA	46,XY[20]	normal	CD13, CD33, partial CD34, CD38, CD117 and CD123	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2479	aml_ohsu_2022_2479_BA2012	Waves1+2	Yes	1	NA	60	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	61	0	Relapse	Relapse	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage|Consolidation|Induction|Experimental|Supportive/Palliative Care	Complete Response	Etoposide, Mitoxantrone	Supportive/Palliative Care	0	NOS	46,XX[20]	normal	partial CD7, CD13, CD33, partial CD34, partial dim CD64, CD117, and CD123 positive	Positive	2.448275862	Positive	NA	NA	NA	FLT3-ITD|NPM1	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2479	aml_ohsu_2022_2479_BA2352	Waves1+2	No	1	NA	60	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	61	138	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	5	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage|Consolidation|Induction|Experimental|Supportive/Palliative Care	Complete Response	Etoposide, Mitoxantrone	Supportive/Palliative Care	0	NOS	46,XX[20]	normal	partial CD7, CD13, CD33, partial CD34, CD58, CD64, CD117, and CD123 positive	Positive	7.333333333	Positive	NA	NA	NA	FLT3-ITD|NPM1	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2479	aml_ohsu_2022_2479_BA2630	Waves1+2	No	1	NA	60	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	61	181	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	5	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage|Consolidation|Induction|Experimental|Supportive/Palliative Care	Complete Response	Etoposide, Mitoxantrone	Supportive/Palliative Care	0	NOS	46,XX[20]	normal	NA	Positive	19	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2451	aml_ohsu_2022_2451_BA2335	Waves1+2	Yes	1	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|Hydroxyurea|Quizartinib|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Experimental	Refractory	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	M2	46,XY[20]	normal	CD7, CD13, CD33, CD34, CD117, CD123, and HLA-DR-positive	Positive	0.5625	Positive	NA	NA	NA	FLT3-ITD|NPM1 (exon 12 insertion W288fs*1)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2313	aml_ohsu_2022_2313_BA2707	Both	No	1	NA	68	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	72	1207	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|MiDAC|Decitabine	3	Consolidation|Induction|Supportive/Palliative Care	Complete Response	Decitabine	Supportive/Palliative Care	9	NOS	47,XY,del(9)(q22),+13[18]/48,idem,+mar[2]	Missing ABL and ASS signal (84%)	partial CD7, CD11b, CD13, CD33, CD34, partial CD64, partial CD117, CD123, HLA-DR, and TdT-positive.	Negative	0	Negative	RUNX1 (p.A147Gfs*13; 42.3%)|RUNX1 (p.R162S; 46.5%)	ASXL1 (p.G646Wfs*12; 27.9%)	NA	RUNX1 (p.A147fs*13 (1 bp insertion frameshift); MAF 35%)|RUNX1 (p.R162S; MAF 50%)|SRSF2 (p.P95R; MAF 44%)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2380	aml_ohsu_2022_2380_BA2825	Waves1+2	Yes	1	NA	70	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with minimal differentiation	70	0	Residual Disease	Residual	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Quizartinib|Idarubicin and Cytarabine	3	Consolidation|Induction|Experimental	Complete Response	Quizartinib	Experimental	155	M0	46,XY[18]	normal	partial CD7, dim CD11b, dim CD13, CD22, dim CD33, bright CD34, CD38, dim CD45, partial CD117, CD123, HLA-DR, and TdT positive	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2380	aml_ohsu_2022_2380_BA2435	Waves1+2	No	1	NA	70	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with minimal differentiation	71	185	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Quizartinib|Idarubicin and Cytarabine	3	Consolidation|Induction|Experimental	Complete Response	Quizartinib	Experimental	155	M0	46,XY[20]	normal	CD34, CD38, CD58, CD117, dimCD123,  HLA-DR, TDT	Positive	1.083333333	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.333333333	UNMATCHED
aml_ohsu_2022_2164	aml_ohsu_2022_2164_BA2916	Waves1+2	Yes	1	NA	65	FALSE	FALSE	TRUE	FALSE	FALSE	Intermediate	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Methotrexate	5	Consolidation|Induction|Experimental|CNS|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M5	46,XX[20]	normal	CD7, CD11b, CD13, CD33, variable CD34, dim CD64, CD117, CD123, HLA-DR and MPO positive	Positive	1.272727273	Positive	NA	NA	NA	FLT3-ITD|NPM1	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2164	aml_ohsu_2022_2164_BA3035	Waves1+2	No	1	NA	65	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with mutated NPM1	66	151	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Methotrexate	5	Consolidation|Induction|Experimental|CNS|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	NOS	46,XX,t(1;15)(p32;q15)[19]/46,XX[1]	normal	CD7, CD13, CD33, partial CD34, CD38, dim CD45, CD58, CD71, CD117, CD123, and HLA-DR-positive	Positive	0.785714286	Positive	NA	NA	NA	FLT3-ITD|NPM1 (Insertion mutation detected in a minority of cells )	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2207	aml_ohsu_2022_2207_BA3039	Waves1+2	Yes	1	NA	31	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with t(6;9)(p23;q34); DEK-NUP214	33	687	Post-DLI|Residual Disease|Post-Transplant	Residual	Bone Marrow Aspirate	9	Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	7	Consolidation|Salvage|Unknown|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Complete Response	Donor Lymphocyte Infusion	Unknown	-1	NOS	46,XX,t(1;19)(p32;q13.3),t(6;9)(p22;q34),t(12;16)(p12;q21)[cp20]	80% t(6;9)(p22;q34)	CD13, CD33, CD34, CD38, CD58, dim CD64, dim CD117, TdT and partial MPO	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2751	aml_ohsu_2022_2751_BA3172	Waves3+4	Yes	1	NA	38	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Mixed phenotype acute leukaemia, T/myeloid, NOS	41	385	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	7	ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Azacitidine|Azacitidine, Lenalidomide|Decitabine|Hydroxyurea|Etoposide, Mitoxantrone	4	Salvage|Induction|Re-induction|Supportive/Palliative Care	Unknown	Hydroxyurea	Supportive/Palliative Care	91	NA	46,XX,del(6)(q13)[cp3]/46,XX,t(4;7)(q11;p11)[2]	Deletion of MB and 6q21 (Consistent with karyotype)	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Leukemias of Ambiguous Lineage	ALAL	0.3	UNMATCHED
aml_ohsu_2022_2418	aml_ohsu_2022_2418_BA2409	Waves1+2	Yes	1	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute monoblastic and monocytic leukaemia	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Refractory	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	M5	46,XX[20]	Normal	Blast Immunphenotype: CD13, CD33, CD34, CD38, dim CD45, CD117, CD123, and HLA-DR positive; Promonocyte Immunophenotype: CD11b, CD13, CD14, CD33, CD64, and HLA-DR	Negative	0	Negative	NA	NA	NA	BRAF (G596R)|WT1 (2400/10000 copies)	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2374	aml_ohsu_2022_2374_BA3021	Waves1+2	Yes	1	NA	56	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	60	309	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	8	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|3+3 plus Sorafenib|Clofarabine|Clofarabine, Cytarabine	4	Consolidation|Salvage|Induction|Re-induction	Complete Response	Cytarabine	Consolidation	64	NOS	46,XY[4]	Normal	CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive	Positive	4.555555556	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2374	aml_ohsu_2022_2374_BA2480	Waves1+2	Yes	1	NA	56	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	60	309	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	8	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|3+3 plus Sorafenib|Clofarabine|Clofarabine, Cytarabine	4	Consolidation|Salvage|Induction|Re-induction	Complete Response	Cytarabine	Consolidation	64	NOS	46,XY[4]	Normal	CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive	Positive	2.448275862	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2099	aml_ohsu_2022_2099_BA2496	Waves1+2	Yes	1	NA	70	FALSE	FALSE	TRUE	FALSE	FALSE	MissingMutations	AML with myelodysplasia-related changes	70	34	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	4	Dasatinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	4	Salvage|Experimental|Maintenance|Re-induction	NA	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	4	M4	46,XY[20]	Normal	CD11b, CD13, CD14, CD15, variable CD16, dim CD33, CD58, bright CD64, HLA-DR positive	Positive	0.111111111	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2503	aml_ohsu_2022_2503_BA2136	Waves1+2	Yes	1	NA	60	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with maturation	62	783	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide, Fludarabine, TBI	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Complete Response	Cyclophosphamide, Fludarabine, TBI	Allogeneic - Sibling	-1	M2	46,XY,del(20)(q11.2)[2]/46,XY[18]	20/200 cells (10%) were missing a signal for D20S108 (20q12)	CD13, CD33, CD34, CD38, CD117, and dim HLA-DR positive	Negative	0	Negative	NA	ASXL1 (p.S846Vfs*21; 33.0%)	NA	JAK2 (V617F; MAF 1.3% (Clinical significance of this very low-level mutation is unknown.) )|SRSF2 (p.P95H ; MAF 40%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2391	aml_ohsu_2022_2391_BA3037	Waves1+2	Yes	1	NA	55	FALSE	FALSE	FALSE	FALSE	FALSE	FavorableOrIntermediate	Therapy-related myeloid neoplasms	55	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M1	46,XX[20]	Normal	partial CD7, CD13, CD25, CD33, partial CD34, dim CD45, CD117, CD123, and partial HLA-DR positive	Positive	NA	Positive	NA	NA	NA	FLT3-ITD|NPM1|WT1 (8000/10000 copies (High))	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2059	aml_ohsu_2022_2059_BA2831	Waves1+2	Yes	1	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML without maturation	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	5	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation|Induction|Experimental|Re-induction|Supportive/Palliative Care	Refractory	Hydroxyurea	Supportive/Palliative Care	9	M1	46,XY[20]	Normal	CD13, CD34, CD38, CD117, CD123, HLA-DR	Positive	0.587301587	Negative	RUNX1 (p.Q283*; 37.0%)|RUNX1 (p.M236Nfs*25; 20.0%)	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2059	aml_ohsu_2022_2059_BA2847	Waves1+2	No	1	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML without maturation	71	262	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	5	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation|Induction|Experimental|Re-induction|Supportive/Palliative Care	Refractory	Hydroxyurea	Supportive/Palliative Care	9	M1	46,XY[20]	Normal	dim/partial CD7, CD13, CD34, CD38, CD58, CD117, CD123,and HLA-DR positive	Positive	0.886792453	Negative	RUNX1 (p.Q283*; 40.7%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2059	aml_ohsu_2022_2059_BA2045	Waves1+2	No	1	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML without maturation	72	297	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	5	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation|Induction|Experimental|Re-induction|Supportive/Palliative Care	Refractory	Hydroxyurea	Supportive/Palliative Care	9	M1	46,XY[20]	Normal	dim/partial CD7, CD13, CD33, CD34, variable CD38, CD58,variable CD117, CD123, and HLA-DR positive	Positive	0.923076923	Negative	RUNX1 (p.Q283*; 51.5%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2446	aml_ohsu_2022_2446_BA2236	Waves1+2	Yes	1	NA	54	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	57	349	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	7	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	5	Consolidation|Salvage|Induction|Re-induction|Maintenance	Complete Response	Decitabine	Re-induction	160	M4	47,XY,+21[17]/47,idem,t(10;22)(q22;q13)[cp3]/46,XY[1]	80% Trisomy 21	CD13, CD33, CD38, CD58, dim CD64, CD117, and CD123	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2799	aml_ohsu_2022_2799_BA3439	Waves3+4	Yes	1	NA	68	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	68	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	1	Ruxolitinib	1	Experimental	NA	Ruxolitinib	Experimental	-1	M2	47,XY,+21[14]/46,XY[6]	Trisomy 21 (48.5% had an extra AML1 signal, consistent with the karyotype.)	NA	Negative	0	Negative	RUNX1 (p.R320*; 61.6%)	ASXL1 (p.G644Wfs*12; 37.3%)	NA	JAK2 (87% allele burden)	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2007	aml_ohsu_2022_2007_BA2918	Waves1+2	Yes	1	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M1	46,XY[20]	Normal	partial CD7, CD13, CD33, CD117, CD123, dim HLA-DR, and MPO positive	Negative	0	Positive	NA	NA	NA	FLT3 (FLT3 I836 deletion)|NPM1 (An insertion mutation is present in exon 12 (near the C-terminus) of NPM	Acute Myeloid Leukemia	AML	1.2	MATCHED
aml_ohsu_2022_2398	aml_ohsu_2022_2398_BA2172	Waves1+2	Yes	7	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	Acute Myeloid Leukemia	18	0	Unknown	Unknown	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2580	aml_ohsu_2022_2580_BA3042	Waves1+2	Yes	1	NA	32	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with maturation	38	488	Residual Disease|Post-Transplant	Residual	Bone Marrow Aspirate	9	HiDAC|Decitabine, Sirolimus|Donor Lymphocyte Infusion|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, Cyclophosphamide	6	Consolidation|Salvage|Induction|Re-induction|Post-Transplant Relapse|Allogeneic - Matched Unrelated Donor	Complete Response	Decitabine, Sirolimus	Salvage	127	M2	46,XX[19]/46,XY[1]	Normal	NA	Negative	0	Negative	NA	NA	NA	CEBPA (Q305?Q312del RNVETQ; MAF 50%)|CEBPA (Y108*(premature stop codon); MAF 50%)|IKZF1 (p.G151R; MAF 40%)|NOTCH1 (p.G2152S; MAF: 50%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2271	aml_ohsu_2022_2271_BA2865	Waves1+2	Yes	1	NA	50	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	50	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|HiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	M0	46,XX,t(11;17)(q13;q21)[20]	While the chromosome 17 breakpoint is clearly within band 17q21 by metaphase chromosome analysis, these results suggest that it is not within the RARA gene	dim CD4, CD13, dim CD15, dim CD33, CD38, CD58,CD64, CD117, CD123, dim HLA-DR, and cMPO	Negative	0	Positive	NA	NA	NA	FLT3 (A680V)|NPM1 (W288fs*12 )|WT1 (5000/10,000 copies)	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2545	aml_ohsu_2022_2545_BA2923	Waves1+2	Yes	1	NA	81	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	81	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	1	Azacitidine	1	Supportive/Palliative Care	NA	Azacitidine	Supportive/Palliative Care	42	M5	46,XX,t(8;16)(p11.2;p13.3)[8]/46,XX,del(7)(q11.2q22),del(20)(q13.1q13.3)[cp3]/46,XX[12]	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2491	aml_ohsu_2022_2491_BA2003	Both	No	3	NA	57	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	58	215	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Unknown	HiDAC	Consolidation	-1	NA	46,XX[20]	Normal	NA	Positive	2.125	Positive	NA	NA	NA	FLT3-ITD|NPM1	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2518	aml_ohsu_2022_2518_BA2751	Waves1+2	Yes	1	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	0	NA	0	NA	NA	NONE	NONE	NA	M4	46,XY[20]	Normal	Blast phenotype:  CD13, partial CD33, CD34, CD38, CD58, CD123, HLA-DR and TdT-positive; Monocytic phenotype:  CD11b, CD14, CD33, CD38, CD58, CD64 and HLA-DR-positive	Positive	1	Negative	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2193	aml_ohsu_2022_2193_BA2055	Waves1+2	Yes	1	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	MiDAC	Consolidation	108	M4	46,XY,inv(16)(p13q22)[20]	 71% CBFB rearrangement	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2771	aml_ohsu_2022_2771_BA3395	Waves3+4	Yes	1	NA	68	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	68	132	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|Azacitidine|Azacitidine, Lenalidomide|Decitabine	3	Unknown|Induction|Re-induction	Refractory	Decitabine	Re-induction	9	NOS	41~46,XY,add(4)(p16),del(5)(q15q33),inv(7)(q11q34),-13,add(14)(p11.1),-16,-17,-18,add(19)(q13.1),-20,i(21)(q10),+1~4mar[cp10]/43~45,idem,-add(4)(p16),der(4)add(4)(p16)add(4)(q31)[cp10]	5q deletion (64%) | Monosomy 16 and derivative chromosome 16 (91%)	CD13, CD33, CD34, CD56, CD117, dim CD123, HLA-DR, partial TdT positive	NA	NA	NA	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2340	aml_ohsu_2022_2340_BA2286	Waves1+2	Yes	1	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with maturation	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Refractory	3+7 (Cytarabine, Daunorubicin)	Induction	7	M2	46,XY[20]	Normal	CD13, CD33, CD34, CD117, dim CD123, HLA-DR,partial MPO (+)	Negative	0	Negative	NA	NA	NA	FLT3-D835	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2384	aml_ohsu_2022_2384_BA2763	Waves1+2	Yes	1	NA	72	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	73	0	Relapse	Relapse	Bone Marrow Aspirate	4	3+7 (Cytarabine, Daunorubicin)|Azacitidine|Azacitidine, Lenalidomide|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Salvage|Induction	Refractory	Azacitidine, Lenalidomide	Salvage	-1	NOS	46,XY[20]	NA	dim CD33, CD38, CD58, CD117, dim CD123, and MPO positive	Negative	0	Positive	NA	NA	NA	IDH1 (p.R132S; MAF 20%)|NPM1 (p.W288fs*12; MAF 36%)|SRSF2 (p.P95L; MAF 35%)|TET2 (p.Q642*, p.C1135Y; MAF 7%,7%  )	Acute Myeloid Leukemia	AML	1.2	MATCHED
aml_ohsu_2022_2489	aml_ohsu_2022_2489_BA2488	Waves1+2	Yes	1	NA	83	FALSE	FALSE	TRUE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	83	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Ruxolitinib|ATRA, Arsenic Trioxide|Idarubicin	3	Induction|Maintenance|Symptom Control	Complete Response	Idarubicin	Symptom Control	0	M3	46,XX,t(15;17)(q24;q21)[12]/46,XX,idem,del(16)(q12.1q24)[3]/46,XX[5]	7% 16q deletion	CD13, CD33, partial CD34, CD64, CD117, CD123, and MPO-positive	Negative	0	Negative	NA	NA	NA	FLT3-D835 (D835H; MAF Unlisted)|JAK2 (p.V617F; MAF 90%)	Acute Myeloid Leukemia	AML	0.933333333	MATCHED
aml_ohsu_2022_2606	aml_ohsu_2022_2606_BA3379	Waves3+4	Yes	1	NA	34	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute undifferentiated leukaemia	34	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Cyclophosphamide, TBI|7+3 (Cytarabine, Idarubicin)|HAM-VD (Cytarabine, Mitoxantrone, Vincristine, Dexamethasone)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Refractory	Cyclophosphamide, TBI	Allogeneic - Sibling	-1	NA	46,XY[20]	cryptic t(14;21) (54.5% of cells had three signals for AML1)	CD2 , CD7 , CD13 , CD34 , dim CD45 , CD117 , HLA-DR , TdT positive	Positive	0.041666667	Negative	NA	NA	NA	FLT3-D835|FLT3-ITD	Acute Leukemias of Ambiguous Lineage	ALAL	0.166666667	UNMATCHED
aml_ohsu_2022_2038	aml_ohsu_2022_2038_BA2887	Waves1+2	Yes	1	NA	24	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myelomonocytic leukaemia	24	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	8	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Radiation|Busulfan, Cyclophosphamide	7	Consolidation|Salvage|Unknown|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	Complete Response	Azacitidine	Maintenance	-1	M4	47,XY,+10[18]/46,XY[2]	Normal	CD11b, dim CD13, dim CD14, CD33, CD34, dim CD38, partialCD56, CD58, partial CD64, CD117, CD123, dim HLA-DR, and MPO	Negative	0	Negative	NA	NA	NA	NOTCH1 (p.V1578delV; MAF 50%)	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2034	aml_ohsu_2022_2034_BA2712	Both	No	2	NA	61	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	61	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	CD2(-), CD4(dim +), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +), CD15(variably and slightly bright +), CD16 (-), CD33(variably bright +), CD34(-), CD36(partial +), CD38(variably +), CD45(variably +), CD56(+), CD64(partial +), CD117(-), HLA-DR(partial dim +), MPO(+), TdT(-). (92% population of medium-sized to large cells)	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 28.6%)	NA	NA	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2087	aml_ohsu_2022_2087_BA2858	Waves1+2	No	1	NA	70	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	73	93	Post-Chemotherapy	Remission	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Maintenance	Complete Response	Azacitidine	Maintenance	-1	NA	46,XY[19]	Normal	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2787	aml_ohsu_2022_2787_BA3354	Waves3+4	Yes	1	NA	83	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	83	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	1	Azacitidine	1	Maintenance	NA	Azacitidine	Maintenance	-1	M2	46,XY[19]	Normal	CD13, CD33, CD34, CD38, CD58, CD117, and MPO	Negative	0	Negative	RUNX1 (p.R204*; 43.0%)	ASXL1 (p.G646Wfs*12; 26.2%)	NA	NA	Acute Myeloid Leukemia	AML	0.366666667	UNMATCHED
aml_ohsu_2022_2762	aml_ohsu_2022_2762_BA3409	Waves3+4	Yes	2	NA	64	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	65	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	7	J1219, quizartinib|7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|Sorafenib|Valproic Acid|E1906, topotecan, carboplatin	4	Induction|Experimental|Re-induction|Maintenance	Refractory	Crenolanib	Experimental	21	M4	46,XX[20]	NA	NA	Positive	1	Negative	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	0.333333333	UNMATCHED
aml_ohsu_2022_2642	aml_ohsu_2022_2642_BA3097	Waves3+4	Yes	2	NA	74	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	75	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	4	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Supportive/Palliative Care	Refractory	5+2 (Cytarabine, Idarubicin)	Salvage	-1	NA	46,XY,t(12;18)(p13;q12)[20]	NA	CD2(-), CD4(-), CD7(+), CD11b(partial dim +), CD13(+), CD14(-), CD15(-), CD16(-), CD33 (variably +), CD34(+), CD36(-), CD38(variably +), CD45(moderate to slightly dim +), CD56(-), CD64(partial +), CD117 (variably +), HLA-DR(partial +), MPO(-), and TdT(-). (Immunophenotypic analysis reveals a 50% population of medium-sized to large cells)	Negative	0	Negative	NA	ASXL1 (p.G645Wfs*12; 40.0%)	NA	NA	Acute Myeloid Leukemia	AML	0.5	UNMATCHED
aml_ohsu_2022_2710	aml_ohsu_2022_2710_BA3288	Waves3+4	Yes	1	NA	70	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	70	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Induction	Refractory	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	M5	44,XY,der(2)t(2;11)(p11.2;q13),add(3)(p12),-9,add(10)(q11.2),-12,add(16)(p13.1)[cp4]/43,idem,-add(10)(q11.2)[cp5]/46,XY[11]	NA	CD11b, variable CD13, variable CD14, CD15, variable CD16, CD33, CD38, CD56, CD58, CD64, dim HLA-DR positive	Negative	0	Negative	NA	NA	TP53 (p.Y205H; 67.9%)	PAX5 (P284A; MAF ~33%)|TET2 (Q876*; MAF ~50%)|TP53 (Y205H; MAF ~66%)	Acute Myeloid Leukemia	AML	0.333333333	UNMATCHED
aml_ohsu_2022_2635	aml_ohsu_2022_2635_BA3387	Waves3+4	Yes	1	NA	41	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	41	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	ATRA (Tretinoin)|7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M2	46,XY,t(8;21)(q22;q22)[20]	RUNX1-RUNX1T1 (All twenty metaphase cells examined had an 8;21 translocation withbreakpoints associated with AML1/ETO fusion.)	partial CD11b, dim CD13, dim CD19, dim CD33, CD34,variable CD38, CD58, dim CD64, CD117, CD123, HLA-DR, dim MPO, and dim TDT	Negative	0	Negative	NA	NA	TP53 (p.R175H; 43.2%)	NRAS (G12D; MAF 40%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2821	aml_ohsu_2022_2821_BA3159	Waves3+4	Yes	3	NA	31	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	31	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	Etoposide, TBI|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Complete Response	Etoposide, TBI	Allogeneic - Sibling	-1	NA	46,XX,inv(16)(p13.1q22)[8]/46,XX[12]	inv(16) positive	CD34+ myeloblasts (60%) and a small population of monoblasts (5%)	Negative	0	Negative	NA	NA	NA	KIT	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2469	aml_ohsu_2022_2469_BA2068	Waves1+2	Yes	2	NA	64	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	64	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Consolidation|Induction	Complete Response	MEC (Cytarabine, Etoposide, Mitoxantrone)	Induction	5	NA	46,XX[14]	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],	CD4(few +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(partial +), CD16(-), CD34(-), CD36(-), CD38(+), CD45(+), CD56(few +), CD64(-), CD117(partial +), HLA-DR(-), MPO(+) and TdT (+)	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	1.166666667	MATCHED
aml_ohsu_2022_2378	aml_ohsu_2022_2378_BA2104	Both	No	1	NA	83	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	Therapy-related myeloid neoplasms	83	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	M5	47,XY,+8[6]/46,XY[13] (Specimen Source: Blood)	trisomy 8 (Specimen Source: Blood)	CD11b, CD13, dimCD14, CD15, dim CD16, CD33,     CD56,     CD58, CD64, CD123, and HLA-DR positive	Negative	0	Positive	NA	NA	NA	FLT3-D835 (bone marrow)|NPM1 (An insertion mutation is present in exon 12 (near the C-terminus) of NPM.)	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2832	aml_ohsu_2022_2832_BA3124	Waves3+4	Yes	1	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute erythroid leukaemia	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	M6	46,XX,del(16)(q22q23)[8]/46,XX[12]	del(16q)	CD13, dim CD14, CD33, CD34, CD38, CD58, CD123, CD117, HLA-DR, partial cTdT and cMPO positive	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2828	aml_ohsu_2022_2828_BA3106	Waves3+4	Yes	2	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	Acute Myeloid Leukemia	NA	12	Unknown	Unknown	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	RUNX1 (p.X170_splice; 34.7%)	ASXL1 (p.R693*; 42.5%)	NA	NA	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2745	aml_ohsu_2022_2745_BA3259	Waves3+4	Yes	1	NA	65	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Azacitidine	1	Induction	Refractory	Azacitidine	Induction	-1	M2	46,XY[20]	normal	CD13, dim CD33, CD34, CD38, CD58, CD117, HLA-DR, and partial MPO	Negative	0	Negative	RUNX1 (p.Q390Afs*210; 42.4%)	NA	NA	IDH2 (p.R140Q; MAF 50%)|RUNX1 (p.Q390Afs; MAF 50%)	Acute Myeloid Leukemia	AML	0.4	UNMATCHED
aml_ohsu_2022_2466	aml_ohsu_2022_2466_BA2921	Both	No	2	NA	70	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	71	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Hypomethylating/Low Dose Cytarabine|Induction	Refractory	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	NA	46,XY,del(7)(q22q36)[7]/47,idem,+22[cp12]/46,XY[1]	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[187/200], (D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	NA	Positive	0.01010101	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2081	aml_ohsu_2022_2081_BA2449	Waves1+2	Yes	1	NA	7	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	7	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	2	Induction|Re-induction	Complete Response	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Re-induction	-1	M1	46,XX,t(8;21)(q22;q22)[19]/46,XX[1]	91.5% AML/ETO fusion, t(8;21)	CD13, CD33, CD34, CD56, CD71, CD117, HLA-DR, MPO-positive	Negative	0	Negative	NA	NA	NA	KIT (D816V; MAF 50%)	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2298	aml_ohsu_2022_2298_BA2360	Waves1+2	Yes	1	bi	78	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated CEBPA	79	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	1	Decitabine	1	Induction	Refractory	Decitabine	Induction	-1	NA	45,X,-Y[19]/46,XY[1]	Normal	CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO +	Negative	0	Negative	NA	NA	NA	CEBPA (1031?1032 ins AAC; MAF 50%)|CEBPA (347?348 del GACCTGT; MAF 50%)|WT1 (p.R369R; MAF 50%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2005	aml_ohsu_2022_2005_BA2802	Both	No	1	NA	52	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Mixed phenotype acute leukaemia, T/myeloid, NOS	53	234	Post-Transplant|Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	6	7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide	5	Salvage|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Decitabine	Salvage	80	NA	45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3]	Deleted 5q	partial CD7, CD13, CD33, CD34, partial CD56, CD58, HLA-DR, and partial MPO-positive CD117, CD123,	Negative	0	Negative	NA	NA	TP53 (p.V216M; 66.9%)	NA	Acute Leukemias of Ambiguous Lineage	ALAL	0.066666667	UNMATCHED
aml_ohsu_2022_2407	aml_ohsu_2022_2407_BA2235	Waves1+2	Yes	1	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	MiDAC	Consolidation	104	M2	46,XX[20]	normal	partial CD7, partial CD11b, CD13, CD33, dim CD45, CD58,     partial CD64, partial CD117, CD123, dimHLA-DR,  MPO positive	Negative	0	Positive	NA	NA	NA	DNMT3A (p.Q696fs*9; MAF 40% )|IDH1 (p.R132H; MAF 40%)|NPM1 (p.W288fs*12; MAF ~40%)|PTPN11 (p.G503A; MAF 40%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2278	aml_ohsu_2022_2278_BA3038	Waves1+2	Yes	1	NA	24	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	24	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine, Methotrexate|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	M4	47,XY,inv(16)(p13q22),+22[20]	62.5% CBFB rearrangement|74% BCR/ABL/ASS	- 14% Myeloid blasts: CD13, CD34, CD38, CD58, partial CD64,     CD117, CD123,          HLA-DR, and MPO positive     - 30% Monoblasts/promonocytes: CD11b, CD13, CD14, CD38, CD58, bright CD64,     HLA-DR, and MPO	Negative	0	Negative	NA	NA	NA	KIT (p.D816H; MAF ~50%)|WT1 (rs16754; MAF ~50%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2239	aml_ohsu_2022_2239_BA3006	Waves1+2	Yes	3	NA	33	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	33	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Refractory	Busulfan, Fludarabine	Allogeneic - Sibling	-1	M2	46,XX[7]	NA	increased CD117 positive, partial CD34 positive myeloblasts,   representing approximately 91% of the leukocytes, consistent with acute myeloid leukemia	Positive	4	Positive	NA	NA	NA	FLT3-ITD|NPM1	Acute Myeloid Leukemia	AML	0.533333333	MATCHED
aml_ohsu_2022_2173	aml_ohsu_2022_2173_BA2245	Waves1+2	Yes	1	NA	65	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with maturation	67	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	8	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cladribine	6	Hypomethylating/Low Dose Cytarabine|Salvage|Consolidation|Unknown|Induction|Re-induction	Refractory	Cladribine	Unknown	5	M2	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2286	aml_ohsu_2022_2286_BA2667	Waves1+2	Yes	1	NA	74	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	M2	46,XY[20]	NA	partial CD7, CD13, CD33, CD34, CD38, CD58, CD117, CD123, TdT, and HLA-DR positive	Negative	0	Negative	RUNX1 (p.A142Gfs*4; 32.2%)	NA	NA	RUNX1 (p.A142Gfs*4; MAF 30% )|SRSF2 (p.P95L; MAF 48%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2326	aml_ohsu_2022_2326_BA2239	Waves1+2	Yes	1	NA	66	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	MiDAC	Consolidation	74	M5	46,XY[20]	normal	CD11b, dim/partial CD13, CD14, CD33, CD38, CD58, CD64,     partial CD117, dim/partial CD123, and HLA-DR positive	Negative	0	Positive	NA	NA	NA	CREBBP (p.Q2208H; MAF 50%)|DNMT3A (p.R882H; MAF 50%)|NPM1 (W288fs*>9; MAF 50%)|WT1 (rs16754; MAF 50%)	Acute Myeloid Leukemia	AML	0.566666667	MATCHED
aml_ohsu_2022_2501	aml_ohsu_2022_2501_BA2359	Waves1+2	Yes	1	NA	56	FALSE	FALSE	FALSE	FALSE	FALSE	FavorableOrIntermediate	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M1	46,XY[20]	normal	CD11b, CD13, CD33, CD38, CD58, CD64, dim CD117, CD123, MPO+	Positive	NA	Positive	NA	NA	NA	DNMT3A (p.N879D; MAF 50%)|FLT3-ITD (MAF 50%)|NPM1 (W228fs*12; MAF 50%)	Acute Myeloid Leukemia	AML	1	MATCHED
aml_ohsu_2022_2235	aml_ohsu_2022_2235_BA2782	Waves1+2	Yes	3	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	46,XY[20]	Normal	atypical monocytic cells expressing weaker than   normal CD13 and CD33, with increased promonocytes/monoblasts representing approximately 44% of the leukocytes, (and increased atypical CD117 positive, CD34 negative myeloblasts showing weak expression   of aberrant CD7 and representing approximately 14% of the leukocytes)	Negative	0	Positive	NA	NA	NA	NPM1	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2097	aml_ohsu_2022_2097_BA2649	Waves1+2	Yes	1	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	ATRA (Tretinoin)|3+7 (Cytarabine, Daunorubicin)	1	Induction	Unknown	3+7 (Cytarabine, Daunorubicin)	Induction	3	M3	46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3] (unusual PML-RARA translocation)	76% Unusual t(15;17), with the fusion signal on the derivative chromosome 15	partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive	Positive	NA	Negative	NA	NA	NA	FLT3-ITD (MAF 40%)|SF3B1 (p.K66N; MAF 40%)|WT1 (rs16754; MAF 50%)	Acute Myeloid Leukemia	AML	0.866666667	MATCHED
aml_ohsu_2022_2125	aml_ohsu_2022_2125_BA2117	Waves1+2	No	2	NA	62	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	62	15	Post-Chemotherapy	Remission	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Induction|Re-induction	Complete Response i	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	5	NOS	46,XY,add(2)(p23),t(3;22)(p21;q13),add(3)(q26),del(6)(q13q27),add(9)(q22),add(9)(q13),add(10)(p11.2),del(14)	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[198],(5'MLL,3'MLL)x2(5'MLLcon3'MLLx2)[199]	CD2(-), CD7(partial and variably +), CD13(+), CD14(-), CD15(-), CD33(bright +), CD34(+), CD36(variably +), CD38(bright +), CD45(+), CD64(-), CD117(variably +), HLA-DR(partial +).	Negative	0	Negative	NA	NA	NA	TP53	Acute Myeloid Leukemia	AML	0.066666667	MATCHED
aml_ohsu_2022_2249	aml_ohsu_2022_2249_BA2257	Waves1+2	Yes	1	NA	41	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	41	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	5	Consolidation|Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	4	M1	46,XX,t(8;21)(q22;q22)[12]/45,idem,-X[6]/46,XX[2]	RUNX1T1 / RUNX1 t(8;21): 87% of cells had a dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis.	CD13, dim CD33, CD34, CD38, CD58, dim/partial CD64, CD117, dim CD123, HLA-DR, and MPO	Negative	0	Negative	NA	NA	NA	TET2 (p.N752fs*60; MAF 40% )	Acute Myeloid Leukemia	AML	0.966666667	MATCHED
aml_ohsu_2022_2070	aml_ohsu_2022_2070_BA2258	Waves1+2	Yes	2	NA	31	TRUE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	36	1020	Post-Chemotherapy|Post-Transplant|Relapse	Relapse	Bone Marrow Aspirate	9	Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide	7	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Experimental|Re-induction	Complete Response	Dasatinib	Experimental	24	NA	46,XX[20]	nuc ish(DXZ1x2)[200]	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(partial +), CD34(+), CD36 (-), CD38(variably +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(-) MPO(-), and TdT(-)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2070	aml_ohsu_2022_2070_BA2592	Waves1+2	No	2	NA	31	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	38	1496	Post-Chemotherapy|Post-Transplant|Residual Disease	Residual	Bone Marrow Aspirate	9	Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide	7	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Experimental|Re-induction	Complete Response	Dasatinib	Experimental	24	NA	46,XX[20]	nuc ish(DXZ1x2)[200]	NA	Negative	0	Negative	NA	NA	NA	BCOR (S259fs*10; MAF 15%)|CCND2 (P281R; MAF 19%)|FLT3-D835 (D835E; MAF 13%)|GATA2 (N297S; MAF 18%)|IKZF1 (Q44*; MAF 14%)|MLL2 (Y2907*; MAF 7%)|PTPN11 (E76V; MAF 17%)|PTPN11 (V45L; MAF 13%)|SETBP1 (H1100R; MAF 51%)|SF3B1 (K700E; MAF 18%)	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2015	aml_ohsu_2022_2015_BA2861	Waves1+2	Yes	1	mono	22	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myelomonocytic leukaemia	22	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	M4	46,XX[24]	normal	partial CD7 ,dim/partial CD10 , CD13 , CD33 , CD34 , CD38 , CD56 , CD64 , dim CD123 , HLA-DR , and MPO positive	Negative	0	Negative	NA	NA	NA	CEBPA (p.D107fs*; MAF ~50%)|WT1 (p.Y385*; MAF 20%)|WT1 (rs16754; MAF ~50%)	Acute Myeloid Leukemia	AML	0.433333333	MATCHED
aml_ohsu_2022_2091	aml_ohsu_2022_2091_BA2684	Waves1+2	Yes	1	NA	2	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	5	0	Residual Disease|Post-Transplant|Post-Chemotherapy	Residual	Peripheral Blood	5	Cyclophosphamide, Fludarabine, TBI|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)|COG-AAML07P1 (Bortezomib, Cytarabine, Etoposide, Idarubicin)	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	-1	M5	46,X,del(X)(q24),del(3)(q23q27),t(4;7)(q12;p15),add(5)(p13),+6,del(6)(q13q23),+8,del(8)(q22),-9,add(9)(q34.1),t(10;11)(p12;q23)inv(11)(q13q23),-20[cp12]/46,XX[8]	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2417	aml_ohsu_2022_2417_BA2598	Waves1+2	Yes	1	NA	72	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Complete Response	3+7 (Cytarabine, Daunorubicin)	Induction	6	M4	46,XY,del(12)(p11.2p13)[15]/46,XY[5]	84% 12p deletion	Myeloid blast immunophenotype: CD13, dim CD33, CD34, CD38, CD58, CD117, HLA-DR and MPO positive | Promonocyte immunophenotype: CD11b, CD13, CD14, CD33, CD38, CD56, CD58, CD64 and HLA-DR positive	Negative	0	Negative	NA	ASXL1 (p.A619Pfs*15; 38.1%)	NA	ASXL1 (p.A619fs*14; MAF 50%)|EZH2 (p.R583*; MAF 95%)|FLT3-D835|FLT3-D835 (MAF unavailable)|PTPN11 (p.D61H; MAF 15%)|RUNX1 ( p.P345?S356del; MAF 25%)|RUNX1 (p.P345?S356del; MAF 25%)|RUNX1 (p.V51; MAF 50%)|RUNX1 (p.V5I; MAF 50%)|TET2 (p.Y867H; MAF 50%)	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2417	aml_ohsu_2022_2417_BA2134	Waves1+2	No	1	NA	72	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	72	8	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Complete Response	3+7 (Cytarabine, Daunorubicin)	Induction	6	M4	46,XY,del(12)(p11.2p13)[15]/46,XY[5]	84% 12p deletion	NA	Negative	0	Negative	NA	ASXL1 (p.A619fs*14; MAF 50%)	NA	ASXL1 (p.A619fs*14; MAF 50%)|EZH2 (p.R583*; MAF 95%)|FLT3-D835|FLT3-D835 (MAF unavailable)|PTPN11 (p.D61H; MAF 15%)|RUNX1 ( p.P345?S356del; MAF 25%)|RUNX1 (p.P345?S356del; MAF 25%)|RUNX1 (p.V51; MAF 50%)|RUNX1 (p.V5I; MAF 50%)|TET2 (p.Y867H; MAF 50%)	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2312	aml_ohsu_2022_2312_BA2337	Waves1+2	Yes	1	NA	53	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	53	4	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	109	M2	46,XX,t(8;21)(q21.3;q22)[18]/46,XX[2]	RUNX1T1/RUNX1 fusion	CD13, dim CD33, CD34, partal CD117, dim CD123, HLA-DR, MPO, and partial dim TdT	Negative	0	Negative	NA	NA	NA	KDM6A (p.Q154fs*7; MAF 8%)|KDM6A (p.V1113fs*; MAF 30%)|KIT (p.D820G; MAF 4%)	Acute Myeloid Leukemia	AML	0.633333333	MATCHED
aml_ohsu_2022_2509	aml_ohsu_2022_2509_BA2909	Waves1+2	Yes	1	NA	8	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	8	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	2	Induction|Intensification	Complete Response	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Intensification	62	M2	46,XY,t(8;21)(q22;q22)[5]/46,idem,der(7)t(7;8)(q22;q11.2)[13]/46,XY[2]	t(8;21) (34%) | t(8;21) and der(7)t(7;8) (56%) | Missing D7S486 signal (70%)	dim CD7, CD13, CD33, CD34, CD38, partial CD56,CD58, CD117, CD123, dim HLA-DR, and MPO	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2473	aml_ohsu_2022_2473_BA2429	Waves1+2	Yes	1	NA	78	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	78	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	2	Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Maintenance	NA	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	NOS	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2191	aml_ohsu_2022_2191_BA2653	Waves1+2	Yes	1	mono	42	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute megakaryoblastic leukaemia	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	Refractory	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	M7	NA	Extra signals were observed for BCR (22q11.2), PML (15q22), MLL (11q23),     RUNX1T1 (8q21.3) and RUNX1 (21q22) in roughly 45-60% of interphase cells.     These results suggest the presence of a hyperdiploid clone.	CD7, CD13, CD33, CD58, partial CD61, CD71, and Factor 8 positive	Negative	0	Negative	NA	NA	NA	CEBPA (p.V119?M120insV; MAF 30% )	Acute Myeloid Leukemia	AML	0.666666667	MATCHED
aml_ohsu_2022_2506	aml_ohsu_2022_2506_BA2947	Waves1+2	Yes	1	NA	14	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	14	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)	1	Induction	Complete Response	COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)	Induction	133	M2	45,X,-Y,t(8;21)(q22;q22)[4]/45,idem,del(9)(q12q22)[13]/46,XY[3]	RUNX1T1/ RUNX1 fusion and t(8;21) (94%)	CD13, CD33, CD34, dim CD45, partial CD56, CD58, dim CD117, HLA-DR, MPO, and partial TdT-positive	Negative	0	Negative	NA	NA	NA	TP53 (p.S366A; MAF 50% )	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2022	aml_ohsu_2022_2022_BA2032	Waves1+2	Yes	2	NA	64	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	65	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	5	Crenolanib|MEC, plexifor, GCSF|Sorafenib|7+3 (Cytarabine, Idarubicin) plus LBH|Clofarabine, Cytarabine	4	Salvage|Induction|Experimental|Re-induction	Refractory	Crenolanib	Experimental	124	NA	46,XX,t(3;11)(q21;p11.2),t(15;15)(q15;q22)[19]/46,XX,t(2;14)(q21;q11.2)[2]	nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2 (5'MLL con 3'MLLx2)[198],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD7(partial +), CD15(partial +), CD33(bright +), CD34(partial +), CD45(+), and CD117(variably +). (80% population of variably-sized cells)	Positive	15.66666667	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2220	aml_ohsu_2022_2220_BA2162	Both	No	1	NA	77	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	7+3 (Cytarabine, Idarubicin)	Induction	7	NA	46,XY,-7,+13,i(17)(q10)[20]	D7S486/ CEP 7:  92/100 cells (92%) had a 1 red/ 1 green signal pattern, indicating monosomy 7, consistent with the metaphase karyotype. | RARA:  79/100 cells (79%) had three signals, consistent with the isochromosome 17q observed in the metaphase karyotype and the presence of three copies of the long arm.  There was no evidence for PML/RARA fusion. | TP53:  89/100 cells (89%) had a single signal, reflecting deletion and consistent with the isochromosome 17q observed in the metaphase karyotype.	CD13, CD33, CD34, CD117, dim CD123, and HLA-DR-positive	Negative	0	Negative	NA	ASXL1 (p.W583*; 47.9%)	NA	ASXL1 (p.W583*; MAF 50%)|ETV6 (p.N384*; MAF 40%)|FBXW7 (p.T196A; MAF 50%)|SRSF2 (p.P95H; MAF 70%)	Acute Myeloid Leukemia	AML	0.366666667	UNMATCHED
aml_ohsu_2022_2142	aml_ohsu_2022_2142_BA2991	Waves1+2	Yes	1	NA	56	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	56	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	3	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Salvage|Induction|Re-induction	Refractory	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	6	NOS	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2339	aml_ohsu_2022_2339_BA2564	Waves1+2	Yes	1	NA	18	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	18	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	2	Induction|Re-induction	Refractory	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Re-induction	-1	M4	46,XX,inv(16)p13.1q22)[4]/47,idem,+22[15]/46,XX[1]	CBFB rearrangement and inv(16) (64%) | +22 (71%)	Blast phenotype:  CD13, CD33, CD34, CD38, CD58, dim CD123,     HLA-DR-positive               - Monocytic phenotype:  CD11b, CD13, CD14, CD33, CD58, CD64, HLA-DR-positive	Negative	0	Negative	NA	NA	NA	KRAS (p.G13D; MAF 10%)|NRAS (p.G13D; MAF 30%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2578	aml_ohsu_2022_2578_BA3043	Waves1+2	Yes	1	NA	51	FALSE	TRUE	FALSE	FALSE	FALSE	FavorableOrIntermediate	AML with mutated NPM1	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	3	M4	46,XX[20]	Normal	dim/partial CD7, variable CD13, CD33, dim/partial     CD64,     CD117, CD123, HLA-DR and cMPO positive	Positive	NA	Positive	NA	NA	NA	DNMT3A (p.R882H; MAF 50%)|FLT3-ITD (exon 14 )|NPM1 (p.W288fs*12; MAF 40%)|WT1 (rs16754; no MAF available)	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2290	aml_ohsu_2022_2290_BA2597	Waves1+2	Yes	4	NA	79	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Azacitidine, Lenalidomide	1	Induction	Refractory	Azacitidine, Lenalidomide	Induction	137	NA	46,XX,del(16)(p11.2)[3]/46,XX[2]	NA	CD34, CD4(dim), CD7, CD11c(dim), CD13, CD33(dim),CD38, CD117, and HLA-DR	Negative	0	Negative	NA	ASXL1 (p.G645Vfs*58; 12.5%)	NA	IDH2 (R140Q)	Acute Myeloid Leukemia	AML	0.466666667	MATCHED
aml_ohsu_2022_2396	aml_ohsu_2022_2396_BA2315	Waves1+2	Yes	4	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	FavorableOrIntermediate	AML with mutated NPM1	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	HiDAC|7+3 (Cytarabine, Idarubicin)|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	NA	46,XY[7]	NA	CD117,HLA-DR, CD13 and CD33.  Blasts also show partial expression of CD34, CD7, CD11c, CD38, CD15, dim CD64, and dim CD4	Positive	NA	Positive	NA	NA	NA	FLT3-ITD|NPM1	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2682	aml_ohsu_2022_2682_BA3262	Waves3+4	Yes	1	NA	78	FALSE	FALSE	TRUE	FALSE	FALSE	MissingKaryo	AML with myelodysplasia-related changes	78	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	3	Azacitidine|Azacitidine, Lenalidomide|Decitabine	2	Maintenance|Supportive/Palliative Care	NA	Decitabine	Supportive/Palliative Care	141	NA	NA	CEP7-7q31: Positive for heterozygous deletion 7q31 (44%).	NA	Negative	0	Negative	NA	NA	NA	FLT3 (N676K; MAF:30%)|GATA2 (A372T; MAF:50%)|NRAS (G13R; MAF: 5%)|U2AF1 (S34F; MAF:50%)	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2683	aml_ohsu_2022_2683_BA3243	Waves3+4	Yes	2	NA	51	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	ATRA, Arsenic Trioxide	1	Experimental	NA	ATRA, Arsenic Trioxide	Experimental	193	M3	46,XY,t(15;17)(q24;q21.1)/46,XY	nuc ish(PML,RARA)x3(PML con RARAx2)[164/200] (Labs conducted twice on day of specimen collection. This is result 1 of 2 on 8/6/2013.) | nuc ish(PML,RARA)x3(PML con RARAx2)[190/200] (Labs conducted twice on day of specimen collection. This is result 2 of 2 on 8/6/2013.)	CD2(partial +), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(+), CD117(+), HLA-DR(-), MPO(+), TdT(-) (Labs conducted twice on day of specimen collection. This is result 1 of 2 on 8/6/2013.) | CD2(partial +), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(variably +), CD45 (variably +), CD56(-), CD64(+), CD117(+), HLA-DR(-) (Labs conducted twice on day of specimen collection. This is result 2 of 2 on 8/6/2013.)	Positive	0.020408163	Negative	NA	NA	NA	FLT3-D835|FLT3-ITD	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2055	aml_ohsu_2022_2055_BA2106	Waves1+2	Yes	4	NA	35	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	37	1	Post-Chemotherapy|Relapse	Relapse	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI	5	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	Complete Response	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	53	M5	46,XX[5]	NA	CD45, DIM CD64, DIM CD13, DIM CD33, CD15, CD38, MPO, CD11C, DIM CD4, DIM PARTIAL CD19, CD117, AND HLA-DR	Negative	0	Positive	NA	NA	NA	FLT3-D835|IDH1|NPM1	Acute Myeloid Leukemia	AML	0.666666667	MATCHED
aml_ohsu_2022_2055	aml_ohsu_2022_2055_BA2939	Waves1+2	No	4	NA	35	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	37	160	Residual Disease|Post-Chemotherapy|Post-Transplant	Residual	Peripheral Blood	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI	5	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	Complete Response	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	53	M5	46,XX[5]	NA	NA	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2559	aml_ohsu_2022_2559_BA2427	Waves1+2	Yes	4	NA	53	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	60	0	Post-Chemotherapy|Relapse	Relapse	Peripheral Blood	5	7+3 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Azacitidine, Gemtuzumab|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Cytarabine	2	Induction|Re-induction	Refractory	Azacitidine, Gemtuzumab	Re-induction	-1	M4eo	47,XX,t(16;16)(p13;q22),+22[20]	CBFB inv(16)	Positive (ABNORMAL CD34+ BLAST POPULATION, 11%, EXPRESSING CD117, CD15,CD13, CD33 (DIM), AND HLA-DR, WITH ABERRANT EXPRESSION OF CD19(DIM-PARTIAL) AND CD22 (DIM-PARTIAL)ABNORMAL MONOCYTIC POPULATION EXPRESSING CD64, CD14, CD34(DIM), CD2 (DIM), CD7 (DIM), AND CD8 (DIM-PARTIAL))	Negative	0	Negative	NA	NA	NA	FLT3-D835	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2274	aml_ohsu_2022_2274_BA2841	Waves1+2	Yes	4	bi	31	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated CEBPA	32	0	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	7	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Fludarabine, Cyclophosphamide, TBI	6	Allogeneic - Sibling|Consolidation|Salvage|Unknown|Induction|Re-induction	Complete Response	Decitabine	Salvage	-1	NA	46,XY[20]	NA	CD34, CD117, CD38, MPO, CD11c (dim),CD13, CD33, CD15, and HLA-DR,CD7 and CD56 (partial)	Negative	0	Negative	NA	NA	NA	CEBPA (Double mutation)	Acute Myeloid Leukemia	AML	0.766666667	MATCHED
aml_ohsu_2022_2429	aml_ohsu_2022_2429_BA2446	Waves1+2	Yes	1	NA	30	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Therapy-related myeloid neoplasms	30	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	4	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Decitabine	Supportive/Palliative Care	31	M1	46,XX,t(9;11)(p11;q34)[19]/46,XX[1]	Disruption of MLL signal and t(9;11) (65%)	CD11b, CD13, CD14,  CD33, CD64, CD56, CD123 and HLA-DR positive	Negative	0	Negative	NA	NA	NA	CREBBP (p.A254T; MAF 50%)|CREBBP (p.T910S; MAF 40%)|FLT3-D835 (p.D835; MAF 35%)	Acute Myeloid Leukemia	AML	0.633333333	MATCHED
aml_ohsu_2022_2429	aml_ohsu_2022_2429_BA2025	Waves1+2	No	1	NA	30	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	31	147	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	4	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Decitabine	Supportive/Palliative Care	31	M1	46,XX,t(9;11)(p22;q23)[20]/46,XX[1]	MLL disruption and t(9;11) (70%)	dim/partial CD13, CD33, CD38, CD56, CD58, CD64, partialCD117, CD123 and HLA-DR positive	Negative	0	Negative	NA	NA	NA	FLT3-D835 (MAF 70%)	Acute Myeloid Leukemia	AML	0.766666667	MATCHED
aml_ohsu_2022_2579	aml_ohsu_2022_2579_BA3045	Waves1+2	Yes	2	NA	46	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	47	0	Post-Chemotherapy|Post-Transplant|Residual Disease	Residual	Peripheral Blood	7	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Crenolanib|PLX3397|Fludarabine, Cyclophosphamide, Thiotepa, TBI|AC220 (Ambit)	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response i	Crenolanib	Experimental	-1	NA	46,X,t(X;11)(p22.1;q13),add(7)(p22),add(17)(q21)[cp3]/45,X,-X,add(1)(q21),add(2)(q37),add(5)(q35),add(7)[cp3]/46,XX[4]	Normal	CD2(dim +), CD7(-), CD13(partial dim +), CD14(-), CD15(partial +), CD33(+), CD34(+), CD38(partial +), CD45(moderately +), CD117(partial +), HLA-DR(variably +)	Positive	0.538461538	Negative	NA	NA	NA	FLT3-D835 (NOT FOUNDATION NO MAF AVAILABLE)|FLT3-ITD (NOT FOUNDATION NO MAF AVAILABLE)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2230	aml_ohsu_2022_2230_BA2645	Waves1+2	Yes	4	NA	73	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute monoblastic and monocytic leukaemia	73	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Decitabine|Stanford Protocol 9153 (TLI, ATG)	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Stanford Protocol 9153 (TLI, ATG)	Allogeneic - Mismatched Unrelated Donor	-1	M5	46,XY[20]	NA	 CD4(subset), CD11c(partial), CD13(partial), CD14(partial), CD15(partial), CD33(subset), CD34(subset), CD38, CD64(subset), CD117(subset), HLA-DR and MPO	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.866666667	MATCHED
aml_ohsu_2022_2543	aml_ohsu_2022_2543_BA2525	Waves1+2	Yes	4	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	Azacitidine, Lenalidomide|Temozolomide, Vorinostat	2	Induction|Re-induction	Refractory	Temozolomide, Vorinostat	Re-induction	-1	NA	46,XX,del(5)(q31q35),inv(7)(p15q32),del(12)(q?15)[2]/45~46,idem,add(3)(q27),-9,-del(12)(q?15),+add(12)(q13),-16,-17,+mar1,+mar2x2[cp16]/46,XX[2]	NA	NA	Positive	0.538461538	Positive	NA	NA	TP53	TP53	Acute Myeloid Leukemia	AML	0.133333333	MATCHED
aml_ohsu_2022_2198	aml_ohsu_2022_2198_BA2542	Waves1+2	No	4	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Cytarabine|Azacitidine|Stanford Protocol 9153 (TLI, ATG)	3	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	NA	Cytarabine	Supportive/Palliative Care	9	NA	46,XX,t(8;19)(q24;q13),del(11)?(q14q23)[19]/46,XX[1]	NA	CD34, CD117, CD38, DIM CD13, CD33, HLA-DR, AND PARTIAL CD7	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2198	aml_ohsu_2022_2198_BA2876	Waves1+2	Yes	4	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Cytarabine|Azacitidine|Stanford Protocol 9153 (TLI, ATG)	3	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	NA	Cytarabine	Supportive/Palliative Care	9	NA	46,XX,t(8;19)(q24;q13),del(11)?(q14q23)[19]/46,XX[1]	NA	CD34, CD117, CD38, DIM CD13, CD33, HLA-DR, AND PARTIAL CD7	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2245	aml_ohsu_2022_2245_BA2357	Waves1+2	Yes	2	NA	52	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	52	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Matched Unrelated Donor	Refractory	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	NA	89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18]	nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200]	partialCD4, partialCD15, dimCD33, CD34, CD38, dimCD45, CD117, HLA-DR, TdT, MPO	Negative	0	Negative	RUNX1 (p.R201Q; 33.9%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.9	MATCHED
aml_ohsu_2022_2245	aml_ohsu_2022_2245_BA2640	Waves1+2	No	2	NA	52	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	54	506	Relapse	Relapse	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Matched Unrelated Donor	Refractory	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	NA	89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18]	nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200]	NA	Positive	1	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2259	aml_ohsu_2022_2259_BA2546	Waves1+2	Yes	1	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Decitabine	Consolidation	-1	M4	42~45,XY,del(4)(q31q35),del(5)(q13q35),add(9)(q21),add(13)(p11.2),-16,-21[cp15]/40~46,sl,+9,-add(9)(q21),-15,+der(16)t(15;16)(q11.1;p13.3),-18,+mar[cp5]	Extra MLL signal (5%) | 5q deletion (95%) | Abnormal 9q (33%) | Partial deletion of RUNX1 (34%)	CD13, CD33, CD34, CD56, CD58, dim CD64, CD117 and partial HLA-DR.	Negative	0	Negative	NA	NA	TP53 (p.X307_splice; 46.6%)|TP53 (p.R273S; 40.4%)	TP53 (Intron 7, 5' splice site mutation; MAF 40%)|TP53 (p.R273S; MAF 40%)	Acute Myeloid Leukemia	AML	0.433333333	MATCHED
aml_ohsu_2022_2403	aml_ohsu_2022_2403_BA2742	Waves1+2	Yes	1	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute monoblastic and monocytic leukaemia	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	0	NA	0	NA	NA	NONE	NONE	NA	M5	46,XY[20]	Normal	CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38,      partial CD56, CD58, CD64, CD123, and HLA-DR positive	Positive	15.66666667	Negative	RUNX1 (p.X205_splice; 56.7%)	NA	NA	DNMT3A (p. R882C; MAF 50%)|DNMT3A (p.R882C; MAF 50%)|FLT3-ITD (MAF 90%)|RUNX1 (Intron 5, 3' splice site mutation; MAF 50%)	Acute Myeloid Leukemia	AML	0.366666667	MATCHED
aml_ohsu_2022_2403	aml_ohsu_2022_2403_BA2316	Waves1+2	No	1	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute monoblastic and monocytic leukaemia	62	1	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	M5	46,XY[20]	Normal	CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38, partial CD56, CD58, CD64, CD123, and HLA-DR positive	Positive	NA	Negative	RUNX1 (p.X205_splice; 44.3%)	NA	NA	DNMT3A (p. R882C; MAF 50%)|DNMT3A (p.R882C; MAF 50%)|FLT3-ITD (MAF 90%)|RUNX1 (Intron 5, 3' splice site mutation; MAF 50%)	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2071	aml_ohsu_2022_2071_BA2007	Waves1+2	Yes	4	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	FavorableOrIntermediate	AML with mutated NPM1	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Decitabine, Midostaurin	1	Induction	Refractory	Decitabine, Midostaurin	Induction	-1	NA	46,XY[20]	NA	CD34+, EXPRESSING CD13, CD33,MPO, AND HLA-DR, WITH ABERRANT COEXPRESSION OF CD15 AND CD117, AND PARTIAL LOSS OF CD38	Positive	NA	Positive	NA	NA	NA	FLT3-ITD|NPM1	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2195	aml_ohsu_2022_2195_BA2421	Waves1+2	Yes	2	NA	75	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	75	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	5	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Consolidation|Induction|Re-induction|Maintenance	Refractory	Azacitidine	Maintenance	34	NA	47,XY,+8,inv(9)(p11q12)c[1]/48,idem,+3[5]/49,idem,+3,+15[1]/50,idem,+3,+8,+mar(8]/46,XY,inv(9}(p11q12)c[5]	nuc ish (D8Z2x3~4)[134/200],(D15Z4x3)[114/200]	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	2.233333333	MATCHED
aml_ohsu_2022_2188	aml_ohsu_2022_2188_BA2225	Waves1+2	Yes	4	NA	77	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Azacitidine, Lenalidomide	1	Induction	Refractory	Azacitidine, Lenalidomide	Induction	-1	M5	46,XY,del(9)(q13q34)[3]/46,XY[14]	NA	CD64, DIM CD14, BRIGHT CD56, CD13, AND CD33,SUBSET EXPRESSING CD34	Negative	0	Negative	NA	ASXL1 (p.V751Gfs*22; 17.4%)	TP53 (p.R273C; 15.4%)	TP53	Acute Myeloid Leukemia	AML	1.066666667	MATCHED
aml_ohsu_2022_2221	aml_ohsu_2022_2221_BA2087	Waves1+2	Yes	2	NA	40	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with t(9;11)(p22;q23); MLLT3-MLL	40	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	NA	46,XX,t(9;11)(p22;q23)[20]	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1) [179/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	brightCD4, partialCD11b, brightCD15, brightCD33, partialCD36, partialCD38, CD45, brightCD64, partialCD117, HLA-DR (86% population of cells)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2261	aml_ohsu_2022_2261_BA2910	Waves1+2	Yes	2	NA	79	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	79	0	Post-Chemotherapy|Relapse	Relapse	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|Crenolanib	2	Induction|Experimental	Complete Response	Crenolanib	Experimental	14	NA	NA	NA	NA	Positive	0.470588235	Positive	NA	NA	NA	FLT3-ITD (High level (>50%))|NPM1 (Positive for insertion mutation in exon 12)	Acute Myeloid Leukemia	AML	0.966666667	MATCHED
aml_ohsu_2022_2128	aml_ohsu_2022_2128_BA2148	Waves1+2	Yes	2	NA	31	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	31	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response i	HiDAC	Consolidation	95	NA	46,XX,inv(16)(p13.1q22)[11]/47,idem,+22[4]/46,XX[5]	nuc ish(D4Z1,D10Z1)x2[199],(SCFD2,LNX,PDGFRA/KIT)x2[200],(5'PDGFRB,3'PDGFRB)x2(5'PDGFRB con 3'PDGFRBx2)[200],(5'FGFR1,3'FGFR1)x2([200],(RUNX1T1,RUNX1)x2[200](ABL1x2,BCRx3)[63/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(ETV6,RUNX1)x2[198],(PML,RARA)x2[200],(CBFBx2)(5’CBFB sep 3’CBFBx1)[147/200]	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial+), CD16(-), CD22(few +), CD33(dim + to -), CD34(+), CD36(-), CD38(variably +), CD41(-), CD45(variably +), CD56(-), CD61(-), CD64(-), CD117(variably +), HLA-DR(partial +), Gly-A(-), MPO(+), TdT(partial +)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2186	aml_ohsu_2022_2186_BA2329	Waves1+2	Yes	1	NA	61	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	61	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	3	Salvage|Induction|Re-induction	Refractory	Decitabine	Salvage	126	M5	47~49,XY,-21,+1~4mar[cp21]/46,XY[2]	Monosomy 21 (30%)	Blasts (15-20%): CD11b, CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, and HLA-DR, and partial TdT positive - Aberrant monocytic population (20%): CD11b, CD13, CD14, bright CD33, dim CD56, CD64, and HLA-DR positive	Negative	0	Negative	NA	NA	NA	CSF3R (p. T618I; MAF: 50%)|WT1 (benign SNP rs16754 (R369R: no amino acid change); MAF: 50%)	Acute Myeloid Leukemia	AML	0.8	MATCHED
aml_ohsu_2022_2186	aml_ohsu_2022_2186_BA2677	Waves1+2	No	1	NA	61	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	62	43	Residual Disease	Residual	Bone Marrow Aspirate	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	3	Salvage|Induction|Re-induction	Refractory	Decitabine	Salvage	126	M5	46~49,XY,-21,+1~4mar[cp20]	Monosomy 21 (45%)	Myeloid blasts:CD13, CD33, CD34, CD38, CD58, dimCD64, CD117, and HLA-DR+    Promonocytes/immature monocytes:CD11b, CD13, CD14, CD33, CD64, and HLA-DR+	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.966666667	MATCHED
aml_ohsu_2022_2789	aml_ohsu_2022_2789_BA3178	Waves3+4	Yes	3	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with t(9;11)(p22;q23); MLLT3-MLL	71	7	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	3	Consolidation|Induction|Re-induction	UNKNOWN	CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	Re-induction	-1	M5a	49,XY,+8,+8,t(9;11)(p22;q23),+der(9)t(9;11)	8q22 (RUNX1T1): gain of two copies present  11q23 (MLL): rearrangement present (95% RUNX, 91% MLL)	CD4+, CD33+, CD117+, HLA-DR+ myeloblasts	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2789	aml_ohsu_2022_2789_BA3282	Waves3+4	No	3	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with t(9;11)(p22;q23); MLLT3-MLL	72	178	Post-Chemotherapy	Remission	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	3	Consolidation|Induction|Re-induction	UNKNOWN	CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	Re-induction	-1	M5a	49,XY,+8,+8,t(9;11)(p22;q23),+der(9)t(9;11)	8q22 (RUNX1T1): gain of two copies present  11q23 (MLL): rearrangement present (95% RUNX, 91% MLL)	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2826	aml_ohsu_2022_2826_BA3093	Waves3+4	Yes	1	NA	73	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	-1	M2	92,XXYY[9]/46,XY[11]	NA	CD13, dim CD33, CD34, CD38, dim CD45, CD58, CD71, CD117,CD123, HLA-DR, and TdT positive	Negative	0	Negative	RUNX1 (L89fs*49; MAF 20-30%)	NA	NA	IDH1 (R132H; MAF 30%)|RUNX1 (L89fs*49; MAF 20-30%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2256	aml_ohsu_2022_2256_BA2060	Waves1+2	No	1	NA	57	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myelomonocytic leukaemia	60	883	Post-Chemotherapy	Remission	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	4	Consolidation|Induction|Re-induction|Maintenance	Complete Response	Azacitidine	Maintenance	-1	M4	46,XY[20]	NA	The atypical, previously identified myeloid blast population (CD117+/CD34-) is not seen. Lymphocytes are about 5%, and mostly T cells which have a reversed CD4:CD8 ratio and no antigen aberrancy. B cells are essentially absent, and NK cells are not increased	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.3	MATCHED
aml_ohsu_2022_2115	aml_ohsu_2022_2115_BA2072	Waves1+2	Yes	1	NA	35	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	35	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	94	M4	46,XX,t(16;16)(p13.1;q22)[16]/47,idem,+22[4]	Trisomy 22 (16%) | t(16;16) (90%)	Myeloid blasts (21%): CD13, CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive. Promonocytic/monocytic cells (55%): CD11b, CD13, CD14, CD33, dim/partial CD34, CD38, CD58, CD64, variable CD123, HLA-DR, and MPO-positive. (Included both populations of cells)	Negative	0	Negative	NA	NA	NA	CREBBP (P552S; MAF 50%)|KDM6A (K395N; MAF 50%)|KIT (D816V; MAF 1%)|NRAS (G13D; MAF 6%)	Acute Myeloid Leukemia	AML	0.033333333	MATCHED
aml_ohsu_2022_2079	aml_ohsu_2022_2079_BA3029	Waves1+2	Yes	2	NA	62	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	63	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	6	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Crenolanib	Experimental	141	NA	46,XY	NA	CD2(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(variably +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD45(moderately +), CD56(-), CD64 (partial +), CD117(variably +), HLA-DR(-), MPO(+), TdT(-).	Positive	10.11111111	Positive	NA	NA	NA	CCND3 (Foundation, P203S; MAF 8%)|CHEK2 (Foundation; T367fs*15; MAF 9%)|DNMT3A (Foundation, R882H; MAF 9%)|FLT3 (Foundation, Y591_V592INSVDFREYEYDLKWEFPRENLEFD; MAF 13%)|NPM1 (Foundation; W288fs*10+;MAF 8%)	Acute Myeloid Leukemia	AML	0.966666667	MATCHED
aml_ohsu_2022_2079	aml_ohsu_2022_2079_BA2735	Waves1+2	No	2	NA	62	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	64	254	Post-Chemotherapy|Post-Transplant|Residual Disease	Residual	Peripheral Blood	6	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Crenolanib	Experimental	141	NA	45,XY,der(12;16)(q10;p10)[2]/46,XY[18]	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[31/200]	NA	Positive	5.666666667	Positive	NA	NA	NA	CCND3 (P203S; MAF unlisted)|CHEK2 (T367fs*15; MAF unlisted)|DNMT3A (R882H; MAF unlisted)|FLT3-ITD|NPM1 (W288fs*10+; MAF unlisted)	Acute Myeloid Leukemia	AML	2.133333333	MATCHED
aml_ohsu_2022_2408	aml_ohsu_2022_2408_BA2733	Waves1+2	Yes	2	NA	33	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	33	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	103	NA	47,XX,inv(16)(p13.1q22),+22	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2x3, D20S108x2)[7/200],(RUNX1T1,RUNX1)x2[197],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198], (CBFBx2)(5’CBFB sep 3’CBFBx1)[140/200]	CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(variably +), CD16(-), CD33(+), CD34(variably +), CD36(-), CD38(+), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(+)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.033333333	MATCHED
aml_ohsu_2022_2408	aml_ohsu_2022_2408_BA2193	Waves1+2	Yes	2	NA	33	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	33	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	103	NA	47,XX,inv(16)(p13.1q22),+22	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2x3, D20S108x2)[7/200],(RUNX1T1,RUNX1)x2[197],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198], (CBFBx2)(5’CBFB sep 3’CBFBx1)[140/200]	CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(variably +), CD16(-), CD33(+), CD34(variably +), CD36(-), CD38(+), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(+)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2281	aml_ohsu_2022_2281_BA2995	Waves1+2	Yes	2	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	Azacitidine	Hypomethylating/Low Dose Cytarabine	55	NA	46,XY	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[29/200],(D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[11/200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial +), CD13(partial +), CD15(-), CD19(-), CD22(partial +), CD33(partial and variably +), CD34(variably +), CD36(partial +), CD38(variably +), CD45(partial +), CD56(-), CD64(partial +), CD117 (partial +), HLA-DR(+), TdT(partial +), MPO(-)	Negative	0	Negative	RUNX1 (p.P333Rfs*261; 48.9%)|RUNX1 (p.D332G; 51.1%)|RUNX1 (p.R162G; 47.3%)	NA	NA	NA	Acute Myeloid Leukemia	AML	1.1	MATCHED
aml_ohsu_2022_2179	aml_ohsu_2022_2179_BA2069	Waves1+2	Yes	1	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with t(9;11)(p22;q23); MLLT3-MLL	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	3	Consolidation|Salvage|Induction	Complete Response	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	4	M5	46,XY,t(9;11)(p22;q23)[20]	MLL rearrangement and t(9;11) (86%)	CD11b, partial CD13, CD33, CD38, CD56, CD58, CD64, partial CD117, CD123, and HLA-DR+	Positive	1.083333333	Positive	NA	NA	NA	No gene mutations found in the 43 genes tested	Acute Myeloid Leukemia	AML	0.1	MATCHED
aml_ohsu_2022_2485	aml_ohsu_2022_2485_BA2100	Waves1+2	Yes	2	NA	73	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	74	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	7	Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)	6	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction	Refractory	Crenolanib	Experimental	33	NA	46,XY,+1,dic(1;15)(q12;p11.2)[2]/46,XY[18]	18].nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD4(partial dim +), CD7(-), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variably +), CD34(+), CD36(-), CD38(variably +), CD45 (variably +), CD56(-), CD64(-), CD79a(-) | CD117(variably +), HLA-DR (variably +), MPO(predominantly -), TdT(-)	Positive	1.222222222	Negative	RUNX1 (p.R201Q; 47.2%)	NA	NA	FLT3-ITD (NOT FOUNDATION NO MAF AVAILABLE)	Acute Myeloid Leukemia	AML	0.766666667	MATCHED
aml_ohsu_2022_2485	aml_ohsu_2022_2485_BA2953	Waves1+2	No	2	NA	73	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	74	37	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	7	Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)	6	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction	Refractory	Crenolanib	Experimental	33	NA	46,XY	nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	CD2(-), CD4(-), CD7(-), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variable and bright +), CD34(variably +) (Within this population, there is a small subset of cells (1.7% of total events) that is CD10(partial +), CD13(partial +), CD19(+), CD20(partial +), CD22(partial +), CD33(+), CD34(variably +), CD38(+), CD45(+), CD79a(+), CD117(partial +), HLA-DR(+) and TdT(partial +).) | CD36(-), CD38(variably +), CD45(moderately +), CD56(-), CD64(partial +), CD117(variably +), HLA-DR(variably +).	Positive	3	Negative	RUNX1 (p.R201Q; 51.8%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.5	MATCHED
aml_ohsu_2022_2288	aml_ohsu_2022_2288_BA2681	Waves1+2	Yes	3	NA	68	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	68	49	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	3	Cyclophosphamide, Fludarabine, TBI|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	3	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Induction	Complete Response	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	NA	46,XX,der(9)t(9;12)(p13;q13),del(11)(q21q25),der(12)add(12)(p11.2)add(12)(q13),del(13)(q14q22)[9]/46,idem,add(12)(q24.3),+13,-del(13)[9]/46,idem,add(17)(p13)[2]	NA	NA	Negative	0	Negative	NA	ASXL1 (p.G645Vfs*58; 8.3%)|ASXL1 (p.C789Wfs*2; 30.5%)	NA	NA	Acute Myeloid Leukemia	AML	0.9	MATCHED
aml_ohsu_2022_2105	aml_ohsu_2022_2105_BA2248	Waves1+2	Yes	2	NA	21	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	22	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	13	HiDAC|Crenolanib|Etoposide|Topotecan|Decitabine|Clofarabine|Thioguanine|7+3 (Cytarabine, Idarubicin)|Cyclophosphamide|Thiotepa|Sorafenib|Mitoxantrone|Vinorelbine	4	Induction|Experimental|Re-induction|Supportive/Palliative Care	Refractory	Crenolanib	Experimental	15	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.6	MATCHED
aml_ohsu_2022_2504	aml_ohsu_2022_2504_BA2191	Waves1+2	Yes	3	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	ATRA, Arsenic Trioxide	1	Induction	Complete Response	ATRA, Arsenic Trioxide	Induction	-1	M3	NA	PML-RARA+ 0.70743	Large population of atypical CD117 positive, bright myeloperoxidase positive, CD34 negative, HLA-DR negative immature myeloid cells, representing approximately 90% of the leukocytes.	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	1.2	MATCHED
aml_ohsu_2022_2108	aml_ohsu_2022_2108_BA2832	Waves1+2	Yes	2	NA	68	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	7+3 (Cytarabine, Idarubicin)	Induction	5	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2248	aml_ohsu_2022_2248_BA2308	Waves1+2	Yes	4	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	72	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	4	Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Maintenance	Refractory	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	NA	45,XY,-7,t(3;3)[20]	NA	CD34+ CD38, CD13,CD33, CD117, HLA-DR, DIM CD7, PARTIAL CD11C, CD2(SUBSET), CD15(MINOR SUBSET), DIM cCD79a(MINOR SUBSET), AND PARTIAL CD4	Positive	5.25	Negative	NA	NA	NA	FLT3-D835	Acute Myeloid Leukemia	AML	0.833333333	MATCHED
aml_ohsu_2022_2248	aml_ohsu_2022_2248_BA2413	Waves1+2	No	4	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	72	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	4	Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Maintenance	Refractory	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	NA	45,XY,-7,t(3;3)[20]	NA	CD34+ CD38, CD13,CD33, CD117, HLA-DR, DIM CD7, PARTIAL CD11C, CD2(SUBSET), CD15(MINOR SUBSET), DIM cCD79a(MINOR SUBSET), AND PARTIAL CD4	Negative	0	Negative	NA	NA	NA	FLT3-D835	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2419	aml_ohsu_2022_2419_BA2701	Waves1+2	Yes	2	NA	51	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	51	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Re-induction	Refractory	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	NA	46,XY[20]	NA	CD1a(-), CD2(-), surface CD3(-), cytoplasmic CD3(partial dim +), CD4(partial dim +), CD5(dim +), CD7(+), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16 (-), CD22(partial dim +), CD33(variably +), CD34(+), CD36(-), CD38(partial +), CD45(variably +), CD56(variably +), CD64(-), | CD117(variably +), HLA-DR(partial +), MPO(-), and TdT(+)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2047	aml_ohsu_2022_2047_BA2634	Waves1+2	Yes	3	NA	74	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with maturation	75	0	Residual Disease	Residual	Peripheral Blood	3	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Etoposide, Mitoxantrone	3	Hypomethylating/Low Dose Cytarabine|Salvage|Induction	Refractory	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	-1	M2	46,XY,add(1)(p34),del(7)(q22),del(20)(q11.2)[20]	normal, no evidence of RUNX1T1/RUNX1 transloc or 11q23 or 16q22	Increased CD34 positive myeloblasts, representing approximately 55% of the leukocytes	Positive	1.941176471	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	1.433333333	MATCHED
aml_ohsu_2022_2272	aml_ohsu_2022_2272_BA2996	Waves1+2	Yes	1	NA	64	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	64	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	M2	46,XY[21]	Loss of ERG1 signal (2%)	CD13, CD33, CD34, partial CD56, CD58, CD117, partial CD123, and HLA-DR positive	Negative	0	Negative	NA	NA	TP53 (C238R; MAF 5% (not confirmed by Sanger seq))	CSF3R (p. H599N; MAF 50%)|TP53 (C238R; MAF 5% (not confirmed by Sanger seq))	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2212	aml_ohsu_2022_2212_BA2937	Waves1+2	Yes	1	NA	61	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	61	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	5	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide	5	Allogeneic - Sibling|Salvage|Induction|Re-induction|Symptom Control	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	NA	42~44,XY,t(1;10)(q12;q21),-5,-7,-11,add(13)(p11.1),der(18)t(11;18)(q14;q21.1),add(20)(q12),+1~3mar[cp4]/41~44,sl,add(4)(q23)[cp9]/41~44,sl,del(4)(q21q?27)[cp5]/41~42,	Monosomy 5 (52%) | 5p deletion (39%) | Monosomy 7 (48%) | Abnormal 7q arm (48%)	CD13, CD33,CD34, CD38, dimCD56, CD58, CD117, and HLA-DR+	Negative	0	Negative	NA	NA	TP53 (p.R248Q; 96.4%)	NA	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2254	aml_ohsu_2022_2254_BA2600	Waves1+2	Yes	4	NA	64	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	64	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	Fludarabine, BCNU, Melphalan|Decitabine, Midostaurin	2	Allogeneic - Sibling|Induction	Complete Response	Fludarabine, BCNU, Melphalan	Allogeneic - Sibling	-1	M4	46,XX,t(2;3)(p13;q25~26)[2]/46,idem,i(14)(q10)[18]	NA	CD34, partial CD117, CD38, CD33, partial CD13,partial CD11C, CD4, partial CD14, partial CD64, partial CD2, and HLA-DR	Positive	1	Negative	RUNX1 (p.P430S; 60.0%)|RUNX1 (p.R166*; 41.2%)	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	1.433333333	MATCHED
aml_ohsu_2022_2365	aml_ohsu_2022_2365_BA2019	Waves1+2	Yes	3	NA	39	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	39	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	7	Nelarabine|POMP (Prednisone, Methotrexate, 6-MP, Vincristine)|3+7 (Cytarabine, Daunorubicin)|HyperCVAD|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	5	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance|Re-induction	Refractory	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	-1	NA	46,XY,t(10;11)(p13;q14)[11]/45,sl,-Y[7]/46,sdl1,t(1;8)(q12;p21)[2]	Normal	Increased atypical myeloblasts (partial CD34+, weak CD7+, partial CD61+), representing approximately 91% of the leukocytes, consistent with persistent acute myeloid leukemia.	Negative	0	Negative	NA	NA	TP53 (p.R282W; 72.5%)	NA	Acute Myeloid Leukemia	AML	0.366666667	UNMATCHED
aml_ohsu_2022_2260	aml_ohsu_2022_2260_BA2412	Waves1+2	Yes	1	NA	85	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	86	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	1	Decitabine	1	Supportive/Palliative Care	NA	Decitabine	Supportive/Palliative Care	169	M5	NA	NA	NA	Negative	0	Negative	NA	NA	TP53 (p.R248W; 72.2%)	NA	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2270	aml_ohsu_2022_2270_BA2334	Waves1+2	Yes	2	NA	30	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with t(6;9)(p23;q34); DEK-NUP214	31	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	6	7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib	3	Salvage|Induction|Experimental	Refractory	Crenolanib	Experimental	52	NA	47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]	NA	CD34(partial +), CD13(+), CD14(-), CD15(few +), CD30(-), CD33(+), CD38(variably +), CD45 (moderately +), CD64(variably +), CD4(partial +), CD117(+), CD123(variably +), HLA-DR(+), CD79a(-), CD22(-), intracellular CD3(-), TdT(-), MPO(partial +), other myeloid and lymphoid antigens(-).	Positive	2.125	Negative	NA	NA	NA	FLT3-D835|FLT3-ITD	Acute Myeloid Leukemia	AML	0.666666667	MATCHED
aml_ohsu_2022_2270	aml_ohsu_2022_2270_BA2050	Waves1+2	No	2	NA	30	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with t(6;9)(p23;q34); DEK-NUP214	31	3	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	6	7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib	3	Salvage|Induction|Experimental	Refractory	Crenolanib	Experimental	52	NA	47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]	NA	CD34(partial +), CD13(+), CD14(-), CD15(few +), CD30(-), CD33(+), CD38(variably +), CD45 (moderately +), CD64(variably +), CD4(partial +), CD117(+), CD123(variably +), HLA-DR(+), CD79a(-), CD22(-), intracellular CD3(-), TdT(-), MPO(partial +), other myeloid and lymphoid antigens(-).	Positive	3.761904762	NA	NA	NA	NA	FLT3-D835|FLT3-ITD	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2109	aml_ohsu_2022_2109_BA2894	Waves1+2	Yes	2	NA	51	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	Complete Response	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	2197	NA	46,XX[20]	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD4(partial dim +), CD5(-),CD7(-), CD11b(-), CD15(partial +/subset bright +), CD16(-), CD22(partial +), CD33(bright +), CD34(partial +), CD36(partial +), CD38(variably +), CD41(partial +), CD45(moderately +), CD56(-), CD61(partial +), CD64(-), CD71(+), CD117(+), HLA-DR(variably +), Gly-A(-).	Negative	0	Positive	NA	NA	NA	FLT3-ITD|NPM1	Acute Myeloid Leukemia	AML	0.6	MATCHED
aml_ohsu_2022_2777	aml_ohsu_2022_2777_BA3230	Waves3+4	Yes	1	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with maturation	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Decitabine	1	Induction	UNKNOWN	Decitabine	Induction	-1	M2	46,XX,del(12)(p12p13)[23]	Normal	dim CD5, CD13, dim CD33, CD34, variable CD38, CD58, CD117, dim CD123 and HLA-DR positive	Positive	0.694915254	Negative	NA	ASXL1 (p.E635Rfs*15; 22.0%)	NA	CREBBP (W1745*; MAF ~50%)|FLT3-ITD (MAF ~50%)|SF3B1 (p.K666M; MAF ~50%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2229	aml_ohsu_2022_2229_BA2779	Waves1+2	Yes	1	NA	53	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction	Refractory	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	45	M2	NA	Monosomy 7 (74%) | Extra copy of RUNX1 (39%)	CD13, partial CD33, CD34, partial CD56, partial CD64, CD117, partial CD123, HLA-DR and MPO-positive	Negative	0	Negative	NA	NA	NA	No gene mutations found in the 43 genes tested	Acute Myeloid Leukemia	AML	0.833333333	MATCHED
aml_ohsu_2022_2159	aml_ohsu_2022_2159_BA2481	Waves1+2	No	2	NA	NA	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Refractory anaemia with excess blasts	NA	4	Unknown	NA	Bone Marrow Aspirate	1	Decitabine	1	Induction	Unknown	Decitabine	Induction	60	NA	46,XY[20]	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	The findings reveal a slightly expanded population of myeloblasts with an essentially unremarkable immunophenotype. There is no definitive immunophenotypic evidence of a hematolymphoid malignancy.	Negative	NA	Negative	NA	NA	NA	NA	Myelodysplastic Syndromes	MDS	0.966666667	MATCHED
aml_ohsu_2022_2036	aml_ohsu_2022_2036_BA2731	Waves1+2	Yes	2	bi	63	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with mutated CEBPA	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	NA	46,XY,del(11)(q14q23)[13]/46,XY[7].ishdel(11)(5'MLL-,3'MLL+)[2].	nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(5'MLLx1,3'MLLx2)(5'MLL con 3'MLLx1)[118/200]	CD7(+), CD11b(-), CD13(dim +), CD14(-), CD15(partial +), CD16(-), CD33(variably +/subset bright +), CD34(+), CD36(-), CD38(+), CD45(+), CD56(partial +), CD64(partial +), CD117(+), HLA-DR(+), MPO(+), TdT(-).	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.9	MATCHED
aml_ohsu_2022_2405	aml_ohsu_2022_2405_BA2418	Waves1+2	Yes	2	NA	47	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	47	2	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	2	Crenolanib|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Salvage|Experimental	NA	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	4	NA	NA	NA	NA	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2359	aml_ohsu_2022_2359_BA2672	Waves1+2	Yes	3	NA	67	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute erythroid leukaemia	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|MiDAC	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	Complete Response	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	M6	46,XY[20]	normal	Atypical myeloblasts (partial CD7+) representing approximately 35% of the total leukocytes. 31% of the leukocytes are lymphocytes, 1% are monocytes, 33% are myeloid cells, and 35% are atypical cells with dim CD45. (Most of the atypical cells are CD34 positive myeloid blasts that express CD13, weak CD33, weak CD117, partial weak CD7 (about one fourth), HLA-DR, and weak myeloperoxidase and but   do not express CD14(MO2), CD42b, CD61, or CD64.  The myeloid cells demonstrate phenotypically   normal expression patterns for the markers evaluated, including CD10, CD13, CD16, CD33, and CD64)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	MATCHED
aml_ohsu_2022_2499	aml_ohsu_2022_2499_BA2294	Waves1+2	Yes	4	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	1	Induction	Complete Response	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Induction	-1	NA	46,XY,t(8;21)(q22;q22)[14]	NA	CD34, PARTIAL CD38, CD33, CD13, CD64, PARTIAL CD11C, PARTIAL CD19, HLA-DR, PARTIAL CD15, CD117, AND MPO	Negative	0	Negative	NA	NA	NA	NRAS	Acute Myeloid Leukemia	AML	1.066666667	MATCHED
aml_ohsu_2022_2012	aml_ohsu_2022_2012_BA2616	Waves1+2	Yes	4	NA	48	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	48	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	5	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Lenalidomide|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction	Refractory	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)	Re-induction	-1	M1	45,XX,?add(2)(q35~37),inv(3)(q21q26),-7[4]/46,XX[1]	NA	CD38, CD7, CD13, partial CD33, partial CD11c, dim CD5, dim CD19, CD4, HLA-DR, partial CD15, and partial CD117	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.833333333	MATCHED
aml_ohsu_2022_2016	aml_ohsu_2022_2016_BA2816	Waves1+2	Yes	4	NA	21	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	21	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	SWOG S1203 (7+3 +/- Vorinostat)|Fludarabine, Cyclophosphamide, TBI	2	Allogeneic - Sibling|Induction	Complete Response	Fludarabine, Cyclophosphamide, TBI	Allogeneic - Sibling	-1	M1	45,XY,-7[6]/47,XY,+13[cp5]/46,XY[12]	NA	CD34, CD4, CD13, CD15, partial CD33, CD38, partial CD117, partial CD11c, HLA-DR, MPO and TdT	Negative	0	Negative	RUNX1 (p.R201*; 33.3%)	NA	NA	NRAS	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2539	aml_ohsu_2022_2539_BA2255	Waves1+2	No	3	NA	62	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	AML with t(9;11)(p22;q23); MLLT3-MLL	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, TBI	Allogeneic - Matched Unrelated Donor	-1	M5a	47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]	8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present (83.5% 11q23, 84.5% 8q22)	Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.833333333	MATCHED
aml_ohsu_2022_2539	aml_ohsu_2022_2539_BA2814	Waves1+2	Yes	3	NA	62	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	AML with t(9;11)(p22;q23); MLLT3-MLL	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	5	7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, TBI	Allogeneic - Matched Unrelated Donor	-1	M5a	47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]	8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present (83.5% 11q23, 84.5% 8q22)	Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.866666667	MATCHED
aml_ohsu_2022_2369	aml_ohsu_2022_2369_BA2631	Waves1+2	Yes	1	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	MiDAC	Consolidation	114	M2	46,XY[21]	Normal	CD7, CD13, CD33, partial CD34, CD38, CD58, CD117, CD123,HLA-DR, and MPO positive	Negative	0	Positive	NA	NA	NA	CEBPA (p. Q83fs*27 (c.245?246insTGTTCCA); MAF 50%)|FLT3 ( p.N841I; MAF 12%)|FLT3 (p.I836delI; MAF 25%)|NPM1 (p.W288fs*>9; MAF 40%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2075	aml_ohsu_2022_2075_BA2023	Waves1+2	Yes	1	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myelomonocytic leukaemia	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Refractory	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	M4	47,XY,+8[16]/46,XY[4]	Trisomy 8 (82%)	partial CD13, CD15,  CD33, CD56, CD38, CD58, CD64, dimCD123, HLA-DR and MPO positive	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 27.3%)	NA	NRAS (p.G12R, MAF 50%)	Acute Myeloid Leukemia	AML	0.466666667	MATCHED
aml_ohsu_2022_2330	aml_ohsu_2022_2330_BA2375	Waves1+2	Yes	1	NA	72	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine	NA	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	M0	46,XY,-7,+mar.ishder(7)del(7)(p11.2)del(7)(q11.2)(D7Z1+)[20]/45,XY,-7[2]/46,XY[3]	Two of twenty-five metaphase cells examined were monosomy 7, shown by  fluorescent in situ hybridization (FISH) in  a companion study  (GLC-13-06587) to be a true clone.  Twenty cells appeared to be missing a  chromosome 7 with an additional small marker.	CD13, dimCD19, partial CD33, partial CD34, CD38, CD58, dim cCD79a, CD117, and TdT positive.	Negative	0	Negative	RUNX1 (p.R166G; MAF 22%)	NA	NA	CBL (p.L370del; MAF 63%)|JAK2 (p.V617F; MAF 43%)|RUNX1 (p.R166G; MAF 22%)|U2AF1 (p.Q157R; MAF 40%)	Acute Myeloid Leukemia	AML	0.466666667	MATCHED
aml_ohsu_2022_2540	aml_ohsu_2022_2540_BA2485	Waves1+2	Yes	1	NA	56	FALSE	TRUE	FALSE	FALSE	FALSE	FavorableOrIntermediate	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Re-induction	Refractory	HiDAC	Consolidation	111	M1	46,XY[20]	Normal	CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive	Positive	NA	Positive	NA	NA	NA	FLT3-ITD (Internal tandem duplication; MAF: 40%)|IDH2 (p.R140Q; MAF: 50%)|NPM1 (p.W288fs*9; MAF: 40%)	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2540	aml_ohsu_2022_2540_BA2254	Waves1+2	Yes	1	NA	56	FALSE	TRUE	FALSE	FALSE	FALSE	FavorableOrIntermediate	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Re-induction	Refractory	HiDAC	Consolidation	111	M1	46,XY[20]	Normal	CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive	Positive	NA	Positive	NA	NA	NA	FLT3-ITD (Internal tandem duplication; MAF: 40%)|IDH2 (p.R140Q; MAF: 50%)|NPM1 (p.W288fs*9; MAF: 40%)	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2373	aml_ohsu_2022_2373_BA2455	Waves1+2	Yes	4	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Hydroxyurea	1	Supportive/Palliative Care	NA	Hydroxyurea	Supportive/Palliative Care	-1	M5	48,XYY,+8[21]	NA	CD38, CD56, CD13(dim), CD64, CD11c, CD4, CD56, HLA-DR, and CD15	Negative	0	Positive	NA	NA	NA	FLT3-D835|NPM1	Acute Myeloid Leukemia	AML	0.666666667	MATCHED
aml_ohsu_2022_2576	aml_ohsu_2022_2576_BA2636	Waves1+2	Yes	4	NA	74	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	Hydroxyurea|Decitabine|Temozolomide, Vorinostat|Azacitidine, MLN4924	4	Salvage|Induction|Re-induction|Symptom Control	Refractory	Decitabine	Salvage	-1	NA	46,XY	NA	NA	Negative	0	Negative	NA	ASXL1 (p.G645Vfs*58; 43.8%)	NA	NA	Acute Myeloid Leukemia	AML	0.3	MATCHED
aml_ohsu_2022_2492	aml_ohsu_2022_2492_BA2325	Both	No	1	NA	74	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Complete Response	3+7 (Cytarabine, Daunorubicin)	Induction	6	M4	46, XX,t(2;16)(p23;p13.3)(13)	NA	CD13, CD14, CD16, CD33, CD64 and HLA-DR	Negative	0	Positive	NA	NA	NA	NPM1 (p.W288fs*>9 (C-terminal frame-shift); MAF 44%)|PTPN11 (p.E76Q; MAF 40%)	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2399	aml_ohsu_2022_2399_BA2169	Waves1+2	Yes	2	NA	38	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	39	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Salvage|Unknown|Induction|Maintenance	NA	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Unknown	6	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.566666667	MATCHED
aml_ohsu_2022_2399	aml_ohsu_2022_2399_BA2246	Waves1+2	No	2	NA	38	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	39	89	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Salvage|Unknown|Induction|Maintenance	NA	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Unknown	6	NA	46,XY,t(3;3)(q21;q26.2),del(5)(q13q31)[cp12]/43~45,idem,-7[cp3]/46,XY[6]	nuc ishFGFR3,IGH)x2[200],(D5S721x2,D5S23x2,EGR1x1)[130/200],(D7Z1x1,D7S522x1)[50/200],(D8Z2,D20S108)x2[198],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],IGH,BCL2)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[198]	CD2(-),CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(slightly bright +),CD34(+), CD36(equivocal), CD38(partial dim +), CD45(+), CD56(variably +), CD64(-), CD117(+), HLA-DR(+/variable).	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.8	MATCHED
aml_ohsu_2022_2017	aml_ohsu_2022_2017_BA2156	Waves1+2	Yes	1	bi	55	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	AML with mutated CEBPA	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M2	46,XY[20]	Normal	CD7, CD13, CD33, CD34, CD38, CD64, CD123, HLA-DR, and MPO	Negative	0	Negative	NA	NA	NA	CEBPA (c.242?243insCTTGGTT (7bp out-of-frame insertion); MAF 50%)|CEBPA (c.912?913insTTG (3 bp in-frame insertion); MAF 50%)	Acute Myeloid Leukemia	AML	1.166666667	MATCHED
aml_ohsu_2022_2567	aml_ohsu_2022_2567_BA2511	Waves1+2	Yes	4	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	AG-221	1	Hypomethylating/Low Dose Cytarabine	NA	AG-221	Hypomethylating/Low Dose Cytarabine	-1	M4	46,XX,inv(3)?(q21q25)[21]	NA	CD34, CD117, CD38, CD56 (minor subset), partial CD13, partial CD33, CD11c, and HLA-DR	Negative	0	Negative	NA	NA	NA	IDH2	Acute Myeloid Leukemia	AML	0.3	MATCHED
aml_ohsu_2022_2297	aml_ohsu_2022_2297_BA2168	Waves1+2	Yes	2	NA	47	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	48	0	Post-Chemotherapy|Post-Transplant|Relapse	Relapse	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	Refractory	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	NA	46,XX	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD4(partial +), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(variably +), CD56(partial +), CD64(-), CD117(partial +), HLA-DR(partial dim +)	Positive	3.166666667	Negative	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2023	aml_ohsu_2022_2023_BA2834	Waves1+2	Yes	4	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	Refractory	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	M2	45,XY,inv(3)(q21q26),-7[20]	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	1.133333333	MATCHED
aml_ohsu_2022_2023	aml_ohsu_2022_2023_BA2505	Waves1+2	Yes	4	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	Refractory	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	M2	45,XY,inv(3)(q21q26),-7[20]	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2413	aml_ohsu_2022_2413_BA2860	Waves1+2	No	1	NA	68	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Myelodysplastic syndrome, unclassifiable	68	0	Unknown	NA	Peripheral Blood	1	Azacitidine	1	Induction	Unknown	Azacitidine	Induction	6	NA	45~48,XY,del(5)(q22q35),+8,del(13)(q12q14),- 20,der(21)t(20;21)(p11.2;p11.1),+der(22)t(?;22)(?;q11.2)[cp15]/46,XY[4]	NA	CD13, CD33, CD34, CD38, CD58, CD117, CD123 and HLA-DR positive	Negative	NA	Negative	NA	NA	NA	NA	Myelodysplastic Syndromes	MDS	1	MATCHED
aml_ohsu_2022_2273	aml_ohsu_2022_2273_BA2871	Waves1+2	Yes	3	NA	80	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	80	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Bevacizumab	1	Unknown	NA	Bevacizumab	Unknown	-1	NA	44-47,XX,del(5)(q13q33),der(14;18)(q10;q10),-20,-21,+1-4mar[cp15]	NA	NA	Negative	0	Negative	NA	NA	TP53 (p.R306*; 28.8%)|TP53 (p.X187_splice; 21.9%)	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2458	aml_ohsu_2022_2458_BA2655	Waves1+2	Yes	2	NA	58	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	59	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	8	E7070, Idarubicin, Cytarabine|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|BL-8040|IGN523	4	Salvage|Induction|Experimental|Re-induction	Refractory	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	NA	46,XY[20]	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x1[47/200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2 (-), CD4(+), CD7(+), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(bright +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+).	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.433333333	MATCHED
aml_ohsu_2022_2045	aml_ohsu_2022_2045_BA2628	Waves1+2	No	1	NA	51	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Refractory anaemia with excess blasts	51	0	NA	NA	Bone Marrow Aspirate	2	Fludarabine, Melphalan|Azacitidine	2	Maintenance|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M6	46,XY,del(20)(q12)[14]/46,XY[6]	20q deletion (38%)	NA	Negative	0	Negative	NA	NA	NA	U2AF1 (p.S34F, MAF 34)	Myelodysplastic Syndromes	MDS	0.4	MATCHED
aml_ohsu_2022_2006	aml_ohsu_2022_2006_BA2665	Waves1+2	No	2	NA	62	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Myelodysplastic syndrome, unclassifiable	62	0	Post-Chemotherapy|Residual Disease	NA	Bone Marrow Aspirate	3	Fludarabine, Melphalan|Lenalidomide|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Induction|Allogeneic - Mismatched Unrelated Donor	Refractory	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	NA	44~45,XX,add(4)(p16),der(5)t(5;12)(q13;q14),-7,-12,del(17)(p11.2p13),+1~3mar[cp14]/45,idem,dup(11)(q23q14)[1]/44,idem,add (1)(p36.3)[cp3]/46,XX[2]	nuc ish(D5S721x2,D5S23x2,EGR1x1)[149/200],(D7Z1,D7S522)x1[155/200],(D8Z2,D20S108)x2[200], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD4(variably +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(+), TdT(-), MPO(-)	Negative	NA	Negative	NA	NA	TP53 (p.E343*; 56.0%)	NA	Myelodysplastic Syndromes	MDS	0.766666667	MATCHED
aml_ohsu_2022_2345	aml_ohsu_2022_2345_BA2227	Waves1+2	Yes	1	NA	17	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML without maturation	17	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Clofarabine, Cyclophosphamide, Etoposide|HAM (Cytarabine, Mitoxantrone)	2	Induction|Re-induction	Refractory	Clofarabine, Cyclophosphamide, Etoposide	Re-induction	5	M1	46,XY[20]	Normal	CD13, partial CD33, CD34, CD38, moderate CD45, CD58, CD117, CD123, TdT, and partial MPO positive.	Negative	0	Negative	NA	NA	NA	MLL (PTD)|WT1 (MAF A382fs*6; 40%)|WT1 (MAF p.R462G; 40%)|WT1 (p.R462G ; MAF 40%)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2563	aml_ohsu_2022_2563_BA2812	Waves1+2	Yes	3	NA	46	FALSE	TRUE	FALSE	FALSE	FALSE	MissingKaryo	Mixed phenotype acute leukaemia, T/myeloid, NOS	46	14	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Leukemias of Ambiguous Lineage	ALAL	0.366666667	MATCHED
aml_ohsu_2022_2562	aml_ohsu_2022_2562_BA2125	Waves1+2	Yes	1	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Decitabine	3	Consolidation|Induction|Re-induction	Complete Response	Azacitidine, Lenalidomide	Re-induction	28	M2	42~45,XX,add(5)(q13),der(17)add(17)(p11.2)add(17)(q11.2),-18,-22[cp6]/43~44,sl,add(13)(q32),add(14)(q11.2),+mar[cp12]/43~44,sl,add(14)(q11.2),-21,	5q deletion (85%) | Loss of RARA on 17q21 (46%)	partial CD7, CD13, partial CD33, CD34, partial CD38, CD58, CD117, dim/partial CD123, partial TdT, HLA-DR positive.	Negative	0	Negative	NA	NA	TP53 (p.V173M; 77.4%)	SUZ12 (V186D)|TP53 (V173M; MAF 80%)	Acute Myeloid Leukemia	AML	0.666666667	MATCHED
aml_ohsu_2022_2314	aml_ohsu_2022_2314_BA2603	Waves1+2	Yes	1	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M4	46,XX[20]	Normal	CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive (Myeloid blast phenotype) | CD11b, variable CD13, CD14, CD33, dimCD56, CD64, HLA-DR-positive (Monocytic phenotype)	Negative	0	Positive	NA	NA	NA	CREBBP (p.V319I; MAF 50%)|DNMT3A (p.R882H; MAF 50%)|DNMT3A (p.T138I; MAF 50%)|NPM1 (p.W288fs*12; MAF 50%)|NRAS (p.Q61H; MAF 40%)	Acute Myeloid Leukemia	AML	0.533333333	MATCHED
aml_ohsu_2022_2300	aml_ohsu_2022_2300_BA2808	Waves1+2	Yes	4	NA	56	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Re-induction	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	NA	40~43,XY,add(1)(p36),-2,-4,-5,-8,-12,-14,-15,-16,-17,?add(17)(p13),der(19)?t(8;19)(q11.2;p13),-20,-22,+7mar[cp18]	NA	CD34, CD38 (dim), CD13, CD33 (dim),CD64 (partial), CD11c, CD4 (partial), CD15, CD117, HLA-DR, and MPO(partial).	Positive	0.388888889	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.633333333	MATCHED
aml_ohsu_2022_2574	aml_ohsu_2022_2574_BA2282	Waves1+2	No	3	NA	41	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	44	0	Post-Chemotherapy|Post-Transplant	Remission	Peripheral Blood	7	Busulfan, Fludarabine|Etoposide, TBI|PETHEMA Trial LPA05 (ATRA (Tretinoin), Idarubicin, Mitoxantrone, Cytarabine)|Idarubicin, Mitoxantrone|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate	5	Allogeneic - Sibling|Consolidation|Induction|Maintenance|Re-induction	Complete Response	Etoposide, TBI	Allogeneic - Sibling	-1	NA	46,XY[20]	48% PML/RARA translocation	CD117+, HLA-DR negative, partial CD34+ (Right inguinal biopsy)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2067	aml_ohsu_2022_2067_BA2482	Both	No	1	NA	10	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	10	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	3	Induction|Intensification|Re-induction	Refractory	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Intensification	29	M2	46,XX,inv(16)(p13q22)[17]/46,XX[3]	CBFB rearrangement and inverted 16 (85%)	CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, dim/partial HLA-DR, and MPO positive	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2227	aml_ohsu_2022_2227_BA2822	Waves1+2	Yes	1	NA	37	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	38	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Maintenance	Refractory	Azacitidine	Maintenance	-1	NA	48~54,XY,add(2)(p13),+5,add(5)(q13),del(5)(q13),+10,+11,+13,+13,del(13)(q32),+14,-15,-16,del(17)(p12),-20,+21,+21,+22,+mar[cp9]/49~52,sl,-del(17)(p12)[cp8]/51~54,sl	Extra chromosome 5 (98%) | 5q deletion (98%) | Monosomy 16 (93%) | Extra copies of chromosome 21 (63%) | Monosomy 17 (99%) | Extra chromosome 11 (99%)	CD10, CD13, CD33, CD34, CD56 and HLA-DR positive	Negative	0	Negative	NA	NA	TP53 (p.R273H; 90.9%)	NRAS (p.G13D, MAF 46%)|TP53 (p.R273H, MAF 96%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2581	aml_ohsu_2022_2581_BA3047	Waves1+2	Yes	1	NA	63	TRUE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with mutated NPM1	63	0	Relapse|Post-Transplant|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	4	Fludarabine, Melphalan|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Allogeneic - Sibling|Salvage|Induction|Supportive/Palliative Care	Refractory	Decitabine	Supportive/Palliative Care	-1	M4	49,XX,+X,+8,+10[13]/46,XY[7]	Trisomy 8 (24%)	dim CD13, CD33, CD34, CD117, CD123, and dim HLADR	Positive	0.538461538	Positive	NA	NA	NA	DNMT3A (p.R882H; MAF 30%)|FLT3-ITD (Weakly positive; MAF 1.3%)|JAK3 (p.V722I; MAF 50%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2554	aml_ohsu_2022_2554_BA2594	Waves1+2	Yes	1	NA	72	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	Azacitidine|Decitabine	3	Consolidation|Induction|Maintenance	Unknown	Azacitidine	Maintenance	36	M4	43~44,X,-Y,t(3;11)(p21.3;p11.2),del(5)(q11.1;q31.1),add(12)(p11.2),-21[cp17]/44~45,idem,-t(3;11),+9[cp4]	Previous FISH results were consistent with the deleted 5q and trisomy 9	CD13, CD33, CD34, partial CD56,variable CD117, dim CD123, and dim HLA-DR+	Negative	0	Negative	NA	NA	TP53 (p.H193R; 90.7%)	TP53 (p.H193R; MAF 92%)	Acute Myeloid Leukemia	AML	0.366666667	MATCHED
aml_ohsu_2022_2205	aml_ohsu_2022_2205_BA2747	Waves1+2	Yes	4	NA	85	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myelomonocytic leukaemia	85	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Decitabine, Midostaurin	1	Induction	Complete Response	Decitabine, Midostaurin	Induction	-1	M4	46,XY[14]	NA	NA	Negative	0	Negative	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	0.533333333	MATCHED
aml_ohsu_2022_2325	aml_ohsu_2022_2325_BA2864	Waves1+2	Yes	4	mono	77	FALSE	FALSE	TRUE	FALSE	FALSE	Intermediate	AML with myelodysplasia-related changes	78	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	Complete Response	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	M4	45,X,-Y,del(7)(p15)[4]/46,XY[16]	NA	CD34, CD117, CD2,PARTIAL CD4, CD13, CD33, CD38, PARTIAL CD64, PARTIAL CD11c, HLA-DR AND DIM MPO	Negative	0	Negative	NA	NA	NA	CEBPA (Double positive)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2231	aml_ohsu_2022_2231_BA2561	Waves1+2	Yes	3	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myelomonocytic leukaemia	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	2	Consolidation|Induction	Complete Response	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	-1	M4	46,XY,add(8)(p21),t(8;19)(p11.2;q13.3)[18]/46,XY[2]	Normal	Large population of atypical myelomonocytic cells (CD4+, bright CD64+, MPO positive, partial CD14), representing 85% of the total leukocytes	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2231	aml_ohsu_2022_2231_BA2977	Waves1+2	No	3	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myelomonocytic leukaemia	75	5	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	5	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	2	Consolidation|Induction	Complete Response	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	-1	M4	46,XY,add(8)(p21),t(8;19)(p11.2;q13.3)[18]/46,XY[2]	Normal	Large population of atypical myelomonocytic cells (CD4+, bright CD64+, MPO positive, partial CD14), representing 85% of the total leukocytes	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2231	aml_ohsu_2022_2231_BA2094	Waves1+2	No	3	NA	75	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myelomonocytic leukaemia	75	265	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	5	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	2	Consolidation|Induction	Complete Response	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	-1	M4	46,XY[20]	Normal	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2331	aml_ohsu_2022_2331_BA2332	Waves1+2	Yes	1	NA	62	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Azacitidine|Methotrexate|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Unknown|Induction	Refractory	Azacitidine	Hypomethylating/Low Dose Cytarabine	182	M0	46,XY[20]	Normal	partial CD7, CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and TdT-positive	Negative	0	Negative	RUNX1 (p.S100F; 12.8%)	NA	NA	RUNX1 (p.A142?E143insGA; MAF 14%)|RUNX1 (p.S100F; MAF 17%)	Acute Myeloid Leukemia	AML	0.833333333	MATCHED
aml_ohsu_2022_2162	aml_ohsu_2022_2162_BA2567	Waves1+2	Yes	3	NA	46	FALSE	TRUE	FALSE	FALSE	FALSE	MissingKaryo	Acute monoblastic and monocytic leukaemia	46	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	8	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Clofarabine|ODSH (2 O, 3-O Desulfated Heparin)	6	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Post-Transplant Relapse	Complete Response	Donor Lymphocyte Infusion	Post-Transplant Relapse	-1	M5	NA	Normal	Increased atypical CD56 positive, weak CD117 positive myelomonocytic cells representing approximately 23% of the leukocytes	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.033333333	MATCHED
aml_ohsu_2022_2561	aml_ohsu_2022_2561_BA2906	Waves1+2	Yes	1	NA	5	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	5	0	Initial Acute Leukemia Diagnosis|Post-Transplant|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	3	ADE (Cytarabine, Daunorubicin & Etoposide)|Cyclophosphamide, TBI|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Allogeneic - Sibling|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	M5	46,XY[25]	MLL rearrangement (76%)	CD4, CD11b, CD15, CD33, bright CD34, CD38, CD58, CD64,CD71, CD117, CD123, HLA-DR and dim/partial MPO positive	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2123	aml_ohsu_2022_2123_BA2956	Waves1+2	Yes	2	NA	56	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	7+3 (Cytarabine, Idarubicin)	Induction	3	NA	46,XY,del(5)(q15q35),inv(16)(p13.1q22)[20]	nuc ish(D5S721x2,D5S23x2,EGR1x1)[182/200],(D7Z1,D7S522)x2[199], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[192],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB sep 3'CBFBx1)[176/200]	CD2(-), CD4(partial dim +), CD7(partial dim +), CD11b(-), CD13(+), CD14(-), CD15(+), CD16(-), CD19(-), CD20(-), CD22(few dim +), CD25(-), CD33(+), CD34(+), CD36 (-), CD38(variably +), CD45(moderately +), CD56(-), CD64(few dim +), CD79a(-), CD117(+), CD123(+) (PB) | HLA-DR(variably +), MPO(+), TdT(+). (PB)	Negative	0	Negative	NA	NA	NA	NRAS (G12D; MAF 16%)|NRAS (G13D; MAF 13%)|NRAS (Q61H; MAF 5%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2204	aml_ohsu_2022_2204_BA2963	Waves1+2	No	1	NA	47	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	47	0	Residual Disease	NA	Peripheral Blood	2	Fludarabine, Melphalan|Fludarabine, Cytarabine	2	Allogeneic - Sibling|Induction	UNKNOWN	Fludarabine, Melphalan	Allogeneic - Sibling	-1	NA	47,XX,+8,del(11)(q23)[18]	Missing MLL signal (79.5%) | Trisomy 8 (70.5%)	CD13, CD33, CD34, CD38, CD58, CD117, CD123, and partial HLA-DR	Negative	NA	Negative	NA	NA	NA	ETV6 (p.V66I; MAF 50%)|TET2 (p.Q491fs*8 (4 bp insertion with frame-shift); MAF 40%)	Myelodysplastic/Myeloproliferative Neoplasms	MDS/MPN	0.766666667	MATCHED
aml_ohsu_2022_2569	aml_ohsu_2022_2569_BA2768	Waves1+2	Yes	1	NA	62	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	62	19	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	3	5+2 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	NA	46,XY,der(7)t(7;11)(q22;q13)[14]/46,XY[6]	Missing D7S486 signal (9.5%) | Three MLL signals (10%)	dim/partial CD7, CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR positive	Negative	0	Negative	NA	NA	NA	DNMT3A (p.G413V; MAF 32%)|DNMT3A (p.R309G; MAF 31%)|IDH1 (p.R132C; MAF 33%)|MLL (PTD)	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2029	aml_ohsu_2022_2029_BA2474	Waves1+2	Yes	1	NA	46	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	46	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC	3	Consolidation|Induction|Re-induction	Complete Response	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	4	M4	46,XX[20]	Normal	dim CD11b, CD13, CD33, partial CD34, dim CD45, dim CD64, CD117, CD123, and dim HLA-DR+	Negative	0	Positive	NA	NA	NA	DNMT3A (p.R882C; MAF 46%)|NPM1 (p.W288fs*12; MAF 43%)|PTPN11 (p.E76Q; MAF 40%)	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2029	aml_ohsu_2022_2029_BA2065	Waves1+2	No	1	NA	46	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	47	424	Relapse	Relapse	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC	3	Consolidation|Induction|Re-induction	Complete Response	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	4	M4	46,XX[20]	Normal	CD13, CD33, partial CD34, partial CD38, dim partial  CD64, CD117 and CD123 positive	Negative	0	Positive	NA	NA	NA	DNMT3A (p.R882C; MAF 39%)|NPM1 (p.W288fs*>9 ; MAF 39%)|PTPN11 (p.E76Q; MAF 41%)	Acute Myeloid Leukemia	AML	0.9	MATCHED
aml_ohsu_2022_2241	aml_ohsu_2022_2241_BA2737	Waves1+2	Yes	2	NA	57	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	57	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea	4	Consolidation|Induction|Re-induction|Supportive/Palliative Care	Refractory	Decitabine, Hydroxyurea	Supportive/Palliative Care	-1	NA	46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD4(+), CD5(equivocal), CD7(-), CD11b(+), CD13(-), CD14(partial +), CD15(+), CD16(-), CD33 (bright +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56(+), CD64(+), CD117(partial +), HLA-DR(+)	Negative	0	Negative	RUNX1 (Y414*; MAF 16%)	NA	NA	CREBBP (MYST3-CREBBP fusion; MAF unlisted)|RUNX1 (Y414*; MAF 16%)	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2241	aml_ohsu_2022_2241_BA2463	Waves1+2	No	2	NA	57	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	58	111	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea	4	Consolidation|Induction|Re-induction|Supportive/Palliative Care	Refractory	Decitabine, Hydroxyurea	Supportive/Palliative Care	-1	NA	46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD4(+), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +),CD15(variably +), CD16(-), CD33(variably +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56 (variable +), CD64(partial +), CD117(-), HLA-DR(+).	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2512	aml_ohsu_2022_2512_BA2998	Waves1+2	No	2	NA	63	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Refractory anaemia with excess blasts	63	0	Residual Disease|Post-Chemotherapy	NA	Bone Marrow Aspirate	4	Azacitidine|Decitabine|Rigosertib|Clofarabine, Cytarabine	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental	Refractory	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	NA	46,XY[20]	nuc ish(FGFR3,IGH)x2[200],(D5S721,D5S23,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(IGH,BCL2)x2[198],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(few +), CD16(-), CD33(+), CD34(bright +), CD33(-), CD38(dim and variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(+) (6.2% population)	Negative	0	Negative	NA	NA	NA	TYK2 (V15A; MAF 49.0%)	Myelodysplastic Syndromes	MDS	0.066666667	MATCHED
aml_ohsu_2022_2020	aml_ohsu_2022_2020_BA2006	Waves1+2	Yes	2	NA	78	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	78	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	45,XX,+i(5)(p10),psudic(12;5)(p13;q11.2),-16,del(17)(p11.2p13)[5]/44,idem,-i(5)[3]/46,XX[12]	nuc ish(D5S721x2,D5S23x2,EGR1x1)[57/200]/(D5S721x4,D5S23x4,EGR1x1)[29/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[83/200]	NA	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 32.6%)	TP53 (p.X307_splice; 76.3%)	NA	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2027	aml_ohsu_2022_2027_BA2936	Waves1+2	Yes	4	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)	2	Induction|Re-induction	Refractory	5+2 (Cytarabine, Idarubicin)	Re-induction	-1	NA	50,XY,+8,+9,+13,+22[17]/46,XY[3]	NA	CD34, CD38, PARTIAL CD56, CD13, PARTIAL CD64, HLA-DR, CD117, PARTIAL MPO, PARTIAL CD79A, AND DIM PARTIAL TDT	Negative	0	Negative	NA	NA	NA	IDH1	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2305	aml_ohsu_2022_2305_BA2110	Waves1+2	Yes	1	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	FavorableOrIntermediate	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Fludarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC	4	Consolidation|Salvage|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine	Consolidation	4	M4	46,XX[20]	Normal	CD11b, partial CD13, partial CD14, dim CD15, partial      CD16, CD33, CD38, CD58, CD64, partial CD123 and HLA-DR positive	Positive	NA	Positive	NA	NA	NA	DNMT3A ( p.R882H; MAF 50%)|FLT3-ITD (MAF 10%)|FLT3-N676K (MAF 12%)|NPM1 (p.W288fs*12; MAF 50%)|PTPN11 (p.F71L; MAF 14%)	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2560	aml_ohsu_2022_2560_BA2438	Waves1+2	Yes	2	NA	74	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	74	0	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care	NA	Decitabine	Supportive/Palliative Care	-1	NA	46,XY,idic(7)(q11.2)[1]/47,idem,+8[9]46,XY[10]	nuc ish(RUNX1T1x3,RUNX1x2)[133/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33 (partial +), CD34(+), CD36(-), CD38(partial +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +), MPO (partial +), TdT(-)	Negative	0	Negative	RUNX1 (p.F330Sfs*271; 17.4%)	NA	NA	BCOR (V1445fs*8; MAF 65%)|ETV6 (A215fs*2; MAF 35%)|RUNX1 (F330fs*154+; MAF 35%)|U2AF1 (S34F; MAF 34%)	Acute Myeloid Leukemia	AML	1.133333333	MATCHED
aml_ohsu_2022_2459	aml_ohsu_2022_2459_BA2071	Waves1+2	No	2	NA	40	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Myelodysplastic syndrome, unclassifiable	39	0	NA	NA	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Clofarabine, Cytarabine	4	Hypomethylating/Low Dose Cytarabine|Salvage|Consolidation|Induction	NA	HiDAC	Consolidation	5	NA	46,XX[20]	nuc ish(D4Z1,D10Z1)x2[200],(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	NA	Positive	0.333333333	Negative	NA	NA	NA	NA	Myelodysplastic Syndromes	MDS	0.766666667	MATCHED
aml_ohsu_2022_2317	aml_ohsu_2022_2317_BA2199	Waves1+2	Yes	4	bi	34	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated CEBPA	34	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	105	NA	46,XX[20]	NA	CD34, CD117,partial CD13, CD33, CD38, partial CD64, dim CD7, variable CD15, HLA-DR and bright MPO	Negative	0	Negative	NA	NA	NA	CEBPA (Double positive: p.Ser17Profs*99 and p.Lys313dup)|KRAS	Acute Myeloid Leukemia	AML	0.6	MATCHED
aml_ohsu_2022_2317	aml_ohsu_2022_2317_BA2915	Waves1+2	No	4	bi	34	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated CEBPA	34	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	105	NA	46,XX[20]	NA	CD34, CD117,partial CD13, CD33, CD38, partial CD64, dim CD7, variable CD15, HLA-DR and bright MPO	Negative	0	Negative	NA	NA	NA	CEBPA (Double positive: p.Ser17Profs*99 and p.Lys313dup)|KRAS	Acute Myeloid Leukemia	AML	0.566666667	MATCHED
aml_ohsu_2022_2348	aml_ohsu_2022_2348_BA2992	Waves1+2	Yes	4	NA	52	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	52	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	Complete Response	SWOG S1203 (7+3 +/- Vorinostat)	Induction	8	NA	46,XX,inv(16)(p13.1q22)[cp20]	NA	CD34, PARTIAL CD117, CD15, CD38, PARTIAL CD13, CD33, CD64, PARTIAL CD14(SUBSET), PARTIAL CD11c, DIM CD4, HLA-DR AND BRIGHT MPO	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2394	aml_ohsu_2022_2394_BA2220	Waves1+2	Yes	1	NA	23	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	23	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	2	Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin)	3	Consolidation|Induction|Experimental	Complete Response	Trametinib	Experimental	197	M6b	48,XY,add(6)(p22),der(7)t(7;19)(p11.1;p12),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp20]	Low-level tetraploidy or near-tetraploidy (5%)	NA	Negative	0	Negative	NA	NA	TP53 (p.G245S; 83.1%)	NRAS (p.G12C; MAF 86%)|TP53 (p.G245S; MAF 87%)	Acute Myeloid Leukemia	AML	0.566666667	MATCHED
aml_ohsu_2022_2394	aml_ohsu_2022_2394_BA2720	Waves1+2	No	1	NA	23	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	24	163	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	2	Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin)	3	Consolidation|Induction|Experimental	Complete Response	Trametinib	Experimental	197	M6b	48,XY,add(6)(p22),der(7)t(7;19)(p11.2;p12),del(9)(p13p22),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp2]/46~48,sl,add(17)(p1?3),add(22)(q13)[cp9]/46~48,sl,add(21)(p11.2)[cp6]/47~48,sl,add(1)(p36.1)[cp2]/48,sl,t(2;17)(p21;p11.2)[1]	Low-level tetraploidy or near-tetraploidy	A CD34 positive blasts population comprises approximately 4% of cellular gated events. Approximately 3% of cells are lymphocytes composed of 28% B cells, 45% T cells and 27% NK cells. | T cells are present in a CD4:CD8 ratio of about 1.1:1 and do not demonstrate aberrant antigen expression. A monoclonal B cell population is not identified.	Negative	0	Negative	NA	NA	TP53 (p.G245S; 89.1%)	NRAS (p.G12C; MAF 97%)|TP53 (p.G245S; MAF 96%)	Acute Myeloid Leukemia	AML	4.233333333	MATCHED
aml_ohsu_2022_2165	aml_ohsu_2022_2165_BA2063	Waves1+2	Yes	2	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	MissingKaryo	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|BL-8040	4	Consolidation|Salvage|Induction|Experimental	Complete Response	Cytarabine	Salvage	-1	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	MATCHED
aml_ohsu_2022_2165	aml_ohsu_2022_2165_BA3330	Waves3+4	No	2	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	72	201	Post-Chemotherapy	Remission	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|BL-8040	4	Consolidation|Salvage|Induction|Experimental	Complete Response	Cytarabine	Salvage	-1	NA	45,X,-Y[3]/46,XY[17]	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[197], (RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2 (5'CBFB con 3'CBFBx2)[200]	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	MATCHED
aml_ohsu_2022_2243	aml_ohsu_2022_2243_BA2759	Waves1+2	Yes	3	NA	73	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	73	1	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine	NA	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	NA	43,XX,-5,add(7)(q22),t(10;13)(p13;q22),-12,-17[12]/46,XX[8]	deletion 5q31 involving the EGR1 locus in 96/200 (48.0  percent) cells scored,  deletion 7q31 involving the D7S486 locus in 85/200 (42.5  percent) cells scored.	Large population of CD34 positive myeloblasts, representing approximately 50% of the leukocytes, consistent with acute myeloid leukemia	Negative	0	Negative	NA	NA	TP53 (p.R273H; 46.8%)	NA	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2474	aml_ohsu_2022_2474_BA2982	Waves1+2	Yes	3	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	5	MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |7+3 (Cytarabine, Idarubicin) plus Sorafenib|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	4	Consolidation|Induction|Experimental|Allogeneic - Matched Unrelated Donor	Complete Response	SGN-CD33A	Experimental	-1	NA	46,XX,inv(3)(q21;q26.2)[20]	3q21.3q26.2 (RPN1/MECOM): rearrangement present (86%)	Most of the atypical cells (percentages shown) are myeloid blasts that express dim CD7, dim CD13, CD33, CD34, CD117, weak myeloperoxidase, and HLA-DR, but do not express cytoplasmic CD3, TDT,   CD14(MO2), CD42b, CD61, or CD64. (Increased atypical CD34 positive, CD7 positive myeloblasts, representing approximately 45% of the leukocytes, most consistent with acute myeloid leukemia.)	Negative	0	Negative	RUNX1 (p.S100Lfs*39; 35.6%)	NA	NA	NA	Acute Myeloid Leukemia	AML	1.333333333	MATCHED
aml_ohsu_2022_2397	aml_ohsu_2022_2397_BA2772	Waves1+2	Yes	2	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	5	NA	46,XY[20]	nuc ish(D4Z1,D10Z1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200]	CD2(-),CD4(partial dim +), CD7(-), CD11b(few +), CD13(+), CD14(-), CD15(partialCD22(-), CD25(appears partial dim +), CD33(bright +), CD34(few +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(partial +), CD79a(-), CD117(+), CD123(partial +), HLA-DR(partial +), MPO(+), TdT(-).	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.766666667	MATCHED
aml_ohsu_2022_2252	aml_ohsu_2022_2252_BA2960	Waves1+2	Yes	4	NA	79	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with maturation	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	Hydroxyurea|Azacitidine, MLN4924	2	Induction|Supportive/Palliative Care	Refractory	Azacitidine, MLN4924	Induction	63	M2	46,XX,add(5)(q31),del(17)(p11.2)[12]/46,XX[3]	NA	NA	Negative	0	Negative	NA	NA	TP53 (p.R337C; 58.9%)|TP53 (p.R175H; 47.3%)	TP53	Acute Myeloid Leukemia	AML	1.066666667	MATCHED
aml_ohsu_2022_2130	aml_ohsu_2022_2130_BA2935	Waves1+2	Yes	4	NA	78	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute monoblastic and monocytic leukaemia	78	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Azacitidine|Sorafenib|Decitabine, Midostaurin	3	Induction|Experimental|Re-induction	Refractory	Sorafenib	Experimental	8	M5	46,XY[25]	NA	NA	Positive	0.886792453	Negative	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	0.133333333	MATCHED
aml_ohsu_2022_2447	aml_ohsu_2022_2447_BA2260	Waves1+2	Yes	3	NA	58	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	58	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin)	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	210	M4	48,XY,+8,inv(16)(p13.1q22),+22[18]/49,sl,+21[2]	8q22 (RUNX1T1): gain present  16q22 (CBFB): rearrangement present  21q22 (RUNX1): gain or rearrangement present (96%, 71.5%, 11% respectively)	Relative increase of CD34 positive myeloblasts representing approximately 20% of the leukocytes and increased promonocytes/monoblasts consistent with acute myeloid leukemia with   myelomonocytic differentiation	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	1.066666667	MATCHED
aml_ohsu_2022_2447	aml_ohsu_2022_2447_BA2787	Waves1+2	No	3	NA	58	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	58	100	Post-Chemotherapy	Remission	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin)	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	210	M4	46,XY[20]	Normal	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2042	aml_ohsu_2022_2042_BA2073	Waves1+2	Yes	4	NA	72	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	72	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	Refractory	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	NA	47,XY,+8[17]/46,XY[3]	NA	CD38, CD13, HLA-DR, CD33 (DIM PARTIAL), CD4 (DIM), MPO (DIM PARTIAL), AND TDT	Negative	0	Negative	RUNX1 (p.R201*; 79.4%)	ASXL1 (p.E635Rfs*15; 14.0%)	NA	IDH1	Acute Myeloid Leukemia	AML	1.066666667	MATCHED
aml_ohsu_2022_2008	aml_ohsu_2022_2008_BA2676	Waves1+2	No	1	NA	48	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Refractory anaemia with excess blasts	48	0	Unknown	NA	Bone Marrow Aspirate	2	Decitabine|Busulfan, Cyclophosphamide	2	Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	NA	47,XY,+8[18]/46,XY[2]	Trisomy 8 (84%)	CD13, CD33, CD34, CD38, CD58, CD117, CD123, MPO+	Negative	NA	Negative	NA	NA	NA	DNMT3A (p.R882C; MAF 45%)|IDH1 (p.R132C; MAF 44%)|TET2 (p.P455R; MAF 45%)	Myelodysplastic Syndromes	MDS	1.133333333	MATCHED
aml_ohsu_2022_2279	aml_ohsu_2022_2279_BA2948	Waves1+2	Yes	3	NA	67	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	67	0	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Azacitidine|Decitabine|Clofarabine	2	Hypomethylating/Low Dose Cytarabine|Induction	UNKNOWN	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	NA	42,X,add(Y)(p11.1),add(3)(q12),add(4)(q25),del(5)(q12q33),-7,add(8)(p11.2),-11,add(13)(p11.2),del(16)(q22),-17,add(19)(q12.3),-20,add(21)(p11.2),-22,+mar[20]	43% del 5q31, 56% del 7q31, 58% del20q	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2102	aml_ohsu_2022_2102_BA2498	Waves1+2	Yes	2	NA	78	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	79	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	3	AG-221|Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Experimental	NA	AG-221	Experimental	-1	NA	46,XX[20]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2 (-), CD4(partial dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD33(variable to bright +), CD34(+), CD36(-), CD38(bright +), CD45(moderately +), CD56(-), CD64(-), CD117(bright +), HLA-DR(variable +), MPO(partial+) and TdT(-).	Negative	0	Negative	NA	ASXL1 (p.L823*; 38.0%)	NA	ASXL1 (L823fs*1; MAF 47%)|DNMT3A (F609fs*3; MAF 42%)|DNMT3A (F909V; MAF 46%)|IDH2 (R172K; MAF 45%)|ROS1 (R560C; MAF 45%)	Acute Myeloid Leukemia	AML	0.966666667	MATCHED
aml_ohsu_2022_2082	aml_ohsu_2022_2082_BA2161	Waves1+2	Yes	1	NA	54	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	54	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	3+7 (Cytarabine, Daunorubicin)|Azacitidine	2	Salvage|Induction	Refractory	Azacitidine	Salvage	196	M4	46,XY,add(5)(q23),der(11)t(11;20)(p11.2;p11.2),der(17)t(5;17)(q31;p12),-20,del(21)(q21)+mar[cp21]	21q deletion (35.5%) | Three MLL signals (32%)	CD13, CD33, CD34, CD117, MPO and HLA-DR	Negative	0	Negative	NA	NA	TP53 (p.T312Nfs*25; 28.0%)	TP53 (p.T312fs*25 (one nucleotide insertion); MAF 30%)	Acute Myeloid Leukemia	AML	0.566666667	MATCHED
aml_ohsu_2022_2684	aml_ohsu_2022_2684_BA3296	Waves3+4	Yes	1	NA	18	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Myeloid sarcoma	18	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy|Post-Transplant	Initial Diagnosis	Bone Marrow Aspirate	3	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|Radiation	2	Re-induction|Allogeneic - Matched Unrelated Donor	NA	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Matched Unrelated Donor	-1	NA	46,XY[20]	MLL (11q23):   88% of cells had a 0r1g1f split signal pattern consistent with rearrangement|9p21: 76% of cells were missing both signals for 9p21, consistent with homozygous deletion of 9p21|ETV6 (12p13): 68% of cells had an extra signal for ETV6 (Solid Tissue/Skin)	CD43, CD68, CD163 (weak) and lysozyme positive (Solid Tissue/Skin)	Negative	0	Negative	NA	NA	NA	EP300 (p.P318A (possible germline polymorphism); MAF 41%)|FAM5C (p.R353C (possible germline polymorphism); MAF 44%)|NOTCH2 (p.E366V; MAF 65%)|PHF6 (p.T12fs*23 (5 bp insertion with frame-shift); MAF 40%)|PTPN11 (p.D61V (confirmed somatic); MAF 39%) (Solid Tissue/Skin)	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2134	aml_ohsu_2022_2134_BA2524	Waves1+2	Yes	4	NA	51	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Stanford Protocol 9022 (BU/CY)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Stanford Protocol 9022 (BU/CY)	Allogeneic - Matched Unrelated Donor	-1	M4eo	46,XX,inv(16)(p13q22)[20]	NA	CD34+ EXPRESSING CD38, CD13, CD33, PARTIAL DIM CD2, PARTIAL CD64; DIM PARTIAL CD11C, PARTIAL DIM CD4, COEXPRESSION OF CD117 AND CD15, HLA-DR, MPO, AND PARTIAL DIM TDT	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.7	MATCHED
aml_ohsu_2022_2448	aml_ohsu_2022_2448_BA2811	Waves1+2	Yes	1	NA	47	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	2	Consolidation|Induction	Complete Response	ATRA, Arsenic Trioxide	Consolidation	31	M3	46,XX,t(15;17)(q24;q21)[4]/45,idem,-22[15]/46,XX[1]	NA	CD2, CD13, CD33, CD34, CD56, CD58, CD64, CD117, CD123, dim/partial HLA-DR, dim/partial TdT and MPO positive	Positive	NA	Negative	NA	NA	NA	FLT3-ITD (MAF 40%)	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2176	aml_ohsu_2022_2176_BA2540	Waves1+2	Yes	4	NA	69	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with t(9;11)(p22;q23); MLLT3-MLL	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Hydroxyurea	1	Induction	Unknown	Hydroxyurea	Induction	NA	M5a	46,XX[1]	NA	CD38, CD56, slightly dim CD4, CD33, dim CD13, CD64, CD11c, CD15 and partial CD117	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.566666667	MATCHED
aml_ohsu_2022_2423	aml_ohsu_2022_2423_BA2358	Waves1+2	Yes	1	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with maturation	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	M2	47,XX,+8[20]	Trisomy 8 (70%)	CD13, partial dim CD33, CD34, CD38, dim CD58, CD117, CD123, dim HLA-DR, and partial MPO.	Negative	0	Negative	RUNX1 (p.T437A; 24.0%)	NA	NA	ASXL1 (p.A636V; MAF 52%)|IDH2 (p.R140Q; MAF 27%)|MLL (PTD)|RUNX1 (p.T437A; MAF 13%)|SRSF2 (p.P95R; MAF 28%)	Acute Myeloid Leukemia	AML	1.633333333	MATCHED
aml_ohsu_2022_2490	aml_ohsu_2022_2490_BA2928	Both	No	1	NA	48	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with t(9;11)(p22;q23); MLLT3-MLL	48	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	Fludarabine, Melphalan|Idarubicin and Cytarabine	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M5	47,XX,+8,t(9;11)(p22;q23)[20]	MLL rearrangement (80%) | Trisomy 8 (78%)	CD4, partial CD11b, CD15, CD33, CD56, CD58, CD64, CD117, CD123, HLA-DR, and butyrate esterase positive	Negative	0	Negative	NA	NA	NA	FLT3-D835 (MAF 10%)|JAK1 (p.I878V; MAF 50%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2336	aml_ohsu_2022_2336_BA2302	Waves1+2	Yes	4	NA	78	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Therapy-related myeloid neoplasms	78	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	1	Azacitidine, MLN4924	1	Induction	Refractory	Azacitidine, MLN4924	Induction	111	NA	46,XX[20]	NA	CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR	Negative	0	Negative	NA	NA	NA	IDH1	Acute Myeloid Leukemia	AML	1.133333333	MATCHED
aml_ohsu_2022_2336	aml_ohsu_2022_2336_BA2343	Waves1+2	No	4	NA	78	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Therapy-related myeloid neoplasms	78	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	1	Azacitidine, MLN4924	1	Induction	Refractory	Azacitidine, MLN4924	Induction	111	NA	46,XX[20]	NA	CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR	Negative	0	Negative	NA	NA	NA	IDH1	Acute Myeloid Leukemia	AML	0.9	MATCHED
aml_ohsu_2022_2388	aml_ohsu_2022_2388_BA2147	Waves1+2	Yes	1	NA	69	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	70	0	Residual Disease	Residual	Bone Marrow Aspirate	3	3+7 (Cytarabine, Daunorubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|5+2 (Ara-C, Daunorubicin)	3	Salvage|Induction|Re-induction	Refractory	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Salvage	4	M4	46,XY,del(5)(q22q33),del(21)(q22q22)[cp20]	5q deletion (92%) | 21q deletion (91%)	CD13, CD15, CD34 (subset), CD38, CD58, CD64, CD117, CD123 and HLA-DR.	Negative	0	Negative	NA	NA	NA	BCOR (p.L1483* (premature protein truncation); MAF 90%)|MLL (PTD)|U2AF1 (p.S34F; MAF 40%)	Acute Myeloid Leukemia	AML	0.466666667	MATCHED
aml_ohsu_2022_2166	aml_ohsu_2022_2166_BA2792	Waves1+2	No	1	NA	51	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Refractory anaemia with excess blasts	51	0	Unknown	NA	Bone Marrow Aspirate	2	Fludarabine, Melphalan|Azacitidine, Lenalidomide	2	Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	NA	47,XY,+8[2]/46,XY[18]	Trisomy 8	CD34/CD117 positive myeloid blasts comprise about 4% of total CD45+ cells with possible partial TdT expression	Negative	NA	Negative	NA	NA	NA	WT1 (p.A382fs*4; MAF 44%)	Myelodysplastic Syndromes	MDS	0.966666667	MATCHED
aml_ohsu_2022_2160	aml_ohsu_2022_2160_BA2651	Waves1+2	Yes	4	NA	22	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with t(9;11)(p22;q23); MLLT3-MLL	22	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	ATRA (Tretinoin)|Cyclophosphamide, TBI|3+7 (Cytarabine, Daunorubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)	4	Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Cyclophosphamide, TBI	Allogeneic - Matched Unrelated Donor	-1	M1	46,XX,t(9;11)(p22;q23)[22]	NA	CD34, CD38 (dim partial), CD13, CD33 (dim partial), CD11c, CD4 (dim partial), HLA-DR, CD117 and MPO	Negative	0	Negative	NA	NA	NA	FLT3-D835	Acute Myeloid Leukemia	AML	0.133333333	MATCHED
aml_ohsu_2022_2148	aml_ohsu_2022_2148_BA2595	Waves1+2	Yes	4	NA	65	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	66	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	8	HiDAC|AG-221|Gilteritinib (ASP2215)|3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|MEC, Lenalidomide|Clofarabine, Cytarabine	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction	Complete Response	AG-221	Experimental	-1	NA	46,XY,t(4;15)(q31;q22),add(12)(p11~12)[cp7]/46~51,XY,del(7)(q11.2q36),add(12)(p11~12),add(20)(q11.2)[cp5]/46,XY,?inv(8)(p21q22)[cp7]/46,XY[cp2]	NA	CD38, CD33; WITH PARTIAL CD34, CD56, CD13, CD11C, CD2 AND CD15/CD117	Negative	0	Negative	NA	NA	NA	IDH2	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2184	aml_ohsu_2022_2184_BA2619	Waves1+2	Yes	1	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Salvage|Induction	Complete Response	HAM (Cytarabine, Mitoxantrone)	Salvage	7	M2	59~62,XX,+X,+1,+2,del(5)(q13q34),+6,+8,+8,+9,+11,+11,i(11)(q10),+12,+14,+16,+19,+22,+mar[cp19]/46,XX[1]	Trisomy 9 (88%) | Missing ERG1 signal (75%) | 2 small red/2 normal red pattern with the PML probe (79%) | Trisomy 11 and i(11q) (92%) | Tetrasomy 8 (87%) | Trisomy 16 (81%)	CD13, CD34, CD58 and CD117	Negative	0	Negative	NA	NA	TP53 (p.R280T; 41.1%)|TP53 (p.X33_splice; 37.9%)	GATA1 (p.N160S; MAF:40%)|NRAS (p.G12D; MAF 11%)|TP53 (Intron 4, 3' Splice site (C.97-1G>A); MAF 26%)|TP53 (p.R280T;  MAF 36%	Acute Myeloid Leukemia	AML	1.033333333	MATCHED
aml_ohsu_2022_2457	aml_ohsu_2022_2457_BA3013	Waves1+2	Yes	4	NA	47	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute monoblastic and monocytic leukaemia	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide	5	Consolidation|Induction|CNS|Re-induction|Supportive/Palliative Care	Complete Response	Hydroxyurea	Supportive/Palliative Care	9	M5	46,XY,t(11;19)(q23;p13.1)[20]	NA	CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19	Positive	0.075268817	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2457	aml_ohsu_2022_2457_BA2278	Waves1+2	Yes	4	NA	47	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute monoblastic and monocytic leukaemia	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	5	HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide	5	Consolidation|Induction|CNS|Re-induction|Supportive/Palliative Care	Complete Response	Hydroxyurea	Supportive/Palliative Care	9	M5	46,XY,t(11;19)(q23;p13.1)[20]	NA	CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19	Positive	4	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2416	aml_ohsu_2022_2416_BA2356	Waves1+2	Yes	1	NA	62	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	63	0	Residual Disease	Residual	Bone Marrow Aspirate	2	3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	Refractory	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	NA	46,XY[19]	NA	Partial CD7, CD13, CD33, CD34, CD38, partial CD56, CD58, CD117, CD123, HLA-DR, and partial TdT	Negative	0	Negative	RUNX1 (p.R162K; 35.1%)	NA	NA	BCOR (p.N119fs*40; MAF 65%)|RUNX1 (p.K117R; MAF 36%)|RUNX1 (p.R162K; MAF 31%)	Acute Myeloid Leukemia	AML	0.566666667	MATCHED
aml_ohsu_2022_2354	aml_ohsu_2022_2354_BA2018	Waves1+2	No	3	NA	44	FALSE	TRUE	FALSE	FALSE	FALSE	IntermediateOrAdverse	Acute myeloid leukaemia, NOS	44	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Ponatinib	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction	Unknown	Ponatinib	Experimental	-1	NA	46,XX[20]	Normal	Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia	Positive	NA	Negative	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	0.766666667	MATCHED
aml_ohsu_2022_2354	aml_ohsu_2022_2354_BA2405	Waves1+2	Yes	3	NA	44	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	44	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Ponatinib	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction	Unknown	Ponatinib	Experimental	-1	NA	46,XX[20]	Normal	Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia	Positive	0.449275362	Negative	RUNX1 (p.Q262*; 72.4%)	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	0.933333333	MATCHED
aml_ohsu_2022_2376	aml_ohsu_2022_2376_BA2856	Waves1+2	Yes	3	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin)	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	129	NA	46,XY[20]	Normal	Increased atypical CD117 positive myeloid blasts (weak CD7  positive, HLA-DR negative), representing 18% of the total  leukocytes, consistent with a myeloid neoplasm	Negative	0	Positive	NA	NA	NA	NPM1	Acute Myeloid Leukemia	AML	1.066666667	MATCHED
aml_ohsu_2022_2352	aml_ohsu_2022_2352_BA2557	Waves1+2	Yes	1	NA	62	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	2	Induction|Re-induction	Refractory	CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	Re-induction	4	M0/M1	NA	Tetrasomy 8 (67%)	partial CD7, CD13, CD33 (variable), CD34, CD38 (variable), CD117(variable)	Positive	0.923076923	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	1.033333333	MATCHED
aml_ohsu_2022_2233	aml_ohsu_2022_2233_BA2781	Waves1+2	Yes	1	NA	68	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Acute undifferentiated leukaemia	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	HyperCVAD Course B (Cytarabine, Methotrexate)|EWALL Protocol|Bu/Cy/TBI|HyperCVAD Course A (Cyclophosphamide, Dexamethasone, Doxorubicin, Vincristine)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Refractory	Bu/Cy/TBI	Allogeneic - Matched Unrelated Donor	-1	NA	46,XY[20]	c/w karyotype	partial CD7, partial CD10, dimCD13, CD34, partial CD117, dim TdT positive	Negative	0	Negative	RUNX1 (p.R107H; 21.1%)	NA	NA	GATA2 (p.L359V; MAF: 40%)|NRAS (p.A59D; MAF: 10%)|NRAS (p.G12S; MAF: 15%)|RUNX1 (p.R107H; MAF: 19%)	Acute Leukemias of Ambiguous Lineage	ALAL	1.233333333	MATCHED
aml_ohsu_2022_2406	aml_ohsu_2022_2406_BA2753	Waves1+2	Yes	1	NA	60	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	62	461	Post-Chemotherapy|Relapse	Relapse	Bone Marrow Aspirate	4	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M2	46,XX[20]	normal	CD7, CD13, CD33, CD34, CD38, and CD123 positive (Initial 7/8/2014 diagnosis: dim CD7, CD13, CD33, CD34, CD38, CD58, and CD117-positive)	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	1.266666667	MATCHED
aml_ohsu_2022_2113	aml_ohsu_2022_2113_BA2699	Waves1+2	Yes	7	NA	NA	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Blastic plasmacytoid dendritic cell neoplasm	NA	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	ASXL1 (p.R693*; 64.3%)	NA	NA	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2385	aml_ohsu_2022_2385_BA2377	Waves1+2	Yes	2	NA	35	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with t(9;11)(p22;q23); MLLT3-MLL	35	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide, Thymoglobulin	Allogeneic - Matched Unrelated Donor	-1	NA	46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1]	nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]	CD2(-), CD4(+), CD7(-), CD11b(+), CD13(partial +), CD14(-), CD15(+), CD16(-), CD33(+), CD34(-), CD36(partial +), CD45(+), CD56(variably +), CD64(+), CD117(partial +), CD79a(-), HLA-DR(+), MPO(-), Tdt(-)	Positive	2.448275862	Positive	NA	ASXL1 (p.D943Qfs*6; 38.5%)	NA	ASXL1 (D943fs*6; MAF 25%)|FLT3-D835 (BMA)|KMT2A (MLL-AF9 fusion)	Acute Myeloid Leukemia	AML	1.1	MATCHED
aml_ohsu_2022_2003	aml_ohsu_2022_2003_BA2499	Waves1+2	Yes	2	NA	71	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	71	0	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	Azacitidine	Hypomethylating/Low Dose Cytarabine	107	NA	NA	NA	NA	Negative	0	Negative	RUNX1 (p.R320*; 46.2%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.966666667	MATCHED
aml_ohsu_2022_2118	aml_ohsu_2022_2118_BA2059	Waves1+2	Yes	4	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML without maturation	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	Complete Response	SWOG S1203 (7+3 +/- Vorinostat)	Induction	7	M1	46,XX[21]	NA	CD34+ BLAST POPULATION, 51%, EXPRESSING HLA-DR, CD38, CD7, DIM PARTIAL CD13, PARTIAL CD33, CD117, PARTIAL MPO, AND PARTIAL TDT	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.033333333	MATCHED
aml_ohsu_2022_2167	aml_ohsu_2022_2167_BA2016	Waves1+2	Yes	2	NA	62	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	63	0	Post-Chemotherapy|Relapse	Relapse	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance	Refractory	HiDAC	Maintenance	5	NA	46,XY[20]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD33(partial +), CD34 (variably +), CD36(-), CD38(variably +), CD45(moderate to dim+), CD56(-), CD64(partial +), CD117(+), and HLA-DR(partial +).	Negative	0	Negative	RUNX1 (p.S331Afs*263; 65.2%)	NA	NA	NA	Acute Myeloid Leukemia	AML	2.766666667	MATCHED
aml_ohsu_2022_2089	aml_ohsu_2022_2089_BA2330	Waves1+2	Yes	1	NA	69	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	70	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|Lenalidomide|Azacitidine	2	Unknown|Induction	Unknown	7+3 (Cytarabine, Idarubicin)	Induction	8	NA	47,XX,del(5)(q22q35),+8[20]	5q deletion (78%) | Trisomy 8 (80%)	CD13, partial CD33, CD34, CD38, dimCD45, CD58, partial CD64, CD117, HLA-DR, and MPO positive.	Negative	0	Negative	NA	ASXL1 (p.G645Vfs*58; 15.0%)	TP53 (p.I251M; 29.0%)|TP53 (p.R249M; 18.6%)	DNMT3A (p.R882H; MAF 37%)|EZH2 (p.K400del; MAF 48%)|IDH1 (p.R132C; MAF 37%)|TP53 (p.I251M; MAF 34%)|TP53 (p.R249M; MAF 37%)	Acute Myeloid Leukemia	AML	0.9	MATCHED
aml_ohsu_2022_2112	aml_ohsu_2022_2112_BA2350	Waves1+2	Yes	2	NA	17	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	17	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	Bu/Cy/ATG|ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC + Midostaurin|Etoposide, Cytarabine	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Unknown	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	-1	NA	46,XY,t(11;19)(q23;p13.1)[19]/46,XY[1]	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2149	aml_ohsu_2022_2149_BA3023	Waves1+2	Yes	4	NA	27	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	27	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	HiDAC|SWOG S1203 (7+3 +/- Vorinostat)	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	137	M2	48,XX,+3,+10[2]/46,XX[18]	NA	CD34, CD38, CD13, CD33, CD11C, CD19, PARTIAL CD4, HLA-DR, PARTIAL CD15, CD117, PARTIAL CD61, AND PARTIAL CD7	Negative	0	Positive	NA	NA	NA	NPM1	Acute Myeloid Leukemia	AML	1.433333333	MATCHED
aml_ohsu_2022_2149	aml_ohsu_2022_2149_BA2074	Waves1+2	No	4	NA	27	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	27	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	HiDAC|SWOG S1203 (7+3 +/- Vorinostat)	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	137	M2	48,XX,+3,+10[2]/46,XX[18]	NA	CD34, CD38, CD13, CD33, CD11C, CD19, PARTIAL CD4, HLA-DR, PARTIAL CD15, CD117, PARTIAL CD61, AND PARTIAL CD7	Negative	0	Positive	NA	NA	NA	NPM1	Acute Myeloid Leukemia	AML	1.7	MATCHED
aml_ohsu_2022_2054	aml_ohsu_2022_2054_BA2095	Waves1+2	Yes	1	NA	69	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	1	Induction	Complete Response	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	-1	M3	45,XX,dic(12;18)(p11.2;p11.2),t(15;17)(q22;q21)[19]/46,XX[1]	PML/RARA fusion (91%)	dim CD2, CD13, CD33, CD34 (variable), CD56, CD58, CD64, CD117, CD123 and cytoplasmic MPO positive; HLA-DR negative	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2452	aml_ohsu_2022_2452_BA3026	Waves1+2	Yes	2	NA	53	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	54	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	Complete Response	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	NA	46,XX,del(17)(p11.2p13)[19]/46,XX[1]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[197]	CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15 (partial +), CD16(-), CD33(variably +), CD34(+), CD36(-), CD38(partial +), CD45(dim to moderately +), CD56(-), CD64(-), CD117(partial +), HLA-DR(-), TdT(predominantly -), MPO(+).	Negative	0	Negative	NA	NA	TP53 (p.R248W; 87.0%)	NA	Acute Myeloid Leukemia	AML	0.8	MATCHED
aml_ohsu_2022_2199	aml_ohsu_2022_2199_BA2275	Waves1+2	Yes	1	NA	57	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Decitabine	1	Induction	Unknown	Decitabine	Induction	10	M2	44~48,XY,-5,del(7)(q22),+11,idic(11)(p11.2)x2,-12,der(13)t(1;13)(p13;p12),add(17)(q25),der(18)t(12;18)(q13;q11.2),-22,+2mar[cp14]/44~47,sl,-9,+16[cp3]/46~47,sl,der(1)t(1;3)(q21;q21),der(3)t(1;3)(q21;q21)ins(3)(3;?)(p21;?),-idic(11)(p11.2)[cp4]/46,XY[1]	EGR1/5p; 88% , consistent with monosomy 5  | D7S486; 96% , consistent with deletion 7q  | BCR; 84% of cells had three signals for BCR (22q11.2)| MLL; 28% of cells had three intact signals for MLL, while another 76% of cells had four intact signals.	CD13, CD33, CD34, CD71, CD117, dim CD123 and HLA-DR+	Negative	0	Negative	NA	NA	TP53 (p.R248Q; 95.8%)	TP53 (p.R248Q; MAF 80%)	Acute Myeloid Leukemia	AML	1	MATCHED
aml_ohsu_2022_2529	aml_ohsu_2022_2529_BA2901	Waves1+2	Yes	2	NA	68	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Induction|Re-induction|Maintenance	Complete Response	Azacitidine	Maintenance	-1	NA	46,XY	IGH-MYEOV and IGH-CCND1 rearrangement; MAF unlisted	CD2(-), CD4(equivocal), CD7(partial +), CD11b (equivocal), CD13(+), CD14(-), CD15(-), CD16(equivocal), CD33(-), CD34(bright +), CD36(-), CD38(dim +), CD45(+), CD56(equivocal), CD64(-), CD117(+), CD123(equivocal), HLA-DR(dim +), MPO(partial +), TdT(-) (Population 1 of 4 (0.02% of total events), consists of small myeloblasts) | CD2(-), CD4(equivocal), CD7(-), CD11b (-), CD13(partial +), CD14(-), CD15(partial +), CD16(-), CD25(-), CD33(variably +), CD34(-), CD36(-), CD38(moderately bright +), CD45(dim +), CD56(-), CD64(-), CD117(+), CD123(+), HLA-DR(partial +), MPO(partial +), TdT(-) (Population 2 of 4 (3.8% of total events), consists of immature myeloid cells) | CD13(partial +), CD14(partial +), CD36(variably +), CD45(variably +), CD56(partial +), HLA-DR(partial +), MPO(partial +) (Population 3 of 4 (61% of total events), consists of monocytes) | CD19(-), CD20(-), CD38(bright +), CD45(-), CD56(+), surface Ig(-), intracellular kappa(+), intracellular lambda(-) (Population 4 of 4 (0.34% of total events), consists of plasma cells)	Negative	0	Positive	NA	NA	NA	DNMT3A (R882C; MAF 50%)|NPM1 (W288fs*10+; MAF 34%)|NRAS (G13D; MAF 44%)	Acute Myeloid Leukemia	AML	0.5	MATCHED
aml_ohsu_2022_2529	aml_ohsu_2022_2529_BA2221	Waves1+2	No	2	NA	68	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	68	184	Post-Chemotherapy	Remission	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Induction|Re-induction|Maintenance	Complete Response	Azacitidine	Maintenance	-1	NA	46,XY	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD38(bright +), CD45(-), CD56(+), intracellular kappa(+), intracellular lambda(-)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	MATCHED
aml_ohsu_2022_2454	aml_ohsu_2022_2454_BA2387	Waves1+2	Yes	1	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Acute monoblastic and monocytic leukaemia	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Mismatched Unrelated Donor	-1	M5	46,XX,idic(7)(q11.2)[20]	NA	CD11b, CD13, CD33, partial CD34,      CD38, CD58, CD64, CD117, CD123, partial HLA-DR and cMPO positive	Negative	0	Negative	NA	NA	NA	BCOR (p.T870fs*46 (2 bp deletion); MAF 50%)|IDH1 (p.R132C; MAF 50%)|MLL (PTD)|PTPN11 (p.S502L; MAF 50% )	Acute Myeloid Leukemia	AML	0.5	MATCHED
aml_ohsu_2022_2104	aml_ohsu_2022_2104_BA2313	Waves1+2	Yes	1	NA	45	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	45	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance	Refractory	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	4	M2	47,XY,der(7)t(1;7)(q10;p10),+8[20]	NA	CD13, variable CD33, CD34, CD38, CD117, CD123, HLA-DR positive	Negative	0	Negative	RUNX1 (p.S308Qfs*292; 40.7%)	NA	NA	CBL (Intron 8, 3' splice site mutation (at invariant AG splice acceptor site); MAF 86%)|EZH2 (p.S538L; MAF 85% )|GATA2 (p.K389delinTFFM; MAF 46% )|RUNX1 (p.S308fs*174; MAF 46% )	Acute Myeloid Leukemia	AML	0.933333333	MATCHED
aml_ohsu_2022_2104	aml_ohsu_2022_2104_BA2517	Waves1+2	No	1	NA	45	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	46	112	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	5	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance	Refractory	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	4	M2	47,XY,der(7)t(1;7)(q10;p10)+8[20]	NA	CD34, CD13, HLA-DR, CD123, and CD58.  In addition there is a predominant (about      60%) and atypical monocytic population expressing: CD11b, CD13, CD14,      patial CD16, CD33dim, partial CD56, CD64bright, HLA-DR.	Negative	0	Negative	RUNX1 (p.S308Qfs*292; 52.1%)	NA	NA	CBL (Intron 8, 3' splice site mutation (at invariant AG splice acceptor site); MAF 94%)|EZH2 (p.S538L; MAF 89%)|GATA2 (p.K389delins; MAF 47%)|RUNX1 (p.S308fs*174; MAF 46%)	Acute Myeloid Leukemia	AML	1	MATCHED
aml_ohsu_2022_2104	aml_ohsu_2022_2104_BA2657	Waves1+2	No	1	NA	45	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	46	196	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	5	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance	Refractory	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	4	M2	47,XY,der(7)t(1;7)(q10;p10)+8[20]	NA	NA	Negative	0	Negative	RUNX1 (p.S308Qfs*292; 42.4%)	NA	NA	NA	Acute Myeloid Leukemia	AML	1.066666667	MATCHED
aml_ohsu_2022_2558	aml_ohsu_2022_2558_BA2962	Waves1+2	Yes	1	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	IntermediateOrAdverse	Acute monoblastic and monocytic leukaemia	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|Cytarabine|Fludarabine, TBI|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Refractory	Fludarabine, TBI	Allogeneic - Mismatched Unrelated Donor	-1	M5	46,XY[20]	Normal	dim partial CD11b, dim variable CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, CD123, HLA-DR, partial TdT, dim MPO positive	Positive	NA	Negative	NA	NA	NA	DNMT3A (intron 7 splice site (at invariant AG splice donor); MAF 50% )|DNMT3A (p.P777L; MAF 50%)|FLT3-ITD (MAF 40%)|IDH2 (p.R140Q; MAF 45%)|MLL (PTD; no MAF available)|WT1 (Intron 1 splice site (at invariant AG splice donor); MAF 90% )	Acute Myeloid Leukemia	AML	0.133333333	MATCHED
aml_ohsu_2022_2013	aml_ohsu_2022_2013_BA2195	Waves1+2	Yes	4	NA	68	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	Refractory	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	NA	42~45,XX,-18[cp14]/43~45,idem,+2~3mar[cp3]/47,XX,+8[cp2]/45,X,-X[1]	NA	CD34+ BLAST POPULATION, 33%, EXPRESSING PARTIAL CD38, PARTIAL CD4, PARTIAL CD11C, HLA-DR, CD117, PARTIAL CD13, PARTIAL CD33, PARTIAL CD15, AND MPO	Negative	0	Negative	RUNX1 (p.S322Nfs*277; 9.7%)	NA	TP53 (p.I195T; 22.2%)|TP53 (p.P151R; 54.8%)	CEBPA (Triple positive)|IDH2	Acute Myeloid Leukemia	AML	0.8	MATCHED
aml_ohsu_2022_2289	aml_ohsu_2022_2289_BA2688	Waves1+2	Yes	2	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute erythroid leukaemia	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin|Fludarabine, Cyclophosphamide, TBI	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Cyclophosphamide, TBI	Allogeneic - Matched Unrelated Donor	-1	M6	46,XX,del(9)(q22q34)[20].	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD34 (partial +), CD2(partial dim +), CD13(dim +), CD33(variably to bright +), CD25(-), CD38(+), CD45(moderately +), CD15 (partial +), CD117(+), CD123(dim +), HLA-DR(partial +), MPO(+), TdT(-), other myeloid and lymphoid antigens (-)	Negative	0	Negative	NA	NA	NA	DNMT3A (R882C; MAF 43%)|IDH2 (R140Q; MAF 3%)|WT1 (splice site 1099-6_1104delCTGCAGGATGTG; MAF 28%)	Acute Myeloid Leukemia	AML	0.366666667	MATCHED
aml_ohsu_2022_2106	aml_ohsu_2022_2106_BA2420	Waves1+2	Yes	1	NA	69	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with minimal differentiation	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Re-induction	Refractory	MiDAC	Consolidation	63	M0	47,XY,+8[2]/46,XY[18]	Consistent with karyotype	dim CD13, dimCD33, CD34, dim CD38, CD58, dimCD64, CD117, CD123, dim HLA-DR, TdT positive	Negative	0	Negative	RUNX1 (p.H242Afs*14; 24.5%)	NA	NA	MLL (PTD)|RUNX1 (p.H242fs*14; MAF 42% )|RUNX1 (p.N136K; MAF 30%)|U2AF1 (p.S34F; MAF 40%)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2510	aml_ohsu_2022_2510_BA2727	Waves1+2	Yes	1	NA	36	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	38	494	Residual Disease|Post-Chemotherapy|Post-DLI|Post-Transplant	Residual	Peripheral Blood	7	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, Cyclophosphamide	6	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Decitabine	Salvage	4	NA	46,XX,inv(3)(q21q26)[5]	FISH) was performed with a MECOM/RPN1 probe set. 125/200 (62.5%) interphase cells scored had a 1 red/ 1 green/ 2 yellow double fusion signal pattern reflecting MECOM/RPN1 fusion and the paracentric inversion of the long arm of a chromosome 3 observed in the metaphase karyotype.  FISH was also perfor	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2169	aml_ohsu_2022_2169_BA2756	Waves1+2	Yes	4	NA	69	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	69	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	4	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	3	Salvage|Induction|Re-induction	Refractory	MEC, Lenalidomide	Salvage	5	NA	46,XY[22]	NA	NA	Positive	NA	Negative	NA	NA	NA	FLT3-ITD|IDH1	Acute Myeloid Leukemia	AML	0.6	MATCHED
aml_ohsu_2022_2169	aml_ohsu_2022_2169_BA2086	Waves1+2	No	4	NA	69	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	69	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	4	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	3	Salvage|Induction|Re-induction	Refractory	MEC, Lenalidomide	Salvage	5	NA	46,XY[22]	NA	NA	Negative	0	Positive	NA	NA	NA	FLT3-ITD|IDH1	Acute Myeloid Leukemia	AML	0.833333333	MATCHED
aml_ohsu_2022_2026	aml_ohsu_2022_2026_BA2122	Waves1+2	No	4	NA	75	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with maturation	77	716	Post-Chemotherapy	Remission	Bone Marrow Aspirate	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	Azacitidine	Hypomethylating/Low Dose Cytarabine	1131	M2	46,XX[8]	NA	NA	Negative	0	Negative	RUNX1 (p.R162K; 95.1%)	ASXL1 (p.Q512*; 56.3%)|ASXL1 (p.G645Vfs*58; 9.1%)	NA	NA	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2370	aml_ohsu_2022_2370_BA2053	Waves1+2	Yes	2	NA	31	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	31	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	5	NA	46,XY,inv(16)(p13.1q22)[7]/46,idem,add(17)(p11.2)[13]	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[198],(CBFBx2)(5’CBFB sep 3’CBFBx1)[164/200]	CD2(partial +), CD4(partial +), CD5(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CDCD33(variably +), CD34(variably +), CD36(few +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(partial +),CD117(+), CD123(variably +), HLA-DR(partial +), MPO(+), TdT(few +).	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2135	aml_ohsu_2022_2135_BA2080	Waves1+2	Yes	2	mono	77	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	78	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|Cytarabine|Bortezomib|Decitabine|Fludarabine, Cytarabine	5	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental	Refractory	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	NA	46,XY[20]	NA	CD2(-), CD4(- to partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(few +), CD16(-), CD19(few +), CD33(variably +), CD34(variably +), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR (+), MPO(partial +), TdT(partial +).	Negative	0	Negative	NA	NA	NA	ATM (S1993fs*23; MAF 44%)|CEBPA (L81fs*72; MAF 92%)|MUTYH (G382D; MAF 49%)|STAG2 (R1205*; MAF 92%)|TET2 (C1273S; MAF 46%)|TET2 (M823fs*1; MAF 47%)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2200	aml_ohsu_2022_2200_BA2415	Waves1+2	No	3	NA	48	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	49	152	Post-Chemotherapy	Remission	Bone Marrow Aspirate	6	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|FLAG-IDA, Gemtuzumab|Cytarabine, Methotrexate	5	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|CNS|Re-induction	Complete Response	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Mismatched Unrelated Donor	-1	M4	46,XY[20]	Normal	Relative increase of phenotypically normal, slightly left shifted myeloid cells without flow cytometric evidence of monoclonality, acute leukemia, plasma cell dyscrasia, or   lymphoproliferative disorder.	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2358	aml_ohsu_2022_2358_BA2081	Waves1+2	Yes	1	NA	64	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myelomonocytic leukaemia	64	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	6	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |R-CHOP (Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine)	4	Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)	Induction	3	M4	46,XX,del(17)(q25)[3]/46,sl,del(3)(q12q21)[cp17]	NA	dim CD4, partial variable CD7, CD13, CD33, partial CD34, CD38, partial CD58, CD117, CD123, HLA-DR, TDT and partial MPO positive.	Negative	0	Negative	RUNX1 (p.R162K; 82.0%)	NA	NA	KRAS (p.G12V; MAF 30%)|NRAS (p.G12D; MAF 7%)|RUNX1 (p.R162K; MAF 85% )	Acute Myeloid Leukemia	AML	0.8	MATCHED
aml_ohsu_2022_2050	aml_ohsu_2022_2050_BA2354	Waves1+2	Yes	1	NA	37	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	37	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Busulfan, Cyclophosphamide	4	Salvage|Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Refractory	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	0	M2	45,X,-Y,t(8;21)(q22;q22)[20]	RUNX1T1/RUNX1:   94% of cells had the dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis.	dim CD7, CD13, dim CD33, CD34, CD38, CD56, dim partial      CD64, CD117, dim CD123, HLA-DR, MPO, dim TdT positive	Negative	0	Negative	NA	NA	NA	EZH2 (p.F445fs*3; MAF 30% )|KIT (p.N822K (exon 17); MAF 5% )|KIT (p.Y418_D419insFL (exon 8); MAF 29%)|TET2 (p.G1160E; MAF 49% )	Acute Myeloid Leukemia	AML	0.5	MATCHED
aml_ohsu_2022_2729	aml_ohsu_2022_2729_BA3273	Waves3+4	Yes	2	NA	NA	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute monoblastic and monocytic leukaemia	NA	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	Cyclophoshamide, TBI, ATG|CALGB 10403	2	Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Cyclophoshamide, TBI, ATG	Allogeneic - Matched Unrelated Donor	-1	M5	47,XY,der(7)t(1;7)(q21;q36),+14[4]/46,XY[16]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2, D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2 [198],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD4(+), CD7(-), CD11b(few dim +), CD13(-), CD14(-), CD15(partial +), CD16(-), CD19(partial +), CD20(-), CD22(partial +), CD25(partial +), CD33(partial +), CD34(+), CD36(-), CD38(+), CD45(partial +) | CD64(-), CD79a(partial +), CD117 (-), HLA-DR(partial +), CD123(variably +), MPO(+), TdT(+)	Negative	0	Negative	NA	NA	NA	IKZF1 (Foundation; S63fs*2)	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2455	aml_ohsu_2022_2455_BA2893	Waves1+2	Yes	3	NA	59	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	Azacitidine, Sorafenib|Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Azacitidine, Sorafenib	Hypomethylating/Low Dose Cytarabine	-1	NA	46,XX[20]	Normal	Large population of CD117 positive myeloblasts (predominantly CD34 negative, HLA-DR negative), representing approximately 71% of the leukocytes consistent with acute myeloid leukemia.	Positive	1	Positive	NA	NA	NA	NPM1	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2389	aml_ohsu_2022_2389_BA2266	Waves1+2	Yes	1	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response i	7+3 (Cytarabine, Idarubicin)	Induction	6	M2	46,XY[20]	Normal	CD13, CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR+	Negative	0	Negative	RUNX1 (p.Y349*; 14.6%)	NA	NA	RUNX1 (p.Y349*; MAF 26% )|SRSF2 (p.P95H; MAF 32% )	Acute Myeloid Leukemia	AML	0.766666667	MATCHED
aml_ohsu_2022_2267	aml_ohsu_2022_2267_BA2044	Waves1+2	Yes	1	NA	57	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, TBI	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Fludarabine, Melphalan, TBI	Allogeneic - Sibling	-1	M2	46,XY,hsr(6)(p21p23)[17]/46,XY[5]	Normal	CD13, CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR+	Negative	0	Negative	RUNX1 (p.Y377*; 11.5%)|RUNX1 (p.I114Afs*25; 33.0%)	NA	NA	RUNX1 (p.I114fs*25; MAF ~50% )|U2AF1 (p.S34F; MAF 43%)	Acute Myeloid Leukemia	AML	1.266666667	MATCHED
aml_ohsu_2022_2335	aml_ohsu_2022_2335_BA2309	Waves1+2	No	7	NA	64	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Essential thrombocythaemia	77	0	Post-Chemotherapy|Residual Disease	NA	Bone Marrow Aspirate	3	Ruxolitinib|Imatinib|Hydroxyurea	2	Induction|Re-induction	NA	Ruxolitinib	Re-induction	-1	NA	47,XY,+der(1;9)(q10;p10)[17]/94,idemx2[2]/46,XY[1]	Fluorescent in situ hybridization (FISH) was performed with a 9p/CEP 9 probe set. Both probes hybridized to the derivative chromosome. 90/100 (90%) interphase cells scored had a 3 red/ 3 green signal pattern, reflecting the extra derivative.	dimCD7, CD13, dim CD33, CD34, CD71, and CD117 positive	Negative	NA	Negative	NA	NA	NA	NA	Myeloproliferative Neoplasms	MPN	0.166666667	UNMATCHED
aml_ohsu_2022_2480	aml_ohsu_2022_2480_BA2489	Waves1+2	Yes	2	NA	63	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	3	AG-221|Azacitidine|Fludarabine, Melphalan, TBI, ATG	3	Hypomethylating/Low Dose Cytarabine|Experimental|Allogeneic - Child	NA	Fludarabine, Melphalan, TBI, ATG	Allogeneic - Child	-1	NA	46,XY[20]	NA	NA	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 31.2%)	NA	ASXL1 (G646fs*12; MAF 30%)|CIITA (Q320fs*41; MAF 51%)|CUX1 (P442fs*16; MAF 38%)|IDH2 (R140Q; MAF 46%)|SRSF2 (P95H; MAF 40%)|STAG2 (R614*; MAF 90%)	Acute Myeloid Leukemia	AML	0.666666667	MATCHED
aml_ohsu_2022_2516	aml_ohsu_2022_2516_BA2908	Waves1+2	Yes	1	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML without maturation	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine	4	Consolidation|Induction|Maintenance|Supportive/Palliative Care	Complete Response	Decitabine	Supportive/Palliative Care	58	M1	46,XY,del(13)(q12q2?1)[14]	all 100 interphase cells scored (100%) were missing one set of 13S319 and RB1 probe signals, consistent with deleted 13q and the metaphase karyotype	CD13, partial/dim CD33, CD38, CD58, CD117 and MPO	Negative	0	Negative	NA	NA	NA	DNMT3A (p.R882H; MAF 44% )|IDH2 (p.R172K; MAF 43%)	Acute Myeloid Leukemia	AML	0.766666667	MATCHED
aml_ohsu_2022_2058	aml_ohsu_2022_2058_BA2054	Waves1+2	Yes	3	NA	49	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	49	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	M5	46,XX,del(17)(p11.2)[15]/46,XX[5]	consistent with karyotype (68% del 17p13)	Most of the atypical cells (data not shown) are myeloid blasts that express CD117, partial CD7 (about 30% positive), CD13, CD33, HLA-DR, weak CD4, and partial CD15 (about 50% positive), but do not express CD34, CD14(MO2), or CD64. (The monocytic cells (percentages shown) are atypical in that they express weaker than normal CD13, with brighter than normal and more uniform than normal CD15, with phenotypically normal expression of bright CD33, bright CD64, CD4, and HLA-DR, and include approximately 80% that are phenotypically consistent with promonocytes/monoblasts, based on the lack of CD14(MO2).)	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2415	aml_ohsu_2022_2415_BA2872	Waves1+2	Yes	1	NA	65	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	65	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	3	3+7 (Cytarabine, Daunorubicin)|Decitabine|5+2 (Ara-C, Daunorubicin)	3	Salvage|Induction|Re-induction	Refractory	Decitabine	Salvage	9	M2	46,XY,i(17)(q10)[20]	TP53/CEP17: 85% of cells were missing a signal for TP53, consistent with deletion due to the i(17) seen on metaphase analysis.  PML/RARA: 69% of cells had three signals for RARA (17q21), consistent with three copies of 17q due to the i(17) seen on metaphase analysis.	CD13, CD33, CD34, CD117, and HLA-DR positive	Negative	0	Negative	NA	NA	NA	ASXL1 (p.R693fs*10; MAF 49% )|CREBBP (p.S893L; MAF 52% )|NRAS (p.G12D; MAF 46% )	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2308	aml_ohsu_2022_2308_BA2526	Waves1+2	Yes	4	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	55	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	5	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine|MEC, Lenalidomide	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction	Complete Response	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	NA	50,XX,del(1)(q32),+8,+9,t(15;16)(q15~21;q12~22),+19,+21[cp20]	NA	ABNORMAL CD34+ BLAST POPULATION, 72%, EXPRESSING DIM PARTIAL CD4, DIM PARTIAL CD7, DIM PARTIAL CD8, CD33, CD38, PARTIAL CD64, CD117, PARTIAL HLA-DR, AND DIM PARTIAL TdT	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2308	aml_ohsu_2022_2308_BA2197	Waves1+2	Yes	4	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	55	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine|MEC, Lenalidomide	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction	Complete Response	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	NA	50,XX,del(1)(q32),+8,+9,t(15;16)(q15~21;q12~22),+19,+21[cp20]	NA	ABNORMAL CD34+ BLAST POPULATION, 72%, EXPRESSING DIM PARTIAL CD4, DIM PARTIAL CD7, DIM PARTIAL CD8, CD33, CD38, PARTIAL CD64, CD117, PARTIAL HLA-DR, AND DIM PARTIAL TdT	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	1.8	MATCHED
aml_ohsu_2022_2523	aml_ohsu_2022_2523_BA2232	Waves1+2	Yes	2	NA	74	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Crenolanib|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Azacitidine, Pracinostat	2	Induction|Maintenance	Complete Response	Crenolanib	Maintenance	433	NA	46,XY,t(6;9)(p23;q34)[18]/46,XY[2]	DEK-NUP214 fusion; MAF unavailable	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(bright +), CD34 (partial +), CD36(equivocal), CD38(variably +), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(partial +), TdT (-), MPO(-).	Positive	0.111111111	Negative	NA	NA	NA	DNMT3A (F827fs*4; MAF 35%)|FLT3 (S585_D586ins28; MAF 14% )|ZRSR2 (D242fs*13; MAF 25%)	Acute Myeloid Leukemia	AML	0.633333333	MATCHED
aml_ohsu_2022_2523	aml_ohsu_2022_2523_BA3145	Waves3+4	No	2	NA	74	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	77	979	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	3	Crenolanib|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Azacitidine, Pracinostat	2	Induction|Maintenance	Complete Response	Crenolanib	Maintenance	433	NA	47,XY,t(6;9)(p23;q34),+8[13]/48,idem,+13[4]/46,XY[3]	DEK-NUP214 fusion; MAF unavailable (DEK-NUP214 fusion; MAF unavailable) | nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[198], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[17/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	NA	Positive	NA	Negative	NA	ASXL1 (p.G645Vfs*58; 10.5%)	NA	DNMT3A (F827fs*4)|FLT3-ITD	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2121	aml_ohsu_2022_2121_BA2041	Waves1+2	Yes	2	NA	32	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	32	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	-1	NA	47,XX,+8[13]/46,XX[7]	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[197],(D8Z2x3,D20S108x2)[101/200], (RUNX1T1x3,RUNX1x2)[91/200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[188], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	CD2(-), CD4(dim +), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD41(-), CD45(+), CD56(-), CD64(-), CD71(+), CD117(+), CD123(+), GLy-A(-), HLA-DR(partial + and variable), TdT(-), MPO(+).	Negative	0	Negative	NA	NA	NA	PTPN11 (G60A; MAF 18%)	Acute Myeloid Leukemia	AML	0.433333333	MATCHED
aml_ohsu_2022_2121	aml_ohsu_2022_2121_BA2096	Waves1+2	No	2	NA	32	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	32	46	Post-Chemotherapy	Remission	Bone Marrow Aspirate	3	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	-1	NA	47,XX,+8[3]/46,XX[17]	nuc ish(D8Z2x3,D20S108x2)[27/200]	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(+ to bright +), CD34(-), CD38(+), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(dim +).	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2575	aml_ohsu_2022_2575_BA2464	Waves1+2	Yes	1	NA	40	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	40	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	ATRA, Arsenic Trioxide	2	Consolidation|Induction	Complete Response	ATRA, Arsenic Trioxide	Consolidation	193	M3	46,XX,t(15;17)(q22;q21)[17]/46,XX[3]	58% PML-RARA  (c/w karyotype)	CD13, CD33, CD58, CD64, CD117, CD123 and MPO positive	Negative	0	Negative	NA	NA	NA	IKZF1 (p.E80X; MAF 37%)|WT1 (p.E340X; MAF 32%)	Acute Myeloid Leukemia	AML	0.666666667	MATCHED
aml_ohsu_2022_2144	aml_ohsu_2022_2144_BA2902	Waves1+2	Yes	4	NA	83	FALSE	FALSE	TRUE	FALSE	FALSE	Intermediate	AML with mutated NPM1	83	1	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	2	Azacitidine|Decitabine, Midostaurin	2	Hypomethylating/Low Dose Cytarabine|Induction	Refractory	Decitabine, Midostaurin	Induction	-1	NA	46,XY[13]	NA	ABNORMAL CD34-NEGATIVE BLAST POPULATION, 65%, EXPRESSING MYELOPEROXIDASE, CD117, CD13, CD33, AND CD56, AND SHOWING PARTIAL EXPRESSION OF CD38, CD64(DIM), CD11c(DIM), CD4(DIM) AND HLA-DR	Positive	1.083333333	Positive	NA	NA	NA	FLT3-ITD|NPM1	Acute Myeloid Leukemia	AML	0.8	MATCHED
aml_ohsu_2022_2124	aml_ohsu_2022_2124_BA2491	Waves1+2	Yes	1	NA	65	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Decitabine	1	Induction	Refractory	Decitabine	Induction	9	M2	45,XY,del(5)(q13q33),del(7)(q11.2),dic(8;9)(q24.3;p22),-18,+r[cp8]/45,XY,del(5)(q13q33),-7,der(18)t(7;18)(p11.2;p11.1)[cp6]/45,sdl1,del(4)(q21q31.1),del(12)(p11.2p13)[cp5]/46,XY[1]	NA	dim CD7, CD13, dim CD33, CD34, CD38, CD58, partial      CD56, CD117, CD123 and HLA-DR positive	Negative	0	Negative	NA	NA	TP53 (p.V272M; 91.9%)	JAK2 (p.V617F; MAF 53% )|TP53 (p.V272M; MAF 88% )	Acute Myeloid Leukemia	AML	1	MATCHED
aml_ohsu_2022_2484	aml_ohsu_2022_2484_BA2541	Waves1+2	Yes	1	NA	39	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute monoblastic and monocytic leukaemia	39	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Methotrexate	3	Induction|CNS|Re-induction	Refractory	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	M5	46,XY,t(6;11)(q27;q23)[20]	MLL: 80% of cells had a split signal pattern consistent with the disruption of MLL due to the t(6;11).	dim CD4, partial CD11b, CD13, CD33, CD34, partial      CD38, partial CD64, CD117, CD123, HLA-DR and dim MPO positive.	Negative	0	Negative	NA	NA	NA	MLL (PTD)	Acute Myeloid Leukemia	AML	0.066666667	MATCHED
aml_ohsu_2022_2127	aml_ohsu_2022_2127_BA2143	Waves1+2	No	2	NA	51	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Myelodysplastic syndrome, unclassifiable	51	0	Unknown	NA	Bone Marrow Aspirate	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine	NA	Decitabine	Hypomethylating/Low Dose Cytarabine	4	NA	44,XX,der(5)t(5;9)(p15;q22)del(5)(q11.2q15),-7,-9,-18,del(20)(q11.2q13.1),+mar[cp8]/43~44,XX,-der(5),del(7)(q11.2q32),add(11)(p15),del(12)(p11.2p13),der(15)t(15;17)(p12;q11.2),-16,-18,+mar[cp9]/43,XX,del(5)(q13q33),del(7),add(11),del(12),der(15),-16,-18,+mar[cp3].ishder(15)(PML+,RARA+)[1].	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[108/200]	CD2 (-), CD4(- to dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD25(dim +), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), CD123(dim +), HLA-DR(variably+), MPO(-), TdT(-)	Negative	NA	Negative	NA	NA	NA	NA	Myelodysplastic Syndromes	MDS	0.3	MATCHED
aml_ohsu_2022_2051	aml_ohsu_2022_2051_BA2380	Waves1+2	No	1	NA	40	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	40	0	Post-Chemotherapy	Remission	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	NOS	47,XX,+8[11]/46,XX[10]	RUNX1T1 (8q21.3): 55% of cells had three signals for RUNX1T1 (8q21.3) consistent with trisomy 8, as seen on metaphase analysis	NA	Negative	0	Negative	NA	NA	NA	ASXL1 (p.E1416G; MAF 52% )	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2813	aml_ohsu_2022_2813_BA3301	Waves3+4	Yes	2	NA	59	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	59	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	5	Dasatinib|7+3 (Cytarabine, Idarubicin)|Sirolimus|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Experimental	Refractory	Dasatinib	Experimental	106	NA	48,XY,+8,+9[20]	nuc ish(D8Z2x3,D20S108x2)[170/200]	CD2(-), CD4(appears partial dim +), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(bright +), CD34(+), CD36(-), CD38(partial +), CD45(moderately +), CD56(partial +), CD64(partial +), CD117 (+), HLA-DR(+).	Negative	0	Negative	NA	NA	NA	BCOR (P512fs*7; MAF 66%)|EP300 (R1462*; MAF 8%)|ETV6 (ETV6-FOXJ2)|HIST1H2BK (T20I; MAF 47%)|PTPN11 (S502P;MAF 41.0%)|STK11 (F354L;MAF 46.0%)|U2AF1 (S34F; MAF 38%)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2482	aml_ohsu_2022_2482_BA2769	Waves1+2	Yes	4	NA	72	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	72	0	Residual Disease	Residual	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine, Midostaurin	3	Induction|Maintenance|Re-induction	Complete Response	7+3 (Cytarabine, Idarubicin)	Re-induction	62	NA	46,XX[20]	NA	NA	Negative	0	Negative	RUNX1 (p.R320*; 24.2%)|RUNX1 (p.R207W; 20.0%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.933333333	MATCHED
aml_ohsu_2022_2178	aml_ohsu_2022_2178_BA2843	Waves1+2	Yes	4	NA	84	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with minimal differentiation	84	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Decitabine, Midostaurin	1	Induction	Refractory	Decitabine, Midostaurin	Induction	-1	M0	46,XY[20]	NA	CD34, CD38, CD117, CD13, CD4, HLA-DR, AND TDT	Positive	0.851851852	Negative	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	0.633333333	MATCHED
aml_ohsu_2022_2435	aml_ohsu_2022_2435_BA2974	Waves1+2	Yes	1	bi	69	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated CEBPA	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	MiDAC	Consolidation	5	M4	46,XY[20]	FISH normal	CD7, CD13, CD33, CD34, CD38,  CD64, CD117, HLA-DR and MPO positive (Myeloid blasts) | CD13, CD14,CD33, CD64, dimCD34, and MPO positive (Monocytes)	Negative	0	Negative	NA	NA	NA	CEBPA (p.K313del; MAF 34%)|CEBPA (p.P23fs*81; MAF 41%)|TET2 (p.G1160E; MAF 51%)|TET2 (p.S1039L; MAF 48%)|WT1 (p.R380fs*5; MAF 31%)	Acute Myeloid Leukemia	AML	0.533333333	MATCHED
aml_ohsu_2022_2517	aml_ohsu_2022_2517_BA2497	Waves1+2	Yes	1	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute monoblastic and monocytic leukaemia	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	MiDAC	Consolidation	5	M5	47,XY,t(1;11)(p32;q23),+8[cp20]	CEP 8:  56% had three signals, consistent with the trisomy 8 in the metaphase karyotype|RUNX1T1: 70% had three signals, consistent with the trisomy 8 in the metaphase karyotype|MLL: 72% reflected MLL rearrangement and its involvement in the 1;11 translocation.	CD11b, CD13, partial CD14, CD15, CD33,CD38, CD45, CD56, CD58, CD64, HLA-DR and MPO-positive	Negative	0	Negative	NA	NA	NA	CREBBP (p.Q1765*; MAF 4% )|KRAS (p.G13D; MAF 27%)	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2119	aml_ohsu_2022_2119_BA2718	Waves1+2	Yes	1	bi	61	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated CEBPA	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Fludarabine, Melphalan	Allogeneic - Sibling	-1	M1	46,XY[20]	Normal	CD7, CD13, CD33, CD34, CD117, HLA-DR, cMPO (+)	Negative	0	Negative	NA	NA	NA	CEBPA (p.A30fs*130; MAF 40%)|CEBPA (p.N307_V308ins; MAF 50%)	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2043	aml_ohsu_2022_2043_BA2575	Waves1+2	Yes	1	NA	36	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	36	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	7+3 (Cytarabine, Idarubicin)	Induction	6	M4	46,XX,inv(16)(p13.1q22)[20]	CBFB; 76/100 cells (76%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement.	Immunophenotyping done on the peripheral blood on 12/1/2014      identified a myeloid blast population with the following immunophenotype:      CD13, partial CD15, CD33, CD34, CD38, CD58, variable CD64, CD117, HLA-DR      and cMPO. And, it identified a promonocyte/monoblast population expressing:	Negative	0	Negative	NA	NA	NA	KRAS (p.G12D; MAF 9% )|NRAS (p.G12D; MAF 10%)	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2404	aml_ohsu_2022_2404_BA3008	Waves1+2	Yes	1	NA	68	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	69	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	2	CPX-351 (Liposomal Cytarabine + Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	3	Salvage|Induction|Re-induction	Refractory	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	4	NA	46,XY[20]	NA	NA	Negative	0	Negative	NA	NA	NA	CBL (p.C404Y; MAF 28%)|SF3B1 (p.K666N; MAF 36% )|TET2 (p.L1047fs*11; MAF 34% )	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2582	aml_ohsu_2022_2582_BA3049	Waves1+2	Yes	1	NA	61	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	Myeloid sarcoma	61	0	Post-Chemotherapy|Post-Transplant|Residual Disease	Residual	Bone Marrow Aspirate	6	Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Busulfan, Cyclophosphamide	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Complete Response	Azacitidine	Hypomethylating/Low Dose Cytarabine	269	NA	46,XY[23]	Normal	NA	Negative	0	Negative	NA	NA	NA	ZRSR2 (p.R452C; MAF 4%)	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2477	aml_ohsu_2022_2477_BA2008	Waves1+2	Yes	4	NA	NA	FALSE	unknown	unknown	FALSE	FALSE	Adverse	Acute Myeloid Leukemia	NA	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	NA	TP53 (p.G266E; 82.1%)	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2461	aml_ohsu_2022_2461_BA2593	Waves1+2	Yes	3	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myelomonocytic leukaemia	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	7+3 (Cytarabine, Idarubicin)	Induction	-1	M4	46,XY[20]	Normal	large population of atypical CD117 positive myeloblasts (partial CD34+, weak CD4+, weak partial CD7+, partial CD64+), representing approximately 57% of the leukocytes and increased   promonocytes/monoblasts representing approximately 13% of the total leukocytes	Positive	1.083333333	Negative	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2573	aml_ohsu_2022_2573_BA2791	Waves1+2	Yes	2	NA	26	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	26	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	ATRA, Arsenic Trioxide	2	Consolidation|Induction	Complete Response	ATRA, Arsenic Trioxide	Consolidation	5	M3	46,XY,t(15;17)(q24;q21.1)[10]/46,XY[10]	nuc ish(PML,RARA)x3(PML con RARAx2)[173/200]	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-/small subset +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(equivocal/appears partial dim +), CD117(+), CD123(-), HLA-DR(-), MPO(appears partial +), TdT(few +).	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.8	MATCHED
aml_ohsu_2022_2150	aml_ohsu_2022_2150_BA2620	Waves1+2	Yes	1	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	0	NA	NA	NA	CD7, minor subset CD11b, CD13, minor subset CD14,      dim CD33, CD34, CD38, CD58, minor subset CD64, CD117, CD123, HLA-DR, subset      myeloperoxidase positive	Positive	NA	Negative	NA	ASXL1 (p.R549Pfs*2; 42.0%)	NA	FLT3-ITD (MAF 45%)	Acute Myeloid Leukemia	AML	0.766666667	MATCHED
aml_ohsu_2022_2486	aml_ohsu_2022_2486_BA2629	Waves1+2	Yes	1	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with minimal differentiation	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Re-induction	Refractory	MiDAC	Consolidation	44	M0	46,XY,t(1;4)(q21;p14)[20]	Normal	partial CD7, partial CD13, CD34, partial CD38,      partial CD117, dim CD123, HLA-DR and TDT positive	Negative	0	Negative	RUNX1 (p.R250Lfs*13; 50.0%)	NA	NA	BCOR (p.S571*; MAF 90% )|MLL (PTD)|ZRSR2 (p.C181F; MAF 88%)	Acute Myeloid Leukemia	AML	0.366666667	MATCHED
aml_ohsu_2022_2180	aml_ohsu_2022_2180_BA3020	Waves1+2	Yes	5	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with minimal differentiation	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	Cyclophosphamide, Fludarabine, TBI|Venetoclax (ABT-199), Azacitidine	2	Experimental|Double Umbilical Cord Blood Transplant (DUCBT)	NA	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	M0	46,XY[12]	Normal	CD34, dim CD45, CD117	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2180	aml_ohsu_2022_2180_BA2965	Waves1+2	No	5	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with minimal differentiation	71	30	Post-Chemotherapy	Remission	Peripheral Blood	2	Cyclophosphamide, Fludarabine, TBI|Venetoclax (ABT-199), Azacitidine	2	Experimental|Double Umbilical Cord Blood Transplant (DUCBT)	NA	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	M0	46,XY[12]	Normal	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2364	aml_ohsu_2022_2364_BA2870	Waves1+2	Yes	1	NA	77	FALSE	FALSE	TRUE	FALSE	FALSE	Favorable	AML with mutated NPM1	77	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	2	Azacitidine|Decitabine	1	Hypomethylating/Low Dose Cytarabine	NA	Azacitidine	Hypomethylating/Low Dose Cytarabine	6	M5	47,XX,+1,add(1)(p22)[15]/47,XX,+1,i(1)(q10)[5]	1p36/1q25: 81% of cells had three signals for 1q25 and two for 1p36, consistent with the larger clone above (ie. the clone with add(1)(p22). Another 13% of cells had four signals for 1q25 and two signals for 1p36, consistent with the smaller clone above (ie. the clone with the i(1)(q10)).	CD4, CD11b, CD15, CD33, CD38, CD58, CD64, CD123 and partial HLA-DR positive	Negative	0	Positive	NA	NA	NA	FLT3-V491L (p.V491L; MAF 9%)|NPM1 (p.W288fs*12; MAF ~50% )|PTPN11 (p.S502L; MAF 44%)	Acute Myeloid Leukemia	AML	1.333333333	MATCHED
aml_ohsu_2022_2151	aml_ohsu_2022_2151_BA2423	Waves1+2	Yes	4	NA	57	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	58	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Binimetinib (MEK162)	3	Consolidation|Induction|Experimental	Refractory	Binimetinib (MEK162)	Experimental	-1	NA	46,XY[14]	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.366666667	MATCHED
aml_ohsu_2022_2103	aml_ohsu_2022_2103_BA2682	Waves1+2	Yes	4	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myelomonocytic leukaemia	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Decitabine, Midostaurin	1	Induction	Refractory	Decitabine, Midostaurin	Induction	206	M4	46,XX,t(5;16)(q31;p13)[3]/46,XX[14]	NA	Partial CD34, cd38, cd117, cd15, cd33, partial cd13, partial cd64, cd11c, dim partial cd4, hla-dr and mpo	Negative	0	Negative	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	1.566666667	MATCHED
aml_ohsu_2022_2294	aml_ohsu_2022_2294_BA2276	Waves1+2	Yes	2	NA	80	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	80	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	Decitabine, ABT-199|Hydroxyurea	2	Unknown|Supportive/Palliative Care	NA	Decitabine, ABT-199	Unknown	-1	NA	46,XY[20]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(few +), CD16 (-), CD33(variably +), CD34(+), CD36(-), CD38(partial + with an unusual pattern of expression vs. CD34), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), HLA-DR(dim +). (21% population of medium-sized to large cells)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	1.1	MATCHED
aml_ohsu_2022_2032	aml_ohsu_2022_2032_BA2348	Waves1+2	No	5	NA	43	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	44	0	Post-Chemotherapy	Remission	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Re-induction	Refractory	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	NA	46,XX,add(3)(q21)[12]/52,sl,+6,+8,+10,+13,+20,+21[8]	Positive for an EVI1 rearrangement: < 0.9% |ABNORMAL - Low level gain of chromosome 8 and 20q12 sequences, trisomy:  < 0.3%)	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2346	aml_ohsu_2022_2346_BA2709	Waves1+2	Yes	2	NA	30	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	30	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Induction|Re-induction	Complete Response	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	-1	NA	46,XX,inv(16)(p13q22)[20]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(RUNX1T1,RUNX1)x2[200],(PML,RARA)x2[200], (5'CBFBx2,3'CBFBx1)(5’CBFB sep 3'CBFBx1)[195/200],(ABL1,BCR)x2[200]	CD34, CD13, partialCD15, CD38, CD45, CD117, CD123, HLA-DR, dimMPO (15% population of variably-sized blasts)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2141	aml_ohsu_2022_2141_BA2789	Waves1+2	Yes	1	NA	66	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	Therapy-related myeloid neoplasms	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	2	M1	NA	Normal	CD13, CD33, dim CD71, CD117, CD123, and MPO	Negative	0	Positive	NA	NA	NA	IDH2 (p.R140Q; MAF 46%)|NPM1 (p.W288fs*9; MAF 42%)	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2552	aml_ohsu_2022_2552_BA2650	Waves1+2	No	5	NA	76	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	76	0	Residual Disease	Residual	Bone Marrow Aspirate	2	AG-221|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Experimental	NA	AG-221	Experimental	-1	NA	46,XY[20]	Normal	positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers	Negative	0	Negative	RUNX1 (p.E422Afs*173; 53.3%)	NA	NA	NA	Acute Myeloid Leukemia	AML	4	MATCHED
aml_ohsu_2022_2552	aml_ohsu_2022_2552_BA2694	Waves1+2	Yes	5	NA	76	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	76	0	Residual Disease	Residual	Peripheral Blood	2	AG-221|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Experimental	NA	AG-221	Experimental	-1	NA	46,XY[20]	Normal	positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers	Negative	0	Negative	RUNX1 (p.E422Afs*173; 58.1%)	ASXL1 (p.E657*; 50.0%)	NA	NA	Acute Myeloid Leukemia	AML	3.833333333	MATCHED
aml_ohsu_2022_2244	aml_ohsu_2022_2244_BA2722	Waves1+2	Yes	1	NA	82	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	82	0	Residual Disease	Residual	Peripheral Blood	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	Azacitidine	Hypomethylating/Low Dose Cytarabine	122	NA	43~46,XX,add(2)(q11.2),-4,del(5)(q23),add(7)(q32),+8,add(11)(q23),-16,del(17)(p12),-18,+22[cp19]/46,XX[1]	NA	NA	Negative	0	Negative	NA	NA	TP53 (p.P151S; 96.9%)	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2583	aml_ohsu_2022_2583_BA3051	Waves1+2	No	2	NA	53	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	56	0	Post-Chemotherapy|Post-Transplant	Remission	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	NA	45~49,X,-Y,add(5)(q11.2),+der(9;8)(q10;q10),+10,der(11)t(11;17)(p15;q11.2)del(11)(q21q22),add(12)(q12),del(13)(q12q22),-17,add(18)(p11.2),add(19)(q13.3),-20,+1~4mar[cp4]/46,XX[16]	nuc ish(RUNX1T1x3,RUNX1x2)[9/200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198](5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD4(-), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(+), CD64(-), CD117(+), CD123(dim +), HLA-DR (+), MPO(few +), TdT(-).	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2283	aml_ohsu_2022_2283_BA2538	Waves1+2	Yes	2	NA	81	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	81	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	AG-221|Hydroxyurea	2	Experimental|Supportive/Palliative Care	NA	AG-221	Experimental	14	NA	46,XY[20]	nuc ish(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(CCND1,IGH)x2[199]	NA	Negative	0	Negative	RUNX1 (p.Q213Rfs*24; 85.5%)	ASXL1 (p.G646Wfs*12; 25.0%)	NA	ASXL1 (Foundation, G646fs*12; MAF 33%)|FLT3 (Foundation, E596_Y597INSYEYDLPYDPRS; MAF 27%)|IDH2 (Foundation, R140Q; MAF 45%)|RUNX1 (Foundation, Q213fs24; MAF 82%)|SRSF2 (FOUNDATION, P95R; MAF 48%)	Acute Myeloid Leukemia	AML	1.266666667	MATCHED
aml_ohsu_2022_2175	aml_ohsu_2022_2175_BA2583	Waves1+2	Yes	5	NA	80	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	80	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	AG-221	1	Experimental	NA	AG-221	Experimental	-1	NA	46,XY,del(20)(q11.2q13.1)[12]/45,sl,-7[3]/45,XY,-7[5]/46,XY[2]	Tetrasomy 5p/q; Monosomy 7; Loss 20q12 (15.5%); Tetrasomy 8cen and 20q12 (7	positive for CD13, dim CD33, CD34, CD38, dim CD45, CD117, HLA-DR and TdT	Negative	0	Negative	RUNX1 (p.R162G; 80.6%)	NA	NA	IDH1 (C.G395A; p.R132H; MAF unknown)	Acute Myeloid Leukemia	AML	0.466666667	MATCHED
aml_ohsu_2022_2056	aml_ohsu_2022_2056_BA2292	Waves1+2	No	5	NA	69	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	70	55	Post-Chemotherapy	Remission	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Rituximab	2	Induction|Experimental	Unknown	Rituximab	Experimental	-1	M6a	46,XY[18]	Normal	NA	Positive	1.222222222	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.633333333	MATCHED
aml_ohsu_2022_2285	aml_ohsu_2022_2285_BA2806	Waves1+2	Yes	2	NA	42	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with mutated NPM1	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	-1	NA	NA	NA	partialCD4, partial/dimCD7, partialCDllb, CD13, partialCD15, partialCD22, partialCD25, brightCD33, partialCD34, CD38, CD45, CD117, partialCD123, HLA-DR, partialMPO, partialTdT	Positive	0.960784314	Positive	NA	ASXL1 (p.G645Vfs*58; 8.0%)	NA	FLT3-ITD|NPM1	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2293	aml_ohsu_2022_2293_BA2268	Waves1+2	Yes	5	NA	68	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	68	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	NA	46,XY[19]	Normal	positive for CD34, CD117,  CD13, CD33 and HLA-DR	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2301	aml_ohsu_2022_2301_BA2153	Waves1+2	Yes	1	NA	70	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with minimal differentiation	70	15	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|Azacitidine, Itacitinib|Azacitidine|Decitabine	2	Salvage|Induction	Refractory	Azacitidine, Itacitinib	Salvage	449	M0	47,XY,+4[9]/46,XY[11]	NA	CD7, CD13, CD33, CD34, CD38, CD56, CD117, CD123, HLA-DR and MPO+ (see Note) (Expression of the following antigens is dim and/or partial:  CD7, CD33, CD34, CD38, CD56, CD123, HLA-DR and MPO.) | Small clonal B cell population (<1% of total cells); CD19, CD20, and kappa+	Negative	0	Negative	NA	ASXL1 (p.Q588*; MAF 43% )	NA	ASXL1 (p.Q588*; MAF 43% )	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2301	aml_ohsu_2022_2301_BA2674	Waves1+2	No	1	NA	70	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with minimal differentiation	71	281	Post-Chemotherapy|Relapse	Relapse	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|Azacitidine, Itacitinib|Azacitidine|Decitabine	2	Salvage|Induction	Refractory	Azacitidine, Itacitinib	Salvage	449	M0	47,XY,+4[2]/46,XY[18]	Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.	partial CD7 (~35%), CD13, partial dim CD33, CD34, CD38, variable CD56, and CD117	Negative	0	Negative	NA	ASXL1 (p.Q588*; MAF 49%)	NA	ASXL1 (p.Q588*; MAF 49%)	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2301	aml_ohsu_2022_2301_BA2809	Waves1+2	No	1	NA	70	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with minimal differentiation	72	423	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|Azacitidine, Itacitinib|Azacitidine|Decitabine	2	Salvage|Induction	Refractory	Azacitidine, Itacitinib	Salvage	449	M0	47,XY,+4[2]/46,XY[18]	Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2262	aml_ohsu_2022_2262_BA3025	Waves1+2	Yes	1	bi	28	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated CEBPA	30	2	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	6	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Fludarabine, Cyclophosphamide, TBI	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	NOS	46,XX,t(2;9)(q31;p21)[17]/46,X,t(X;9)(q22;p21)[3]	NA	CD7, CD13, CD33, CD34, CD38, CD58, dim CD71, CD117, HLA-DR, MPO and partial TDT positive.	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2258	aml_ohsu_2022_2258_BA2777	Waves1+2	Yes	1	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	MiDAC	Consolidation	113	M2	46,XY[20]	Normal	CD13, CD33, CD38, CD58, CD117, CD123, MPO      positive | CD5+ B cell lymphoproliferative disorder (approximately 5% of total      marrow cellularity)                - Immunophenotype: CD5, CD19, dim CD20, CD23, dim kappa positive	Negative	0	Positive	NA	NA	NA	NPM1 (p.W288fs*12; MAF 45%)|NRAS (p.G12D; MAF 4%)|NRAS (p.G13D; MAF 17%)|PTPN11 (p.T73I; MAF4% )	Acute Myeloid Leukemia	AML	1.3	MATCHED
aml_ohsu_2022_2225	aml_ohsu_2022_2225_BA2523	Waves1+2	Yes	4	NA	46	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	46	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	5	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine	4	Consolidation|Salvage|Induction|Re-induction	Complete Response	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	-1	M4	46,XY[20]	NA	MPO, HLA-DR, CD11c,CD13, CD33, DIM CD7, PARTIAL CD64, PARTIAL CD4, AND LACKING CD34	Negative	0	Positive	NA	NA	NA	DNMT3A|IDH1|NPM1|NRAS	Acute Myeloid Leukemia	AML	0.933333333	MATCHED
aml_ohsu_2022_2225	aml_ohsu_2022_2225_BA2206	Waves1+2	No	4	NA	46	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	47	375	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	5	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine	4	Consolidation|Salvage|Induction|Re-induction	Complete Response	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	-1	M4	46,XY[20]	Normal	CD7, CD13, CD33, partial CD34, CD117 and dim CD123+	Positive	NA	Positive	NA	NA	NA	DNMT3A (p.R882C; MAF 47%)|DNMT3A (p.V778M; MAF 48% )|FLT3-ITD (MAF ~3-4%)|IDH1 (p.R132C; MAF 47%)|NPM1 (p.W288fs*9; MAF 50%)|NRAS (p.G13D; MAF 17%)	Acute Myeloid Leukemia	AML	1.3	MATCHED
aml_ohsu_2022_2324	aml_ohsu_2022_2324_BA3027	Waves1+2	Yes	5	NA	53	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	53	33	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)	2	Induction|Re-induction	Complete Response	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	17	NA	53~55,XX,+1,+2,der(5)t(5;13)(q13;q12),+6,add(7)(q32),+8,+11,-13,+14,i(17)(q10),+19,+19,+21,+mar[cp7]/46,XX[7]	Gain of 8 (4/301 cells); Gain of 8q22/21q22 (7.7/301 cells); Gain 11q23 (5/200 cells)	NA	Negative	0	Negative	NA	NA	TP53 (p.S215R; 15.2%)	NA	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2214	aml_ohsu_2022_2214_BA2835	Waves1+2	Yes	2	NA	75	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	46,XY[20]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD4(partial +), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD33(partial +), CD34(+), CD36(subset +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(variably +), MPO(partial +), TdT(small subset +) (56% population of variably-sized cells)	Negative	0	Negative	NA	ASXL1 (p.E635Rfs*15; 18.8%)	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	MATCHED
aml_ohsu_2022_2189	aml_ohsu_2022_2189_BA2049	Waves1+2	Yes	1	NA	42	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	Complete Response	SWOG S1203 (7+3 +/- Vorinostat)	Induction	3	M2	46,XY[20]	Normal	CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, dim HLA-DR and partial MPO+	Negative	0	Positive	NA	NA	NA	IDH2 (p.R140Q; MAF 46% )|NOTCH1 (p.H2488R; MAF 47%)|NPM1 (p.W288fs*12; MAF 45%)|PTPN11 (p.D61A; MAF 44%)	Acute Myeloid Leukemia	AML	0.066666667	MATCHED
aml_ohsu_2022_2250	aml_ohsu_2022_2250_BA2441	Waves1+2	Yes	1	NA	50	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	50	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Salvage|Induction	Refractory	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	4	M0	43~47,XY,del(1)(q42),r(2)(p2?3q37),t(3;5)(q27;q31),del(4)(q31),+del(5)(q31),add(5)(q11.2),-7,del(11)(q23),add(12)(p13),-22,+mar[cp11]/43~46,idem,add(14)(q24)[cp8]	deleted 5q and three short arm signals; monosomy 7 and the metaphase karyotype; no evidence for MLL deletion or rearrangement	CD7, CD11b, CD13, dim CD33, CD34, CD38, CD58,   CD117 and HLA-DR+	Negative	0	Negative	NA	NA	TP53 (p.R273H; 53.6%)|TP53 (p.G105D; 52.9%)	NRAS ( p.Q61K; MAF 37%)|TP53 (p.G105D, MAF 60%)|TP53 (p.R273H; MAF 44%)	Acute Myeloid Leukemia	AML	0.5	MATCHED
aml_ohsu_2022_2409	aml_ohsu_2022_2409_BA2514	Waves1+2	Yes	2	NA	67	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	67	0	Post-Chemotherapy|Post-Transplant|Post-DLI|Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea	3	Salvage|Experimental|Supportive/Palliative Care	NA	Sorafenib	Experimental	-1	NA	46,XX[20]	nuc ish(DXZ1x2)[182]//(DXZ1,DYZ3)x1[18]. nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2) [200]	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD33(variably +), CD34(+), CD36 (-), CD38(+), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+)	Negative	0	Negative	NA	NA	TP53 (p.R283C; 47.5%)	NA	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2409	aml_ohsu_2022_2409_BA2695	Waves1+2	No	2	NA	67	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	68	254	Post-Chemotherapy|Post-DLI|Post-Transplant|Residual Disease	Residual	Peripheral Blood	4	AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea	3	Salvage|Experimental|Supportive/Palliative Care	NA	Sorafenib	Experimental	-1	NA	47,XX,+11[5]/48,idem,+19[15]	nuc ish(DXZ1x2)[181]//(DXZ1,DYZ3)x1[19] nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[176/200],(PML,RARA)x2[196], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	NA	Positive	1.325581395	Negative	NA	NA	TP53 (p.R283C; 45.1%)	FLT3-ITD|IDH1 (R132G)|IDH1 (p.R132G; MAF 51%)|KMT2A (MLL-PTD (exons 2-10))|TP53 (p.R283C; MAF 49%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2400	aml_ohsu_2022_2400_BA2520	Waves1+2	Yes	5	NA	80	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	AML with minimal differentiation	80	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Cytarabine|Decitabine|PF-04449913 (Hedgehog Inhibitor), LDAC	3	Consolidation|Salvage|Experimental	NA	Decitabine	Salvage	-1	M0	46,XY,del(20)(q11.2q13.1)[15]/46,XY[5]	Positive for deletion of 20q12 in 11.5% of 200 cells	positive for dim CD7, dim CD10, CD34, CD38, dim CD45, cCD79a, CD99, HLA-DR, TdT, dim PAX5	Negative	0	Negative	RUNX1 (p.R204*; 45.5%)|RUNX1 (p.S141*; 45.1%)	ASXL1 (p.D720Rfs*18; 14.1%)	NA	ASXL1 (p.718_724del; MAF 50.3%)|RUNX1 (p.R177X; MAF 47%)|RUNX1 (p.S114X; MAF 44.8%)|SRSF2 (p.P95H; MAF 45.1%)	Acute Myeloid Leukemia	AML	0.966666667	MATCHED
aml_ohsu_2022_2237	aml_ohsu_2022_2237_BA2671	Waves1+2	Yes	5	NA	73	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	73	1	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	FLX925|Azacitidine, Lenalidomide|Venetoclax (ABT-199)	2	Salvage|Experimental	NA	Azacitidine, Lenalidomide	Salvage	76	M5	46,XY[20]	Normal	positive for CD34, CD117, CD13, CD33, and HLA-DR	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 47.4%)	NA	ASXL1 (p.G643fs; MAF 32.9%)|GATA2 (p.A318T; MAF 48.8%)|IDH1 (p.G105G; MAF 50%)|SRSF2 (p.P95H; MAF 46.9%)|TET2 (p.E798X; 49.6%)|TET2 (p.Q414X; MAF 49.6%)	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2001	aml_ohsu_2022_2001_BA2702	Waves1+2	Yes	5	NA	68	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	68	34	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	3	AG-221|Azacitidine|Clofarabine	3	Hypomethylating/Low Dose Cytarabine|Unknown|Experimental	NA	AG-221	Experimental	-1	NA	46,XY,r(7)(p1?3q2?2)[12]/46,XY[5]	loss of 7q31 sequences in 85% of assayed cells	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	1.033333333	MATCHED
aml_ohsu_2022_2174	aml_ohsu_2022_2174_BA2805	Waves1+2	Yes	5	NA	83	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	83	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	AG-221	1	Experimental	NA	AG-221	Experimental	-1	NA	45,XX,-7[20]	Monosomy 7 (94%)	positive for CD13, HLA-DR, CD34, and CD117, with aberrant loss of CD33, and with aberrant expression of CD7	Negative	0	Negative	NA	NA	NA	IDH2 (p.R140Q; MAF 46.4%)|KIT (p.M541L; MAF 48.7%)	Acute Myeloid Leukemia	AML	0.7	MATCHED
aml_ohsu_2022_2362	aml_ohsu_2022_2362_BA3028	Waves1+2	Yes	5	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Complete Response	Venetoclax (ABT-199), Azacitidine	Induction	115	NA	46,XX[20]	NA	positive for CD33, CD13, CD117, and myeloperoxidase; negative for CD34 and HLA-DR	Negative	0	Positive	NA	NA	NA	ASXL1 (p.A1312V; MAF 33.6%)|IDH1 (p.A1312V; MAF 32.1%)|NPM1 (p.L258fs; MAF 31.1%)	Acute Myeloid Leukemia	AML	0.766666667	MATCHED
aml_ohsu_2022_2362	aml_ohsu_2022_2362_BA2479	Waves1+2	Yes	5	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Complete Response	Venetoclax (ABT-199), Azacitidine	Induction	115	NA	46,XX[20]	NA	positive for CD33, CD13, CD117, and myeloperoxidase; negative for CD34 and HLA-DR	Negative	0	Positive	NA	NA	NA	ASXL1 (p.A1312V; MAF 33.6%)|IDH1 (p.A1312V; MAF 32.1%)|NPM1 (p.L258fs; MAF 31.1%)	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2217	aml_ohsu_2022_2217_BA2157	Waves1+2	Yes	5	NA	65	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	65	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|Clofarabine, Cytarabine	3	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction	Complete Response	Clofarabine, Cytarabine	Re-induction	-1	NA	46,XX,add(2)(q13),-3,-5,add(6)(q21),del(7)(q22),+11,dic(11;17)(p11.2;p11.2),inv(11)(q13q23),add(12)(p12),add(14)(q22),-17,add(19)(p12),-22,+3mar[1]/45-48,sl,+add(1)(q12),del(7)(q22),+3-5mar[cp8]/47-48,sdl1,+8[cp4]/46,XX[3]	FISH assays were positive for loss of 5q31 sequences in 91.5% of cells, and positive for trisomy for 7 centromere with disomy for 7q31 in 54.2% of cells.	The myeloblasts were positive for CD34, CD117, CD13, CD33, and HLA-DR. A subset of the myeloblasts showed aberrant expression of CD56.	Negative	0	Negative	NA	NA	TP53 (loss exons 10-11)	ETV6 (IL34-ETV6 rearrangement)|IDH1 (p.G105G; MAF 52.8%)|MEN1 (rearrangement intron 3)|NF1 ((From Foundation Medicine) R192*, R1968* - subclonal, R765fs*26 - subclonal, FCHSD2-NF1 fusion)|TP53 (loss exons 10-11)	Acute Myeloid Leukemia	AML	0.533333333	MATCHED
aml_ohsu_2022_2303	aml_ohsu_2022_2303_BA2281	Waves1+2	Yes	1	NA	25	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	25	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	1	Induction	Complete Response	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	28	M3	46,XY,t(4;15;17)(q21;q22;q21),add(12)(p12)[1]/46,idem,t(5;22)(q11.2;q11.2)[18]/46,XY[1]	FISH c/w PML/RARA fusion	CD13, dim CD15, CD34, bright CD33, variable CD56, CD64, CD117, CD123, variable HLA-DR, and bright MPO	Positive	NA	Negative	NA	NA	NA	FLT3-ITD (MAF 44%)	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2069	aml_ohsu_2022_2069_BA2932	Waves1+2	Yes	1	NA	29	FALSE	TRUE	FALSE	FALSE	FALSE	IntermediateOrAdverse	AML without maturation	29	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M1	46,XX[20]	Normal	dim CD2, dim CD7, CD13, dim CD19, dim CD20,      CD33, partial CD34, variable CD38, dim CD64, CD117, CD123, and HLA-DR      positive.	Positive	NA	Negative	NA	NA	NA	FLT3-ITD (MAF 50%)|MLL (PTD)	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2000	aml_ohsu_2022_2000_BA2123	Waves1+2	Yes	2	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine	NA	Decitabine	Hypomethylating/Low Dose Cytarabine	214	NA	46,XY[20]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199](RUNX1T1, RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33 (bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR (+), GLy-A(-), MPO(partial +), TdT(-).	Negative	0	Positive	NA	NA	NA	DNMT3A (W297*; MAF 44%)|FLT3-D835 (D835Y; MAF 6%)|GATA2 (P161A; MAF 51%)|NPM1 (W288fs*10+; MAF 26%)	Acute Myeloid Leukemia	AML	0.9	MATCHED
aml_ohsu_2022_2275	aml_ohsu_2022_2275_BA2844	Waves1+2	Yes	2	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	Complete Response	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	NA	46,XY[20]	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD19(few appear very dim +), CD25(-), CD33(variably +), CD34(variably +), CD36(subset +), CD38(+), CD45 (variably +), CD56(+), CD64(partial +), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(-). (73% population of medium to large sized cells)	Negative	0	Negative	NA	NA	NA	ASXL1 (G967DEL; MAF 45%)|CEBPA (A111FS*56; MAF 48%)|GATA2 (A318V; MAf 37%)|GATA2 (L321F; MAF 7%)|NRAS (G13V; MAF 37%)	Acute Myeloid Leukemia	AML	2.066666667	MATCHED
aml_ohsu_2022_2170	aml_ohsu_2022_2170_BA2660	Waves1+2	Yes	1	NA	43	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myelomonocytic leukaemia	43	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction|Re-induction|Supportive/Palliative Care	Refractory	Cytarabine	Supportive/Palliative Care	125	M4	46,XX[20]	Normal	Myeloid blast (52%) immunophenotype: CD13, variable CD33, CD34, variable CD38, variable CD117, HLA-DR, and TdT positive | Monocytic blast/promonocyte (28%) immunophenotype: dim CD2, CD11b, CD13, variable CD14, bright CD33, dim CD34, CD38, CD58, CD64, and HLA-DR positive	Positive	NA	Negative	RUNX1 (p.R250Lfs*13; 46.7%)	NA	NA	FLT3-ITD (MAF 47%)|RUNX1 (p.K110Q; MAF 38%)|SUZ12 (p.E261fs*2; MAF 52%)	Acute Myeloid Leukemia	AML	0.466666667	MATCHED
aml_ohsu_2022_2242	aml_ohsu_2022_2242_BA2836	Waves1+2	Yes	2	NA	59	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	107	NA	46,XY[20]	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(- to partial dim +), CD16(-), CD25(-), CD33(+ to slightly bright +), CD34(partial +), CD36(equivocal), CD38(slightly dim and variable), CD45(dim +), CD56(-), CD64(-), CD117(+), CD123(+), HLA-DR(+), MPO(+), TdT(-).	Negative	0	Positive	NA	NA	NA	CEBPA (H224fs*97; MAF 7%)|CEBPA (Y181*; MAF 15%)|IDH2 (R140Q; MAF 35%)|NPM1 (W288fs*10+; MAF 26%)|POT1 (splice site 1164-1G>A; MAF 48%)|SRSF2 (P95R; MAF 37%)	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2366	aml_ohsu_2022_2366_BA2714	Waves1+2	Yes	1	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)	3	Salvage|Induction|Re-induction	Complete Response	Azacitidine	Salvage	6	M4	46,XY[20]	Normal	dim CD4, dim CD7, dim CD11b, CD13, CD33, variable CD34, CD38, CD58, variable CD64, CD117, CD123, dim HLA-DR, MPO, and dim TdT	Negative	0	Positive	NA	NA	NA	FLT3-V491L (p.V491L; MAF 51%)|NPM1 (p.W288fs*12; MAF 50%)|SF3B1 (p.K666Q; MAF 47%)|WT1 (p.Y395fs*51; MAF 49%)	Acute Myeloid Leukemia	AML	0.766666667	MATCHED
aml_ohsu_2022_2366	aml_ohsu_2022_2366_BA3317	Waves3+4	No	1	NA	60	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	62	769	Post-Chemotherapy|Relapse	Relapse	Bone Marrow Aspirate	3	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)	3	Salvage|Induction|Re-induction	Complete Response	Azacitidine	Salvage	6	M4	46,XY,t(3;4)(p21;q21)[20]	Normal	CD13, CD34, dim CD33, CD38, CD58, CD71, CD117, CD123, partial TdT, and partial MPO+	Negative	0	Positive	NA	NA	NA	FLT3 (p.N841T; MAF 43%)|NPM1 (p.W288fs*12; MAF 41%)|SF3B1 (p.K666Q; MAF 48%)|WT1 (p.Y395fs*51; MAF 44%)	Acute Myeloid Leukemia	AML	0.733333333	UNMATCHED
aml_ohsu_2022_2024	aml_ohsu_2022_2024_BA2606	Waves1+2	Yes	1	NA	60	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Decitabine	1	Induction	Unknown	Decitabine	Induction	8	M2	46,XY[20]	Normal	partial dim CD7, CD13, dim CD33, CD34, CD38, CD58, CD117,  HLA-Dr and variable MPO	Negative	0	Negative	NA	ASXL1 (p.S747Pfs*25; 32.6%)	NA	ASXL1 (p.S747fs*25; MAF 38%)|IDH1 (p.R132C; MAF 34%)|SRSF2 (p.P95R; MAF 35%)	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2263	aml_ohsu_2022_2263_BA2440	Waves1+2	Yes	5	NA	76	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	76	1	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	41~42,XY,del(3)(p13p21),add(4)(q21),add(5)(q11.2),-7,-10,add(12)(p11.2),-15,add(15)(q21),add(17)(p11.2),-19,-20,-22,+2mar[cp6]/42~43,sl,+21[cp5]/42,sl,i(21)(q10)[cp2]/43~44,sl,+add(7)(p11)[cp2]/43~46,sl,+add(7)(p11),+21[cp4]/81~87<4n>,slx2[cp2]	Loss of chromosome 5q31 sequences (73.5%)|Loss of chromosome 7 sequences (monosomy 7) (61.5%)|Gain of 21q22 (AML1) sequences (11.5%)|Polysomy for 8, 20q (7.5%), 11q, 15q, 16q and 17q sequences	NA	Negative	0	Negative	NA	NA	NA	ASXL1 (p.E1102D; MAF 31.1%)|DNMT3A (p.F543C; MAF 35.7%)	Acute Myeloid Leukemia	AML	1.7	MATCHED
aml_ohsu_2022_2445	aml_ohsu_2022_2445_BA2036	Waves1+2	Yes	3	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	UNKNOWN	7+3 (Cytarabine, Idarubicin)	Induction	-1	NA	NA	NA	Large population of atypical myeloblasts (CD56 positive,  weak CD117 positive, CD34 negative, HLA-DR negative),  representing approximately 87% of the leukocytes,  consistent with acute myeloid leukemia	Negative	0	Positive	NA	NA	NA	KMT2A (p.Ile3572Ser (NM_001197104.1); MAF 44.1%)|NPM1 (p.Trp288fs (NM_002520.6); MAF 27.4%)|TET2 (p.His724fs; MAF 43.5%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2306	aml_ohsu_2022_2306_BA2828	Waves1+2	Yes	1	NA	64	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	64	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	2	Induction|Re-induction	Refractory	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	5	M4	46,XY,inv(16)(p13q22)[17]/46,XY[3]	c/w karyotype	NA	Negative	0	Negative	NA	NA	NA	KRAS (p.G12D; MAF 27%)|NOTCH1 (p.G2299S; MAF 47%)	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2334	aml_ohsu_2022_2334_BA2251	Waves1+2	Yes	1	bi	85	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated CEBPA	85	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	Azacitidine	Hypomethylating/Low Dose Cytarabine	105	NA	46,XY[20]	Normal	NA	Negative	0	Negative	NA	NA	NA	CEBPA (p.F77*83; MAF 50%)|CEBPA (p.K313_V314insK; MAF 50%)|TET2 (p.I1025L; MAF 50%)	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2584	aml_ohsu_2022_2584_BA3053	Waves1+2	Yes	3	NA	63	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	64	0	Residual Disease|Post-Chemotherapy|Post-Transplant	Residual	Peripheral Blood	5	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Sorafenib	5	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental	Complete Response	Sorafenib	Experimental	-1	M1	46,XY[6]	NA	NA	Positive	0.785714286	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2114	aml_ohsu_2022_2114_BA2952	Waves1+2	Yes	1	NA	16	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with t(9;11)(p22;q23); MLLT3-MLL	16	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine, Mitoxantrone|Etoposide, Cytarabine	2	Induction|Intensification	Complete Response	Cytarabine, Mitoxantrone	Intensification	-1	M5	46,XX,t(9;11)(p22;q23)[3]/50,sl,+6,+8,+der(9)t(9;11),+19[14]/51,sdl1,+5[3]	MLL:   14% of cells had a pattern consistent with the t(9;11) seen on metaphase analysis.  An addition 65% of cells had a signal pattern, consistent with the clone with the +der(9). | BCR/ABL+ASS:   62% of cells had three signals for both ABL and ASS (9q34), consistent with the clone with +9. | RUNX1T1 (8q22):   69% of cells had three signals for RUNX1T1, consistent with the clone with +8. | EGR1:   7% of cells had three signals for EGR1 (5q31), consistent with the clone with +5.	CD11b, dim CD13, dim CD15, CD33, CD38, dim CD45, CD56,      CD58, bright CD64, dim CD117, CD123, HLA-DR, and variable MPO positive	Negative	0	Negative	NA	NA	NA	KRAS (p.G13D; MAF 6%)|NRAS (p.Q61H; MAF 19%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2495	aml_ohsu_2022_2495_BA2410	Waves1+2	Yes	2	NA	57	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin) plus Crenolanib	1	Induction	Complete Response i	7+3 (Cytarabine, Idarubicin) plus Crenolanib	Induction	-1	NA	46,XX[20]	Normal	It reveals 0.23% CD34 (+) myeloid blasts with the following immunophenotype: CD2(-), CD7(-), CD13(+), CD15(-/few +), CD33 (bright +), CD36(few +), CD38(partial +), CD45(+), CD64(-), CD117(+), HLA-DR(-), MPO (partial +). (A limited/targeted immunophenotypic analysis could be performed on this paucicellular specimen.) | CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(variably +), CD15(-/few +), CD33(bright +), CD34(-), CD36(- /few +), CD38(+), CD45(+), CD56(-), CD64(few +), CD117(+), and HLA-DR(-) (There is also a 16% population of medium-sized cells with the following immunophenotype)	Positive	NA	Positive	NA	NA	NA	ASXL1 (E981G; MAF 49%)|DNMT3A (F290fs*24; MAF 40%)|FLT3-ITD (MAF 18%)|JAK2 (N322I; MAF 51%)|NPM1 (W288fs*10+; MAF 38%)	Acute Myeloid Leukemia	AML	0.633333333	MATCHED
aml_ohsu_2022_2342	aml_ohsu_2022_2342_BA2139	Waves1+2	Yes	3	NA	48	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	48	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|TBI, VP-16	4	Consolidation|Induction|CNS|Allogeneic - Matched Unrelated Donor	Complete Response	TBI, VP-16	Allogeneic - Matched Unrelated Donor	-1	M5b	46,XX	NA	Large population of atypical monocytic cells (weaker than  normal CD33, partial loss of CD13) including  promonocytes/monoblasts representing approximately 50% of  the leukocytes suggestive of acute monoblastic or monocytic  leukemia. | Large population of atypical monocytic cells (weaker than normal CD33, partial loss of CD13) including promonocytes/monoblasts representing approximately 50% of the leukocytes	Positive	0.785714286	Positive	NA	NA	NA	DNMT3A (p.Arg882Cys; MAF 47.1%)|FLT3-ITD|NPM1 (p.Trp288fs (NM_002520.6); MAF 27.9%)	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2464	aml_ohsu_2022_2464_BA2051	Waves1+2	Yes	5	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	HiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, Thiotepa, TBI	3	Consolidation|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	NA	46,XY,inv(16)(p13.1q22)[18]/47,sl,+22[2]	FISH positive for CBFB rearrangement in 49% of cells	Flow cytometry shows the large majority of analyzed cells fall within the monocyte gate, which are predominantly mature as evidenced by coexpression of CD14 and CD64. A smaller subset of cells within the monocyte gate consists of immature monocytes with decreased expression of CD14 and/or CD64. (A discrete population of myeloblasts is also present.)	Negative	0	Negative	NA	NA	NA	NRAS (p.Q61K; MAF 24.1%)	Acute Myeloid Leukemia	AML	0.833333333	MATCHED
aml_ohsu_2022_2323	aml_ohsu_2022_2323_BA2532	Waves1+2	Yes	2	NA	42	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate|Methotrexate	3	Induction|Experimental|Maintenance	Complete Response	ATRA, 6-MP, Methotrexate	Maintenance	-1	M3	46,XX,t(15;17)(q24;q21.1)[1]	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x3(PML con RARAx2)[154/200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD4(partial +), CD11b(few dim +), CD13(+), CD14(-), CD15(-), CD16 (-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(+), CD117(variably +), CD123(+), HLA-DR(-), myeloperoxidase(+), and TdT(-).	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.366666667	MATCHED
aml_ohsu_2022_2110	aml_ohsu_2022_2110_BA2986	Waves1+2	Yes	1	NA	48	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	56	0	Residual Disease|Post-Chemotherapy|Post-DLI|Post-Transplant	Residual	Bone Marrow Aspirate	7	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Mitoxantrone|Busulfan, Cyclophosphamide	5	Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction	Refractory	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	5	NA	46,XX,t(1;11)(q44;q13),del(6)(p23)[9]/46,idem,t(17;20)(q25;q11.2)[11]	All probe results were within normal laboratory limits.      *Note: while it was not disrupted, MLL (11q23) was observed on the end of      the derivative chromosome 1 on available metaphase cells, reflecting the      t(1;11).	dim CD2, CD13, CD33, CD34, CD38, CD117, dim CD123, dim      HLA-DR, and TdT positive	Negative	0	Negative	NA	NA	NA	BCOR (p.A1262S; MAF 45% )|DNMT3A (p.R882H; MAF 15% )|GATA1 (c.-12C>T; MAF 35%)	Acute Myeloid Leukemia	AML	1.833333333	MATCHED
aml_ohsu_2022_2246	aml_ohsu_2022_2246_BA2494	Waves1+2	Yes	5	NA	60	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	Acute megakaryoblastic leukaemia	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Azacitidine	1	Induction	Complete Response	Azacitidine	Induction	-1	M7	46,XY,del(13)(q12q14)[3]/46,XY[17]	Normal	CD3  - Scattered cells positive, 5-10% of marrow cells CD20  - Scattered cells positive, 5-10% of marrow cells CD34  - Rare cells positive, <1% of marrow cells CD30  - Negative CD43  - Positive in >60% of marrow cells, including the clusters of immature cells (CD117  - Scattered and small loose clusters of cells positive, 10-15% of marrow cells CD138  - Occasional cells positive, 2% of marrow cells Glycophorin A - Occasional cells positive, 3-5% of marrow cells MPO  - Scattered and clusters of cells positive, 20% of marrow cells)	Negative	0	Negative	RUNX1 (p.A338Rfs*262; 22.2%)	NA	NA	JAK2 (p.V617F; MAF 3.8%)|TET2 (p.R1261L; MAF 27.7%)	Acute Myeloid Leukemia	AML	0.8	MATCHED
aml_ohsu_2022_2585	aml_ohsu_2022_2585_BA3056	Waves1+2	Yes	5	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	53	0	Post-Chemotherapy|Residual Disease|Post-Transplant	Residual	Peripheral Blood	6	AG-221|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide	6	Hypomethylating/Low Dose Cytarabine|Unknown|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	AG-221	Experimental	-1	NA	46,XY[20]	NA	positive for CD13, CD33, CD34, CD38, dim CD45, CD117, HLA-DR and MPO	Negative	0	Negative	NA	NA	NA	IDH2 (p.R172K; MAF 30.2%)|TET2 (p.G335D; MAF 20.7%)	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2585	aml_ohsu_2022_2585_BA3054	Waves1+2	No	5	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	53	0	Residual Disease|Post-Transplant|Post-Chemotherapy	Residual	Bone Marrow Aspirate	6	AG-221|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide	6	Hypomethylating/Low Dose Cytarabine|Unknown|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	AG-221	Experimental	-1	NA	46,XY[20]	NA	positive for CD13, CD33, CD34, CD38, dim CD45, CD117, HLA-DR and MPO	Negative	0	Negative	NA	NA	NA	IDH2 (p.R172K; MAF 30.2%)|TET2 (p.G335D; MAF 20.7%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2502	aml_ohsu_2022_2502_BA2666	Waves1+2	Yes	2	NA	77	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Vincristine, Dexamethasone	1	Supportive/Palliative Care	NA	Vincristine, Dexamethasone	Supportive/Palliative Care	13	NA	45~54,XX,+2,del(5)(q22q35),+6,+6,+8,-11,add(13)(p11.2),+19,+22,+r,1~48dmin[cp19]/69~70,idem,+1,+3,+4,+del(5),+8,+8,+10,+10,+11,+13,+14,+14,+15,+15,+17,+18,+19[cp3]/46,XX[1].ishadd(13)(5'MLLamp,3'MLLamp)[2]	(D5S2064x3~4,D5S630x3~4, EGR1x2)[7/200],(D7Z1,D7S522)x2[200],(D8Z2x3~5,D20S108x2)[115/200],(RUNX1T1x3~5,RUNX1x2)[109/200], (ABL1x2,BCRx3)[110/200],(5'MLL,3'MLL)x1(5'MLL con 3'MLLx1,5'MLL amp,3'MLL amp)[110/200],(ETV6,RUNX1)x2 [199],(PMLx4,RARAx3)[95/200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]	CD7(-), CD10(-), CD11b(partial dim +), CD13(variably +), CD15(+), CD19(+), CD20(-), CD22(partial +), CD25(few +), CD33(-), CD34(+), CD36 (-), CD38(variably +), CD45(dim+/variably +), CD56(-), CD64(appears partially dim +), CD117(partial +), CD123(dim +), CD79a(partial +), | HLA-DR(variably +), TdT(+), and MPO(partial dim +; 20% positive).	Negative	0	Negative	NA	NA	TP53 (p.R280Efs*65; 35.7%)|TP53 (p.R175H; 27.2%)	NA	Acute Myeloid Leukemia	AML	0.866666667	MATCHED
aml_ohsu_2022_2533	aml_ohsu_2022_2533_BA2515	Waves1+2	Yes	2	mono	74	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	75	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	Refractory	HiDAC	Consolidation	48	NA	46,XY[18]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[198],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial dim +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD22 (-), CD25(-), CD33(variably +), CD34(bright +), CD36(-), CD38(bright +), CD45(moderate/dim +), CD56(-), CD64(-), CD79a (-), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(partial +) (34% population of variably-sized cells)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	1.066666667	MATCHED
aml_ohsu_2022_2566	aml_ohsu_2022_2566_BA2748	Waves1+2	Yes	1	bi	10	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated CEBPA	10	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M2	46,XX[20]	Normal	variable CD7, variable CD13, CD33, partial CD34, bright CD38, partial CD56, CD58, variable CD71, CD117, CD123, HLA-DR, and MPO positive	Negative	0	Negative	NA	NA	NA	CEBPA (p.G96fs*12; MAF ~50% )|CEBPA (p.G96fs*12; MAF ~50%)|CEBPA (p.R306_N307insPPT; MAF ~50%)|MLL (PTD (low level mutation))|NRAS (p.G12A, MAF 6%)|NRAS (p.G12A; MAF 6% )|NRAS (p.G12D; MAF 5% )|NRAS (p.G12D; MAF 5%)|NRAS (p.G13D; MAF 8%)|NRAS (p.G13R; MAF 5%)|NRAS (p.Q61H; MAF 10%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2566	aml_ohsu_2022_2566_BA2577	Waves1+2	No	1	bi	10	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated CEBPA	12	568	Post-Chemotherapy|Relapse	Relapse	Bone Marrow Aspirate	4	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M2	47,XX,+10[19]/46,XX[1]	Normal	variable CD7,  dim CD13, CD33, CD34 bright CD38,CD56, CD58, CD117, HLA-DR positive	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2453	aml_ohsu_2022_2453_BA2622	Waves1+2	Yes	1	NA	76	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	2	Consolidation|Induction	Complete Response	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	77	M0	47,XY,+8[3]/46,XY[17]	5% trisomy 8	#1 Immunophenotype: CD13, CD34, CD38, dim CD45, CD58, CD117, HLA-DR and TdT positive | #2 Immunophenotype: dim CD4, partial CD13, dim CD34, CD38, CD58, CD123, HLA-DR, and partial TdT positive	Negative	0	Negative	RUNX1 (p.A338Rfs*256; 73.3%)	ASXL1 (p.G646Wfs*12; 20.0%)	NA	CBL (p.Y371H; MAF 43%)|EZH2 (p.K30fs*8; MAF 48%)|RUNX1 (p.A338fs*; MAF 41%)|SF3B1 (p.H662Q; MAF 28%)	Acute Myeloid Leukemia	AML	0.633333333	MATCHED
aml_ohsu_2022_2453	aml_ohsu_2022_2453_BA2758	Waves1+2	No	1	NA	76	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	77	417	Post-Chemotherapy|Relapse	Relapse	Peripheral Blood	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	2	Consolidation|Induction	Complete Response	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	77	M0	47,XY,+8[cp14]/47,sl,der(21)t(1;21)(q11;p11.1)[2]/46~47,sl,der(22)t(1;22)(q11;p11.2)[cp2]/46,XY[1]	50/100 (50%) interphase cells scored had a signal pattern reflecting trisomy 8.	dim CD4, CD13, bright CD34, dim CD45, CD117, HLA-DR, and dim TdT positive	Negative	0	Negative	RUNX1 (p.A338Rfs*256; 71.0%)	ASXL1 (p.G646Wfs*12; 21.1%)	NA	NA	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2453	aml_ohsu_2022_2453_BA2930	Waves1+2	No	1	NA	76	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	77	472	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	2	Consolidation|Induction	Complete Response	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	77	M0	47,XY,+8[cp15]/47,sl,der(22)t(1;22)(q11;p11.2)[2]/46,XY,dup(1)(q21q42)[cp2]	60/100 (60%) interphase cells scored had a signal pattern reflecting trisomy 8.	Positive (The myeloid blasts are CD13, CD34, CD38, CD117, and HLA-DR;Atypical monocytic cells comprise approximately 41% of analyzed events and are CD11b, CD13, CD14, CD64, and dim HLA-DR positive. T cells show a CD4:CD8 ratio of 6.9:1 without aberrant antigen expression. B cells are polytypic by surface light chain expression)	Negative	0	Negative	RUNX1 (p.A338Rfs*256; 76.9%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.866666667	MATCHED
aml_ohsu_2022_2098	aml_ohsu_2022_2098_BA2164	Waves1+2	Yes	1	NA	1	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute megakaryoblastic leukaemia	3	0	Relapse|Post-Transplant|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	5	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide, Thymoglobulin|Etoposide|COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)|Doxorubicin	4	Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance	Complete Response	Etoposide	Maintenance	-1	M7	48,XX,+14,der(14)t(14;17)(q32;q21),+21[10]/46,XY[10]	37% trisomy 21, 38.5% XX, 61.5% XY (donor)	partial CD7, dim/partial CD33, CD34, CD38, CD56, CD58,  and CD117 positive	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2327	aml_ohsu_2022_2327_BA2970	Waves1+2	Yes	2	NA	63	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	2	Ruxolitinib|Hydroxyurea	1	Supportive/Palliative Care	NA	Hydroxyurea	Supportive/Palliative Care	103	NA	46,XY[20]	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD34(+), CD7(partial +), CD13(+), CD33(+), CD38(partial +), CD45(moderately +), CD56 (+), CD117(+), HLA-DR(variably +), other myeloid and lymphoid antigens(-).	Positive	9	Positive	NA	ASXL1 (p.W898*; 42.1%)	NA	ASXL1 (Foundation; W898*; MAF 47%)|KRAS (Foundation; A59T mutation; MAF 47%)|KRAS (Foundation; G13C; MAF 3%)|SUZ12 (Foundation; W617*; MAF 49%)	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2586	aml_ohsu_2022_2586_BA3058	Waves1+2	Yes	5	NA	56	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	58	0	Residual Disease|Post-Chemotherapy|Post-Transplant	Residual	Bone Marrow Aspirate	5	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|Azacitidine	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Allogeneic - Matched Unrelated Donor	Complete Response	AG-221	Experimental	-1	NA	48,XY,+8,+8[14]/46,XY[6]	Gain of chromosome 8 centromere, trisomy 3.5%, and terasomy 19.0%	positive for CD13, HLA-DR, CD34, and CD117, with aberrant expression of CD7 and aberrant loss of CD33, and with a subset of these blasts showing aberrant co-expression of CD34 and myeloperoxidase.	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 14.7%)	NA	ASXL1 (p.G642fs; MAF 26.4%)|IDH2 (p.R140Q; MAF 36.4%)|PHF6 (p.G306E; MAF 65%)|U2AF1 (p.Q157R; MAF 43.1%)	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2587	aml_ohsu_2022_2587_BA3059	Waves1+2	No	5	NA	59	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Refractory cytopenia with multilineage dysplasia	59	0	Post-Chemotherapy	NA	Peripheral Blood	1	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	1	Unknown	NA	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	Unknown	-1	NA	46,XX,del(9)(q21q31-33)[10]/46,XX[10]	positive for a low level of findings consistent with trisomy 8, seen in 1.7% of cells.	NA	Negative	NA	Negative	NA	NA	NA	ASXL1 (p.686_687del; MAF 40.4%)|ASXL1 (p.E1102D; MAF 30.7%)|CEBPA (p.E10K; MAF 26.7%)|RUNX1 (p.R142fs; MAF 30%)	Myelodysplastic Syndromes	MDS	NA	UNMATCHED
aml_ohsu_2022_2587	aml_ohsu_2022_2587_BA3061	Waves1+2	No	5	NA	59	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Refractory cytopenia with multilineage dysplasia	59	0	Post-Chemotherapy	NA	Bone Marrow Aspirate	1	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	1	Unknown	NA	R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone)	Unknown	-1	NA	46,XX,del(9)(q21q31-33)[10]/46,XX[10]	positive for a low level of findings consistent with trisomy 8, seen in 1.7% of cells.	NA	Negative	NA	Negative	NA	ASXL1 (p.C687Yfs*30; 28.6%)	NA	ASXL1 (p.686_687del; MAF 40.4%)|ASXL1 (p.E1102D; MAF 30.7%)|CEBPA (p.E10K; MAF 26.7%)|RUNX1 (p.R142fs; MAF 30%)	Myelodysplastic Syndromes	MDS	0.166666667	UNMATCHED
aml_ohsu_2022_2470	aml_ohsu_2022_2470_BA2238	Waves1+2	Yes	5	NA	33	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	33	2	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|Clofarabine, Cytarabine	2	Induction|Re-induction	Refractory	Clofarabine, Cytarabine	Re-induction	-1	NA	45,XX,-17[15]/46,XX[2]	90.5% monosomy 17, 6% trisomy 11q23	positive for CD13, CD33, CD34, CD38, CD45, CD117, HLA-DR and MPO	Negative	0	Negative	RUNX1 (p.R201*; 48.0%)	NA	TP53 (p.R175H; 92.9%)	DNMT3A (p.V468M; MAF 51.2%)|IDH2 (p.R172K; MAF 46.1%)|RUNX1 (p.R174X; MAF 48.2%)|TET2 (p.G355D; MAF 50.5%)|TP53 (p.R43H; MAF 76.7%)	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2107	aml_ohsu_2022_2107_BA2839	Waves1+2	Yes	2	NA	44	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	44	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	47,XY,+21[19]/46,XY[1]	nuc ish(RUNX1T1x2,RUNX1x3)[140/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-­), CD7(dim + to -­), CD11b(-­), CD13(+), CD14(-­), CD15 (partial +), CD33(bright +), CD34(partial +), CD36(-­), CD38(variably +), CD45(+), CD56(-­), CD64(partial +), CD117(+), HLA-­DR(variably +)	Positive	0.960784314	Negative	RUNX1 (p.E223*; 64.8%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.433333333	MATCHED
aml_ohsu_2022_2048	aml_ohsu_2022_2048_BA2112	Waves1+2	Yes	1	NA	29	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with minimal differentiation	29	15	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	5	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Refractory	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	4	M0	46,XY,t(6;11)(q27;q23),del(12)(p11.2p13)[13]/46,XY[7]	MLL Rearrangement (53%), 6;11 translocations, ETV6 (44%), deleted chomosome 12 short arm	NA	Negative	0	Negative	NA	NA	NA	KDM6A (p.R1363* MAF:32%)|NRAS (p.G12D; MAF 15%)	Acute Myeloid Leukemia	AML	1.1	MATCHED
aml_ohsu_2022_2048	aml_ohsu_2022_2048_BA3080	Waves3+4	No	1	NA	29	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with minimal differentiation	32	1079	Relapse|Post-Transplant|Post-Chemotherapy	Relapse	Peripheral Blood	5	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Refractory	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	4	M0	47,XY,t(3;4)(p21;q35),+4,t(6;11)(q27;q23),del(12)(p11.2p13)[16]/46,XY[4]	MLL:  87% of cells had a 1r1g1f split signal pattern consistent with MLL rearrangement.	NA	Negative	0	Negative	NA	NA	NA	CBL (p.P494A; VAF 16%)|CREBBP (p.E1561fs*72; VAF 30%)|EP300 (p.V1926G; VAF 19%)|PTPN11 (p.G503A; VAF 33%)|TCF3 (p.K522Q; VAF 31%)	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2442	aml_ohsu_2022_2442_BA2868	Waves1+2	Yes	3	bi	69	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated CEBPA	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Azacitidine	1	Induction	Refractory	Azacitidine	Induction	-1	NA	NA	NA	weak  CD7, CD13, partial CD15, weak CD33, CD34, weak CD64, CD117,  myeloperoxidase, and HLA-DR, but do not express CD14(MO2),  CD42b, or CD61.	Negative	0	Negative	NA	NA	NA	CEBPA (c.117delC; MAF 27.2%)|CEBPA (c.938_939insATC; MAF 18.1%)|TET2 (c.3454G>T; MAF 40.9%)|WT1 (c.1137_1138insA; MAF 43.7%)|WT1 (c.872+1G>A; MAF 40%)	Acute Myeloid Leukemia	AML	1.066666667	MATCHED
aml_ohsu_2022_2236	aml_ohsu_2022_2236_BA3011	Waves1+2	Yes	1	NA	32	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	32	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	ATRA, Arsenic Trioxide	2	Consolidation|Experimental	NA	ATRA, Arsenic Trioxide	Consolidation	232	M3	46,XY,t(15;17)(q22;q21)[20]	70% PML/RARA	CD13, CD33, CD64, CD117, CD123 and  MPO-positive	Positive	NA	Negative	NA	NA	NA	FLT3-ITD (MAF 7%)|MPL (p.E484G, MAF 3%)|WT1 (p.F451C; MAF 51% )	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2412	aml_ohsu_2022_2412_BA2052	Waves1+2	Yes	2	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	NA	46,XY,inv(4)(p14p16.1)[3]/46,XY[16]	nuc ish(D5S2064,D5S630,EGR1)x4[32/200],(D7Z1,D7S522)x4[17/200],(D8Z2, D20S108)x4[27/200],(RUNX1T1,RUNX1)x4[32/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[21/200],(PML,RARA)x4 [34/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[35/200]	CD2 (-), CD7(few +), CD11b(-), CD13(partial dim +), CD14(-), CD15(partial dim +), CD16(-), CD22(partial dim +), CD33(-), CD34(bright +), CD36(-), CD38(moderately bright +), CD45(partial +), CD56(-), CD64(-), CD117(partial +), HLADR(+) (32% population of medium to large cells)	Negative	0	Negative	NA	NA	NA	BCOR (Foundation; Q1337*; MAF 56%)|CTCF (Foundation; R49H; MAF 19%)|RUNX1 (Foundation; loss, splice site 477_508+22>GGG; MAF 50%)|SRSF2 (Foundation; R94_S101del;MAF 39%)|TET2 (Foundation; splice site 3409+2T>G; MAF 51%)	Acute Myeloid Leukemia	AML	1.833333333	MATCHED
aml_ohsu_2022_2073	aml_ohsu_2022_2073_BA2510	Waves1+2	Yes	5	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|Venetoclax (ABT-199), Azacitidine|Fludarabine, Cyclophosphamide, TBI	3	Experimental|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	NA	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	NA	48,XY,+8,der(11)t(11;?)(q23;?),+21[19]/46,XY[1]	Gain of 8q22 and 21q22 (88%)	positive for CD11b, CD13, CD33, CD38, dim CD45, dim CD56, CD64, and HLA-DR	Negative	0	Negative	NA	ASXL1 (p.W960*; 48.8%)	NA	ASXL1 (p.W960X; MAF 29.4%)|PTPN11 (p.E76V; MAF 29.5%)	Acute Myeloid Leukemia	AML	0.1	MATCHED
aml_ohsu_2022_2521	aml_ohsu_2022_2521_BA2691	Waves1+2	Yes	1	NA	83	FALSE	FALSE	FALSE	FALSE	FALSE	MissingKaryo	Therapy-related myeloid neoplasms	83	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2571	aml_ohsu_2022_2571_BA2366	Waves1+2	Yes	5	NA	81	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	81	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	1	Venetoclax (ABT-199), Azacitidine	1	Experimental	NA	Venetoclax (ABT-199), Azacitidine	Experimental	-1	NA	46,XX,-7,+8[7]/47,sl,+8[6]/46,XX[6]	44% loss chromosome 7, 28% trisomy 8, 28% tetrasomy 8,	positive for CD34, CD38, dim CD45, CD117, HLA-DR and MPO	Negative	0	Negative	NA	NA	NA	IDH1 (p.R132C; MAF 16.3%)	Acute Myeloid Leukemia	AML	1.6	MATCHED
aml_ohsu_2022_2487	aml_ohsu_2022_2487_BA2374	Waves1+2	Yes	1	NA	36	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	36	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	2	Induction|Experimental	Complete Response	ATRA, Arsenic Trioxide	Experimental	-1	M3	46,XX,der(15)t(15;17)(q22;q21),der(17)t(15;17)del(17)(q21)[15]/46,XX[1]	95% of cells had a variant abnormal signal pattern with PML/RARA fusion.  PML (15q22) (SO) / RARA (17q21) (SG) t(15;17)	Immunophenotype: CD13, CD33, partial CD34, CD64, CD117, CD123 and MPO positive	Positive	NA	Negative	NA	NA	NA	FLT3-ITD (MAF 50%)	Acute Myeloid Leukemia	AML	0.466666667	MATCHED
aml_ohsu_2022_2101	aml_ohsu_2022_2101_BA2804	Waves1+2	Yes	5	mono	87	FALSE	FALSE	TRUE	FALSE	FALSE	Intermediate	Acute monoblastic and monocytic leukaemia	87	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	AG-120|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Experimental	NA	AG-120	Experimental	-1	M5	47,XY,+21[3]/46,XY[9]	9.5% gain 21q22	A distinct blastic population, expressing CD7, CD13, CD15, CD33, CD34, CD38, dim CD45, CD64, MPO, and HLA-DR | A large monocytic population, positive for CD11b, CD13, CD14, CD15, CD33, CD38, CD45, CD64, HLA-DR and MPO	Negative	0	Negative	NA	NA	NA	ASXL1 (p.G642fs; MAF 31.6%)|CEBPA (p.A66fs; MAF 37.3%)|CEBPA (p.Q162fs; MAF 50.3%)|IDH1 (p.R132C; MAF 48.7%)|TP53 (p.N107D; MAF 97.6%)	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2456	aml_ohsu_2022_2456_BA2670	Waves1+2	Yes	2	NA	72	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	73	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	4	Lenalidomide|Azacitidine|Decitabine|Clofarabine, Cytarabine	2	Hypomethylating/Low Dose Cytarabine|Maintenance	NA	Clofarabine, Cytarabine	Hypomethylating/Low Dose Cytarabine	-1	NA	46,XX,+1,der(1;21)(q10;q10)[6]/46,XX[14]	nuc ish(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200]	NA	Negative	0	Negative	NA	NA	NA	RUNX1 (PB)|SF3B1 (PB)	Acute Myeloid Leukemia	AML	0.3	MATCHED
aml_ohsu_2022_2133	aml_ohsu_2022_2133_BA2675	Waves1+2	Yes	1	mono	10	FALSE	TRUE	FALSE	FALSE	FALSE	IntermediateOrAdverse	AML without maturation	10	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|Unknown|MiDAC	3	Unknown|Induction|Re-induction	Refractory	Unknown	Unknown	-1	M2	46,XY[20]	NA	variable CD7, dim CD11b, CD13, CD33, partial CD34, dim CD64, CD117, CD123, HLA-DR, and dim MPO positive	Positive	NA	Negative	NA	NA	NA	CEBPA (p.R142fs*19; MAF 52%)|FLT3-ITD (MAF 48%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2387	aml_ohsu_2022_2387_BA2031	Waves1+2	Yes	1	NA	2	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute monoblastic and monocytic leukaemia	2	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M5	46,XX,t(6;11)(q27;q23)[19]/46,XX[1]	NA	CD4, CD11b, variable CD13, CD15, CD33, variable CD56, CD58, CD64, lysozyme, and dim HLA-DR positive	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2387	aml_ohsu_2022_2387_BA2146	Waves1+2	No	1	NA	2	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute monoblastic and monocytic leukaemia	3	397	Post-Chemotherapy|Relapse	Relapse	Bone Marrow Aspirate	4	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M5	46,XX,t(6;11)(q27;q23)[12]/46,XX[8]	71/100 (71%) interphase cells scored had the 1 red/ 1 green/ 1 yellow signal pattern, consistent with MLL rearrangement and the 6;11 translocation observed in the metaphase karyotype.	CD4, CD11b, variable CD13, CD15, CD33, CD58, CD64, CD117, and dim HLA-DR positive	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2064	aml_ohsu_2022_2064_BA2589	Waves1+2	Yes	5	NA	42	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myelomonocytic leukaemia	42	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|AG-221|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	3	Salvage|Induction|Experimental	Refractory	AG-221	Experimental	-1	NA	46,XX[20]	Normal	positive for CD13, CD34, CD38, dim CD45, CD117, HLA-DR, and MPO	Negative	0	Negative	NA	NA	NA	ASXL1 (p.G652S; MAF 41.3%)|ASXL1 (p.S1231F; MAF 50.4%)|DNMT3A (p.S307fs; MAF 45.6%)|IDH1 (c.C315T; p.G105G; MAF 46.6%)|IDH2 (p.R140Q; MAF 43.8%)|SRSF2 (p.P95H; MAF 42.2%)	Acute Myeloid Leukemia	AML	0.666666667	MATCHED
aml_ohsu_2022_2338	aml_ohsu_2022_2338_BA2933	Waves1+2	Yes	3	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with maturation	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	7+3 (Cytarabine, Idarubicin)	Induction	-1	M2	46,XY[20]	Normal	partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive)	Positive	NA	Negative	RUNX1 (p.R166Q; 41.5%)|RUNX1 (p.R162K; 47.6%)	ASXL1 (p.E635Rfs*15; 20.2%)	NA	ASXL1 (p.Glu635Argfs*15; MAF 9%)|CSF3R (p.Tyr779*; MAF 5.4%)|IDH2 (p.Arg140Gln; 37.7%)|PHF6 (p.Arg319*; MAF 88.6%)|RUNX1 (p.Arg162Lys; MAF 43%)|RUNX1 (p.Arg166Gln; MAF 35.3%)|SMC1A (p.Arg790Gln; 9.2%)|U2AF1 (p.Gln157Pro; MAF 51.3%)	Acute Myeloid Leukemia	AML	1.566666667	MATCHED
aml_ohsu_2022_2338	aml_ohsu_2022_2338_BA2198	Waves1+2	Yes	3	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with maturation	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	7+3 (Cytarabine, Idarubicin)	Induction	-1	M2	46,XY[20]	Normal	partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive)	Negative	0	Negative	RUNX1 (p.R166Q; 46.0%)|RUNX1 (p.R162K; 44.5%)	ASXL1 (p.E635Rfs*15; 10.5%)	NA	ASXL1 (p.Glu635Argfs*15; MAF 9%)|CSF3R (p.Tyr779*; MAF 5.4%)|IDH2 (p.Arg140Gln; 37.7%)|PHF6 (p.Arg319*; MAF 88.6%)|RUNX1 (p.Arg162Lys; MAF 43%)|RUNX1 (p.Arg166Gln; MAF 35.3%)|SMC1A (p.Arg790Gln; 9.2%)|U2AF1 (p.Gln157Pro; MAF 51.3%)	Acute Myeloid Leukemia	AML	1.5	MATCHED
aml_ohsu_2022_2066	aml_ohsu_2022_2066_BA2066	Waves1+2	Yes	1	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea|Fludarabine, Melphalan, TBI, ATG	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Child	Complete Response	Fludarabine, Melphalan, TBI, ATG	Allogeneic - Child	-1	M5	46,XX,t(1;11)(p36.1;q23),add(9)(p22)[13]/46,sl,del(2)(p21p23),del(20)(q11.2-13.1)[4]/46,sl,add(12)(p11.2)[2]	MLL: 85%  The t(1;11) with these breakpoints in not common, but has been associated with monoblastic leukemia	CD4, partial CD11b, CD15, CD33, CD38, moderate CD45, partial CD56, CD64, CD123, partial CD117, and HLA-DR	Negative	0	Negative	NA	ASXL1 (p.R693*; 19.8%)	NA	ASXL1 (p.R693*; MAF 19%)|BCOR (p.S209L (possibly a benign germline polymorphism); MAF 48%)|FLT3 (p.A680V; MAF 17%)|FLT3 (p.I836delI (in-frame deletion of one amino acid in TK domain); MAF 11%)|NRAS (p.G12S; MAF 19%)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2449	aml_ohsu_2022_2449_BA2422	Waves1+2	No	2	NA	74	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Myelodysplastic syndrome associated with isolated del(5q)	74	0	Residual Disease|Post-Chemotherapy	NA	Bone Marrow Aspirate	2	Lenalidomide|Azacitidine	2	Hypomethylating/Low Dose Cytarabine|Maintenance	NA	Azacitidine	Hypomethylating/Low Dose Cytarabine	6	NA	42~44,XX,-3,del(4)(q25q33),der(5)t(3;5)(q21;q22),del(7)(p15p22),-9,-9,-13,-16,add(17)(p11.2),add(19)(p13.3), +mar1,+mar2[cp4]/41~43,idem,-del(7),+der(7)t(7;15)(p12;q15)add(7)(q11.2),+der(7;9)(q11.2;q13)del(7)(q11.2q22), -15,-21,+mar3[cp5]/42~44,idem,-del(7),+der(7),+der(7;9),-15,-add(19) (+add(19)(p13.1),-21,+mar3[cp10]/46,XX[1] .ish der(7)(D7Z1+,PML+),der(7;9)(D7Z1+,D7S522+),mar3(RUNX1+)[cp8])	nuc ish(D5S2064x2,D5S630x2,EGR1x1) [91/200],(D7Z1x3,D7S522x2)[11/200],(D8Z2,D20S108)x2[196],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[196],(PMLx3,RARAx2)[28/200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[101/200]	CD2(-), CD7(partial dim +), 11b(-), CD13(+), CD14 (-), CD15(-), CD33(variably +), CD34(bright +), CD36(+), CD38(slightly variably +), CD45(+), CD117(variably +), HLA-DR(-).	Negative	NA	Negative	NA	NA	TP53 (p.R337L; 45.2%)	TP53 (Foundation; R337L)	Myelodysplastic Syndromes	MDS	1	MATCHED
aml_ohsu_2022_2077	aml_ohsu_2022_2077_BA2344	Waves1+2	Yes	3	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Therapy-related myeloid neoplasms	71	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	5	7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone	4	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care	Refractory	Hydroxyurea	Supportive/Palliative Care	-1	NA	46,XX,del(7)(q22q36)[20]	ABNORMAL FISH RESULT 7cen (D7Z1), 7q31 (D7S486): deletion present	CD7, CD13, weak CD33, CD34, CD117, and HLA-DR	Negative	0	Negative	NA	NA	NA	FLT3-ITD (MAF 4%)|WT1 (c.1138delinsAA; MAF 31.2%)	Acute Myeloid Leukemia	AML	1.366666667	MATCHED
aml_ohsu_2022_2077	aml_ohsu_2022_2077_BA2534	Waves1+2	No	3	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	72	249	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone	4	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care	Refractory	Hydroxyurea	Supportive/Palliative Care	-1	NA	46,XX,del(7)(q22q36)[18]/46,sl,t(1;10)(p13;q24)[2]	- 3 copies of the MECOM locus at 3q26.2, suggestive of a  rearrangement or gain of this locus, in 156/200 (78.0  percent) cells scored.  - deletion 7q31 involving the D7S486 locus in 162/200 (81.0  percent) cells scored.	NA	Positive	0.315789474	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	1.366666667	MATCHED
aml_ohsu_2022_2350	aml_ohsu_2022_2350_BA2459	Waves1+2	Yes	2	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML without maturation	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	7+3 (Cytarabine, Idarubicin)	Induction	8	M1	92<4n>,XXYY[13]/46,XY[7]	The AML FISH panel analysis showed evidence of extra copies of the RUNX1T1 (8q24) and RUNX1 (21q22) genes in 95.5%, extra copies of the PML (15q24) and RARA (17q21.1) genes in 95.5%, and extra copies of the CBFB (16q22) gene in 96% of the cells examined.)	CD2(-), CD4(partial dim +), CD7(-), CD11b (variably +), CD13(variably +), CD14(predominantly -), CD15(predominantly -/few scattered +), CD16(-), CD20(small subset +), CD33(partial +), CD34(variably +), CD36(small subset +), CD38(variably +), CD45(variably +), CD56(-), CD61 (-), CD64(-), (cont.above) (CD79a(small subset +), CD117(small subset +), HLA-DR(predominantly + and variable), TdT(+), MPO(-))	Positive	0.234567901	Negative	NA	NA	NA	IDH1 (p.R132C; MAF unlisted)	Acute Myeloid Leukemia	AML	0.966666667	MATCHED
aml_ohsu_2022_2240	aml_ohsu_2022_2240_BA2229	Waves1+2	Yes	5	NA	61	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	Cyclophosphamide, Fludarabine, TBI|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	NA	46,XX,del(5)(q31q33),der(21)(qter->q22::p11.2->qter),del(21)(q22)[19]	65% Loss 5q31; 14.5% Gain of 8 centromere, trisomy; Trisomy for 21q22  (40.5%), and trisomy for 8q22 and 21q22 (7.0%)	positive CD13, CD34, dim CD45, CD117 and HLA-DR	Negative	0	Negative	NA	NA	NA	BCOR (p.1189_1192del; MAF 33.1%)|NRAS (p.G12D; MAF 10%)|SRSF2 (p.P95H; MAF 34.4%)	Acute Myeloid Leukemia	AML	1.2	MATCHED
aml_ohsu_2022_2329	aml_ohsu_2022_2329_BA2559	Waves1+2	Yes	5	NA	42	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute monoblastic and monocytic leukaemia	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, TBI	3	Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	M5	46,XX[20]	Normal	The immature cells were positive for CD13, CD33, and many showed aberrant expression of CD7. The myeloblast portion was positive for CD34, CD117, and HLA-DR.  The immature monocyte portion was negative for CD34 and CD117, and expressed variable CD64 (including some cells with bright CD64), CD11b, an	Positive	NA	Negative	NA	NA	NA	FLT3-ITD (MAF 34.8%)|RUNX1 (p.L29S; MAF 52.7%)	Acute Myeloid Leukemia	AML	0.133333333	MATCHED
aml_ohsu_2022_2343	aml_ohsu_2022_2343_BA2093	Waves1+2	Yes	1	NA	51	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)|Bu/Cy/TBI	5	Consolidation|Salvage|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Refractory	Azacitidine	Salvage	62	M0	60~61<3n>,XYY,-1,-2,-3,-4,-5,del(5)(q13q33),-6,-7,+8,-9,+11,-12,+13,-15,-16,-17,-18,+21,+22[cp15]/70~73,idem,+Y,+1,+2,+5,+del(5)(q13q33),+6,+9,+11,+12,+20,+20[cp4]/46,XY[1]	EGR-1/ D5S23, D5S721: 60/100 cells (60%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the first clone, above; 38 cells (38%) had a 2 red/ 4 green signal pattern, consistent with two copies of the deleted 5q in the second clone.	partial CD7, CD13, dim partial CD22, CD33, CD3,  partial CD56, dim CD71, CD117, dim CD123, and dim HLA-DR	Negative	0	Negative	NA	NA	TP53 (p.X187_splice; 40.1%)|TP53 (p.X125_splice; 28.4%)	NRAS (p.G13D; MAF ~40%)|TP53 (Splice site (3' splice site mutation, intron 5); MAF 42%)|TP53 (Splice site (5' splice site mutation in intron 4); MAF 44%)	Acute Myeloid Leukemia	AML	1.033333333	MATCHED
aml_ohsu_2022_2304	aml_ohsu_2022_2304_BA2000	Waves1+2	Yes	3	mono	24	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	24	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	6	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	5	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	Refractory	Busulfan, Fludarabine	Allogeneic - Sibling	-1	NA	46,XX[20]	Normal	weak CD4, partial  CD7, partial CD11b, CD13, CD33, partial CD34, weak CD64,  CD117, MPO, and HLA-DR	Positive	0.666666667	Negative	NA	NA	NA	CEBPA (p.Gln41fs; MAF 4%)|FLT3-ITD (p.Glu611_Phe612ins27; MAF 8%)|JAK3 (p.Gln865Glu; MAF 48.9%)	Acute Myeloid Leukemia	AML	0.7	MATCHED
aml_ohsu_2022_2532	aml_ohsu_2022_2532_BA2425	Waves1+2	Yes	1	NA	68	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	NA	43-45,XX,del(5)(q16q33),der(7)t(7;12)(q11.1;q12)ins(7;?)(q11.1;?),-12,der(21;22)(q10;q10),+mar[cp20]/46,XX[1]	NA	CD13, CD33, CD34, CD71, CD117, dimCD123, HLA-DR, and dim CD 64 positive (Peripheral Blood)	Negative	0	Negative	NA	NA	TP53 (p.L130Pfs*19; 33.3%)	TP53 (p.I254N; MAF 40%)	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2019	aml_ohsu_2022_2019_BA2905	Waves1+2	Yes	5	NA	77	FALSE	FALSE	TRUE	FALSE	FALSE	Intermediate	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	3	AG-221|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Experimental|Maintenance	NA	AG-221	Experimental	-1	NA	47,XY,+11[8]/46,XY[12]	35% gain of 11q23	CD34, CD117, HLA-DR, CD13, and CD33. A subset of the myeloblasts showed aberrant co-expression of CD34 and myeloperoxidase.  A subset of the myeloblasts showed aberrant expression of CD56.	Negative	0	Negative	NA	NA	NA	ASXL1 (p.G642fs; MAF 32.1%)|CEBPA (p.K90fs; MAF 39.1%)|EZH2 (p.F246fx; MAF 91.4%)|IDH2 (p.R140Q; MAF 49.2%)|RUNX1 (p.L29S; MAF 52.9%)|STAG2 (p.D884fs; MAF 89.8%)|TET2 (p.P1723S; MAF 48.4%)|TET2 (p.Y867H; MAF 50.3% )	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2010	aml_ohsu_2022_2010_BA2304	Waves1+2	Yes	3	NA	52	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Therapy-related myeloid neoplasms	52	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, ATG, Methotrexate	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan, ATG, Methotrexate	Allogeneic - Matched Unrelated Donor	-1	M5	46,XX,t(9;11)(p22;q23)[5]	11q23 (MLL): rearrangement present (89.5%)	The monocytic cells (percentages shown) are  atypical in that they express partial CD56 (about 50%  positive), but otherwise demonstrate phenotypically normal  expression of CD13, bright CD33, bright CD64, CD15, HLA-DR,  and partial myeloperoxidase (Flow cytometric analysis of the bone marrow aspirate  specimen indicates that 4% of the CD45 positive leukocytes  are lymphocytes, 89% are monocytic cells, and 7% are  myeloid cells.) | CD10, CD11b, CD13,  CD16, CD33, and CD64 (Myeloid (phenotypically normal))	Negative	0	Negative	NA	NA	NA	KRAS (p.Gly13Asp; MAF 38.9%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2494	aml_ohsu_2022_2494_BA2976	Waves1+2	Yes	1	NA	85	FALSE	FALSE	TRUE	FALSE	FALSE	Intermediate	AML with myelodysplasia-related changes	85	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	1	Azacitidine	1	Maintenance	NA	Azacitidine	Maintenance	232	M4	46,XY,del(12)(p11.2p13)[20]	ETV6: 84% of cells were missing a signal for ETV6 (12p13), consistent with the deletion seen on metaphase analysis.	CD34, CD117, dim CD123, CD33, dim HLA-DR, CD13, and CD58. (Blasts) | CD64, CD11b, CD33, CD15, dim HLA-DR, CD13, dim CD71, and CD58. (Monoblasts/promonocytes.)	Negative	0	Negative	NA	NA	NA	NRAS (p.Q61R; MAF 30%)|U2AF1 (p.S34F ; MAF 50%)	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2292	aml_ohsu_2022_2292_BA2386	Waves1+2	Yes	2	NA	52	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	52	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	Complete Response	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	M1	46,XX[20]	nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+ and dim +), CD14(-), CD15(+), CD16(-), CD25(-), CD33(slightly bright +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(small subset +), CD64(-), CD117(dim and variably +), CD123(variably +), HLA-DR(+), TdT(-), MPO(+).	Negative	0	Positive	NA	NA	NA	FLT3 (Foundation; A680V; MAF 6%)|FLT3 (Foundation; Y842C; MAF 2%)|KDM6A (Foundation; P738fs*2;MAF 31%)|NPM1 (Foundation; W288fs*10+; MAF 25%)|TET2 (Foundation; Q742*; MAF 45%)|TET2 (Foundation; R1712fs*6;MAF 44%)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2292	aml_ohsu_2022_2292_BA2879	Waves1+2	No	2	NA	52	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	53	462	Relapse	Relapse	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	Complete Response	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	M1	46,XX[20]	nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2292	aml_ohsu_2022_2292_BA3400	Waves3+4	No	2	NA	52	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	54	616	Relapse	Relapse	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	Complete Response	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	M1	46,XX[20]	nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	NA	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2147	aml_ohsu_2022_2147_BA2181	Waves1+2	Yes	3	NA	70	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	70	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	-1	NA	46,XX,del(7)(q22q36)[11]/46,XX[2]	NA	CD13, CD34, dim CD45, partial CD117, HLA-DR, and minimal (3%) myeloperoxidase	Positive	1.222222222	Negative	RUNX1 (p.R162S; 96.2%)	NA	NA	DNMT3A (c.2645G>A; MAF 41.8%)|FLT3-ITD (c.1797delins22; MAF 19%)|IDH1 (c.394C>T; MAF 46.7%)|RUNX1 (c.486G>C; MAF 89.5%)	Acute Myeloid Leukemia	AML	0.766666667	MATCHED
aml_ohsu_2022_2424	aml_ohsu_2022_2424_BA2035	Waves1+2	Yes	1	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML without maturation	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	5	Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC|Midostaurin|Hydroxyurea	5	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Maintenance	Complete Response	Midostaurin	Maintenance	284	M1	NA	Normal	dim CD33, CD34, CD38, dim CD45, CD117, and MPO	Positive	NA	Negative	NA	NA	NA	DNMT3A (p.R882H; MAF ~50%)|FLT3-ITD (MAF 40%)|IDH1 (p.R132S; MAF ~50%)|SRSF2 (p.P95L; MAF ~40% )	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2524	aml_ohsu_2022_2524_BA2760	Waves1+2	Yes	5	NA	54	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	54	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin) plus Sorafenib	1	Induction	Complete Response	7+3 (Cytarabine, Idarubicin) plus Sorafenib	Induction	19	NA	50,XX,+8,+10,+12,+21[20]	- Gain of chromosome 8 in 55% of cells - Gain of 8q22 (ETO) sequence in 77.8% of cells; 21q22 (AML1) gain in 12% and loss in 77.8% cells	CD11b, CD13, CD14 (subset), CD33, CD34 (subset), CD38, CD45, CD64 (subset), HLA-DR and MPO	Negative	0	Negative	RUNX1 (p.D198N; 35.5%)	NA	NA	EZH2 (p.D146H; MAF 51.6%)|RUNX1 (p.D171N; MAF 19.8%)	Acute Myeloid Leukemia	AML	0.3	MATCHED
aml_ohsu_2022_2291	aml_ohsu_2022_2291_BA2201	Waves1+2	Yes	1	NA	68	FALSE	TRUE	FALSE	FALSE	FALSE	FavorableOrIntermediate	AML with mutated NPM1	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	HiDAC|3+7 (Cytarabine, Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	-1	M5	46,XY[20]	Normal	Variable CD13, variable CD14, CD33, variable CD64, CD117, CD123, and partial HLA-DR positive	Positive	NA	Positive	NA	NA	NA	FLT3-ITD (MAF 91%)|IKZF1 (p.Q156H; MAF 45%)|NPM1 (p.W288fs*; MAF 49%)|SF3B1 (p.K666Q; MAF 50%)	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2072	aml_ohsu_2022_2072_BA2642	Waves1+2	Yes	5	NA	83	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	83	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	AG-221	1	Experimental	NA	AG-221	Experimental	-1	NA	46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.1),del(19)(p13.3)[20]	FISH assays were positive for findings consistent with trisomy 8 in 79% to 90% of assayed cells, and positive for loss of 16q22 sequences in 91.5% of assayed cells.	positive for CD34, CD117, HLA-DR, and CD13, with aberrant loss of CD33, and with a subset of the blasts showing aberrant co-expression of CD34 and myeloperoxidase	Negative	0	Negative	NA	NA	NA	IDH1 (p.G105G; MAF 50%)|IDH2 (p.R140Q; MAF 37.8%)	Acute Myeloid Leukemia	AML	0.566666667	MATCHED
aml_ohsu_2022_2072	aml_ohsu_2022_2072_BA2355	Waves1+2	Yes	5	NA	83	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	83	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	AG-221	1	Experimental	NA	AG-221	Experimental	-1	NA	46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.1),del(19)(p13.3)[20]	FISH assays were positive for findings consistent with trisomy 8 in 79% to 90% of assayed cells, and positive for loss of 16q22 sequences in 91.5% of assayed cells.	positive for CD34, CD117, HLA-DR, and CD13, with aberrant loss of CD33, and with a subset of the blasts showing aberrant co-expression of CD34 and myeloperoxidase	Negative	0	Negative	NA	NA	NA	IDH1 (p.G105G; MAF 50%)|IDH2 (p.R140Q; MAF 37.8%)	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2088	aml_ohsu_2022_2088_BA2113	Waves1+2	Yes	1	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Decitabine	1	Induction	Unknown	Decitabine	Induction	9	M2	45~46,XX,add(1)(q42),del(5)(q31q35),del(6)(q13),del(9)(q13q34),del(17)(p13),i(21)(q10)[cp12]/46~47,idem,+mar[cp6]/46,XX[2]	EGR1 (5q31): 73% of cells were missing a signal for EGR1 (5q31), consistent with the deletion seen on metaphase analysis.  TP53 (17p13.1): 71% of cells were missing a signal for TP53 (17p13.1), consistent with the deletion seen on metaphase analysis.  RUNX1 (21q22): 77% of cells had three signals fo	CD13, dimCD33, CD34, CD38, CD58, partial CD64, CD117, CD123, and HLA-DR positive.	Negative	0	Negative	NA	NA	TP53 (p.R248Q; 53.3%)	TP53 (p.R248Q; MAF 56%)|U2AF1 (p.Q157P; MAF 41%)	Acute Myeloid Leukemia	AML	0.6	MATCHED
aml_ohsu_2022_2402	aml_ohsu_2022_2402_BA2155	Waves1+2	Yes	2	bi	72	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated CEBPA	73	0	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction	Complete Response	Azacitidine	Hypomethylating/Low Dose Cytarabine	112	M0	46,XX,der(3)t(3;17)(q29;q21)[19]/46,XX,t(3;21)(q26.2;q22)[2]	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1, D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD19 (-/few dim +), CD25(-), CD33(partial +), CD34(partial +), CD36(-), CD38(bright and variably +), CD45(+), CD56(variably +), CD64(-), CD117(variably +), CD123(-/few +), MPO(+), TdT(-/few dim +) (87% pop of med to large size cells) | HLA-DR(partial +)	Negative	0	Negative	NA	NA	TP53 (p.X187_splice; 30.4%)	CEBPA (Foundation; M1fs*60; MAF 34%)|CEBPA (Foundation; N307_V308insVETQQK; MAF 36%)|TP53 (Foundation; splice site 560-2insA; MAF 44%)	Acute Myeloid Leukemia	AML	1.166666667	MATCHED
aml_ohsu_2022_2039	aml_ohsu_2022_2039_BA2955	Waves1+2	Yes	1	NA	66	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute monoblastic and monocytic leukaemia	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	3+7 (Cytarabine, Daunorubicin), Bortezomib|MiDAC|Fludarabine, Cytarabine|Ibrutinib	4	Allogeneic - Sibling|Consolidation|Induction|Maintenance	Refractory	Ibrutinib	Maintenance	382	M5	47,XX,+6[6]/46,XX[19]	IGH/MAF: 74/100 cells (74%) had variant abnormal 0-1 red/ 1-4 green/ 2-7 yellow signal patterns reflecting IGH/MAF fusion. The majority of cells (56%) were 0 red/ 1 green/ 3 yellow. IGH: 68/100 (68%) cells scored had signal patterns consistent with IGH rearrangement and the 14;16 translocation,above | CDKN2C/CKS1B: 61/100 cells (61%) had 3-6 CKS1B (1q21) signals and 2 CDKN2C signals, reflecting gain of 1q. | The IGH/CCND1 and IGH/FGFR3 probe sets had extra IGH signals reflecting IGH involvement in the 14;16	dimCD4, CD11b, CD13, dimCD14, CD33, CD56, CD58, CD64, dimCD123 and HLA-DR positive; Minor subset of blasts with immunophenotype: CD13, CD33, CD34, CD58, CD117, dimCD123, HLA-DR and MPO positive.	Positive	NA	Negative	RUNX1 (p.P240Qfs*22; 40.0%)	NA	NA	BCOR (p.G1659E MAF ~10%,)|FLT3-ITD (MAF 38%)|NRAS (p.Q61R MAF ~5%)|RUNX1 (p.P240fs*22; MAF 37%)|RUNX1 (splice site [at invariant AG (G>A) splice acceptor site at end of Intron 6];  MAF 36% ))	Acute Myeloid Leukemia	AML	0.866666667	MATCHED
aml_ohsu_2022_2328	aml_ohsu_2022_2328_BA2502	Waves1+2	Yes	1	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with minimal differentiation	50	0	Residual Disease	Residual	Peripheral Blood	6	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction	Refractory	Hydroxyurea	Hypomethylating/Low Dose Cytarabine	365	M0	48,XX,+11,+13[19]	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2060	aml_ohsu_2022_2060_BA2322	Waves1+2	Yes	1	NA	35	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	35	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	112	M2	46,XX,inv(16)(p13.3q22)[21]	CBFB:  83/100 cells (83%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting CBFB rearrangement and consistent with the inverted  chromosome 16 in the metaphase karyotype.	Partial CD2, CD33, CD34, CD38, CD117, CD123, partial HLA-DR, dim MPO and partial TdT positive.	Negative	0	Negative	NA	NA	NA	NRAS (p.Q61P; MAF 15% )	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2588	aml_ohsu_2022_2588_BA3062	Waves1+2	No	1	NA	40	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML without maturation	47	0	Post-Transplant|Post-Chemotherapy	Remission	Bone Marrow Aspirate	8	Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	6	Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Sibling	-1	M1	46,XY[20]	Normal	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2065	aml_ohsu_2022_2065_BA2020	Waves1+2	Yes	3	NA	51	FALSE	TRUE	FALSE	FALSE	FALSE	FavorableOrIntermediate	AML with mutated NPM1	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Consolidation|Induction	Refractory	Busulfan, Fludarabine	Allogeneic - Sibling	-1	M4	46,XY[20]	Normal	CD13, partial CD15, CD33, CD117,  myeloperoxidase, and partial HLA-DR (atypical cells with dim CD45 - 45% of leukocytes) | CD13,  bright CD33, and bright CD64 (Monocytic (19% of leukocytes)) | CD13, CD33, and CD64, with  a left shift (increased percentage that lack CD10, CD11b,  and CD16) (Myeloid (19% of leukocytes))	Positive	NA	Positive	NA	NA	NA	FLT3-ITD (c.1775_1816dup; MAF 3%)|IDH2 (R140Q; MAF 42.3%)|NPM1 (c.860_863dup; MAF 14.5%)|PTPN11 (c.1507G>A; MAF 4%)|PTPN11 (c.1508G>A; MAF 15.4%)	Acute Myeloid Leukemia	AML	0.533333333	MATCHED
aml_ohsu_2022_2357	aml_ohsu_2022_2357_BA2166	Waves1+2	Yes	1	NA	70	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	70	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	3+7 (Cytarabine, Daunorubicin)|MiDAC	2	Consolidation|Induction	Complete Response	MiDAC	Consolidation	78	M2	46,XX[19]	Normal	CD13, CD33, CD38, CD117 and subset MPO positive	Negative	0	Positive	NA	NA	NA	NPM1 (p.W288fs*12; MAF ~11%)	Acute Myeloid Leukemia	AML	0.933333333	MATCHED
aml_ohsu_2022_2076	aml_ohsu_2022_2076_BA2886	Waves1+2	Yes	1	NA	66	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Myeloid sarcoma	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	3	Consolidation|Induction|Re-induction	Refractory	Azacitidine	Consolidation	1013	NA	46,XX[20]	Normal	CD13, CD33, CD34, CD38, CD58, CD117 and  HLA-DR	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.433333333	MATCHED
aml_ohsu_2022_2014	aml_ohsu_2022_2014_BA2226	Waves1+2	Yes	1	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	Complete Response	SWOG S1203 (7+3 +/- Vorinostat)	Induction	153	M5	46,XX[20]	Normal	Blast immunophenotype: partial CD11b, CD13, CD33, CD38, CD58, partial CD64, partial CD117 and a subset with MPO - Blast/promonocyte immunophenotype: CD11b, CD13, partial CD14, CD15, CD33, CD38, CD58 and CD64	Negative	0	Positive	NA	NA	NA	FLT3-D835 (p.D835Y; MAF: 40%)|NPM1 (p.W288fs*12; MAF 40%)	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2513	aml_ohsu_2022_2513_BA2376	Waves1+2	Yes	1	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	7+3 (Cytarabine, Idarubicin)	Induction	6	M5	46,XY[20]	Normal	dim CD4, CD11b, partial CD14, CD15, dim CD33, CD38, CD56, CD58, CD64 and HLA-DR positive	Negative	0	Positive	NA	NA	NA	DNMT3A (p.S714C; MAF 35%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G13V; MAF 6%)|PTPN11 (p.A72V; MAF 10%)|TET2 (p.Q876*; MAF 6%)	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2360	aml_ohsu_2022_2360_BA2889	Waves1+2	Yes	1	NA	34	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	34	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	ATRA, Arsenic Trioxide	1	Induction	Complete Response	ATRA, Arsenic Trioxide	Induction	-1	M3	46,XX,t(15;17)(q22;q21)[8]/46,idem,add(6)(p23),der(6)add(6)(p21)add(6)(q13),add(9)(p22),add(11)(q21),add(14)(q24)[12]	21/200 (10.5%) interphase cells  scored had the 1 red/ 1 green/ 2 yellow fusion signal pattern consistent  with PML/RARA fusion.	CD13, CD33, CD38, CD58, CD64, CD117, CD123, and  MPO-positive	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2371	aml_ohsu_2022_2371_BA2200	Waves1+2	Yes	3	NA	59	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	59	0	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	3	Azacitidine, Sorafenib|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)	3	Consolidation|Induction|Re-induction	Complete Response	Azacitidine, Sorafenib	Re-induction	-1	NA	46,XY,t(3;4)(p21;q25)[3]/46,XY[17]	NA	CD4, CD7, CD11b, CD13,  CD33, partial CD34, CD117, HLA-DR, partial weak TdT and  partial CD64	Positive	NA	Positive	NA	NA	NA	DNMT3A (c.2251T>C; MAF 36.9% (33.1% on 3/13/15))|FLT3-ITD (c.1759_1800dup; MAF 24% (39% on 3/13/15))|NPM1 (c.860_863dup; MAF 9.9% (24% on 3/13/15))	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2356	aml_ohsu_2022_2356_BA2121	Waves1+2	Yes	1	NA	36	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	36	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	HiDAC|3+7 (Cytarabine, Daunorubicin)|Hydroxyurea	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	103	M2	45,X,-Y,t(8;2;21)(q22;p21;q22)[20]	RUNX1T1/RUNX1: (92%)	CD13, CD33, partial CD34, CD64, CD19 dim, CD71, CD117 partial, HLA-DR, dim CD123, CD58 and MPO	Negative	0	Negative	NA	NA	NA	CBL (p.E369_Y371delinsH; MAF 31%)	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2577	aml_ohsu_2022_2577_BA2944	Waves1+2	Yes	3	NA	23	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	23	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)	2	Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)	Allogeneic - Matched Unrelated Donor	-1	M1	46,XY,add(6)(q23),del(7)(q33),t(8;21)(q22;q22)[2]/46,sl,add(17)(p11.1)[5]/46,sdl1,add(16)(p11.2)[2]/46,sdl2,add(3)(q21)[8]/46,sdl3,add(20)(q11.2)[3]	62% t(8;21) (RUNX1T1;RUNX1) translocation present	CD13, CD33, CD34, CD38, CD117, HLA-DR, cMPO, CD19 and partial CD56	Negative	0	Negative	NA	NA	NA	BRCA2 (c.6275_6276delTT; MAF unlisted)|BRCA2 (c.6859A>T; MAF unlisted)|FLT3-ITD (MAF unlisted)	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2589	aml_ohsu_2022_2589_BA3064	Waves1+2	Yes	3	NA	38	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	40	0	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Peripheral Blood	6	Azacitidine, Sorafenib|Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Sorafenib|Cladribine, Cytarabine, Idarubicin	7	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Experimental|Intensification|Re-induction	Refractory	Sorafenib	Experimental	38	NA	NA	Normal	CD4,  CD11b, dim CD13, variable CD15, CD33, partial CD34  (approximately 25%), variable CD64 (dim to bright), CD117,  HLA-DR, and myeloperoxidase	Positive	4	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2432	aml_ohsu_2022_2432_BA2033	Waves1+2	Yes	5	NA	71	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	71	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	2	Lenalidomide|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care	NA	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	NA	45,XY,add(3)(p10),add(5)(q11.2),psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter)[1]/44,sl,-add(3)(p10), +der(3;13)(q10;q10)[2]/48,sdl1,+8,+14,+21,+22[8]/42-44,sl,-add(3)(p10),add(4)(p15),-7,-8, add(12)(p11.2),+mar,+1-2r[cp7]/80-82 < 4n > ,slx2,-2,add(4)(q22)x2,-6,+8,+8,add(8)(p23)x2, (dic(8;11)(p12;p11.2)x2,-psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter),-10,der(10;17)(q10;q10), der(12;13)(p10;q10),der(14;17)(q10;q10),-16,-17,-18,add(20)(p11.2)[cp4])	FISH assays were positive for loss of 5q31 sequences in 85.5% of cells, positive for findings consistent with trisomy 8 in 49% of cells, and positive for findings consistent with monosomy 7 in around 8% of cells.	Flow cytometry was negative for increased myeloblasts. The flow showed a mild increase in   immature monocytic cells, but not to the degree seen in the marrow smears. This is likely   attributable to hemodilution of the sample received for flow cytometry. (Aberrant CD56, unusually dim CD38 - but only 3-4% assayed cells are myeloblasts)	Negative	0	Negative	NA	NA	TP53 (p.P151H; 97.9%)	TET2 (p.G355D; MAF 33.8%)|TP53 (p.P19H; MAF 8.9%)	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2116	aml_ohsu_2022_2116_BA2867	Waves1+2	Yes	2	mono	78	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with mutated CEBPA	78	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine	NA	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	NA	46,XY[20]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD7 (-), CD10(-), CD11b(-), CD13(dim +), CD14(-), CD15(+), CD16(-), CD19(-), CD22(partial +), CD33(-), CD34(bright +), CD36 (-), CD38(variably +), CD45(partial dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(partial +), MPO(-) and TdT(+) (Population #1 - 5.3%) | CD2(-), CD7(-), CD10 (-), CD11b(-), CD13(bright and variably +), CD14(-), CD15(-), CD16(-), CD22(-), CD33(partial +), CD34 (variably +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(partial +), MPO(partial +), and TdT (-). (Population #2 - 25%)	Negative	0	Negative	RUNX1 (p.P383Afs*217; 46.0%)	NA	NA	NA	Acute Myeloid Leukemia	AML	1.7	MATCHED
aml_ohsu_2022_2080	aml_ohsu_2022_2080_BA2089	Waves1+2	Yes	1	NA	68	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	68	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Leukapheresis	2	3+7 (Cytarabine, Daunorubicin)|Azacitidine	2	Induction|Maintenance	Refractory	3+7 (Cytarabine, Daunorubicin)	Induction	7	M5	46,XY[20]	normal	NA	Negative	0	Negative	NA	ASXL1 (p.G645Wfs*12; 60.0%)	NA	ASXL1 (p.G645fs*12; MAF 52%)|IDH1 (p.R132L; MAF 47%)|KRAS (p.G12A; MAF 36%)|MLL (Partial tandem duplication )|SRSF2 (p.P95H; MAF 49%)	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2080	aml_ohsu_2022_2080_BA2034	Waves1+2	No	1	NA	68	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	68	72	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	2	3+7 (Cytarabine, Daunorubicin)|Azacitidine	2	Induction|Maintenance	Refractory	3+7 (Cytarabine, Daunorubicin)	Induction	7	M5	46,XY[19]	normal	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2202	aml_ohsu_2022_2202_BA2224	Waves1+2	Yes	1	NA	62	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	Decitabine|Hydroxyurea	2	Induction|Re-induction	Complete Response i	Hydroxyurea	Re-induction	263	M2	46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]	EGR1 (73.5%) ;  TP53: (85.5%)	CD7, CD34, CD117, HLA-DR, CD13, CD33, dim CD123, variable CD15 and subset MPO	Negative	0	Negative	NA	NA	TP53 (p.G266V; 65.7%)	JAK2 (p.V617F; MAF 1.5%)|SF3B1 (p.G742D; MAF 35%)|TP53 (p.G266V; MAF 55%)	Acute Myeloid Leukemia	AML	0.5	MATCHED
aml_ohsu_2022_2202	aml_ohsu_2022_2202_BA2470	Waves1+2	No	1	NA	62	TRUE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	63	412	Relapse	Relapse	Peripheral Blood	2	Decitabine|Hydroxyurea	2	Induction|Re-induction	Complete Response i	Hydroxyurea	Re-induction	263	M2	46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]	EGR1 (73.5%) ;  TP53: (85.5%)	NA	Negative	0	Negative	NA	NA	TP53 (p.G266V; 91.4%)	NA	Acute Myeloid Leukemia	AML	0.5	MATCHED
aml_ohsu_2022_2265	aml_ohsu_2022_2265_BA2046	Waves1+2	Yes	2	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	Complete Response	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	-1	NA	46,XY[19]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	CD2(-), CD4(-), CD7(subset +), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+).	Negative	0	Negative	RUNX1 (N260fs*223+; MAF 26%)	NA	NA	IDH1 (R132C; MAF 42%)|NF1 (N935H; MAF 49%)|RUNX1 (N260fs*223+; MAF 26%)|SRSF2 (P95L; MAF 38%)	Acute Myeloid Leukemia	AML	1.2	MATCHED
aml_ohsu_2022_2111	aml_ohsu_2022_2111_BA2972	Waves1+2	Yes	1	bi	40	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated CEBPA	40	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	HiDAC|3+7 (Cytarabine, Daunorubicin)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	-1	M1	46,XY[20]	normal	dim CD7, CD13, CD33, CD34, CD38, partial CD56 (25%), CD58, dim CD64, CD117, dim CD123, HLA-DR, and MPO+.	Negative	0	Negative	NA	NA	NA	CEBPA (p.K313_V314insK; MAF 39%)|CEBPA (p.S28fs*81; MAF 28%)|ZRSR2 (p.R378W; VAF 100%)	Acute Myeloid Leukemia	AML	0.366666667	MATCHED
aml_ohsu_2022_2411	aml_ohsu_2022_2411_BA2978	Waves1+2	Yes	1	NA	14	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	14	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	8	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Donor Lymphocyte Infusion|HiDAC|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide|Clofarabine, Cytarabine	4	Allogeneic - Sibling|Salvage|Induction|Re-induction	Complete Response	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)	Allogeneic - Sibling	-1	M2	46,XX,t(8;21)(q21.3;q22)[17]/49,sl,+4,+15,+der(21)t(8;21)[2]/53,sdl,-4,+13,+18,+19,+20,+21[4]	All twenty-three metaphase cells examined were abnormal, with t(8;21), leading to RUNX1/RUNX1T1 fusion.   Two subclones, comprising 6 cells total, had an additional copy of the der(21).	CD13, CD33, CD34, CD38, CD56, CD58, dim/partial CD64, CD117, CD123, HLA-DR and MPO	Negative	0	Negative	NA	NA	NA	FBXW7 (p.G79S; MAF 50%)|KIT (p.D816Y; MAF 45%)|NRAS (p.G12D; MAF 45%)	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2238	aml_ohsu_2022_2238_BA2829	Waves1+2	Yes	1	NA	53	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	54	7	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	4	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	Refractory	Sorafenib	Experimental	49	NA	46,XY,add(3)(p24)[cp4]/46,XY[14]	normal	CD117 (Initial diagnosis on 7/27/2015 BMBX: CD7, dim CD11b, CD13, CD33, partial CD34, CD58, CD117, CD123, dim MPO, and HLA-DR positive)	Positive	NA	Positive	NA	NA	NA	CBL (p.I423N; MAF <0.5%)|DNMT3A (p.R882C; MAF 0.9%)|FLT3-ITD (MAF 2.9)|NPM1 (p.W288fs*12; MAF 0.7%)|TET2 (p.Q548*; MAF 0.7%)	Acute Myeloid Leukemia	AML	1	MATCHED
aml_ohsu_2022_2238	aml_ohsu_2022_2238_BA2579	Waves1+2	No	1	NA	53	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	54	30	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	4	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	Refractory	Sorafenib	Experimental	49	NA	46,XY[12]	normal	dim variable CD7, dim CD11b, CD13, CD33, CD34, CD58, CD117, and CD123	Positive	NA	Positive	NA	NA	NA	DNMT3A (p.R882C; MAF 6%)|FLT3-ITD (MAF 15-20%)|NPM1 (p.W288fs*12; MAF 6%)|TET2 (p.Q548*, MAF 6%)	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2238	aml_ohsu_2022_2238_BA2249	Waves1+2	No	1	NA	53	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	54	63	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	4	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	Refractory	Sorafenib	Experimental	49	NA	46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]	normal	dimCD7, CD13, dimCD11b, CD33, variable CD34, CD58,  CD117, CD123, and HLA-DR positive	Positive	9	Positive	NA	NA	NA	DNMT3A (p.R882C; MAF 45%)|FLT3-D835 (p.D835H; MAF 15%)|FLT3-ITD (MAF 78%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.Q548*; MAF 45%)	Acute Myeloid Leukemia	AML	1.1	MATCHED
aml_ohsu_2022_2238	aml_ohsu_2022_2238_BA2979	Waves1+2	No	1	NA	53	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	54	75	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	4	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	Refractory	Sorafenib	Experimental	49	NA	46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]	normal	NA	Positive	19	Positive	NA	NA	NA	DNMT3A (p.R882C; MAF 45%)|FLT3-D835 (p.D835H; MAF 15%)|FLT3-ITD (MAF 78%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.Q548*; MAF 45%)	Acute Myeloid Leukemia	AML	0.9	MATCHED
aml_ohsu_2022_2437	aml_ohsu_2022_2437_BA2851	Waves1+2	Yes	1	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with maturation	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	Refractory	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	7	M2	46,XX[20]	Normal	partial CD7, CD13, CD33, CD34, variable CD38, CD117, CD123, partial HLA-DR and dim MPO	Negative	0	Negative	NA	NA	NA	DNMT3A (p.R882H; MAF 45%)|FLT3-D835 (p.D835Y; MAF 3%)|MLL (Partial Tandem Duplication)|NRAS (p.G13D; MAF 35%)|NRAS (p.Q61R; MAF 3%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2215	aml_ohsu_2022_2215_BA2587	Waves1+2	Yes	1	NA	64	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	64	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	6	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC|Hydroxyurea|Cytarabine, Methotrexate	5	Consolidation|Induction|Allogeneic - Child|CNS|Re-induction	Complete Response	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)	Allogeneic - Child	-1	M5	46,XY,inv(16)(p13q22)[20]	CBFB (77%)	dim CD2, variable CD5, CD13, CD33, CD34, CD38, variable CD64, CD117, dim CD123, HLA-DR, and MPO (Blast immunophenotype) | dim CD4, CD11b, CD14, dim CD15, CD33, dim CD34, CD38, CD64, dim HLA-DR, and bright MPO (Monocytic/blast equivalent immunophenotype)	Negative	0	Negative	NA	NA	NA	KIT (p.D816V; MAF 45% )	Acute Myeloid Leukemia	AML	0.5	MATCHED
aml_ohsu_2022_2025	aml_ohsu_2022_2025_BA2461	Waves1+2	No	1	NA	66	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	66	0	Post-Chemotherapy	Remission	Bone Marrow Aspirate	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Refractory	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	NA	46,XY[20]	Normal	The analysis was performed by flow cytometry on the bone marrow aspiratespecimen. The analysis shows CD34+ blasts account for 1% of CD45+ events. Maturing myeloid precursors and monocytic cells demonstrate a normal pattern of myelomonocytic antigen expression. | Lymphocytes account for 5% of CD45+ events and include 90% T cells and 7% NK cells. T cells demonstrate a CD4:CD8 ratio of 2.4:1 without aberrant antigen expression. B cells are essentially absent; no definitive monoclonal B cell population is identified	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2122	aml_ohsu_2022_2122_BA2024	Waves1+2	Yes	1	NA	48	FALSE	TRUE	FALSE	FALSE	FALSE	FavorableOrIntermediate	AML with mutated NPM1	48	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	ADE (Cytarabine, Daunorubicin & Etoposide)	1	Induction	Unknown	ADE (Cytarabine, Daunorubicin & Etoposide)	Induction	7	NA	46,XY[20]	Normal	CD33, CD117 positive, negative for CD34 and HLA-DR	Positive	NA	Positive	NA	NA	NA	FLT3-ITD (MAF 33%)|IDH2 (p.R140Q; MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2049	aml_ohsu_2022_2049_BA2623	Waves1+2	Yes	3	NA	72	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	72	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	2	Azacitidine|Momelotinib	2	Hypomethylating/Low Dose Cytarabine|Experimental	NA	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	NA	46,XY,inv(16)(p13.1q22)[20]	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2511	aml_ohsu_2022_2511_BA2426	Waves1+2	Yes	5	NA	62	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	7+3 (Cytarabine, Idarubicin)	Induction	-1	NA	46,XY,inv(16)(p13.1q22)[20]	positive for rearrangement of CBFB in 60.5% of cells.	positive for CD13, CD33, HLA-DR, CD34, and CD117, with partial aberrant expression of CD7. (Peripheral blood) | positive for CD34, CD117, HLA-DR, CD13, and CD33 (Marrow)	Negative	0	Negative	NA	NA	NA	EZH2 (p.D146H; MAF 50%)	Acute Myeloid Leukemia	AML	0.566666667	MATCHED
aml_ohsu_2022_2386	aml_ohsu_2022_2386_BA2271	Waves1+2	Yes	1	NA	8	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Myeloid leukaemia associated with Down syndrome	8	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	ADE (Cytarabine, Daunorubicin & Etoposide)|Cytarabine	2	Induction|CNS	Complete Response	Cytarabine	CNS	151	M1	47,XY,+21c[20]	RUNX1 (21q22): 89% of cells had three signals for RUNX1 (21q22) consistent with the three copies of chromosome 21 seen on metaphase analysis.	dim CD11b, variable CD13, dim variable CD14, CD15, CD38, CD58, dim CD64, and MPO	Negative	0	Positive	NA	NA	NA	NPM1 (p.W288fs*12; MAF 50%)	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2420	aml_ohsu_2022_2420_BA3004	Waves1+2	Yes	1	NA	76	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	5+2 (Cytarabine, Idarubicin)|Decitabine	2	Induction|Re-induction	Refractory	5+2 (Cytarabine, Idarubicin)	Re-induction	4	M1	46,XX[22]	Normal	dimCD13, CD33, CD45, CD56, dimCD117 and MPO positive	Positive	NA	Positive	NA	NA	NA	ASXL1 (p.G966delG; MAF 50%)|DNMT3A (p.R736H; MAF 45%)|FLT3-ITD (MAF 20%)|NPM1 (p.W288fs*12; MAF 35%)	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2478	aml_ohsu_2022_2478_BA3010	Waves1+2	Yes	6	NA	71	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	71	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	3	Vidaza|Rituximab|Decitabine	2	Consolidation|Maintenance	NA	Decitabine	Maintenance	86	NA	46,XY[20]	NA	Positive for CD34, CD117, HLADR, CD33, CD13 but negative for CD14, CD64, CD11b, CD19, and CD3 (Peripheral Immunophenotyping) | The blasts are positive for CD34 and CD117 (Bone marrow Immunophenotyping)	Negative	0	Negative	RUNX1 (p.R320*; 40.9%)	ASXL1 (p.G646Wfs*12; 39.4%)	NA	BCOR (p.A603pfs*66; MAF55%)|KRAS (p.G12V; MAF 49%)|RUNX1 (pR320*; MAF 47%)|SRSF2 (p.P95H; MAF 49%)|STAG2 (p.Y636*; MAF 96%)	Acute Myeloid Leukemia	AML	0.333333333	UNMATCHED
aml_ohsu_2022_2393	aml_ohsu_2022_2393_BA2662	Waves1+2	Yes	1	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	FavorableOrIntermediate	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea	4	Consolidation|Unknown|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M5	46,XX[20]	Normal	NA	Positive	NA	Positive	NA	NA	NA	CEBPA (p.K298Q; MAF 25%)|DNMT3A (p.R882C; MAF 44%)|FLT3-ITD (MAF 25%)|IDH2 (p.R140Q; MAF 18%)|NPM1 (p.W288fs*12; MAF 46%)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2044	aml_ohsu_2022_2044_BA2280	Waves1+2	Yes	1	NA	72	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	72	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib	2	Induction|Experimental	Refractory	Ponatinib	Experimental	15	M1	46,XX[20]	Normal	CD13, CD33, CD38, partial CD56, partialCD64, CD117, dimCD123, and MPO	Positive	NA	Positive	NA	NA	NA	CEBPA (p.E163*; MAF 39%)|FLT3-ITD (MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)	Acute Myeloid Leukemia	AML	0.866666667	MATCHED
aml_ohsu_2022_2044	aml_ohsu_2022_2044_BA2277	Waves1+2	No	1	NA	72	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	72	40	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib	2	Induction|Experimental	Refractory	Ponatinib	Experimental	15	M1	46,XX[5]	Normal	NA	Positive	0.639344262	Positive	NA	NA	NA	CEBPA (p.E163*; MAF 40%)|FLT3-ITD (MAF 45%)|NPM1 (p.W288fs*12; MAF 32%)	Acute Myeloid Leukemia	AML	0.833333333	MATCHED
aml_ohsu_2022_2137	aml_ohsu_2022_2137_BA2230	Waves1+2	Yes	1	NA	54	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	54	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	HiDAC|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	NA	47,XY,+8[3]/46,XY[17]	1% RUNX1T1	NA	Negative	0	Positive	NA	NA	NA	FLT3 (p.N841I; MAF 40%)|NPM1 (p.W288fs*12; MAF 20%)|U2AF1 (p.R156H; MAF 40%)	Acute Myeloid Leukemia	AML	0.1	MATCHED
aml_ohsu_2022_2218	aml_ohsu_2022_2218_BA2658	Waves1+2	Yes	1	NA	24	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myelomonocytic leukaemia	24	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	7	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Decitabine|Fludarabine, Cyclophosphamide, TBI |Busulfan, Cyclophosphamide	7	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance|Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	M4	46,XY[20]	Normal	dimCD13, CD33, CD34, CD56, CD117, and  CD123	Negative	0	Negative	NA	NA	NA	NRAS (p.G12C; MAF 40%)	Acute Myeloid Leukemia	AML	0.7	MATCHED
aml_ohsu_2022_2218	aml_ohsu_2022_2218_BA2484	Waves1+2	No	1	NA	24	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myelomonocytic leukaemia	24	42	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	7	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Decitabine|Fludarabine, Cyclophosphamide, TBI |Busulfan, Cyclophosphamide	7	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance|Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	M4	46,XY[21]	Normal	immunophenotype (10% by flow): dim CD13, CD33, CD34, variable  CD56, variable CD117, and dim CD123-positive  - Promonocyte immunophenotype (70% by flow): CD11b, CD13, CD14, variable  CD16, CD33, variable CD56, CD64, and HLA-DR- positive	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.566666667	MATCHED
aml_ohsu_2022_2257	aml_ohsu_2022_2257_BA2512	Waves1+2	Yes	3	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	SGN-CD33A	1	Experimental	NA	SGN-CD33A	Experimental	-1	M5	NA	Normal	partial CD56, bright CD33,  CD13, bright CD64, HLA-DR (Monocytic cells)	Negative	0	Positive	NA	NA	NA	DNMT3A (c.2645G>A; MAF 45.4%)|FLT3-D835 (c.2503G>T (D835Y); MAF 15.5%)|NPM1 (c.860_863dup; MAF 11%)|PTPN11 (c.178G>C; MAF 8.4%)|PTPN11 (c.211T>C; MAF 10%)|TET2 (c.3955-2A>G; MAF 45.4%)	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2375	aml_ohsu_2022_2375_BA2457	Waves1+2	Yes	2	NA	44	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	44	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	4	NA	46,XX[20]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2 (-), CD4(partial +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34 (-), CD36(-), CD38(bright +/variable), CD45(+), CD56(-), CD64(-), CD117(+) and HLA-DR(partial +).	Negative	0	Positive	NA	NA	NA	NPM1 (W288FS*10+; MAF 24.0%)	Acute Myeloid Leukemia	AML	0.833333333	MATCHED
aml_ohsu_2022_2381	aml_ohsu_2022_2381_BA2394	Waves1+2	Yes	3	NA	73	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	73	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	Azacitidine	Hypomethylating/Low Dose Cytarabine	7	NA	45,X,-Y[20]	Normal	NA	Negative	0	Negative	RUNX1 (c.319C>G; MAF 73.9%)	ASXL1 (c.1940dup; MAF 37.9%)	NA	ASXL1 (c.1940dup; MAF 37.9%)|BCORL1 (c.3496dup: MAF 7.5%)|RUNX1 (c.319C>G; MAF 73.9%)|TET2 (c.3803+1G>A; MAF 39.3%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2018	aml_ohsu_2022_2018_BA2950	Waves1+2	Yes	6	NA	44	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with minimal differentiation	47	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	1	Radiation	1	Unknown	NA	Radiation	Unknown	14	NA	46,XX[20]	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small precentage of tumor cells with chromosome abnormalities may not be detected due to the cells examined.	The blasts are positive for HLA-DR, CD34, CD117 (PARTIAL), CD13, CD(PARTIAL/DIM), CD33, TDT (DIM, SUBSET) and are negative for CD11b, CD14, CD64, MPO and all B and T cell markers. (Bone Marrow Immunophenotyping)	Positive	1	Negative	RUNX1 (p.L98Pfs*40; 46.8%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2156	aml_ohsu_2022_2156_BA2981	Waves1+2	Yes	6	NA	76	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	77	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	1	Azacitidine	1	Unknown	NA	Azacitidine	Unknown	424	NA	48-51,XX,del(4)(q25),del(5)(q11.2),-17,-18,+22,+3-5mar[20]	NA	POSITIVE FOR DIM CD45, HLADR, CD34, CD117, CD13, CD33, CD43, CD81, CD58. (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	TP53 (p.R175H; 91.7%)	NA	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2226	aml_ohsu_2022_2226_BA2934	Waves1+2	No	1	NA	74	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	74	0	Post-Chemotherapy	Remission	Peripheral Blood	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|MiDAC	2	Consolidation|Induction	Refractory	MiDAC	Consolidation	3	NA	46,XX[20]	normal	NA	NA	NA	NA	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2226	aml_ohsu_2022_2226_BA2668	Waves1+2	No	1	NA	75	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Therapy-related myeloid neoplasms	75	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	Complete Response	Azacitidine	Hypomethylating/Low Dose Cytarabine	752	M5	46,XX,t(9;11)(p22;q23)[20]	85% MLL rearrangement (c/w karyotype)	dim CD13, CD33, CD56, bright CD64, CD117, CD123 and HLA-DR-positive; MPO and CD34-negative (Discrete population compared to diagnosis)	Negative	0	Negative	NA	NA	NA	No gene mutations found in the 76 genes tested	Acute Myeloid Leukemia	AML	0.066666667	MATCHED
aml_ohsu_2022_2351	aml_ohsu_2022_2351_BA2539	Waves1+2	No	3	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	50	0	Post-Chemotherapy	Remission	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)|MiDAC	4	Consolidation|Induction|Re-induction|Maintenance	Refractory	Azacitidine	Maintenance	8	NA	46,XX[20]	showed multiple RUNX1 signals as well as a 3rd RUNX1 signal at 7p consistent with t(7;21)(p22;q22).	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2177	aml_ohsu_2022_2177_BA2339	Waves1+2	Yes	6	NA	30	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with t(9;11)(p22;q23); MLLT3-MLL	31	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response i	HiDAC	Consolidation	93	NA	46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[19]/46,XX[1]	This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on previous sample.	There are increased abnormal cells in the monocyte gate that stain positive for CD38, CD11b, CD14, CD64, CD33, with partial MPO, HLADR, CD13 expression. (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2177	aml_ohsu_2022_2177_BA2786	Both	No	6	NA	30	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with t(9;11)(p22;q23); MLLT3-MLL	31	25	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response i	HiDAC	Consolidation	93	NA	46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[20]	This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on previous sample. (Cytogenetics)	POSITIVE FOR CD33, CD11B, CD64, CD4 AND MPO (SUBSET/DIM) AND ARE NEGATIVE FOR CD117, CD13, CD34, HLA-DR AND TDT (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2425	aml_ohsu_2022_2425_BA2738	Waves1+2	Yes	1	NA	66	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Decitabine	1	Induction	Unknown	Decitabine	Induction	-1	M2	46,XY,t(4;9)(q21;p22)[7]/46,sl,add(1)(p13),add(15)(q15)[6]/45,sdl1,-18[4]/49,sdl2,+add(1)(p13),+6,+8,+18[2]/46,XY[1]	20% CEP 8, 24% RUNX1T1/RUNX1, 23% PML/RARA	CD13, CD33, CD34, CD38, CD58, CD117, and HLA-DR positive	Negative	0	Negative	NA	NA	NA	JAK2 (p.V16F. MAF 15%)	Acute Myeloid Leukemia	AML	0.633333333	MATCHED
aml_ohsu_2022_2074	aml_ohsu_2022_2074_BA2256	Waves1+2	Yes	6	NA	25	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	26	49	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	4	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Cladribine, Cytarabine, Idarubicin	3	Consolidation|Induction|Re-induction	Complete Response	Azacitidine, Sorafenib	Re-induction	67	NA	46,XX,t(7;12)(q22;p13)[12]/46,XX,t(7;17)(p10;q10),-9,+mar[7]/46,XX[1]	This test has detected a translocation between 7 and 12 in 12 cells; a translocation between 7 and 17 with loss of a chromosome 9 and a marker in 7 cells.	These are positive for CD34, CD117, HLADR, CD33 but negative for CD13 and CD11b. TdT and CD79a are partially expressed. (Bone Marrow Immunophenotyping)	Positive	1	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2172	aml_ohsu_2022_2172_BA2483	Waves1+2	Yes	1	NA	63	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	64	44	Residual Disease	Residual	Peripheral Blood	6	7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Supportive/Palliative Care	Complete Response	Hydroxyurea	Supportive/Palliative Care	29	NA	48,XX,+8,+21[16]/46,XX[4]	RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on banded chromosomes and the partner remains unkn	CD4, partial CD11b, partial CD13, CD33, CD34, CD38,  partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive | CD4, partial CD11b, partial CD13, CD33, CD34, CD38, partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	1.233333333	MATCHED
aml_ohsu_2022_2172	aml_ohsu_2022_2172_BA3002	Waves1+2	No	1	NA	63	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	64	58	Residual Disease	Residual	Peripheral Blood	6	7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Supportive/Palliative Care	Complete Response	Hydroxyurea	Supportive/Palliative Care	29	NA	48,XX,+8,+21[16]/46,XX[4]	RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21 MLL: 68% of cells had a split signal pattern consistent with MLL (11q23)	CD4, partial CD11b, partial CD13, CD33, CD34, CD38, partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	1.866666667	MATCHED
aml_ohsu_2022_2251	aml_ohsu_2022_2251_BA2109	Waves1+2	Yes	1	NA	52	FALSE	TRUE	FALSE	FALSE	FALSE	MissingKaryo	Acute myelomonocytic leukaemia	52	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	81	M4	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NOTCH1 (p.K2181R ; MAF 50%)|SRSF2 (p.P95H ; MAF 50%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2507	aml_ohsu_2022_2507_BA2242	Waves1+2	Yes	1	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	6	Fludarabine, Melphalan|Ruxolitinib|7+3 (Cytarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC|Ibrutinib	5	Consolidation|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	Refractory	Ruxolitinib	Maintenance	-1	M1	NA	normal	partial CD13, CD33, CD38, moderate CD45, CD56, CD58,  CD64, dim CD117, CD123 and MPO+	Negative	0	Positive	NA	NA	NA	CREBBP (p.R2353Q; MAF 51%)|NPM1 (p.W288fs*12; MAF 46%)|TET2 (p.Q270*; MAF 90%)	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2140	aml_ohsu_2022_2140_BA2132	Waves1+2	Yes	6	NA	70	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	70	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Azacitidine	1	Induction	Unknown	Azacitidine	Induction	37	NA	46,XX,del(5)(q22q35)[20]	Positive for 5q deletion in 91% of cells.	POSITIVE FOR CD34, HLA-DR, CD117 AND CD33, AND NEGATIVE FOR MPO, TdT, CD13, CD19, CD20 AND CD10. (Bone Marrow Immunophenotyping)	Positive	0.333333333	Negative	NA	NA	NA	FLT3-ITD|MLL |U2AF1 (p.S34F; MAF 35%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2498	aml_ohsu_2022_2498_BA2618	Waves1+2	Yes	1	NA	83	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	83	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	2	AG-221|Azacitidine, SGN-CD33A	2	Induction|Experimental	Refractory	AG-221	Experimental	-1	NA	46,XY[20]	Normal	NA	Negative	0	Negative	NA	ASXL1 (p.Y425*; 46.8%)	NA	CREBBP (p.M2408V; MAF 48%)|IDH2 (p.R140Q; MAF 47%)|NRAS (p.G12D; MAF 49%)	Acute Myeloid Leukemia	AML	1	MATCHED
aml_ohsu_2022_2004	aml_ohsu_2022_2004_BA2846	Waves1+2	Yes	1	NA	75	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	Therapy-related myeloid neoplasms	75	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	2	Hydroxyurea|Decitabine	1	Supportive/Palliative Care	NA	Decitabine	Supportive/Palliative Care	4	M1	46,XY[20]	Normal	CD33, dim CD38, variable CD56, CD58, dim CD64, CD117, CD123, and MPO positive.	Negative	0	Positive	NA	NA	NA	IDH2 (p.R140Q; MAF 47%)|NPM1 (p.W288fs*12 (4 nt insertion with frameshift); MAF 17%)|SRSF2 (p.P95L; MAF 37%)	Acute Myeloid Leukemia	AML	0.5	MATCHED
aml_ohsu_2022_2433	aml_ohsu_2022_2433_BA2521	Both	No	1	NA	44	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	44	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	6	Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea|Busulfan, Cyclophosphamide|7+3 (Cytarabine, Idarubicin) plus Dasatinib	5	Allogeneic - Sibling|Induction|Experimental|Re-induction|Post-Transplant Relapse	Complete Response i	Azacitidine	Post-Transplant Relapse	81	M5	46,XX[20]	Normal	CD13, CD33, subset CD34, variable CD117, CD123, HLA-DR, and variable MPO positive - Monocytic/blast equivalent immunophenotype: CD11b, CD13, subset CD14, variable CD16, CD33, CD64, dim CD123, and HLA-DR positive	Positive	2.333333333	Positive	NA	NA	NA	DNMT3A (p.R882H; MAF 48%)|FLT3-ITD (MAF 70%)|NPM1 (p.W288fs*12; MAF 46%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2139	aml_ohsu_2022_2139_BA2885	Waves1+2	Yes	1	NA	81	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	81	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Azacitidine	1	Induction	Unknown	Azacitidine	Induction	6	M5	46,XX[20]	Normal	CD11b, variable CD13, variable CD14, CD33, CD56, CD64, dim CD123 and dim HLA-DR positive	Negative	0	Positive	NA	ASXL1 (p.G645Vfs*58; 16.7%)	NA	ASXL1 (p.W796fs*22; MAF 48%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.S825fs*1; MAF 49%)	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2368	aml_ohsu_2022_2368_BA2639	Waves1+2	Yes	1	NA	36	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	36	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	6	Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M2	46,XX,t(16;16)(p13.2;q22)[20]	CBFB: 191/200 cells (95.5%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement, consistent with the 16;16 translocation observed in the metaphase karyotype.	Immunophenotype: CD13, partial CD15, dim CD33, CD34, CD38, dim CD45, CD58, variable CD64, variable CD117, CD123, and dim HLA-DR positive.	Negative	0	Negative	NA	NA	NA	KIT (p.T417_D419delinsY; MAF 33%)	Acute Myeloid Leukemia	AML	0.433333333	MATCHED
aml_ohsu_2022_2138	aml_ohsu_2022_2138_BA2775	Waves1+2	Yes	3	NA	26	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	27	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	-1	NA	46,XY[15]	Normal	weak  CD13, CD33, partial CD117, and myeloperoxidase	Negative	0	Positive	NA	NA	NA	IDH2 (p.Arg140Gln; MAF 45.9%)|NPM1 (p.Trp288fs; MAF 19.5%)	Acute Myeloid Leukemia	AML	0.433333333	MATCHED
aml_ohsu_2022_2410	aml_ohsu_2022_2410_BA2402	Waves1+2	Yes	1	NA	82	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Therapy-related myeloid neoplasms	82	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	46,XX	trisomy 8 in 5 of 20 metaphase cells	NA	Negative	0	Negative	NA	NA	NA	DNMT3A (p.R882H; MAF 39%)|GATA1 (p.R191C; MAF 51%)|IDH2 (p.R172K; MAF 36%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2201	aml_ohsu_2022_2201_BA2925	Waves1+2	No	4	NA	77	FALSE	FALSE	TRUE	FALSE	FALSE	IntermediateOrAdverse	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	Azacitidine, Sorafenib|Decitabine, Midostaurin	2	Induction|Re-induction	Refractory	Azacitidine, Sorafenib	Re-induction	-1	NA	46,XY[20]	CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)	ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56	Positive	NA	Negative	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	0.633333333	MATCHED
aml_ohsu_2022_2201	aml_ohsu_2022_2201_BA2097	Waves1+2	Yes	4	NA	77	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	Azacitidine, Sorafenib|Decitabine, Midostaurin	2	Induction|Re-induction	Refractory	Azacitidine, Sorafenib	Re-induction	-1	NA	46,XY[20]	CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)	ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56	Positive	0.612903226	Negative	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	0.866666667	MATCHED
aml_ohsu_2022_2590	aml_ohsu_2022_2590_BA3065	Waves1+2	Yes	1	NA	69	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	72	0	Post-Transplant|Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	7	7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Sorafenib|MiDAC|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	7	Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction|Maintenance|Supportive/Palliative Care	Complete Response	Sorafenib	Maintenance	-1	NA	46,XY[18]	Normal	Immunophenotype: dim CD13, CD33, CD117, CD123 and MPO positive.	Positive	NA	Positive	NA	NA	NA	CEBPA (p.A240fs*83 (7 bp insertion with frameshift); MAF 19%)|CREBBP (p.P1150S; MAF 18%)|FLT3-ITD (MAF 56%)|IDH2 (p.R140Q; MAF 29%)|NPM1 (p.W288fs*12; MAF 29%)|SRSF2 (p.P95L; MAF 22%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2421	aml_ohsu_2022_2421_BA2114	Waves1+2	No	1	NA	68	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Chronic myelomonocytic leukaemia	68	0	Unknown	NA	Bone Marrow Aspirate	7	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC|Enasidenib|Hydroxyurea|Enasidenib, Cytarabine	6	Consolidation|Salvage|Induction|Re-induction|Maintenance|Supportive/Palliative Care	Complete Response	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Salvage	4	M4	46,XX[20]	Normal	CD19, CD20, and surface kappa light chain positive (For B cell population)	Negative	0	Positive	NA	NA	NA	DNMT3A (p.R882H; MAF 34%)|FLT3-D835 (p.D835V; MAF 11%)|KRAS (p.G13D; MAF 8%)|MYD88 (p.L265P; MAF 8%)|NPM1 (p.W288fs*12; MAF 25%)	Myelodysplastic/Myeloproliferative Neoplasms	MDS/MPN	1.266666667	MATCHED
aml_ohsu_2022_2287	aml_ohsu_2022_2287_BA2661	Waves1+2	Yes	3	NA	56	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response i	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	NA	46,XY[20]	Normal	84% are monocytes, and 9% are myeloid  cells. The monocytic cells (percentages shown) appear  atypical with expression of CD13, bright CD33, and bright  CD64, but weaker than normal HLA-DR and include 48% that  are phenotypically consistent with promonocytes/monoblasts	Negative	0	Positive	NA	NA	NA	DNMT3A (p.Val716Asp; MAF 45%)|FLT3-D835 (p.Asp835Val; MAF 30.5%)|NPM1 (p.Trp288fs; MAF 16.1%)|RAD21 (p.Glu178*; MAF 12%)	Acute Myeloid Leukemia	AML	1.266666667	MATCHED
aml_ohsu_2022_2196	aml_ohsu_2022_2196_BA2399	Waves1+2	Yes	2	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI |7+3 (Cytarabine, Idarubicin) plus Crenolanib	4	Consolidation|Induction|Allogeneic - Child|Maintenance	Complete Response	Cyclophosphamide	Maintenance	1	NA	46,XY[29]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(dim +), CD14(-), CD15(-/few dim +), CD16(-), CD33(+), CD34 (partial +), CD36(equivocal/small subset appears +), CD38(partial +), CD45(+), CD56(-), CD64(-/few dim +), CD117(+), HLA-DR(+ and variable), TDT(-), MPO(+)	Positive	1	Negative	NA	NA	NA	FLT3-ITD (S584_S585INSSDNEYFYVDFRE; MAF 29.0%)|IDH1 (R132H; MAF 47.0%)|MLL (Foundation; MLL-PTD Exons 2-8; not GeneTrails)|TET2 (SPLICE SITE 3500+1G>A; MAF 48.0%)	Acute Myeloid Leukemia	AML	0.766666667	MATCHED
aml_ohsu_2022_2068	aml_ohsu_2022_2068_BA2692	Waves1+2	Yes	1	NA	58	FALSE	FALSE	TRUE	FALSE	FALSE	Favorable	Therapy-related myeloid neoplasms	58	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	7	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide|Fludarabine, Cytarabine	7	Consolidation|Salvage|Unknown|Induction|Maintenance|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Azacitidine	Unknown	-1	M2	46,XX,inv(16)(p13.1q22)[16]/46,XX[4]	CBFB: 69/100 cells (69%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement and consistent with the inverted chromosome 16 in the metaphase karyotype.	CD13, variable CD15, CD33, CD34, variable CD64, CD117, dim CD123, dim HLA-DR, MPO and subset TdT-positive	Negative	0	Negative	NA	NA	NA	KDM6A (p.I598V; MAF 50%)|KRAS (p.G12D; MAF 4%)|NRAS (p.G12S; MAF 6%)	Acute Myeloid Leukemia	AML	0.466666667	MATCHED
aml_ohsu_2022_2514	aml_ohsu_2022_2514_BA2103	Waves1+2	Yes	2	NA	54	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	54	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	88	NA	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[196],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198] (MDS Fish Panel) | nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200] (AML FISH Panel)	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(-), CD16(-), CD33(variably +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(partial +), CD64 (partial +), CD117(variably +), HLA-DR(-).	Negative	0	Positive	NA	NA	NA	FLT3 (I836DEL; MAF 18.0%)|FLT3 (N841I; MAF 8.0%)|FLT3 (V491L; MAF 3.0%)|FLT3 (V592A; MAF 1.0%)|IDH2 (R140Q; MAF 47.0%)|NPM1 (W288FS*10+; MAF 35.0%)|SRSF2 (P95L; MAF 41.0%)	Acute Myeloid Leukemia	AML	0.8	MATCHED
aml_ohsu_2022_2210	aml_ohsu_2022_2210_BA2850	Waves1+2	Yes	6	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	50	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Induction|Re-induction	Refractory	Busulfan, Fludarabine	Allogeneic - Sibling	-1	NA	46,XY[20]	NA	These are postive for CD34, CD117, HLADR, CD13 and CD33. These are negative for CD3, CD20, CD4, CD11b. (Bone Marrow Immunophenotyping)	Positive	1.5	Negative	RUNX1 (p.E454Gfs*149; 21.4%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.7	MATCHED
aml_ohsu_2022_2210	aml_ohsu_2022_2210_BA2993	Waves1+2	No	6	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	50	30	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Induction|Re-induction	Refractory	Busulfan, Fludarabine	Allogeneic - Sibling	-1	NA	46,XY[20]	NA	NA	Positive	1.5	Negative	RUNX1 (p.E454Gfs*149; MAF 51%)	NA	NA	DNMT3A (p.r882H; MAF 45%)|FLT3-ITD|MLL |RUNX1 (p.E454Gfs*149; MAF 51%)	Acute Myeloid Leukemia	AML	0.633333333	MATCHED
aml_ohsu_2022_2210	aml_ohsu_2022_2210_BA2566	Waves1+2	No	6	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	50	63	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Induction|Re-induction	Refractory	Busulfan, Fludarabine	Allogeneic - Sibling	-1	NA	46,XY[20]	NA	CD117 stains clusters and scattered immature mononuclear cells with atypia, 20%. CD34 is negative. (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	0.6	MATCHED
aml_ohsu_2022_2210	aml_ohsu_2022_2210_BA3389	Waves3+4	No	6	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	51	225	Post-Chemotherapy|Post-Transplant	Remission	Bone Marrow Aspirate	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Induction|Re-induction	Refractory	Busulfan, Fludarabine	Allogeneic - Sibling	-1	NA	46,XY[20]	NA	No increased or immunophenotypically abnormal blast cell populations identified. (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2319	aml_ohsu_2022_2319_BA2027	Waves1+2	Yes	4	NA	70	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	70	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Hydroxyurea	1	Supportive/Palliative Care	NA	Hydroxyurea	Induction	1	NA	NA	Negative	Positive (increased CD34 positive blasts (50-60%), CD71 Decreased erythroid cells (less than 5%), CD61 Few scattered megakaryocytes, E-cadherin; Scattered immature erythroid precursors, CD117: Increased immature myeloid cells and blasts (70-80%), CD3: Scattered small interstitial T-cells (less than 5%), CD20 Scattered small interstitial B-cells (less than 5%)) | Negative (AML related recurrent cytogenetic abnormalities including t(15;17)) | Positive (PAX-5: Positive in few scattered small lymhocytes, CD138: scattered interstitial and perivascular plasma cells (less than 5%), Iron strian: Storage iron present in decalcified section, Reticulin Stain: Normal reticulin fiber pattern)	Positive	4	Positive	NA	NA	NA	DNMT3A (p.R882H; MAF 50%)|NPM1 (p.W288fs*12;MAF 40%)|SOCS1 (p.Q210H; MAF 50%)|TET2 (p.S460F; MAF 45%)	Acute Myeloid Leukemia	AML	0.466666667	MATCHED
aml_ohsu_2022_2009	aml_ohsu_2022_2009_BA2451	Waves1+2	Yes	1	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML without maturation	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Re-induction	Refractory	Azacitidine	Re-induction	-1	M1	46,XY,t(8;17)(p21;q11.2),del(17)(q2?4)[5]/46,XY[15]	Normal	dim/partial cCD3, variable CD7, CD13, dimCD33, CD34,  CD38, CD117, dim CD123, dim HLA-DR, partial TdT, and partial MPO positive Monoclonal B cell population identified	Negative	0	Negative	RUNX1 (p.E223*; 41.0%)	NA	NA	BCOR (p.Y1350*; MAF 65%)|FBXW7 (p.T15_G16insP; MAF 50%)|RUNX1 (p.E223*; MAF 25%)|STAG2 (p.G977fs*8; MAF 55%)	Acute Myeloid Leukemia	AML	1	MATCHED
aml_ohsu_2022_2009	aml_ohsu_2022_2009_BA3322	Waves3+4	No	1	NA	62	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML without maturation	63	487	Post-Chemotherapy	Remission	Bone Marrow Aspirate	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Re-induction	Refractory	Azacitidine	Re-induction	-1	M1	 46,XY[20)	NA	CD5, CD19, CD20 and dim surface kappa light chain +	Negative	0	Negative	RUNX1 (p.E223*; MAF 1%)	ASXL1 (p.S1028*; MAF 14%)	NA	ASXL1 (p.S1028*; MAF 14%)|BCOR (p.Y1350*; MAF 6%)|FBXW7 (p.T15_G16insP; MAF 49%)|FLT3|RUNX1 (p.E223*; MAF 1%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2341	aml_ohsu_2022_2341_BA2174	Waves1+2	Yes	1	NA	46	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	46	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	7	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG	4	Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Fludarabine, Melphalan, ATG	Double Umbilical Cord Blood Transplant (DUCBT)	-1	NA	46,XX,del(3)(p25),add(6)(p22),t(10;12)(p15;q13)[5]/46,XX[18]	Normal	Immunophenotype: CD13, CD34, CD38, CD58, CD117, CD123, HLA-DR and TdT-positive; small subset of blasts also express CD19, CD22, and CD79a	Negative	0	Negative	NA	NA	NA	DNMT3A (p.I824V; VAF 50%)|GATA1 (p.S412R; MAF 60%)|NRAS (p.G13R; MAF 50%)|RUNX1 (p.T196I ; MAF 50%)|U2AF1 (p.I24T; MAF 5%)	Acute Myeloid Leukemia	AML	1.266666667	MATCHED
aml_ohsu_2022_2341	aml_ohsu_2022_2341_BA2314	Waves1+2	No	1	NA	46	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	46	163	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	7	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG	4	Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Fludarabine, Melphalan, ATG	Double Umbilical Cord Blood Transplant (DUCBT)	-1	NA	46,XX[19]	Normal	NA	Negative	0	Negative	NA	NA	NA	NRAS (p.G13R;MAF 47%)	Acute Myeloid Leukemia	AML	1.733333333	MATCHED
aml_ohsu_2022_2136	aml_ohsu_2022_2136_BA2004	Waves1+2	Yes	1	NA	77	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	77	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	Azacitidine	Hypomethylating/Low Dose Cytarabine	253	M2	NA	EGR-1/ D5S23, D5S721: 58/200 cells (29%) had a 1 red/ 2 green signal pattern, consistent with a deleted 5q. D7S522/CEP 7: 38/200 cells (19%) had a 1 red/ 2 green signal pattern, consistent with a deleted 7q. CBFB: 40/200 cells (20%) had a single signal indicating deleted 16q22. TP53/CEP 17: 12/200 c	NA	Negative	0	Negative	NA	NA	TP53 (p.V272_R273insL; MAF 75%)	DNMT3A (p.E285D; MAF 40% )|KDM6A (p.Y215fs*2; MAF 40%)|TP53 (p.V272_R273insL; MAF 75%)	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2344	aml_ohsu_2022_2344_BA3001	Waves1+2	Yes	1	NA	51	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	HiDAC|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	-1	M1	46,XX[20]	Normal	Immunophenotype: CD7, CD13, CD33, CD38, CD117, CD123 and MPO positive	Negative	0	Positive	NA	NA	NA	CBL (p.R420Q; MAF ~20%)|FLT3 (p.N841K; MAF ~30%)|IDH2 (p.R140Q; MAF ~30%)|NPM1 (p.W288fs*12; MAF ~25%)	Acute Myeloid Leukemia	AML	1.166666667	MATCHED
aml_ohsu_2022_2565	aml_ohsu_2022_2565_BA2664	Waves1+2	No	2	NA	63	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Myelodysplastic syndrome, unclassifiable	63	0	Residual Disease	NA	Bone Marrow Aspirate	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	NA	46,XX,add(5)(q11.2),inv(9)(p11q12)c[1]/46,idem,add(4)(p14),-add(5),+del(5)(q31q35),del(7)(q11.2q34),add(18)(q23) [cp4]/45,idem,-7,der(12)inv(12)(p13q24.1)add(12)(p13),-18,der(21)t(1;21)(p13;p11.2),+mar[cp11]/46,XX[4].	nuc ish (D5S2064x2,D5S630x2,EGR1x1)[62/200],(D7Z1x2,D7S522x1)[79/200],(D8Z2,D20S108)x2[198],(RUNX1T1x2, RUNX1x3)[10/200],(5'MLL,3'MLL)x3~5(5'MLL con 3'MLLx3~5)[22/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2 (5'CBFB con 3'CBFBx2)[200]	The cytospin and smear preparations reveal maturing hematopoietic precursors and scattered small lymphocytes. (no +/- data)	Negative	NA	Negative	NA	NA	TP53 (p.H193Y; 42.5%)	BRCA2 (T3085FS*26; MAF 45.0%)|TP53 (H193Y; MAF 65.0%)	Myelodysplastic Syndromes	MDS	0.633333333	MATCHED
aml_ohsu_2022_2090	aml_ohsu_2022_2090_BA2911	Waves1+2	Yes	1	NA	24	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	Therapy-related myeloid neoplasms	24	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Leukapheresis	6	AG-120|ATRA (Tretinoin)|HiDAC|3+7 (Cytarabine, Daunorubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|5+2 (Ara-C, Daunorubicin)	5	Consolidation|Salvage|Induction|Experimental|Re-induction	Complete Response	AG-120	Salvage	77	NA	NA	normal	CD13, CD33, CD38, CD58, CD117 and CD123 positive.	Positive	NA	Positive	NA	NA	NA	FLT3 (p.V592G; MAF 6%)|FLT3-ITD ((57 bp in-frame insertion); MAF 3% )|IDH1 (p.W288fs*12; MAF 50%)|NPM1 (p.W288fs*12; MAF 50% )	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2222	aml_ohsu_2022_2222_BA2311	Waves1+2	Yes	2	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myelomonocytic leukaemia	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI	4	Consolidation|Induction|Allogeneic - Child|Maintenance	Complete Response	Cyclophosphamide	Maintenance	1	M4	46,XX[20]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD34(+), CD13(dim +), CD15(partial +), CD33(dim to partial +), CD34(+), CD38(variably +), CD45(dim +), CD56(-), CD64 (small subset +), CD117(+), HLA-DR(partial +), other myeloid and lymphoid antigens(-).	Negative	0	Negative	NA	NA	NA	IDH2 (R140Q; MAF 51.0%)|KMT2A (Foundation; MLL-PTD exons 2-10)|PAX5 (V26G; MAF 1.0%)|SRSF2 (R94_S101DEL; MAF 40.0%)	Acute Myeloid Leukemia	AML	0.6	MATCHED
aml_ohsu_2022_2155	aml_ohsu_2022_2155_BA2669	Waves1+2	Yes	1	NA	24	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	24	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	Hydroxyurea|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	1	Induction	Complete Response	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	24	M3	46,XY,t(15;17)(q22;q21)[20]	Cytogenetic testing (FISH) for the t(15;17) - PML-RARA translocation is positive in about 98% of the cells (GLC-16-338);	CD13, CD33, CD64, dim CD71, dim CD117 and MPO (+).	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2183	aml_ohsu_2022_2183_BA3040	Waves1+2	Yes	4	NA	69	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	7+3 (Cytarabine, Idarubicin)	Induction	7	NA	45,XY,add(1)(p13),del(5)(q13q33),add(6)(q13),-7,del(7)(q11.2),der(9)t(1;9)(p13;q22),add(12)(p13),-15,-16,-17,+3mar[19]/43~45,idem,der(3)t(3;17)(p21;q11.2),-17[cp3]	COMPLEX DEL(5q)/DEL(7q)/-7 CLONE OBSERVED, CONSISTENT WITH AML	Positive (ABNORMAL CD34+ BLAST POPULATION, 29%, EXPRESSINGMYELOPEROXIDASE (VARIABLE), CD34, CD38, CD117, CD33, CD4, HLA-DR,CD13 (PARTIAL), CD56 (dim minor subset), AND CD61 (dim subset))	Negative	0	Negative	NA	NA	TP53 (p.Y220C; 48.0%)|TP53 (p.F113V; 39.4%)	NA	Acute Myeloid Leukemia	AML	0.666666667	MATCHED
aml_ohsu_2022_2041	aml_ohsu_2022_2041_BA2724	Waves1+2	Yes	2	NA	67	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Decitabine	1	Supportive/Palliative Care	NA	Decitabine	Supportive/Palliative Care	-1	NA	46,XX[20]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD4(partial dim +), CD7(few dim +), CD11b(-), CD13 (variably +), CD14(-), CD15(partial +), CD16(-), CD19(partial dim +), CD33(variably +), CD34(-), CD36(-), CD38(+), CD45 (moderate +), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+), MPO(+). (Population #1; 6.5% medium-sized cells) | CD2(dim +), CD4(dim +), CD11b(variably +), CD13(variably +), CD14(partial +), CD15(variably +), CD16(partial +), CD33(slightly bright +), CD34(-), CD36(+), CD38 (variably +), CD45(+), CD64(+), CD117(-), HLA-DR(partial +), MPO(+). (Population #2; 42% medium-sized to large monocytic cells)	Negative	0	Positive	NA	NA	NA	NPM1 (W288FS*10+; MAF 37.0%)|NRAS (Q61K; MAF 43.0%)	Acute Myeloid Leukemia	AML	1.066666667	MATCHED
aml_ohsu_2022_2322	aml_ohsu_2022_2322_BA2837	Waves1+2	Yes	2	NA	78	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	80	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	5	AG-120|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Consolidation|Induction|Experimental|Maintenance	Complete Response	AG-120	Experimental	-1	NA	45,XY,-7[2]/45,XY,t(6;8)(q21;q21.2),-7,del(10)(q24q26),t(12;15)(p13;q15)[19]	nuc ish(D5S2064,D5S630,EGR1)x2 [200],(D7Z1x2,D7S522x1)[1/200]/(D7Z1,D7S522)x1[185/200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(subset +), CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial +), CD38(variably +), CD45(+), CD56(partial +), CD64(-), CD117(+), HLA-DR(partial +). (63% population)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2145	aml_ohsu_2022_2145_BA2821	Waves1+2	Yes	1	NA	37	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	37	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Hydroxyurea	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction	Refractory	Azacitidine	Consolidation	-1	M0/M1	46,XX[20]	Normal	variable CD11b, CD13, dim CD19, dim CD33, CD34, variable CD64, CD117, CD123, and HLA-DR	Negative	0	Negative	NA	NA	NA	ASXL1 (p.A1312V; MAF 50%)|KRAS (p.K117N; MAF 48%)|WT1 (p.L378P; MAF 48%)|WT1 (p.R380fs*69 (1 bp deletion with frameshift); MAF 48%)	Acute Myeloid Leukemia	AML	0.3	MATCHED
aml_ohsu_2022_2337	aml_ohsu_2022_2337_BA2363	Waves1+2	Yes	1	NA	79	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	79	35	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	4	Azacitidine|Decitabine|Hydroxyurea|V212	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care	NA	Hydroxyurea	Supportive/Palliative Care	-1	NA	46,XY[22]	Normal	CD13, dim CD33, bright CD34, CD38, CD117, dim HLA-DR positive	Negative	0	Negative	RUNX1 (p.R320*; 44.9%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2316	aml_ohsu_2022_2316_BA2233	Waves1+2	Yes	4	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Hydroxyurea	1	Induction	Complete Response	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	M1	46,XY[5]	D5S721, EGR1  del(5q)/monosomy 5, D7Z1, D7S522  del(7q)/monosomy 7, D8Z2 trisomy #8, D20S108, 20qter del(20q)	CD117, MPO,CD38(PARTIAL), CD33(DIM) AND NOT EXPRESSING CD34 AND HLA-DR	Negative	0	Positive	NA	NA	NA	FLT3 (p.D839G; MAF~45%)|IDH2 (p.R140L; MAF ~50%)|MLL2 (p.V2338I; MAF ~50%)|NPM1 (p.W288fs*12;MAF ~35%)|SRSF2 (p.P95H, MAF~55%)	Acute Myeloid Leukemia	AML	0.5	MATCHED
aml_ohsu_2022_2232	aml_ohsu_2022_2232_BA2744	Waves1+2	Yes	1	NA	76	FALSE	FALSE	TRUE	FALSE	FALSE	Favorable	AML with mutated NPM1	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	1	Hydroxyurea	1	Supportive/Palliative Care	NA	Hydroxyurea	Supportive/Palliative Care	7	M1	46,XY[20]	Normal	CD13, CD33, CD38, variable CD56, CD58, CD117 and MPO positive	Positive	0.176470588	Positive	NA	NA	NA	FLT3-ITD (MAF 45%)|NPM1 (p.W288fs*12; MAF 50%)|TET2 (p.W564*; MAF 50%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2031	aml_ohsu_2022_2031_BA2501	Waves1+2	Yes	3	NA	36	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	36	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Methotrexate, Mercaptopurine, Tretinoin|ATRA, Idarubicin|ATRA, Cytarabine, Idarubicin	3	Consolidation|Induction|Maintenance	Complete Response	Methotrexate, Mercaptopurine, Tretinoin	Maintenance	-1	M3	46,XY,t(15;17)(q24;q21)[18]/46,XY[2]	Normal	weak partial CD2, CD13, CD33, CD64, CD117, and  myeloperoxidase	Positive	0.25	Negative	NA	NA	NA	CEBPA (c.935A>G; MAF 45%, except VUS)|FLT3-ITD (c.1780_1800dup; MAF 17%)	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2197	aml_ohsu_2022_2197_BA2301	Waves1+2	Yes	5	NA	42	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	-1	NA	46,XX[19]	Normal	Positive (A large blastic population is noted, positive for CD45 and CD64. A small subset of blasts also express CD13 and CD14. The blasts are negative for CD10, CD16, CD19, CD34 and CD117.)	Negative	0	Positive	NA	NA	NA	NPM1 (c.859_860insTCTG; p.W288fs)|WT1 (c.933_934ins10; p.R312fs; c.938_939insCGGTC; p.A314fs)	Acute Myeloid Leukemia	AML	0.466666667	MATCHED
aml_ohsu_2022_2568	aml_ohsu_2022_2568_BA2880	Waves1+2	Yes	5	NA	85	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Myeloid sarcoma	85	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	46,XY[20]	Normal	NA	Negative	0	Negative	NA	NA	NA	EZH2 (c.436G>C; p.D146H)|TET2 (c.5182G>T; p.E1728X)	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2347	aml_ohsu_2022_2347_BA2621	Waves1+2	Yes	6	NA	74	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	45,XY,-7,del(12)(p11.2p13)[20]	Monosomy 7 is detected in 87% of cells.	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2436	aml_ohsu_2022_2436_BA2852	Waves1+2	Yes	6	NA	74	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	75	0	Post-Chemotherapy|Relapse	Relapse	Peripheral Blood	1	Azacitidine, MLN4924	1	Induction	Complete Response	Azacitidine, MLN4924	Induction	498	NA	48,XY,+8,del(20)(q11.2),+21[14]/46,XY[6]	This test has detected a 20q deletion, trisomy 8, and trisomy 21 in 14 cells. All these abnormalities are commonly seen in AML and MDS.	These are positive for CD34, CD117, HLA-DR, and CD33. (Bone Marrow Immunophenotyping)	Negative	0	Negative	RUNX1 (p.G165Dfs*2; 11.1%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2383	aml_ohsu_2022_2383_BA2133	Waves1+2	No	6	NA	73	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with mutated NPM1	73	0	Post-Chemotherapy	Remission	Peripheral Blood	4	Ruxolitinib|AG-221|Cytarabine|Azacitidine	4	Induction|Experimental|Maintenance|Supportive/Palliative Care	Complete Response	Cytarabine	Supportive/Palliative Care	8	NA	NA	NA	NA	Negative	0	Positive	NA	NA	NA	IDH2 (p.R140Q; MAF 32%)|JAK2 (p.V617F; MAF 30%)|NPM1 (p.W288Cfs*12; MAF 35%)|SRSF2 (p.R94dup; MAF 31%)|WT1 (p.R440Tfs*14; MAF 29%)	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2383	aml_ohsu_2022_2383_BA2473	Both	No	6	NA	73	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with mutated NPM1	73	56	Post-Chemotherapy	Remission	Bone Marrow Aspirate	4	Ruxolitinib|AG-221|Cytarabine|Azacitidine	4	Induction|Experimental|Maintenance|Supportive/Palliative Care	Complete Response	Cytarabine	Supportive/Palliative Care	8	NA	46,XX[20]	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited number of cells examined. (Cytogenetics)	CD34 positive blasts are rare, <1% (Bone Marrow Immunophenotyping)	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2383	aml_ohsu_2022_2383_BA2222	Waves1+2	No	6	NA	73	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with mutated NPM1	74	252	Post-Chemotherapy	Remission	Bone Marrow Aspirate	4	Ruxolitinib|AG-221|Cytarabine|Azacitidine	4	Induction|Experimental|Maintenance|Supportive/Palliative Care	Complete Response	Cytarabine	Supportive/Palliative Care	8	NA	46,XX[20]	This test has not detected clonal abnormalities in the cells analyzed.	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2465	aml_ohsu_2022_2465_BA2866	Waves1+2	Yes	4	NA	58	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	58	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	Sorafenib|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Experimental	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	M2	47,XY,t(8;22)(p11.2;q11.2),+19[20]	t(8;22) clone observed, consistent with a neoplastic process	Positive (CD34-Dim)	Negative	0	Negative	RUNX1 (p.S322Ffs*278; 45.9%)	NA	NA	ATM (p.P604S; VAF ~50%)|PHF6 (p.G306R; VAF ~75%)|RUNX1 (p.S322fs*278 (Single base pair insertion, frame shift  mutation); MAF ~40%)	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2035	aml_ohsu_2022_2035_BA2212	Waves1+2	Yes	2	NA	75	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	75	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	3	Vidaza|Decitabine|Fludarabine, Cytarabine	2	Salvage|Supportive/Palliative Care	NA	Fludarabine, Cytarabine	Salvage	-1	NA	46,XY,t(1;12)(p32;p13)[3]/46,XY[17]	nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[194],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]	CD2(-), CD4(-),CD7(-), CD10(partial +), CD11b(-), CD13(dim +), CD14(-), CD38(variably +/small subset -), CD45(dim to moderately +), CD56(-), CD64(-), CD117(variably +), HLA-DR(variably +). | Population #2 (0.48% of total events) comprises small cells with the following immunophenotype: CD5(- to partial dim +),CD10(-), CD19(slighty bright +), CD20(bright +), CD38(-), CD45(+), kappa(-), lambda(dim +).	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 39.3%)	NA	ASXL1 (G646fs*12; MAF 37.0%)|BCOR (S1608*; MAF 3.0%)|KRAS (G12R; MAF 5.0%)|STAG2 (Q932fs*6; MAF 91.0%)|SUZ12 (E601fs*10; MAF 38.0%)|TET2 (C127fs*92; MAF 6.0%)|TET2 (S1870*; MAF 45.0%)	Acute Myeloid Leukemia	AML	0.8	MATCHED
aml_ohsu_2022_2219	aml_ohsu_2022_2219_BA2477	Waves1+2	Yes	1	NA	67	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	M4	46,XY[20]	Normal	partial CD7, CD13, dim CD15, CD33, CD38, CD58, CD117, dim CD123, HLA-DR and partial MPO+. (BM) | dim CD4, CD11b, variable CD13, partial CD14, dim CD15, variable CD16, CD33, CD38, CD58, CD64, CD123 and HLA-DR. (Promonocyte/blast equivalents)	Negative	0	Positive	NA	NA	NA	DNMT3A (p.R882H; MAF 46% )|FLT3 (p.V592D; MAF 43% )|IDH1 (p.R132H; MAF 46%  )|NPM1 (p.W288fs*12 MAF 47% )|SETBP1 (p.K459E; MAF 50% )	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2219	aml_ohsu_2022_2219_BA2244	Waves1+2	No	1	NA	67	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	68	261	Post-Chemotherapy	Remission	Leukapheresis	5	AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	M4	46,XY,t(4;8)(q21;p23)[2]/46,XY[18]	Normal	NA	Negative	0	Positive	NA	ASXL1 (p.G645Vfs*58; 10.0%)	NA	NA	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2219	aml_ohsu_2022_2219_BA3089	Waves3+4	No	1	NA	67	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	68	429	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	5	AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	M4	46,XY[20]	Normal	CD7, CD13, CD33, CD38, CD58, CD117, CD123, partial MPO+	Negative	0	Positive	NA	NA	NA	DNMT3A (p.R882H; MAF 46%)|FLT3 (p.V592D; MAF 39%)|IDH1 (p.R132H, MAF 39%)|IDH2 (p.R140Q; MAF 39%)|NPM1 (p.W288fs*12; MAF 41%)|NRAS (p.Q61P; MAF 40%)|SETBP1 (p.K459E; MAF 40%)	Acute Myeloid Leukemia	AML	0.366666667	UNMATCHED
aml_ohsu_2022_2526	aml_ohsu_2022_2526_BA2190	Waves1+2	Yes	1	NA	65	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	AML with minimal differentiation	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Re-induction	Refractory	MiDAC	Consolidation	-1	M0	46,XY[20]	normal	CD13, CD33, bright CD34, CD38, CD58, CD117, and TdT	Negative	0	Negative	NA	NA	NA	CREBBP (p.M118I; MAF 50%)	Acute Myeloid Leukemia	AML	0.366666667	MATCHED
aml_ohsu_2022_2266	aml_ohsu_2022_2266_BA2685	Waves1+2	Yes	6	NA	67	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	67	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	4	Vidaza|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Decitabine	Salvage	83	NA	46, XY, del (3) (q12q21) [2]/47, idem, +8[11]/47, idem, der (15) t (1;15) (q21;p11.2) [7]	Trisomy 8 is detected in 28% of cells.	Positive for CD34, CD117, HLADR, CD33, CD13 and Negative for CD11b and CD64 (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 28.0%)	NA	BCOR (p.KB39Qfs*5; MAF 45%)|KIT (p.T916A; MAF 50%)|NRAS (p.G12A; MAF 24%)|SRSF2 (p.P95R; MAF 40%)	Acute Myeloid Leukemia	AML	1.366666667	MATCHED
aml_ohsu_2022_2266	aml_ohsu_2022_2266_BA2875	Waves1+2	No	6	NA	67	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	67	55	Post-Chemotherapy	Remission	Bone Marrow Aspirate	4	Vidaza|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Decitabine	Salvage	83	NA	46, XY, del (3) (q12q21) [2]/47, idem, +8[11]/47, idem, der (15) t (1;15) (q21;p11.2) [7]	Trisomy 8 is detected in 28% of cells.	Positive for CD34, CD117, CD13, HLA-DR, CD33 and CD38 (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 40.0%)	NA	NA	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2544	aml_ohsu_2022_2544_BA2273	Waves1+2	Yes	6	NA	67	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	Cytarabine|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Complete Response	Cytarabine	Consolidation	35	NA	46,XY[20]	The translocations commonly seen in AML are not detected. Loss of RARA and CBFB genes are detected in 14-39% of cells.	These are positive for CD34, CD117, HLADR, CD33, CD13, CD14 and CD11b. (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	TP53 (p.Y220C; 42.0%)	BCOR (MAF 49%)|IDH1 (p.R132C MAF 12%)|JAK2 (p.V617F; MAF 43%)|MLL |NF1 (MAF 18%)|TP53 (p.Y220C; MAF 35%)	Acute Myeloid Leukemia	AML	1.066666667	MATCHED
aml_ohsu_2022_2544	aml_ohsu_2022_2544_BA2490	Waves1+2	No	6	NA	67	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	67	36	Post-Chemotherapy	Remission	Bone Marrow Aspirate	2	Cytarabine|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Complete Response	Cytarabine	Consolidation	35	NA	46,XY[20]	The translocations normally seen in AML are not detected.	No increased or immunophenotypically abnormal blast cell populations identified. (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2057	aml_ohsu_2022_2057_BA2659	Waves1+2	Yes	1	mono	86	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	86	0	Residual Disease	Residual	Bone Marrow Aspirate	3	AG-221|Azacitidine|Hydroxyurea	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Experimental	NA	Hydroxyurea	Consolidation	55	NA	47,XY,+8[20]	(FISH) was performed with a chromosome 8 probe, listed below. 95/100 (95%) interphase cells scored had three signals, consistent with trisomy 8 and the metaphase karyotype.	dimCD7, CD13, dimCD14, dimCD20, CD33, CD34, CD117, CD123, dim HLA-DR and MPO positive	Negative	0	Negative	NA	NA	NA	BCOR (p.S1139*; MAF 80%)|CEBPA (p.R343fs*79; MAF 40%)|DNMT3A (p.E285*; MAF 45%)|DNMT3A (p.G707fs*72; MAF 45%)|IDH2 (p.R140Q; MAF 40%)|SRSF2 (p.P95H; MAF 40%)	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2310	aml_ohsu_2022_2310_BA2124	Waves1+2	Yes	3	NA	67	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|IDAC	2	Consolidation|Induction	Complete Response	IDAC	Consolidation	-1	NA	46,XY[20]	Normal	CD33, CD38, CD56, CD117, and myeloperoxidase	Negative	0	Positive	NA	NA	NA	NPM1 (p.Trp288fs; MAF 16.4%)|TET2 (p.Leu1081fs; MAF 42.3%)|TET2 (p.Leu1780fs; MAF 46.3%)|ZRSR2 (p.Arg126*; MAF 97.7%)	Acute Myeloid Leukemia	AML	1.433333333	MATCHED
aml_ohsu_2022_2276	aml_ohsu_2022_2276_BA2369	Waves1+2	Yes	6	NA	75	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	75	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	1	Vidaza	1	Supportive/Palliative Care	NA	Vidaza	Supportive/Palliative Care	-1	NA	46,XY[20]	NA	These are positive for HLA-DR, CD34,CD117, CD33, CD11B, CD64 but Negative for CD13, CD14, CD16, MPO, TDT and all B and T cell markers (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.366666667	MATCHED
aml_ohsu_2022_2534	aml_ohsu_2022_2534_BA2586	Waves1+2	Yes	3	NA	58	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	58	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)	2	Induction|Re-induction	Refractory	CLAG (Cladribine, Cytarabine, Filgrastim)	Re-induction	143	NA	46,XY,ins(10;11)(p12;q23q23)[9]/49,sl,+4,+6,+21[4]/46,XY[7]	- 11q23 rearrangement involving the KMT2A (MLL) locus in  51/200 (25.5 percent) cells scored,  - 3 copies of the RUNX1 locus at 21q22 in 91/200 (45.5  percent) cells scored.	CD13, partial CD15, CD33, CD34, weak CD64,  very weak partial CD117, and myeloperoxidase	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.433333333	MATCHED
aml_ohsu_2022_2426	aml_ohsu_2022_2426_BA2400	Waves1+2	Yes	1	NA	44	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	44	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	99	M2	NA	Normal	CD13, CD33, CD117, CD123, dim HLA-DR and MPO | CD11b, CD13, CD33, CD117, CD64, CD123, and dim HLA-DR. (Blasts with monocytic differentiation (about 10% of blasts).)	Negative	0	Positive	NA	NA	NA	FLT3-ITD (MAF 2%)|IDH1 (p.R132H; MAF 44%)|NPM1 (p.W288fs*12; MAF 44%)|PTPN11 (p.R265Q; MAF 3%)	Acute Myeloid Leukemia	AML	0.5	MATCHED
aml_ohsu_2022_2061	aml_ohsu_2022_2061_BA2762	Waves1+2	Yes	2	NA	22	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	22	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Fludarabine, Melphalan|Crenolanib|7+3 (Cytarabine, Idarubicin) plus Crenolanib	3	Allogeneic - Sibling|Induction|Experimental	Complete Response	Fludarabine, Melphalan	Allogeneic - Sibling	-1	NA	46,XX[20]	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[200]	CD2(-), CD4(partial dim +), CD7(variably +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +).	Positive	0.666666667	Positive	NA	NA	NA	FLT3-ITD (K602_W603INSCEYDLK; MAF 33.0%)|NPM1 (K292FS*6+; MFA 35.0%)|TCL1A (E54FS*28; MAF 44.0%)|WT1 (A382FS*4; MAF 40.0%)	Acute Myeloid Leukemia	AML	0.3	MATCHED
aml_ohsu_2022_2537	aml_ohsu_2022_2537_BA2312	Waves1+2	Yes	3	mono	62	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	7+3 (Cytarabine, Idarubicin)	Induction	7	NA	46,XX[20]	Normal	partial weak  CD7, CD13, CD33, CD34, CD117, myeloperoxidase, and partial  HLA-DR	Negative	0	Negative	NA	NA	NA	CEBPA (c.68dup; MAF 21%)|DNMT3A (c.2645G>A; MAF 43.9%)|NRAS (c.35G>A; MAF 30.2%)|WT1 (c.1140dup; MAF 4%)|WT1 (c.1142C>A; MAF 36.4%)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2206	aml_ohsu_2022_2206_BA2813	Waves1+2	Yes	5	NA	64	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	64	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	NA	46,XY[20]	Normal	Positive (The large majority of cells (around 90%) are an abnormal population of myeloblasts. The myeloblasts are positive for CD33, CD13, HLA-DR, and CD117, and show uniform aberrant expression of CD7. A subset of the blasts are positive for myeloperoxidase, and a smaller subset shows dim aberrant expression of CD19. The blasts are almost entirely negative for CD34.)	Positive	0.428571429	Positive	NA	NA	NA	DNMT3A (c.2645G>A; p.R882H)|FLT3-ITD (FLT3-ITD 63bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs)	Acute Myeloid Leukemia	AML	0.866666667	MATCHED
aml_ohsu_2022_2471	aml_ohsu_2022_2471_BA2211	Waves1+2	Yes	1	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Consolidation|Induction	Complete Response i	Azacitidine	Consolidation	34	M1	46,XX[20]	normal	CD13, CD33, CD38, CD56, CD58, partial CD64, CD117, CD123, and MPO positive	Positive	1	Positive	NA	NA	NA	FLT3-ITD (MAF 50%)|NPM1 (p.W288fs*12; MAF 45%)	Acute Myeloid Leukemia	AML	0.3	MATCHED
aml_ohsu_2022_2321	aml_ohsu_2022_2321_BA2171	Waves1+2	Yes	1	NA	73	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	7+3 (Cytarabine, Idarubicin)	Induction	3	M1	46,XX[20]	Normal	CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, and MPO	Positive	0.428571429	Positive	NA	NA	NA	DNMT3A (p.R326P; MAF 50%)|FLT3-ITD (MAF 46%)|IDH2 (p.R140Q; MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2522	aml_ohsu_2022_2522_BA2746	Waves1+2	Yes	5	NA	56	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	4	Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	-1	NA	46,XX[19]	Normal	Positive (Approximately 55% of assayed cells are an abnormal population of immature monocytic cells (consistent with monoblasts and promonocytes). Approximately 30% of assayed cells are mature monocytes. Both the immature and mature monocytic cells show uniform aberrant expression of CD56. A small population of myeloblasts (CD117+/CD34neg) is present, accounting for less than 5% of assayed cells.)	Positive	0.111111111	Positive	NA	NA	NA	ASXL1 (c.1954G>A; p.G652S)|DNMT3A (c.2644C>T; p.R882C)|FLT3 (c.2503G>T; p.D835Y)|FLT3-ITD (FLT3-ITD 21 bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs)	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2522	aml_ohsu_2022_2522_BA3075	Waves1+2	No	5	NA	56	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	56	224	Post-Transplant|Relapse	Relapse	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	4	Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	-1	NA	46,XX[19]	Normal	NA	Positive	7.333333333	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2395	aml_ohsu_2022_2395_BA2798	Waves1+2	Yes	6	NA	71	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	5	AG-120|KB004|Lenalidomide|Venetoclax (ABT-199), Azacitidine|Decitabine	4	Salvage|Induction|Experimental|Maintenance	Refractory	Venetoclax (ABT-199), Azacitidine	Salvage	77	NA	46,XY,del(7)(q32),add(13)(p11.2)[15]	This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies.	These are positive for CD34, CD117, HLADR, CD33 and CD13 (Bone Mrrow Immunophenotyping)	Negative	0	Negative	RUNX1 (p.G408Vfs*193; 34.8%)	ASXL1 (p.Q428*; 43.9%)	NA	ASXL1 (p.Q428*; MAF 44%)|CEBPA (p.A4S; MAF 47%)|IDH1 (p.R132C; MAF 45%)|JAK2 (p.V617F; MAF 57%)|MLL |RUNX1 (p.G406Vfs*193; MAF 39%)|TET2 (p.R1366S; MAF 40%)	Acute Myeloid Leukemia	AML	1.066666667	MATCHED
aml_ohsu_2022_2395	aml_ohsu_2022_2395_BA2883	Waves1+2	No	6	NA	71	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	71	57	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	5	AG-120|KB004|Lenalidomide|Venetoclax (ABT-199), Azacitidine|Decitabine	4	Salvage|Induction|Experimental|Maintenance	Refractory	Venetoclax (ABT-199), Azacitidine	Salvage	77	NA	46,XY,del(7)(q32),add(13)(p11.2)[20]	This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies.	They are positive for CD34, HLADR, CD117, CD13 and MPO and negative for TDT. (Bone Marrow Immunophenotyping)	Negative	0	Negative	RUNX1 (p.G408Vfs*193; 20.4%)	ASXL1 (p.Q428*; 43.4%)	NA	NA	Acute Myeloid Leukemia	AML	1.066666667	MATCHED
aml_ohsu_2022_2395	aml_ohsu_2022_2395_BA3342	Waves3+4	No	6	NA	71	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	72	315	Post-Chemotherapy	Remission	Peripheral Blood	5	AG-120|KB004|Lenalidomide|Venetoclax (ABT-199), Azacitidine|Decitabine	4	Salvage|Induction|Experimental|Maintenance	Refractory	Venetoclax (ABT-199), Azacitidine	Salvage	77	NA	46,XY,del(7)(q32),add(13)(p11.2)[20]	This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies.	NA	Negative	0	Negative	NA	ASXL1 (p.Q428*; 44.3%)	TP53 (p.R248W; 8.8%)	NA	Acute Myeloid Leukemia	AML	0.533333333	UNMATCHED
aml_ohsu_2022_2515	aml_ohsu_2022_2515_BA2288	Waves1+2	Yes	7	NA	72	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute Myeloid Leukemia	73	0	Residual Disease	Residual	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2146	aml_ohsu_2022_2146_BA2801	Waves1+2	No	6	NA	72	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Myelodysplastic syndrome, unclassifiable	73	0	Residual Disease	NA	Peripheral Blood	1	Vidaza	1	Supportive/Palliative Care	NA	Vidaza	Supportive/Palliative Care	268	NA	NA	NA	NA	Negative	NA	Negative	RUNX1 (p.S322Nfs*277; 44.4%)	ASXL1 (p.R693*; 38.7%)	NA	ASXL1 (p.R693* MAF 48%)|EZH2 (p.1131T, MAF 71%)|EZH2 (p.C565R MAF 27%)|JAK2 (p.V617F, MAF 26%)|KRAS (p.Q61P, MAF 13%)|RUNX1 (p.S322Nfs*277, MAF 42%)|TET2 (p.Q1813*, MAF 51%)|TET2 (p.Q866Rfs*14, MAF 39%)|ZRSR2 (p.R295*, MAF 97%)	Myelodysplastic Syndromes	MDS	0.466666667	UNMATCHED
aml_ohsu_2022_2691	aml_ohsu_2022_2691_BA3407	Waves3+4	No	6	NA	29	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	29	38	Post-Chemotherapy	Remission	Bone Marrow Aspirate	5	Bu/Cy/ATG|HiDAC|3+7 (Cytarabine, Daunorubicin)|Etoposide, Mitoxantrone|Clofarabine, Cytarabine	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Clofarabine, Cytarabine	Re-induction	6	NA	46,XX,t(6;11)(q27;q23)[18]/46,XX[2]	This test has detected  a 6;11 translocation in 18 of 20 metaphase cells analyzed. The translocation has led to rearrangement of the MLL gene as shown by FISH. This result is consistent with the diagnosis of AML. (Cytogenetics) | Except for 9;11 translocation, all translocations involving the MLL gene in AMLare associated with an unfavorable prognosis. (Cytogenetics (Continued))	Myeloblasts 1% positive for CD34, CD117, HLADR, CD13, CD33, for TDT and all B and T-cell markers. (Bone marrow Immunophenotyping)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2046	aml_ohsu_2022_2046_BA3030	Waves1+2	No	1	NA	70	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	70	0	Unknown	NA	Bone Marrow Aspirate	1	Hydroxyurea	1	Induction	Unknown	Hydroxyurea	Induction	-1	NA	46,XX[20]	Normal	CD13, CD33, CD34, partial CD117, CD123, HLA-DR	Positive	0.428571429	Negative	NA	NA	NA	FLT3-ITD (MAF 45%)|IKZF1 (p.N159S ; MAF 45%)|SF3B1 (p.K666N ; MAF 45%)	Myelodysplastic/Myeloproliferative Neoplasms	MDS/MPN	0.5	MATCHED
aml_ohsu_2022_2441	aml_ohsu_2022_2441_BA2588	Waves1+2	Yes	1	NA	59	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC	3	Consolidation|Induction|Re-induction	Complete Response	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	4	M2	46,XY[20]	Normal	CD13, CD33, CD117, CD123, and HLA-DR	Negative	0	Positive	NA	NA	NA	DNMT3A (p.R882C; MAF 40%)|NPM1 (p.W288fs*12 ; MAF 40%)|PTPN11 (p.K70R; MAF 40%)|SOCS1 (p.Q210H ; MAF 55%)	Acute Myeloid Leukemia	AML	0.9	MATCHED
aml_ohsu_2022_2497	aml_ohsu_2022_2497_BA2296	Waves1+2	Yes	1	bi	46	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated CEBPA	46	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	120	M2	46,XX[19]	Normal	CD13, CD33, CD34, partial CD64, CD71, CD117, CD123, and HLA-DR	Negative	0	Negative	NA	NA	NA	CEBPA (p.R297P ; MAF 50%)|CEBPA (p.T98fs*10 ; MAF 40%)|TET2 (p.Q758*; MAF 45%)	Acute Myeloid Leukemia	AML	1	MATCHED
aml_ohsu_2022_2037	aml_ohsu_2022_2037_BA2300	Waves1+2	Yes	3	NA	79	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	43-45,X,-Y,del(5)(q22q35),del(7)(q22),+8,-9,add(9)(p13),+11,-13,-14,add(16)(q24),-17,-18,del(20)(q11.2q13.2),+2-3mar[cp21]	5q31 (EGR1): deletion present  8q22 (RUNX1T1): gain present  11q23 (KMT2A; also known as MLL): gain present	NA	Negative	0	Negative	NA	NA	TP53 (p.X225_splice; 93.2%)	KIT (p.Asp816Val; MAF 44.4%)|TP53 (p.?; MAF 91%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2161	aml_ohsu_2022_2161_BA2903	Waves1+2	Yes	6	NA	59	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	59	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	6	HiDAC|Lenalidomide|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Etoposide, Mitoxantrone|Cytarabine, OXi4503	5	Salvage|Induction|Experimental|Frontline|Re-induction	Refractory	Cytarabine, OXi4503	Experimental	4	NA	NA	NA	NA	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 50.0%)	NA	NRAS (p.Q61H, MAF 21%)|RAD21 (p.G273V ,MAF 64%)	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2430	aml_ohsu_2022_2430_BA2652	Waves1+2	Yes	1	mono	50	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML without maturation	50	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Refractory	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	M1	46,XX[20]	Normal	CD13, dimCD33, CD34, CD38, CD117, dimCD123, dim HLA-DR, and dim MPO positive.	Negative	0	Negative	NA	NA	NA	ASXL1 (p.N1036S; MAF 50%)|CEBPA (p.N321D; MAF 20%)|DNMT3A (p.R882C; MAF 20%)|IDH1 (p.R132C; MAF 20%)|MLL (Partial tandem duplication )	Acute Myeloid Leukemia	AML	0.566666667	MATCHED
aml_ohsu_2022_2488	aml_ohsu_2022_2488_BA2545	Waves1+2	Yes	1	NA	37	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Myeloid sarcoma	37	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Unknown	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	NA	46,XY[20]	Normal	NA	Negative	0	Negative	NA	NA	NA	TET2 (p.L307R; MAF 51%)	Acute Myeloid Leukemia	AML	0.133333333	MATCHED
aml_ohsu_2022_2311	aml_ohsu_2022_2311_BA2945	Waves1+2	No	6	NA	64	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	64	0	Post-Chemotherapy	Remission	Bone Marrow Aspirate	5	Radiation|Paclitaxel|Doxorubicin|Cisplatin|5-FU	2	Symptom Control|Supportive/Palliative Care	NA	Paclitaxel	Supportive/Palliative Care	274	NA	46,XX[20]	NA	Granulocytes are significantly decreased (Bone marrow Immunophenotyping)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2311	aml_ohsu_2022_2311_BA2529	Waves1+2	No	6	NA	64	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	64	126	Post-Chemotherapy	Remission	Bone Marrow Aspirate	5	Radiation|Paclitaxel|Doxorubicin|Cisplatin|5-FU	2	Symptom Control|Supportive/Palliative Care	NA	Paclitaxel	Supportive/Palliative Care	274	NA	46,XX[20]	NA	No increased or immunophenotypically abnormal nlast cell populations identified. (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2468	aml_ohsu_2022_2468_BA2840	Waves1+2	Yes	1	NA	78	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	78	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	3	Ruxolitinib|Hydroxyurea|Decitabine, Ruxolitinib	3	Induction|Experimental|Maintenance	Refractory	Decitabine, Ruxolitinib	Induction	7	M7	46,XX,t(7;13)(q22;q12),del(20)(q11.2)[1]/46,sl,dup(1)(p25),del(2)(q21q23),add(8)(q13q22)[3]/46,sdl,add(5)(p15)[8]/46,sdl,add(12)(p13)[3]/46,sdl,add(12)(p13),add(13)(p12)[4]/46,XX[1]	RUNX1T1 (8q21.3): 35% of cells had three signals for RUNX1T1 on 8q. No evidence for t(8;21). | FISH was also performed with a probe for chromosome 20, so that the stemline clone and all subclones could be followed by interphase FISH. 88/100 cells were missing a signal for D20S108 (20q12), consistent with the deletion of 20q seen in all abnormal cells above.	CD33, CD34 (subset), CD41, CD58, CD61 and Factor-8 positive	Negative	0	Negative	NA	NA	NA	GATA1 (p.M1V; MAF 32%)|MPL (p.S505N; MAF 70%)|TET2 (p.V636fs*3; MAF 46%)	Acute Myeloid Leukemia	AML	0.566666667	MATCHED
aml_ohsu_2022_2171	aml_ohsu_2022_2171_BA2790	Waves1+2	Yes	1	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Azacitidine	1	Induction	UNKNOWN	Azacitidine	Induction	66	M0	41~47,XY,+1,del(1)(q42),add(2)(q33),del(5)(q13q33),der(7)add(7)(p22)add(7)(q11.2),-9,-10,der(12)add(12)(p13)ins(?;12)(?q13),13,add(13)(q34),-16,17,add(19)(q13.3),21,+r,+1~4mar[cp13]/41~47,idem,-der(7)[cp7]	deleted 5q, deleted 7q, and monosomy 17 in the majority of cells scored. 52% of cells also had three RUNX1 (21q22) signals consistent with chromosome 21 material being present in marker and/or additional material of uncertain origin | Interestingly, metaphase FISH showed an ABL/ASS signal set on a derivative chromosome, as well as the normal chromosome 9, indicating that there is not full monosomy 9.	dimCD7, CD13, CD33, CD34, partial CD56, CD117, dimCD123	Negative	0	Negative	NA	NA	TP53 (p.R248W; 57.8%)	MLL2 (p.P2557L; MAF 51%)|TP53 (p.R248W; MAF 57%)	Acute Myeloid Leukemia	AML	0.6	MATCHED
aml_ohsu_2022_2531	aml_ohsu_2022_2531_BA2528	Waves1+2	Yes	1	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with maturation	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	3	Induction|Frontline|Maintenance	Refractory	Azacitidine	Maintenance	-1	M2	46,XY[19]	Normal	CD13, CD33, CD34, CD38, CD117, CD123, dim HLA-DR, TdT, and MPO positive	Negative	0	Negative	NA	NA	NA	DNMT3A (p.R882H; MAF 41%)|SF3B1 (p.K700E; MAF 43%)	Acute Myeloid Leukemia	AML	1.166666667	MATCHED
aml_ohsu_2022_2535	aml_ohsu_2022_2535_BA2646	Waves1+2	Yes	1	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	ATRA, Arsenic Trioxide	1	Induction	Complete Response	ATRA, Arsenic Trioxide	Induction	-1	M3	46,XY,t(3;16)(p13;q22),t(13;14)(q32;q24),t(15;17)(q22;q21)[20]	PML/RARA: 98/100 cells (98%) had a 1 red/ 1 green/ 2 yellow signal pattern, reflecting PML/RARA fusion and consistent with the 15;17 translocation observed in the metaphase karyotype.	CD13, CD33, CD38, CD58, CD64, dim CD71, CD123, CD117, MPO positive -FISH for t(15;17)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2591	aml_ohsu_2022_2591_BA3067	Waves1+2	Yes	1	NA	59	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	59	6	Post-Chemotherapy|Post-Transplant|Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Fludarabine, Melphalan|Azacitidine|Sorafenib	3	Allogeneic - Mismatched Unrelated Donor|Experimental|Maintenance	NA	Sorafenib	Experimental	12	M2	45,X,-Y,der(2)t(2;5)(q37;p13),-5,-18,add(19)(p13.3),+21,+21[cp13]/45,sl,-der(2)t(2;5)(q37;p13),add(2)(q11.2),add(12)(q15)[7]	EGR-1/ D5S23, D5S721/CEP 8: 64/100 cells (56%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q, | 56/100 cells (56%) had a 2 red/ 4 green signal pattern, reflecting 4 copies of RUNX1 on 21q and consistent with the tetrasomy 21 observed in the metaphase karyotype.	CD13, dim CD33, CD43, CD117	Negative	0	Negative	NA	NA	TP53 (p.X225_splice; 46.1%)	GATA1 (p.G283R; MAF 50%)|MLL (Partial tandem duplication (Pathogenic) )|TP53 (Splice site mutation (mutation at 3' end of intron 6 at  invariant AG splice site); MAF 50%)	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2591	aml_ohsu_2022_2591_BA3068	Waves1+2	No	1	NA	59	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	59	27	Post-Chemotherapy|Post-Transplant|Residual Disease	Residual	Peripheral Blood	3	Fludarabine, Melphalan|Azacitidine|Sorafenib	3	Allogeneic - Mismatched Unrelated Donor|Experimental|Maintenance	NA	Sorafenib	Experimental	12	M2	45,X,-Y,der(2)t(2;5)(q37;p13),-5,-18,add(19)(p13.3),+21,+21[cp13]/45,sl,-der(2)t(2;5)(q37;p13),add(2)(q11.2),add(12)(q15)[7]	94/100 cells (94%) had a 1 red/ 2 green/ 2 aqua signal pattern, indicating a deleted 5q, as previously observed. There was no evidence for the previous trisomy 8.	CD13, dim CD33, partial CD34, dim CD117	Negative	0	Negative	NA	NA	TP53 (p.X225_splice; 75.0%)	GATA1 (p.G283R; MAF 50%)|MLL (Partial tandem duplication (Pathogenic) )|TP53 (Splice site mutation (mutation at 3' end of intron 6 at  invariant AG splice site); MAF 50%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2181	aml_ohsu_2022_2181_BA2240	Waves1+2	Yes	1	NA	61	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	61	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea	4	Consolidation|Induction|Experimental|Re-induction	Complete Response	Sorafenib	Experimental	61	NA	NA	NA	NA	Positive	9	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2181	aml_ohsu_2022_2181_BA2613	Waves1+2	No	1	NA	61	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	61	9	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea	4	Consolidation|Induction|Experimental|Re-induction	Complete Response	Sorafenib	Experimental	61	NA	46,XX[19]	Normal	CD7, CD13, CD33, partial CD34, partial CD64, CD117, CD123, HLA-DR and partial MPO+	Positive	NA	Positive	NA	NA	NA	DNMT3A (p.P777S; MAF 90%)|FLT3-ITD (MAF 75%)|IDH1 (p.R132H; MAF 45%)|NPM1 (p.W288fs*12; MAF 40%)	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2185	aml_ohsu_2022_2185_BA2926	Waves1+2	Yes	3	NA	58	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	58	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine	3	Salvage|Induction|Symptom Control	Refractory	Azacitidine	Symptom Control	-1	NA	[46,XY]	Normal	Increased CD117 positive, partial CD34 positive myeloblasts representing approximately 61% of the leukocytes most consistent with acute myeloid leukemia	Negative	0	Negative	NA	NA	NA	ASXL2 (p.Val1277Ala; MAF 89.5%)|DNMT3A (p.Trp297* (NM_175629.2); MAF 82.1%)|IDH1 (p.Arg132Cys (NM_005896.3); MAF 39.1%)	Acute Myeloid Leukemia	AML	0.766666667	MATCHED
aml_ohsu_2022_2052	aml_ohsu_2022_2052_BA2272	Waves1+2	Yes	1	NA	12	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myelomonocytic leukaemia	12	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	4	Cytarabine|Sorafenib|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide	3	Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Refractory	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	M4	47,XY,+8[19]/46,XY[1]	RUNX1T1 signal consistent with the trisomy 8 clone	dimCD11b, dimCD13, CD14, dimCD33, CD64, variable CD123, HLA-DR CD13,dimCD33, dim variable CD34, CD117, CD123, HLA-DR	Positive	0.538461538	Negative	NA	NA	NA	FLT3-ITD (~16 amino acid insertion; MAF 11%)|FLT3-ITD (~8 amino acid insertion; MAF 20%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2085	aml_ohsu_2022_2085_BA2306	Waves1+2	Yes	6	NA	50	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	50	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Refractory	HiDAC	Consolidation	182	NA	46,XY,t(8;21)(q22;q22)[20]	NA	NA	Negative	0	Negative	NA	NA	NA	ASXL1 (p.P581R, MAF 46%)|PDGFRB (p.D111N, MAF 52%)|SMC1A (p.R586Q, MAF 96%)	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2085	aml_ohsu_2022_2085_BA2842	Waves1+2	No	6	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	50	21	Residual Disease	Residual	Peripheral Blood	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Refractory	HiDAC	Consolidation	182	NA	46,XY,t(8;21)(q22;q22)[20]	RUNX1/RUNX1T1 fusion positive in 6.5% of cells	NA	Negative	0	Negative	NA	NA	NA	ASXL1 (p.P581R, MAF 46%)|PDGFRB (p.D111N, MAF 52%)|SMC1A (p.R586Q, MAF 96%)	Acute Myeloid Leukemia	AML	0.066666667	MATCHED
aml_ohsu_2022_2085	aml_ohsu_2022_2085_BA2855	Waves1+2	No	6	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	50	73	Post-Chemotherapy	Remission	Bone Marrow Aspirate	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Refractory	HiDAC	Consolidation	182	NA	46,XY[20]	RUNX1/RUNX1T1 fusion negative	No morphological evidence of acute leukemia (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.466666667	MATCHED
aml_ohsu_2022_2085	aml_ohsu_2022_2085_BA2040	Both	No	6	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	51	249	Post-Chemotherapy	Remission	Bone Marrow Aspirate	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Refractory	HiDAC	Consolidation	182	NA	46,XY[20]	RUNX1/RUNX1T1 fusion negative (Cytogenetics)	Positive for CD34, CD117, HLADR, CD13 AND CD33.  (Bone Marrow Immunphenotyping)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.666666667	MATCHED
aml_ohsu_2022_2592	aml_ohsu_2022_2592_BA3070	Waves1+2	No	1	NA	49	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	51	0	Post-Chemotherapy|Post-Transplant	Remission	Peripheral Blood	7	HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	6	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care	Complete Response	Decitabine	Supportive/Palliative Care	115	NA	46,XY[20]	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2592	aml_ohsu_2022_2592_BA3071	Waves1+2	No	1	NA	49	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	51	46	Residual Disease|Post-Chemotherapy|Post-Transplant	Residual	Peripheral Blood	7	HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	6	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care	Complete Response	Decitabine	Supportive/Palliative Care	115	NA	46,XY[19]	Normal	NA	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2592	aml_ohsu_2022_2592_BA3072	Waves1+2	No	1	NA	49	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	51	129	Post-Chemotherapy|Post-Transplant|Residual Disease	Residual	Peripheral Blood	7	HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	6	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Supportive/Palliative Care	Complete Response	Decitabine	Supportive/Palliative Care	115	NA	46,XY,t(6;19)(p23;q13.1)[11]/46,XY[9]	Positive (Cells Scored: 200 Probe(s): Leica DEK (SG) / NUP 214 (SO) t(6;9) DC, DF)	NA	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2550	aml_ohsu_2022_2550_BA2765	Waves1+2	Yes	3	NA	39	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	40	0	Post-Chemotherapy|Post-Transplant|Residual Disease	Residual	Peripheral Blood	4	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	5	Allogeneic - Sibling|Salvage|Induction|Re-induction|Supportive/Palliative Care	Refractory	Azacitidine	Salvage	4	NA	46,XX,der(7)t(3;7)(q26;q21)[9]/46,XX[11]	NA	Increased atypical CD34 positive, CD7 positive myeloblasts	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2450	aml_ohsu_2022_2450_BA2904	Waves1+2	Yes	3	NA	60	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	61	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|IDAC	2	Consolidation|Induction	UNKNOWN	IDAC	Consolidation	-1	NA	46,XX,inv(16)(p13q22)[20]	NA	Increased atypical CD34+myeloblasts representing 80%of leukocytes suggestive of recurrent AML.	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2527	aml_ohsu_2022_2527_BA2365	Waves1+2	No	7	NA	NA	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Myelodysplastic/myeloproliferative neoplasm, unclassifiable	74	0	Unknown	NA	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	46,XX[20]	NA	NA	Negative	NA	Negative	NA	NA	NA	NA	Myelodysplastic/Myeloproliferative Neoplasms	MDS/MPN	0	UNMATCHED
aml_ohsu_2022_2309	aml_ohsu_2022_2309_BA2726	Waves1+2	Yes	1	NA	29	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	AML with mutated NPM1	29	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	5	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib	3	Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Hydroxyurea	Supportive/Palliative Care	2	M5	47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]	Normal	CD11b, CD13, CD14, CD33, CD56 and bright CD64+	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2309	aml_ohsu_2022_2309_BA3076	Waves1+2	No	1	NA	29	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	29	82	Post-Chemotherapy|Relapse|Post-Transplant	Relapse	Peripheral Blood	5	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib	3	Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Hydroxyurea	Supportive/Palliative Care	2	M5	47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]	Normal	NA	Negative	0	Positive	NA	NA	NA	KRAS (p.G12V; MAF 76%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2309	aml_ohsu_2022_2309_BA3077	Waves1+2	No	1	NA	29	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	29	126	Post-Chemotherapy|Residual Disease|Post-Transplant	Residual	Peripheral Blood	5	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib	3	Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Hydroxyurea	Supportive/Palliative Care	2	M5	47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]	Normal	NA	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2247	aml_ohsu_2022_2247_BA2234	Waves1+2	Yes	1	NA	72	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	72	1	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	4	3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea	3	Salvage|Induction|Re-induction	Refractory	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Salvage	5	M5	46,XX,t(1;11)(p32;q23)[20]	MLL: 94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal	dim CD4, CD11b, partial CD13, partial CD14, CD15, CD33, partial CD56, CD58, bright CD64, partial CD123 and HLA-DR-positive	Negative	0	Negative	NA	NA	NA	DNMT3A (p.E283*; MAF 30%)	Acute Myeloid Leukemia	AML	0.133333333	MATCHED
aml_ohsu_2022_2318	aml_ohsu_2022_2318_BA2022	Waves1+2	Yes	3	NA	33	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	33	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	ATRA, Arsenic Trioxide	2	Consolidation|Induction	Complete Response	ATRA, Arsenic Trioxide	Consolidation	-1	M3	NA	This analysis showed evidence of a PML-RARA rearrangement in 177/200 (88.5 percent) interphase cells scored.	Large population of CD117pos, CD34neg, HLA-DR neg myeloblasts, representing 78% of leukocytes consistent w/AML.	Positive	0.923076923	Negative	NA	NA	NA	FLT3-ITD (p.Leu601_Lys602ins9; MAF 15%)	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2572	aml_ohsu_2022_2572_BA2228	Waves1+2	Yes	2	NA	60	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	60	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	5	HiDAC|AG-221|3+7 (Cytarabine, Daunorubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Salvage|Induction|Experimental	Complete Response	AG-221	Experimental	-1	NA	46,XX[20]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	The study reveals a minute subset of myeloblasts with mild immunophenotypic variation; the significance of this finding is unclear and it is not diagnostic for recurrent or persistent myeloid neoplasia. (No evidence of disease by flow)	Negative	0	Positive	NA	NA	NA	FLT3 (R311Q; MAF 48%)	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2182	aml_ohsu_2022_2182_BA2037	Waves1+2	Yes	1	NA	34	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	34	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|anti-CD33|Azacitidine	3	Induction|Experimental|Re-induction	Refractory	anti-CD33	Experimental	-1	M1	46,XY,t(3;3)(q21;q26),der(7)del(7)(p11.1)del(7)(q11.1)[13]/45,idem,-der(7)[6]/46,XY[1]	D7S522/CEP 7: 65/100 cells (65%) had a signal pattern consistent with the deleted chromosome 7 long arm from the small marker observed in the metaphase karyotype; 9 cells (9%) had a signal pattern consistent with the monosomy 7 sideline observed in the metaphase karyotype.	CD2, CD11b, CD13, CD33, CD34, CD38, CD56, CD58, CD117,  CD123, and HLA-DR positive	Negative	0	Negative	NA	NA	NA	NRAS (p.Q61H; MAF 45%)	Acute Myeloid Leukemia	AML	0.566666667	MATCHED
aml_ohsu_2022_2320	aml_ohsu_2022_2320_BA2184	Waves1+2	Yes	1	bi	47	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated CEBPA	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Complete Response	Cyclophosphamide, Fludarabine, TBI	Allogeneic - Sibling	-1	M1	46,XY[20]	Normal	CD7, CD13, CD33, CD34, CD38, CD58, CD117, dim CD123 HLA-DR and MPO+ ,	Negative	0	Negative	NA	NA	NA	CEBPA (p.D320_N321ins22; MAF 50%)|CEBPA (p.R35fs*125; MAF 50%)|CREBBP (p.P505L; VAF 45%)	Acute Myeloid Leukemia	AML	0.3	MATCHED
aml_ohsu_2022_2040	aml_ohsu_2022_2040_BA2295	Waves1+2	Yes	1	NA	34	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	34	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response i	HiDAC	Consolidation	135	M2	46,XX,inv(16)(p13,1q22)[17]/46,XX[3]	Positive for rearrangement of the CBFB gene at 16q22 on chromosome 16. Negative for BCR-ABL1 translocation or other abnormalities in this panel.	CD13, dim CD33, subset CD34, CD38, CD117, 123, MPO(+)	Negative	0	Negative	NA	NA	NA	NRAS (p.G12D; MAF 6%)	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2213	aml_ohsu_2022_2213_BA3009	Waves1+2	Yes	1	NA	26	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	26	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	4	Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	M0	46,XX,r(2)(p23q31),der(4)t(4;16)(q21;q12-13)del(16)(q22q22),der(16)t(4;16)(q21;q12-13),add(18)(p11.2),del(20)(q13.2)[16]/46,XX[4]	CBFB: 88% of cells were missing a signal for CBFB, consistent withdeletion associated with the unbalanced t(4;16) seen on chromosome analysis. No evidence for disruption. This probe will be useful in following this abnormal clone.	CD13, partial CD15, CD34, CD38, partial CD56, CD58, partial CD117 and CD123+	Negative	0	Negative	NA	NA	NA	PTPN11 (p.D61G; MAF 15%)|TET2 (p.S1039L; MAF 50%)	Acute Myeloid Leukemia	AML	0.8	MATCHED
aml_ohsu_2022_2355	aml_ohsu_2022_2355_BA2891	Waves1+2	No	1	NA	63	FALSE	FALSE	FALSE	FALSE	TRUE	NonAML	Plasma cell myeloma	63	0	NA	NA	Peripheral Blood	2	CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone)|RVD (Bortezomib, Dexamethasone, Lenalidomide)	2	Induction|Re-induction	Unknown	RVD (Bortezomib, Dexamethasone, Lenalidomide)	Re-induction	-1	NA	44,XX,+5,add(5)(q11.1),der(8)t(8;13)(p12;q12),-13,-14,t(15;21)(q10;q10),add(20)(p13)[13]/46,XX[7]	87% IgH/MAF fusion; 62% 5q deletion	bright CD38, moderate CD45, CD138, cytoplasmic kappalight chain+.	Negative	NA	Negative	NA	NA	NA	NA	Mature B-Cell Neoplasms	MBN	0	UNMATCHED
aml_ohsu_2022_2549	aml_ohsu_2022_2549_BA2442	Waves1+2	Yes	3	NA	66	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	UNKNOWN	7+3 (Cytarabine, Idarubicin)	Induction	6	NA	47,XX,+8[18]	Normal	Large population of CD117 pos myeloblasts, representing 80% of leukocytes, consistent w/ AML.	Positive	0.428571429	Negative	NA	NA	NA	FLT3-ITD (p.Tyr591_Val592ins16; MAF 10%)|WT1 (p.Val379fs; MAF 13%)|ZRSR2 (p.Arg415Trp; MAF 48.9%)	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2463	aml_ohsu_2022_2463_BA2882	Waves1+2	Yes	1	NA	29	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Therapy-related myeloid neoplasms	29	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	2	HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	2	Induction|Re-induction	Complete Response	HiDAC	Re-induction	4	M5	46,XY,t(9;11)(p22;q23)[20]	94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, consistent with MLL rearrangement and the 9;11 translocation observed in the metaphase karyotype.	CD11b, varibleCD13, CD14, brightCD33, CD64, and HLA-DR positive	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2553	aml_ohsu_2022_2553_BA2656	Waves1+2	Yes	7	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	AML with mutated NPM1	20	2	Unknown	Unknown	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2078	aml_ohsu_2022_2078_BA2838	Waves1+2	No	6	NA	66	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Primary myelofibrosis	67	0	Residual Disease	NA	Bone Marrow Aspirate	1	Hydroxyurea	1	Unknown	NA	Hydroxyurea	Unknown	263	NA	46,XY[17]	Normal	Not detected for the FLT3 Internal Tandem Duplication (ITD). Not detected for the FLT3 TKD Mutation. No BCR-ABL1 transcripts are detected. MLL partial tandem duplication (MLL-PTD) is not detected. Pathogenic alterations are detected in the ASXL1, BRAF, EZH2, JAK2, NRAS and SETBP1 genes. (Bone Marrow Immunophenotyping) | Positive for CD34, CD117, HLADR, CD33, and CD13 | Negative for MPO and TDT	Negative	NA	Negative	NA	NA	NA	ASXL1 (p.A640Dfs*20, MAF 40%)|BRAF (p.G469A, MAF 7%)|EZH2 (MAF 43%)|JAK2 (p.V617F, MAF 46%)|NRAS (p.G12S, MAF 18%)|SETBP1 (p.D868N, MAF 15%)|SETBP1 (p.G870S, MAF 11%)	Myeloproliferative Neoplasms	MPN	0.3	MATCHED
aml_ohsu_2022_2078	aml_ohsu_2022_2078_BA2319	Waves1+2	No	6	NA	66	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Primary myelofibrosis	67	119	Residual Disease|Post-Chemotherapy	NA	Bone Marrow Aspirate	1	Hydroxyurea	1	Unknown	NA	Hydroxyurea	Unknown	263	NA	46,XY[17]	This test has not detected clonal abnormalities in the cells analyzed.	These are positive for CD34, CD117, HLADR, CD33 and CD13. (Bone Marrow Immunophenotyping)	Negative	NA	Negative	NA	NA	NA	NA	Myeloproliferative Neoplasms	MPN	0.466666667	MATCHED
aml_ohsu_2022_2277	aml_ohsu_2022_2277_BA2385	Waves1+2	No	6	NA	81	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Chronic myelomonocytic leukaemia	81	0	Unknown	NA	Bone Marrow Aspirate	NA	NA	NA	NA	NA	NA	NA	NA	NA	45,X,-X,del(9)(q13)[12]/46,sl,i(X)(q10)[8]	NA	Not detected for the FLT3 Internal Tandem Duplication (ITD). Not detected for the FLT3 TKD Mutation. MLL partial tandem duplication (MLL-PTD) is not detected. Pathogenic alteration is detected in the TET2 gene. Genomic alterations of uncertain significance are detected in the EZH2 and NF1 genes. (Bone Marrow Immunophenotyping) | MLL partial tandem duplication is not detected. Not detected for the FLT3 ITD and TKD mutations. (Bone Marrow Immunophenotyping (Continued))	Negative	NA	Negative	NA	NA	NA	EZH2 (p.L128S ,MAF 49%)|NF1 (p.F2388I, MAF 45%)|TET2 (p.R1452*, MAF 98%)	Myelodysplastic/Myeloproliferative Neoplasms	MDS/MPN	0.566666667	MATCHED
aml_ohsu_2022_2100	aml_ohsu_2022_2100_BA2705	Waves1+2	Yes	5	NA	39	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	40	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	2	Unknown|GCLAC (GCSF, Clofarabine & Cytarabine)	2	Induction|Re-induction	UNKNOWN	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	-1	NA	46,XY[15]	Negative	Positive (CD7, CD11b, CD13, CD33, dim CD34, CD38, dim CD45, CD117, HLA-DR)	Positive	0.923076923	Positive	NA	NA	NA	FLT3-ITD (ITD (39bp ins); VAF 39%)|NPM1 (c.859_860insTCTG; p.W288fs)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2440	aml_ohsu_2022_2440_BA2347	Waves1+2	Yes	6	NA	62	FALSE	FALSE	TRUE	FALSE	FALSE	Intermediate	AML with myelodysplasia-related changes	62	34	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	Azacitidine|Fludarabine, Melphalan, ATG	2	Unknown|Allogeneic - Matched Unrelated Donor	NA	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	M4	46, XY [20]	The abnormalities normally seen in MDS are not detected.	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2440	aml_ohsu_2022_2440_BA2379	Waves1+2	No	6	NA	62	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	62	81	Residual Disease	Residual	Bone Marrow Aspirate	2	Azacitidine|Fludarabine, Melphalan, ATG	2	Unknown|Allogeneic - Matched Unrelated Donor	NA	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	NA	46,XY[12]	The abnormalities normally seen in MDS are not detected.	A very dim/negative CD45 population was also detected by the flow analysis. This population is negative for all the myeloid and lymphoid markers including CD34. This is mentioned here for documentation purposes but we believe that they do not represent blasts. (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2440	aml_ohsu_2022_2440_BA2180	Waves1+2	No	6	NA	62	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	63	232	Residual Disease	Residual	Peripheral Blood	2	Azacitidine|Fludarabine, Melphalan, ATG	2	Unknown|Allogeneic - Matched Unrelated Donor	NA	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	NA	46,XY[12]	The abnormalities normally seen in MDS are not detected.	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2462	aml_ohsu_2022_2462_BA2967	Waves1+2	Yes	3	NA	58	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	58	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)	2	Induction|Re-induction	Refractory	CLAG (Cladribine, Cytarabine, Filgrastim)	Re-induction	-1	NA	44-45,XY,-4,-5,add(7)(q11.2),  der(16)del(16)(p13.1)del(16)(q22),-17,add(18)(q21),+1-3mar[cp18]  /46,XY[2]	NA	Increased CD34+ myeloblasts, representing 42% of leukocytes, suspicious for AML	Negative	0	Negative	NA	NA	TP53 (p.R248Q; 71.7%)	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2208	aml_ohsu_2022_2208_BA2752	Waves1+2	Yes	6	NA	68	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	68	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	4	Vidaza|Fludarabine, Melphalan|HiDAC|3+7 (Cytarabine, Daunorubicin)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Refractory	Fludarabine, Melphalan	Allogeneic - Sibling	0	NA	46,XY[20]	NA	These are positive for CD34, CD117, HLADR, CD33, and CD13. (Bone Marrow Immunophenotyping)	Positive	0.162790698	Negative	RUNX1 (p.G170Efs*7; 32.5%)|RUNX1 (p.R162W; 36.4%)	NA	NA	FLT3-ITD|MLL	Acute Myeloid Leukemia	AML	0.8	MATCHED
aml_ohsu_2022_2062	aml_ohsu_2022_2062_BA2078	Waves1+2	Yes	5	NA	64	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	65	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	2	FLX925|7+3 (Cytarabine, Idarubicin)	2	Induction|Experimental	Complete Response	FLX925	Experimental	-1	NA	46,XX,t(11;19)(q23;p13.1)[16]/46,sl,add(1)(p34)[2]/46,XX[2]	MLL Rearrangment	Negative (CD10, CD20, CD22, Cyt CD79a, Cyt CD3, CD7, CD16, CD56, CD14, CD15, CD64, CD117, HLA-DR, TdT) | Positive (CD38, CD11b, CD13, CD33, CD34, Dim CD45, MPO,)	Negative	0	Negative	NA	NA	NA	GATA2 (c.1145G>A; p.R382Q)|TET2 (c.5162T>G; p.L1721W (SNP))	Acute Myeloid Leukemia	AML	0.866666667	MATCHED
aml_ohsu_2022_2519	aml_ohsu_2022_2519_BA2663	Waves1+2	No	7	NA	67	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Chronic myelomonocytic leukaemia	66	0	Residual Disease	NA	Bone Marrow Aspirate	2	Cytarabine|Decitabine	2	Induction|Supportive/Palliative Care	UNKNOWN	Cytarabine	Induction	-1	NA	NA	Trisomy 8	NA	Negative	0	Negative	RUNX1 (p.R166*; 44.9%)	NA	NA	ASXL1|EZH2|PTPN11|RUNX1|STAG2	Myelodysplastic/Myeloproliferative Neoplasms	MDS/MPN	1.133333333	MATCHED
aml_ohsu_2022_2264	aml_ohsu_2022_2264_BA2397	Waves1+2	Yes	7	NA	59	FALSE	TRUE	FALSE	FALSE	FALSE	MissingKaryo	AML with mutated NPM1	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	Atypical monocytes (are about 91.5%). They are CD45+, CD33+, HLADR++.CD13+, CD14+. CD15++, CD64++, CD116++, CD11b+++,CD11c++,CD38+ and CD34(-),CD117(-). A small population of monoclonal B-cells, CD19+, CD5+(<1%)	Positive	NA	Positive	NA	NA	NA	DNMT3A (p.Arg882His)|FLT3-ITD (p.Val579_Leu601dup)|NPM1 (p.Trp288Cysfs*12)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2367	aml_ohsu_2022_2367_BA2570	Waves1+2	Yes	2	NA	46	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	46	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	7+3 (Cytarabine, Idarubicin)	Induction	6	NA	46,XY[20]	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(+), surface CD3(-),  cytoplasmic CD3(dim +), CD4(-), CD7(partial +), CD11b(partial +),  CD13(variably +), CD14(few +), CD15(-), CD16(-),  CD33(-), CD34(partial +), CD36(-), CD38(bright +), CD45(dim  +), CD56(small subset +), CD64(-), CD117(+), HLA-DR(partial +), MPO(partial +), TdT(partial dim+)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2209	aml_ohsu_2022_2209_BA2764	Waves1+2	No	7	NA	77	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	79	0	Post-Chemotherapy	Remission	Bone Marrow Aspirate	1	Decitabine	1	Induction	Complete Response	Decitabine	Induction	-1	NA	NA	Translocation between the long arm of chromosome 3 and short arm of chromosome 12.	NA	Positive	NA	Positive	NA	NA	NA	FLT3-ITD|NPM1	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2363	aml_ohsu_2022_2363_BA2209	Waves1+2	Yes	5	NA	59	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	64	0	Relapse	Relapse	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, TBI	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	NA	47,XY,+13[2]/94,slx2[2]/46,XY[19]	5p15.2/5q31(EGR1), 7 centromere/7q31, 8 centromere/20q12, 12 centromere/13q14 D13S319/13q34 (13qter)	Negative (CD10, CD19, CD20, CD22, Cyt CD79a, Cyt CD3, CD7, CD16, CD56, CD11b, CD14, CD15, CD33, CD64, MPO) | Positive (CD38, CD13, CD34, Dim CD45, Dim CD117, HLA-DR, TdT)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.6	MATCHED
aml_ohsu_2022_2332	aml_ohsu_2022_2332_BA2989	Waves1+2	Yes	2	NA	70	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	71	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	2	Azacitidine|Decitabine	1	Hypomethylating/Low Dose Cytarabine	NA	Azacitidine	Hypomethylating/Low Dose Cytarabine	98	NA	47,XY,+21[19]/46,XY[1]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],	CD2(-), CD4(dim +), CD7(-), CD10(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD22(-), CD19(partial +), CD33(partial +), CD34(+), CD36(-), CD38(bright and variably +), CD45(+), CD56(-), CD64(-), CD79a(-), CD117(+), HLA-DR(predominantly + and variable), TdT(partial +), and MPO(-) | In addition, there is a 0.92% population of CD117(bright +)/CD34(-)/CD45(dim +)/CD33(- to dim +) small cells with low orthogonal light scatter. The exact identity of these cells is uncertain	Positive	0.086956522	Negative	RUNX1 (p.I366Vfs*231; 65.5%)	NA	NA	BCOR (Foundation; R1480*; MAFs: 88%)|BCORL1 (Foundation; P304fs*117; MAFs: 72%)|FLT3-ITD|NF1 (Foundation; I679fs*21; MAFs: 5%)|NF1 (Foundation; V2649fs*31 (subclonal); MAFs: 12%)|PHF6 (Foundation; R225*; MAFs: 87%)|PTPN11 (Foundation; A72T; MAFs: 8%)|RUNX1 (Foundation; I366fs*114+; MAFs: 57%)|TET2 (Foundation; Q742*; MAFs: 41%)	Acute Myeloid Leukemia	AML	0.4	UNMATCHED
aml_ohsu_2022_2296	aml_ohsu_2022_2296_BA2605	Waves1+2	Yes	3	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	46,XX[20]	NA	Relative increase in CD117pos,CD34neg myeloid blasts, representing 16% of total leukocytes, most consistent with myeloid neoplasm such as advanced MDS or AML.	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2528	aml_ohsu_2022_2528_BA2261	Waves1+2	Yes	2	NA	62	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	62	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	4	Vidaza|7+3 (Cytarabine, Idarubicin)|Lenalidomide|Hydroxyurea	3	Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care	Refractory	Hydroxyurea	Supportive/Palliative Care	-1	NA	46~47,XX,del(5)(q15q35),i(8)(q10),add(11)(q23),add(17)(p11.2),add(21)(q22),+2~3mar[cp3]/47~49,idem,add(7)(q11.2),-add(11),+11,+14,-20[cp4]/45~49,idem,del(7)(q22q36),-add(11),+11,+14,-20[cp2]/45~48,idem,der(7)del(7)(q22q31)dic(7;20)(q36;q11.2),-add(11),+11,+14[	nuc ish(D5S2064x2,D5S630x2,EGR1x1)[184/200],(D7Z1x2,D7S522x1)[115/200],(D8Z2x2,D20S108x1)[142/200],(RUNX1T1x3,RUNX1x2)[180/200],(5'MLL amp,3'MLL amp)(5'MLL con 3'MLL amp)[66/200],(PML,RARA)x2[197],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+),CD56(+), CD64(-), CD117(partial +), HLA-DR(partial +). | In addition, there is a 0.01% population of small cells with the following immunophenotype: CD5(+), CD10(-), CD19(+), CD20(dim+), CD38(-), CD45(+), lambda(dim +), and kappa(-).	Negative	0	Negative	NA	NA	TP53 (p.R213Dfs*34; 85.5%)	TP53 (R213fs; MAF 34%)	Acute Myeloid Leukemia	AML	1.066666667	MATCHED
aml_ohsu_2022_2556	aml_ohsu_2022_2556_BA2721	Waves1+2	Yes	1	NA	69	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	AML with maturation	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	8	7+3 (Cytarabine, Idarubicin)|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|IMGN779 (Immunogen Trial)|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924|Azacitidine, Midostaurin, Ponatinib	4	Salvage|Induction|Experimental|Re-induction	Refractory	IMGN779 (Immunogen Trial)	Salvage	-1	M2	46,XX[20]	normal	CD13, CD34, CD58, CD117, partial MPO and HLA-DR +	Positive	1	Negative	RUNX1 (p.A187T; MAF 42%)	NA	NA	CREBBP (p.S893L; MAF 41%)|FLT3-ITD (MAF 47%)|RUNX1 (p.A187T; MAF 42%)|SF3B1 (p.K700E; MAF 51%)|TET2 (p.K751fs*61; MAF 44%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2556	aml_ohsu_2022_2556_BA2401	Waves1+2	No	1	NA	69	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with maturation	69	46	Post-Chemotherapy	Remission	Bone Marrow Aspirate	8	7+3 (Cytarabine, Idarubicin)|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|IMGN779 (Immunogen Trial)|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924|Azacitidine, Midostaurin, Ponatinib	4	Salvage|Induction|Experimental|Re-induction	Refractory	IMGN779 (Immunogen Trial)	Salvage	-1	M2	46,XX[20]	normal	Positive (CD13, dim CD33, CD34, CD38, CD58 and CD123+)	Positive	0.075268817	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2094	aml_ohsu_2022_2094_BA2728	Waves1+2	Yes	1	NA	58	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	58	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Azacitidine|SWOG S0919 (Ida/Ara+Pravastatin) |Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Maintenance	Complete Response	Azacitidine	Maintenance	102	M2	46,XX,t(3;3)(q21;q26)[20]	98/100 (98%) interphase cells scored had a 1 red/ 1 green/ 2 yellow signal pattern, interphase cells scored had a 1 red/ 1 green/ 2 yellow signal pattern, consistent with RPN1/MECOM fusion. Two metaphases showed a fusion signal on one derivative 3 and red, yellow and green signals on the other deriv	variable CD11b, CD13, dim CD33, CD34, CD58, CD117, CD123	Negative	0	Negative	NA	NA	NA	NRAS (p.G12D; MAF 47%)|SF3B1 (p.K666N; MAF 47%)	Acute Myeloid Leukemia	AML	0.7	MATCHED
aml_ohsu_2022_2192	aml_ohsu_2022_2192_BA2715	Waves1+2	Yes	2	NA	81	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	81	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	2	Vidaza|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care	NA	Decitabine	Supportive/Palliative Care	3	NA	45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]	nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5’CBFB con 3’CBFB dimx1,5’CBFB con 3’CBFBx1)[200]	CD4(+), CD5(partial +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(predominantly -), CD16(-), CD33(+), CD34(+), CD36(-),CD38(variably +), CD45(variably +), CD56(predominantly -), CD64(partial +), CD117(+), HLA-DR(predominantly + and variable),MPO(-), TdT(-).	Negative	0	Negative	NA	NA	TP53 (p.R273H; 39.7%)|TP53 (p.L206Wfs*41; 32.4%)	EP300 (Foundation; EP300-ZNF205 fusion)|TP53 (Foundation; L206fs*41; MAFs: 31%)|TP53 (Foundation; R273H; MAFs: 38%)	Acute Myeloid Leukemia	AML	1.066666667	MATCHED
aml_ohsu_2022_2192	aml_ohsu_2022_2192_BA2116	Waves1+2	No	2	NA	81	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	81	41	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	2	Vidaza|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care	NA	Decitabine	Supportive/Palliative Care	3	NA	45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]	nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5’CBFB con 3’CBFB dimx1,5’CBFB con 3’CBFBx1)[200]	NA	Negative	0	Negative	NA	NA	TP53 (p.R273H; 56.3%)|TP53 (p.L206Wfs*41; 40.7%)	NA	Acute Myeloid Leukemia	AML	1.1	MATCHED
aml_ohsu_2022_2530	aml_ohsu_2022_2530_BA2469	Waves1+2	Yes	6	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML without maturation	51	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	4	Busulfan, Fludarabine|5+2 (Cytarabine, Idarubicin)|HiDAC|7+3 (Cytarabine, Idarubicin, Bortezomib	3	Unknown|Induction|Re-induction	Unknown	Busulfan, Fludarabine	Unknown	-1	NA	46,XX[20]	NA	FLT3 (ITD) Not detected. Not detected for the FLT3 TKD Mutation. Pathogenic alterations are detected in the BCOR, IDH2 and WT1 genes. Positive for CD34, HLADR, CD117, CD13, CD33 and CD43 and negative for CD11B, CD14, CD64, TDT and MPO. (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	NA	BCOR (p.E1348Ifs, MAF 32%)|IDH2 (p.R172K, MAF 41%)|WT1 (p.T171Cfs*116, MAF 39%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2033	aml_ohsu_2022_2033_BA2269	Waves1+2	Yes	6	NA	34	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute monoblastic and monocytic leukaemia	34	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|Cytarabine|Etoposide, Mitoxantrone	3	Unknown|Induction|Re-induction	Refractory	Cytarabine	Unknown	6	NA	46,XX[20]	NA	NA	Negative	0	Negative	NA	NA	TP53 (p.R282Q; 46.6%)	CSF3R (p.A470V, MAF 51%)|DNMT3A (p.R882C, MAF 51%)|NRAS (p.G13R, MAF 48%)|TP53 (p.R282Q, MAF 51%)	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2414	aml_ohsu_2022_2414_BA2098	Waves1+2	Yes	1	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M5	46,XX[20]	Normal	Positive (dim CD4, CD11b, variable CD13, partial CD14, CD33, variable CD56, bright CD64, dim CD123 and HLA-DR-positive, comprising ~75% of WBCs. There is also about 5% of blasts are positive for CD117, CD13, CD33, HLA-DR, CD123, amd CD11b. Lymphocytes account for 13% of WBCs and include 74% T cells, 19% B cells and 7% NK cells. T cells show a CD4:CD8 ratio of 5:1 without aberrant antigen expression.) | Positive (B cells are polytypic by surface light chain expression with a kappa to lambda ratio of 1.2:1.)	Negative	0	Positive	NA	NA	NA	IDH1 (p.R132H; MAF 37%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G13D; MAF 38%)	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2414	aml_ohsu_2022_2414_BA2090	Waves1+2	No	1	NA	61	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	61	34	Post-Chemotherapy	Remission	Peripheral Blood	3	Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M5	46,XX[19]	Normal	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2228	aml_ohsu_2022_2228_BA2951	Waves1+2	Yes	3	NA	65	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	65	3	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	47,XX,+X,inv(3)(q21q26.2),-7,+22[2]/48,sl,+21[18]	evidence of monosomy 7 in 191/200 (95.5 percent) cells scored	NA	Negative	0	Negative	RUNX1 (p.D198G; 66.7%)	NA	NA	CALR (p.Leu367fs; MAF 24%)|CBL (p.? ; MAF 16.5%)|DNMT3A (p.Ala571Pro; MAF 51.5%)|EZH2 (p.Pro636Ala; MAF 94.7%)|FLT3 (p.Val579Ala; MAF 2.3 %)|PTPN11 (p.Gly60Ser; MAF 49.1%)|RUNX1 (p.Asp198Gly; MAF 63.7%)	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2083	aml_ohsu_2022_2083_BA2778	Waves1+2	Yes	1	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	6	Fludarabine, Melphalan|Ruxolitinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC|Hydroxyurea	5	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance	Refractory	Ruxolitinib	Maintenance	496	M5	46,XX[20]	Normal	Positive (CD11b, variable CD13, CD14, CD33, dim CD56, bright CD64, and HLA-DR+)	Negative	0	Positive	NA	NA	NA	FBXW7 (p.T15_G16insP; MAF 48%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G12S; MAF 40%)|TET2 (p.H437fs*7; MAF 42%)	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2129	aml_ohsu_2022_2129_BA2163	Waves1+2	Yes	1	NA	67	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	67	0	Residual Disease	Residual	Bone Marrow Aspirate	4	Fludarabine, Melphalan|Azacitidine|Hydroxyurea|Idarubicin and Cytarabine	3	Allogeneic - Sibling|Induction|Re-induction	Refractory	Fludarabine, Melphalan	Allogeneic - Sibling	-1	NA	45,XY,+5,dic(5;8)(q11.2;p12)x2,del(7)(q22q32),-18,del(20)(p11.2)[cp20]	5p/5q: 88/100 (88%) cells had one signal for EGR1 (5q31) and three signals for 5p, consistent with the metaphase karyotype; 5 cells (5%) had one EGR1 signal and four 5p signals, consistent with a previous sideline with three copies of the dicentric 5;8 chromosome.   | BCR: 15/200 (7.5%) cells had three signals for BCR (22q11.2) consistent with a previous sideling that had trisomy 22 (the same sideline with three copies of the dicentric 5;8 chromosome). There was no evidence for BCR/ABL fusion.	Positive (CD7, CD13, dimCD33, CD34, variable CD38, CD56, dim CD58, variable CD117, dimCD123 and dim HLA-DR positive)	Negative	0	Negative	NA	NA	TP53 (p.K132R; 39.4%)|TP53 (p.X126_splice; 51.3%)	DNMT3A (p.G570E; MAF 44%)|JAK2 (p.V617F; MAF 3%)|TP53 (Intron 4 3' splice site mutation; MAF 42%)|TP53 (p.K132R; MAF 45%)	Acute Myeloid Leukemia	AML	0.966666667	MATCHED
aml_ohsu_2022_2664	aml_ohsu_2022_2664_BA3153	Waves3+4	Yes	5	mono	49	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Mixed phenotype acute leukaemia, T/myeloid, NOS	49	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	NA	46,XY[20]	Normal	Positive (CD38, CD7, CD2) | Negative (CD10, CD19, CD22, CD16, CD56, CD13, CD14, CD15, CD33, CD34, CD117, MPO, HLA-DR) | Dim Positive (cCD3, CD11b, CD64)	Negative	0	Negative	NA	NA	NA	CEBPA ([c.937A>C; c.940G>A; c.941T>A;c.943C>G] p.K313_V314_L315delinsQKV)	Acute Leukemias of Ambiguous Lineage	ALAL	0.133333333	MATCHED
aml_ohsu_2022_2557	aml_ohsu_2022_2557_BA2817	Waves1+2	Yes	2	NA	73	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	77	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	6	Vidaza|AG-221|Bortezomib|Cytarabine|Lenalidomide|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Experimental|Supportive/Palliative Care	NA	AG-221	Experimental	267	NA	88<4n>,XXYY,+del(1)(p22p36),i(2)(p10),-5,-7,-7,-21,-21[12]	nuc ish(RUNX1T1x4,RUNX1x2)[200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[200],(PML,RARA)x4[200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[174/200]	92% population of variably-sized cells with the following immunophenotype: CD2(-), CD4(-), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(+), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(variably +), HLA-DR(partial +).	Negative	0	Negative	RUNX1 (loss)	NA	NA	IDH2 (R140Q)|PTPN11 (E76Q)|RUNX1 (loss)	Acute Myeloid Leukemia	AML	0.5	MATCHED
aml_ohsu_2022_2542	aml_ohsu_2022_2542_BA2820	Waves1+2	Yes	1	NA	73	FALSE	FALSE	TRUE	FALSE	FALSE	Intermediate	AML with mutated NPM1	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|Hydroxyurea	1	Induction	unknown	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)	Induction	21	M4	46,XY[20]	normal	Positive (Myeloid blast immunophenotype: CD13, CD33, dim CD64, CD117, CD123 (+) Monocytic/monoblastic immunophenotype: bright CD11b, CD13, bright CD14, CD33, bright CD64, HLA-DR (+))	Positive	1	Positive	NA	NA	NA	DNMT3A (p.R882H; MAF 42%)|EP300 (p.N674D; MAF 50%)|EP300 (p.V2140I; MAF 50%)|FLT3-ITD (MAF ~48%)|MLL2 (p.M3398V; MAF 51%)|NPM1 (p.W288fs*12; MAF 43%)	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2255	aml_ohsu_2022_2255_BA2704	Waves1+2	Yes	1	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	61	3	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Hydroxyurea	1	Induction	Unknown	Hydroxyurea	Induction	8	M1	46,XX[20]	Normal	partial CD13, CD33, dim/partial CD56, CD58, dim CD117, CD123 and MPO	Positive	0.851851852	Positive	NA	NA	NA	FLT3-ITD (MAF ~50%)|IDH2 (p.R140Q; MAF ~50%)|NPM1 (p.W288fs*12; MAF ~50%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2390	aml_ohsu_2022_2390_BA2723	Waves1+2	Yes	6	NA	25	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	26	0	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Peripheral Blood	5	Bu/Cy/ATG|HiDAC|3+7 (Cytarabine, Daunorubicin)|Decitabine|Clofarabine, Cytarabine	5	Consolidation|Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Decitabine	Salvage	9	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2390	aml_ohsu_2022_2390_BA2492	Waves1+2	No	6	NA	25	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	26	28	Residual Disease|Post-Chemotherapy|Post-Transplant	Residual	Bone Marrow Aspirate	5	Bu/Cy/ATG|HiDAC|3+7 (Cytarabine, Daunorubicin)|Decitabine|Clofarabine, Cytarabine	5	Consolidation|Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Decitabine	Salvage	9	NA	46,XY,-3,del(5)(q31q35),der(7)t(7;?)(p11.2;?),+der(11)(q23),-12,+mar[20]	NA	MONOBLASTS, 61%. These are dim45positive and also express CD13, CD33, CD11b, CD14, CD64  but lack CD16, CD34, CD117, HLADR  (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2153	aml_ohsu_2022_2153_BA2088	Waves1+2	No	6	NA	45	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	46	0	Post-Chemotherapy	Remission	Bone Marrow Aspirate	4	HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|3+7 (Cytarabine, Daunorubicin)|Cyclophosphamide, Etoposide, Cytarabine	4	Consolidation|Salvage|Induction|Re-induction	Refractory	CLAG (Cladribine, Cytarabine, Filgrastim)	Salvage	23	NA	45,XX,-7[4]/46,sl,+mar[2]/46,XX[14]	NA	MLL-PTD is not detected. FLT3-ITD not detected. FLT3-TKD mutation not detected. Pathogenic alterations are detected in the DNMT3A and IDH1 genes. Genomic alteration of uncertain significance is detected in the DNMT3A gene. (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2153	aml_ohsu_2022_2153_BA3202	Waves3+4	No	6	NA	45	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	47	148	Post-Chemotherapy	Remission	Bone Marrow Aspirate	4	HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|3+7 (Cytarabine, Daunorubicin)|Cyclophosphamide, Etoposide, Cytarabine	4	Consolidation|Salvage|Induction|Re-induction	Refractory	CLAG (Cladribine, Cytarabine, Filgrastim)	Salvage	23	NA	45,XX,-7[4]/46,sl,+mar[2]/46,XX[14]	NA	POSITIVE FOR CD34, CD117, HLADR, CD33 AND CD13. (Bone Marrow Immunophenotype)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	NA	UNMATCHED
aml_ohsu_2022_2095	aml_ohsu_2022_2095_BA2614	Waves1+2	Yes	3	bi	55	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	-1	NA	46,XX[20]	Normal	Increased atypical CD117pos, partial CD34+, partial HLA-DR pos myeloblasts (CD7+), representing about 55% of leukocytes, consistent with AML.	Negative	0	Positive	NA	NA	NA	CEBPA (p.Ala40fs; MAF 20.3%)|CEBPA (p.Lys304Thr; MAF 26.5%)|DNMT3A (p.Arg882His; MAF 39.1%)|NPM1 (p.Trp288fs; MAF 9.6%)|TET2 (p.Gln1501*; MAF 39%)	Acute Myeloid Leukemia	AML	0.8	MATCHED
aml_ohsu_2022_2618	aml_ohsu_2022_2618_BA3139	Waves3+4	Yes	1	NA	30	TRUE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	31	504	Post-Chemotherapy|Post-Transplant|Relapse	Relapse	Peripheral Blood	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine|Fludarabine, Cytarabine	4	Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Fludarabine, Cytarabine	Re-induction	5	NA	40~42,X,-Y,dic(5;12)(q13;p11.2),del(7)(q22q36),add(9)(q31),add(13)(q22),ins(?;14)(?;q11.2),-15,add(15)(p11.2),del(16)(q11.1),-17,-18,add(19)(q13.4),-20,der(21)t(3;21)(q22.3;q13),+mar[cp12]/40~41,sl,add(2)(q31)[cp7]/46,XY[1]	84.5% of cells were missing a signal for EGR1, consistent with 5q deletion, and as seen previously.	NA	Negative	0	Negative	NA	NA	TP53 (p.M340Cfs*5; 41.0%)|TP53 (p.R273H; 47.8%)	BCL6 (p.C475R; VAF 6%)|TP53 (p.M340fs*5; MAF 42%)|TP53 (p.R273H; MAF 47%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2618	aml_ohsu_2022_2618_BA3285	Waves3+4	No	1	NA	30	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	31	573	Post-Chemotherapy|Post-Transplant|Residual Disease	Residual	Peripheral Blood	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine|Fludarabine, Cytarabine	4	Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Fludarabine, Cytarabine	Re-induction	5	NA	39~41,X,-Y,dic(5;12)(q13;p11.2),del(7)(q22q36),add(9)(q31),add(13)(q22),ins(?;14)(?;q11.2),-15,add(15)(p11.2),del(16)(q11.1),-17,-18.add(19)(q13.4),-20,der(21)t(3;21)(q22.3;q13)[cp16]/46,XY[5]	84.5% of cells were missing a signal for EGR1, consistent with 5q deletion, and as seen previously.	NA	Negative	0	Negative	NA	NA	TP53 (p.M340Cfs*5; 50.0%)|TP53 (p.R273H; 42.2%)	NA	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2536	aml_ohsu_2022_2536_BA2784	Waves1+2	Yes	1	NA	83	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	85	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine	NA	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	NA	NA	NA	NA	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2422	aml_ohsu_2022_2422_BA2584	Waves1+2	Yes	3	NA	42	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	Complete Response	Busulfan, Fludarabine	Allogeneic - Sibling	-1	NA	45,XY,t(3;17)([21;q11.2),add(4)(q21),add(5)(p15),ins(10;11)(p12;q23q13),der(12;18)(q10;q10)[19]/46,XY[1]	11q23 rearrangement involving the  KMT2A (MLL) locus in 184/200 (92.0 percent) cells scored | One cell line showed the following clonal abnormalities in 19/20 (95%) cells: an apparent insertion of material form the long arm of chromosome 11 into the short arm of chromosome 10;  a translocation between chromosomes 3 and 17; added material on the long arm of chromosome 4 and on the short arm of chromosome 5; an unbalanced whole arm rearrangement between the long arms of chromosomes 12	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2599	aml_ohsu_2022_2599_BA3132	Waves3+4	Yes	6	NA	72	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	72	0	Residual Disease	Residual	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	47, XY, del (6) (q13q23), +8, der(20) t (20;?) (q11.2-13.1;?) [6]	There are only 6 metaphase cells available for analysis. All have clonal abnormalities including 6q deletion, trisomy 8 and rearrangement involving 20q. This karyotype is consistent with the clinical diagnosis of AML. (Cytogenetics)	Positive for CD34, HLADR, MPO, CD14 and CD33. Negative for CD117, CD11b, cd13 and CD64. (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	NA	IDH2 (p.R140Q, MAF 46%)|NRAS (p.Q61K, MAF 45%)|SRSF2 (p.P95H, MAF 47%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2187	aml_ohsu_2022_2187_BA2443	Waves1+2	No	2	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	54	0	Post-Chemotherapy	Remission	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	58	NA	46,X,t(X;2)(q22;p13)[20]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	The findings reveal a small population of CD34(+) myeloblasts demonstrating immunophenotypic variation of unclear significance	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	1	MATCHED
aml_ohsu_2022_2158	aml_ohsu_2022_2158_BA2083	Waves1+2	Yes	2	NA	52	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	52	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	7+3 (Cytarabine, Idarubicin)	Induction	-1	NA	39,X,-X,-4,-5,-7,-16,-17,-18[2]/39,idem,add(9)(q22)[3]/38,idem,-12[3]/46,XX[12]	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PMLx2,RARAx1)[147/200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[125/200]	CD4(+), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(bright +), CD34(+), CD36(-/small subset +), CD38(partial +), CD45(+),CD56(-), CD64(partial dim +), CD117(+), HLA-DR(partial +), MPO(-), and TdT(-)	Negative	0	Negative	NA	NA	TP53 (p.D281G; 43.9%)	NA	Acute Myeloid Leukemia	AML	1.133333333	MATCHED
aml_ohsu_2022_2830	aml_ohsu_2022_2830_BA3079	Waves3+4	Yes	3	NA	68	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	7+3 (Cytarabine, Idarubicin)	Induction	-1	NA	45,XY,+1,der(1;14)(p10;q10),add(3)(p25),-5,del(12)(p11.2p13)[6]/44,XY,sl,del(7)(q11.2),der(8)del(8)(p21)t(8;17)(q24;q21),-17,+19,-22[cp10]/63<3n>,sdl1,-3,-4,-6,+8,del(8)(p21)x2,+9,+13,-15,-18,-21[cp4]	5p15.2 (D5S23): gain present  5q31 (EGR1): deletion present  7cen (D7Z1), 7q31 (D7S486): deletion and monosomy present  | t(8;21)(q22;q22) (RUNX1T1;RUNX1): gain present  11q23 (KMT2A; also known as MLL): gain present  16q22 (CBFB): gain present  17q21 (RARA): gain present	NA	Negative	0	Negative	NA	NA	TP53 (p.N239*; 57.9%)	TP53 (p.Asn239*; MAF 58.4%)|TP53 (p.Ser166_Gln167del; MAF 12%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2439	aml_ohsu_2022_2439_BA2547	Waves1+2	Yes	3	NA	69	FALSE	TRUE	FALSE	FALSE	FALSE	MissingKaryo	Acute myeloid leukaemia, NOS	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus CX-01|IDAC	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Busulfan, Fludarabine	Allogeneic - Sibling	-1	NA	NA	NA	normocytic, normochromic, mild anisopoikilocytosis, no sig. polychromasia. Leukocyte number-decreased,leukocyte morph-within normal limits.	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.933333333	MATCHED
aml_ohsu_2022_2333	aml_ohsu_2022_2333_BA2417	Waves1+2	Yes	2	NA	70	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myelomonocytic leukaemia	70	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	3	Vidaza|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	Complete Response	Vidaza	Hypomethylating/Low Dose Cytarabine	4	NA	NA	NA	CD11b(partial +), CD13(equivocal), CD15(bright +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(bright +), CD45(bright +), CD56(+),CD64(bright+), CD117(-), and HLA-DR(+).	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2444	aml_ohsu_2022_2444_BA2361	Waves1+2	Yes	5	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin) plus Enasidenib|Busulfan, Cyclophosphamide	2	Allogeneic - Sibling|Induction	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	NA	46,XX,del(5)(q22q35)[2]/46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.2)[14]/46,XX[3]	Probe: 8 centromere/20q12 | Normal (5p15.2/ 5q31 (EGR1); 7 centromere/ 7q31)	Negative (CD19) | Negative (CD22) | Positive (CD38) | Negative (CD7) | Negative (CD56) | Negative (CD11b) | Positive (CD13) | Negative (CD14) | Negative (CD15) | Negative (CD33) | Positive (CD34) | Negative (CD45) | Negative (CD64) | Negative (CD117) | Negative (MPO) | Positive (HLA-DR)	Negative	0	Negative	NA	NA	NA	ASXL1 (c.190 0_1922 delAGAGAGGCGGCCACCACTGCCAT; p.R634Rfs; MAF 33%)|IDH2 (c.419G>A; P.R140Q; MAF 46%)	Acute Myeloid Leukemia	AML	0.6	MATCHED
aml_ohsu_2022_2284	aml_ohsu_2022_2284_BA2450	Waves1+2	Yes	1	NA	46	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	46	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	5	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Sunitinib	Consolidation	2	NA	NA	metaphases positive for 45XX monosomy chromosome 17,20/22 metaphases positive for 46XX diploid	NA	Positive	0.25	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.533333333	MATCHED
aml_ohsu_2022_2284	aml_ohsu_2022_2284_BA2994	Waves1+2	No	1	NA	46	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	47	14	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	5	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Sunitinib	Consolidation	2	NA	NA	metaphases positive for 45XX monosomy chromosome 17,20/22 metaphases positive for 46XX diploid	NA	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.6	MATCHED
aml_ohsu_2022_2284	aml_ohsu_2022_2284_BA2824	Waves1+2	No	1	NA	46	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	47	23	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	5	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Sunitinib	Consolidation	2	NA	NA	Positive	variable CD7, CD13, dim CD33, partial CD34, CD38,dim CD58, partial and variable CD117 and CD123 positive	Positive	0.515151515	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.633333333	MATCHED
aml_ohsu_2022_2224	aml_ohsu_2022_2224_BA2987	Waves1+2	Yes	1	NA	52	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	52	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	MiDAC|Idarubicin and Cytarabine|FLAG-IDA plus Midostaurin|Azacitidine, Midostaurin, Ponatinib|7+3 (Cytarabine, Idarubicin) plus Dasatinib	4	Consolidation|Salvage|Induction|Maintenance	Complete Response	Idarubicin and Cytarabine	Salvage	3	M5	46,XX[20]	Normal	CD11b, CD13, CD14, CD15, CD33, CD56, bright CD64 and dim HLA-DR-positive	Negative	0	Positive	NA	NA	NA	DNMT3A (p.R882C; MAF 45%)|FLT3 (p.D835A; MAF 4%)|FLT3 (p.N841K; MAF; 7%)|NPM1 (p.W288fs*12; MAF 46%)|NRAS (p.G12D; 17%)|TET2 (p.G1137D; MAF 31%)	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2224	aml_ohsu_2022_2224_BA2079	Waves1+2	No	1	NA	52	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	52	34	Post-Chemotherapy	Remission	Peripheral Blood	5	MiDAC|Idarubicin and Cytarabine|FLAG-IDA plus Midostaurin|Azacitidine, Midostaurin, Ponatinib|7+3 (Cytarabine, Idarubicin) plus Dasatinib	4	Consolidation|Salvage|Induction|Maintenance	Complete Response	Idarubicin and Cytarabine	Salvage	3	M5	46,XX[20]	Normal	NA	Negative	0	Negative	NA	NA	NA	DNMT3A (p.R882C; MAF 14%)	Acute Myeloid Leukemia	AML	0.1	MATCHED
aml_ohsu_2022_2224	aml_ohsu_2022_2224_BA3099	Waves3+4	No	1	NA	52	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	53	383	Post-Chemotherapy|Relapse	Relapse	Peripheral Blood	5	MiDAC|Idarubicin and Cytarabine|FLAG-IDA plus Midostaurin|Azacitidine, Midostaurin, Ponatinib|7+3 (Cytarabine, Idarubicin) plus Dasatinib	4	Consolidation|Salvage|Induction|Maintenance	Complete Response	Idarubicin and Cytarabine	Salvage	3	M5	46,X,t(X;7)(q21;q32)[20]	Normal	variable CD7, CD13, CD33, partial CD34, CD38, CD58,  CD117, CD123 and HLA-DR  (Immunophenotypic shift is noted from the prior leukemic blast  population.)	Positive	13.28571429	Positive	NA	NA	NA	DNMT3A (p.R882C; MAF 46%)|FLT3-ITD (MAF ~90%)|NPM1 (p.W288fs*12; MAF 44%)	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2379	aml_ohsu_2022_2379_BA3024	Waves1+2	Yes	2	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	MissingKaryo	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Induction	Refractory	Decitabine	Hypomethylating/Low Dose Cytarabine	5	NA	NA	nuc ish(RUNX1T1x2,RUNX1x1)[34/200],(ABL1x2,BCRx1)[51/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(-/few dim +), CD16(-),CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+), CD56(partial +), CD64(-), CD117(variably +), HLA-DR(+and dim/few -), MPO(-), TdT(-).	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2203	aml_ohsu_2022_2203_BA2552	Waves1+2	Yes	6	NA	67	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	69	0	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Peripheral Blood	6	AG-120|7+3 (Cytarabine, Idarubicin)|Cytarabine|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG	6	Consolidation|Salvage|Induction|Experimental|Post-Transplant Relapse|Allogeneic - Matched Unrelated Donor	Complete Response	Cytarabine	Post-Transplant Relapse	3	NA	NA	NA	NA	Positive	0.666666667	Positive	NA	NA	NA	IDH1 (p.R132S, MAF 46%)|NPM1 (p.W288Cfs*12, MAF 57%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2546	aml_ohsu_2022_2546_BA2472	Waves1+2	Yes	2	NA	78	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	78	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|Decitabine|7+3 (Cytarabine, Idarubicin) plus Azacitidine|IDAC|Etoposide, Cytarabine	4	Induction|Re-induction|Maintenance|Supportive/Palliative Care	Refractory	Etoposide, Cytarabine	Supportive/Palliative Care	-1	NA	46,XY[20]	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	CD2(-), CD3(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(small subset+), CD16(-), CD19(-), CD20(-), CD33(+), CD34(+),CD36(-), CD38(dim+), CD45(dim +), CD56(-), CD64(variably+), CD117(+), HLA-DR(dim +), MPO(partial +), and TdT(-).	Negative	0	Negative	RUNX1 (p.L89Pfs*49; 15.8%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2028	aml_ohsu_2022_2028_BA2144	Waves1+2	Yes	1	NA	56	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|ME (Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Salvage|Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Refractory	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M2	46,XX[20]	Normal	CD13, CD34, CD38, CD117, and dim HLA-DR +.	Negative	0	Negative	RUNX1 (p.R201*; 45.8%)	ASXL1 (p.G645Vfs*58; 14.3%)	NA	ASXL1 (p.T601A; MAF 45%)|BCOR (p.Y1350fs*1; MAF 43%)|DNMT3A (p.R882H; MAF 46%)|FLT3 (p.A680V; MAF 37%)|IDH2 (p.R140Q; MAF 43%)|NRAS (p.Q61K; MAF 9%)|PRDM1 (p.I117M; MAF 49%)|RUNX1 (p.N434fs*166; MAF 37%)|RUNX1 (p.R201*; MAF 45%)	Acute Myeloid Leukemia	AML	1.6	MATCHED
aml_ohsu_2022_2816	aml_ohsu_2022_2816_BA3420	Waves3+4	No	1	NA	75	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Myelodysplastic syndrome, unclassifiable	75	1	NA	NA	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	47,XY,+19[12]/46,XY[8]	Normal	NA	Negative	NA	Negative	NA	NA	NA	ATM (p.R3047*; MAF 9%)|CSF3R (p.A832V; MAF 49%)|IDH2 (p.R140W; MAF 16%)|SRSF2 (p.P95_R102del; MAF 25%)	Myelodysplastic Syndromes	MDS	0.633333333	MATCHED
aml_ohsu_2022_2467	aml_ohsu_2022_2467_BA2047	Waves1+2	Yes	1	NA	69	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	69	1	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	ATRA, Idarubicin|ATRA, Arsenic Trioxide	2	Consolidation|Induction	Complete Response	ATRA, Arsenic Trioxide	Consolidation	-1	M3	46,XX,t(15;17)(q24;q21)[20]	PML/RARA fusion	dim CD2, CD13, dim CD15, CD33, CD38, CD58, CD64, CD117, CD123, variable HLA-DR and bright MPO positive	Positive	0.851851852	Negative	NA	NA	NA	FLT3-ITD (MAF 42%)|NOTCH1 (p.P2438L ; MAF 47%)	Acute Myeloid Leukemia	AML	0.066666667	MATCHED
aml_ohsu_2022_2483	aml_ohsu_2022_2483_BA2101	Waves1+2	Yes	1	NA	68	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	7+3 (Cytarabine, Idarubicin)	Induction	-1	M2	46,XY,del(7)(q22),inv(16)(p13.1q22)[18]/46,XY[2]	CBFB, D7S486/ CEP 7	CD5, CD19, dim CD20, dim CD22, CD23 and light chain negative	Negative	0	Negative	NA	NA	NA	FLT3-ITD (MAF 3%)|FLT3(p.D839G; MAF 3%)|DNMT3A(p.R882H; MAF 16%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2126	aml_ohsu_2022_2126_BA2082	Waves1+2	Yes	2	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	47,XY,t(8;19)(q24.1;q13.1),+10[17]/46,XY[3]	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.833333333	MATCHED
aml_ohsu_2022_2555	aml_ohsu_2022_2555_BA2284	Waves1+2	Yes	2	NA	44	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	44	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	NA	45,XX,der(13;14)(q10;q10)?c[20]	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	NA	Positive	0.851851852	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2481	aml_ohsu_2022_2481_BA2456	Waves1+2	Yes	2	NA	65	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Cytarabine	1	Supportive/Palliative Care	NA	Cytarabine	Supportive/Palliative Care	-1	NA	NA	nuc ish (PML,RARA)x2[199]	NA	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.833333333	MATCHED
aml_ohsu_2022_2382	aml_ohsu_2022_2382_BA2175	Waves1+2	Yes	2	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Decitabine	1	Supportive/Palliative Care	NA	Decitabine	Supportive/Palliative Care	-1	NA	45,XX,der(5)inv(5)(p13q15)del(5)(q15q33),-16,-17,der(17)t(17;17)(p13;q11.2),der(18;22)(q10;q10),+22,+r[cp20] .ish r(MLL+)[2]	nuc ish(D4Z1,D10Z1)x2[200],(D5S2064x2,D5S630x2,EGR1x1)[196/200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[197],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3) [142/200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[200]	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2377	aml_ohsu_2022_2377_BA2507	Waves1+2	Yes	5	NA	33	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	33	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	-1	NA	46,XY,inv(16)(p13.1q22)[20]	Positive for CBFB rearrangment for 91% of cells	Positive (CD38, CD13, CD33, CD34, CD45, CD117, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD14, CD15, CD64, TdT)	Negative	0	Negative	NA	NA	NA	TET2 (c.652G>A; p.V218M; MAF 50%)	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2493	aml_ohsu_2022_2493_BA2563	Waves1+2	Yes	3	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Busulfan, Fludarabine|IDAC plus Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Sorafenib	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	NA	46,XY[20]	Normal	NA	Positive	0.063829787	Positive	NA	NA	NA	DNMT3A (p.Arg326Cys; MAF 44.5%)|FLT3-ITD (p.Phe594_Asp600dup; MAF 45%)|NPM1 (p.Trp288fs; MAF 20.7%)|TET2 (p.Ala911fs; MAF 40.6%)|TET2 (p.His1036fs; MAF 39.4%)	Acute Myeloid Leukemia	AML	0.6	MATCHED
aml_ohsu_2022_2194	aml_ohsu_2022_2194_BA2092	Waves1+2	Yes	1	NA	46	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	46	0	Relapse	Relapse	Bone Marrow Aspirate	7	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate	6	Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction	Complete Response i	Dasatinib	Experimental	-1	NA	46,XX[20]	Normal	dim CD7, CD13, CD33, CD71, CD117, CD123,  HLA-DR and MPO	Positive	NA	Positive	NA	ASXL1 (p.G645Vfs*58; 12.0%)	NA	DNMT3A (p.R882H; MAF 35% )|FLT3-ITD (MAF 20%)|JAK3 (p.H529R; MAF 49% )|NPM1 (p.W288fs*12; MAF 20%)	Acute Myeloid Leukemia	AML	0.866666667	MATCHED
aml_ohsu_2022_2194	aml_ohsu_2022_2194_BA3164	Waves3+4	No	1	NA	46	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	47	124	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Peripheral Blood	7	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate	6	Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction	Complete Response i	Dasatinib	Experimental	-1	NA	46,XX,t(10;16)(q22;q24)[10]/46,X,t(X;1)(q23;q44),t(10;16)(q22;q24)[3]/46,X,t(X;13)(p21;q14),t(3;22)(q13.2;p11.1),t(5;6)(q31;q24),add(9)(q13),t(10;16)(q22;q24)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[2]/46,sl,der(1)t(1;2)(p13;q11.2),-2, (der(3)t(3;5)(q12;p15),del(6)(q13q23),+22[2]/46,XX[1])	Normal	partial CD7, CD13, CD33, partial CD34, CD38,  CD58, CD71, partial CD117, CD123, and HLA-DR +	Positive	11.5	Positive	NA	NA	NA	DNMT3A (p.R882H; MAF 43%)|FLT3-ITD (Internal tandem duplication (~75 bp; in-frame); MAF 79%)|JAK3 (p.H529R; MAF 50%)|NPM1 (p.W288fs*12; MAF 36%)	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2194	aml_ohsu_2022_2194_BA3235	Waves3+4	No	1	NA	46	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	47	168	Residual Disease|Post-Chemotherapy|Post-Transplant	Residual	Peripheral Blood	7	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate	6	Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction	Complete Response i	Dasatinib	Experimental	-1	NA	46,XX,t(10;16)(q22;q24)[cp12]/46,sl,t(1;4)(q41;q33),t(7;9)(p15;q32)[5]/46,sl,t(X;1)(q23;q44)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[1]	NA	NA	Positive	15.66666667	Positive	NA	NA	NA	FLT3-ITD (ITD; MAF 60%)	Acute Myeloid Leukemia	AML	0.333333333	UNMATCHED
aml_ohsu_2022_2803	aml_ohsu_2022_2803_BA3298	Waves3+4	Yes	3	NA	66	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|IDAC	3	Consolidation|Induction|Re-induction	Complete Response	CLAG (Cladribine, Cytarabine, Filgrastim)	Re-induction	-1	NA	46,XY,del(9)(q13q22)[4]/46,XY[16]	This analysis showed evidence of t(8;21)(q22;q22) (RUNX1T1-RUNX1 translocation) in a total of 152/200 (76.0 percent) cells scored. The signal pattern observed with this probe set is suggestive of a  three-way rearrangement.  | A subset of these cells (109/200; 54.5 percent) showed loss of one copy of the RUNX1T1 locus, suggesting clonal evolution.	NA	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 11.9%)|ASXL1 (p.R417*; 23.6%)	NA	ASXL1 (p.Gly646fs; MAF 2.4%)|ASXL1 (p.Ser1143Arg; MAF 49.2%)|KIT (p.Asn822Lys; MAF 5.6%)|NRAS (p.Gly12Cys; MAF 1.2%)|SF3A1 (p.Arg95Cys; MAF 49.9%)|TET2 (p.Gln913fs; MAF 3%)|TET2 (p.Glu537*; MAF 19.3%)	Acute Myeloid Leukemia	AML	0.533333333	MATCHED
aml_ohsu_2022_2190	aml_ohsu_2022_2190_BA2734	Waves1+2	Yes	1	NA	77	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	79	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	2	Lenalidomide|Azacitidine	1	Supportive/Palliative Care	NA	Lenalidomide	Supportive/Palliative Care	45	NA	46,XX[20]	Normal	NA	Negative	0	Negative	RUNX1 (p.R204*; 77.3%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2434	aml_ohsu_2022_2434_BA2576	Waves1+2	Yes	1	bi	28	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated CEBPA	29	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Fludarabine, Cyclophosphamide, TBI, Rituximab	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Complete Response	Fludarabine, Cyclophosphamide, TBI, Rituximab	Allogeneic - Sibling	-1	NA	46,XX[20]	Normal	CD7, CD13, CD33, CD34, partial CD56, CD117,  HLA-DR,          MPO and dim TdT-positive	Negative	0	Negative	NA	NA	NA	ASXL1 (p.D656N; MAF 46%)|CEBPA (p.Q311*; MAF 15%)|TET2 (p.R544*; MAF 16%)	Acute Myeloid Leukemia	AML	0.733333333	MATCHED
aml_ohsu_2022_2520	aml_ohsu_2022_2520_BA2984	Waves1+2	Yes	1	NA	81	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	81	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Vidaza, BI836858 (anti-CD33)	1	Induction	Complete Response	Vidaza, BI836858 (anti-CD33)	Induction	-1	M1	46,XY[19]	Normal	dim CD13, CD33, CD38, CD58, dim CD64, CD71, dim CD117 and CD123-positive	Negative	0	Positive	NA	NA	NA	CSF3R ( p.T640N; MAF: 14%)|EZH2 (p.G709D; MAF: 17%)|EZH2 (p.R684C; MAF: 4%)|IDH2 (p.R140Q; MAF: 46%)|KDM6A (Splice site-Intron 5 3' end mutation; MAF:3%)|NPM1 (p.W288fs*12; MAF: 39%)	Acute Myeloid Leukemia	AML	0.7	MATCHED
aml_ohsu_2022_2307	aml_ohsu_2022_2307_BA2414	Waves1+2	Yes	5	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	50	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	2	GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	NA	46,XY,add(1)(p11),del(5)(q15q33),del(7)(q22q36),der(11)t(1;11)(p31;p12-14)[20]	Loss of 5q31 sequences for 99% of total cells | Loss of 7q31 sequences for 96% of total cells	Positive: CD38, CD56, CD13, CD34, CD45, CD117, HLA-DR | Partially positive: CD7, CD11b, CD33, CD64 | Negative: CD19, CD22, Cyt CD79a, Cyt CD3, CD14, CD15, MPO, TdT	Positive	0.818181818	Negative	NA	NA	NA	BCOR (C.3067T>C; p.F1023L)|FLT3-ITD|NOTCH1 (c.7625G>A; p.S2542N)	Acute Myeloid Leukemia	AML	0.366666667	MATCHED
aml_ohsu_2022_2168	aml_ohsu_2022_2168_BA2697	Waves1+2	Yes	3	NA	65	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	3	Vidaza|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)	3	Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	NA	45,XX,-7[20]	7cen (D7Z1), 7q31 (D7S486): monosomy present	NA	Negative	0	Negative	NA	NA	NA	DNMT3A (p.Gln231fs; MAF 33.2%)|IDH2 (p.Arg140Gln; MAF 44.2%)|NRAS (p.Gln61Glu; MAF 47.8%)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2117	aml_ohsu_2022_2117_BA2999	Waves1+2	Yes	1	NA	53	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	54	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	7	AG-120|7+3 (Cytarabine, Idarubicin)|Azacitidine|MGD006 (CD123 x CD3) |MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	5	Salvage|Induction|Experimental|Re-induction|Maintenance	Refractory	Incyte trial (azacitidine and JAK 1 inhibitor)	Salvage	-1	NA	46,XY,t(4;12)(q12;p13)[10]/46,XY[10]	42/100 (42%) interphase cells scored were positive for  ETV6 rearrangement.  Metaphase FISH showed part of the ETV6 signal (red) on  the long arm of chromosome 4.  Based on the breakpoint, ETV6/CHIC2 fusion  is predicted, consistent with AML	partial CD7, CD13, CD33, CD38, CD34, CD58, CD117, CD123,  HLA-DR positive	Negative	0	Negative	RUNX1 (p.R166*; 41.5%)	NA	NA	DNMT3A (p.R882H; MAF 49%)|IDH1 (p.R132S; MAF 48%)|RUNX1 (p.R166*; MAF 50%)|SRSF2 (p.P95H; MAF 50%)	Acute Myeloid Leukemia	AML	0.333333333	UNMATCHED
aml_ohsu_2022_2280	aml_ohsu_2022_2280_BA2644	Waves1+2	No	3	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC	3	Consolidation|Induction|Allogeneic - Child	Complete Response	Busulfan, Fludarabine	Allogeneic - Child	-1	NA	46,XY[11]	Normal	NA	Negative	0	Negative	NA	NA	NA	BCOR (p.Tyr354*; MAF 72.2%)|DNMT3A (p.Phe755Ser; MAF 38.6%)|DNMT3A (p.Thr835Met; MAF 47%)|IDH1 (p.Arg132Cys; MAF 2.9%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2280	aml_ohsu_2022_2280_BA2011	Waves1+2	Yes	3	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with myelodysplasia-related changes	63	1	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC	3	Consolidation|Induction|Allogeneic - Child	Complete Response	Busulfan, Fludarabine	Allogeneic - Child	-1	NA	46,XY[11]	Normal	NA	Negative	0	Negative	NA	NA	NA	BCOR (p.Tyr354*; MAF 72.2%)|DNMT3A (p.Phe755Ser; MAF 38.6%)|DNMT3A (p.Thr835Met; MAF 47%)|IDH1 (p.Arg132Cys; MAF 2.9%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2538	aml_ohsu_2022_2538_BA2217	Waves1+2	Yes	1	bi	47	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated CEBPA	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	116	M1	46,XY[20]	NA	CD7, CD13, CD33, CD34, CD38, partial CD56,  CD58, dim CD64, CD117, CD123, HLA-DR, and cMPO	Negative	0	Negative	NA	NA	NA	CEBPA (p.I68fs; MAF 50%)|CEBPA (p.K313_V314insK; MAF 50%)|EZH2 (p.S519P; MAF 51%)|NRAS (p.G13D, MAF 3%)|WT1 (p.M392fs*10; MAF 13%)|WT1 (p.R458*; MAF 23%)	Acute Myeloid Leukemia	AML	0.7	MATCHED
aml_ohsu_2022_2234	aml_ohsu_2022_2234_BA2454	Waves1+2	Yes	2	NA	73	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Decitabine	1	Supportive/Palliative Care	NA	Decitabine	Supportive/Palliative Care	-1	NA	46,XY[20]	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[195],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	NA	Negative	0	Negative	RUNX1 (p.S322*; 51.4%)	ASXL1 (p.R693*; 50.0%)	NA	NA	Acute Myeloid Leukemia	AML	1.1	MATCHED
aml_ohsu_2022_2431	aml_ohsu_2022_2431_BA2776	Waves1+2	Yes	1	NA	61	FALSE	FALSE	TRUE	FALSE	FALSE	Intermediate	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Hydroxyurea	1	Supportive/Palliative Care	NA	Hydroxyurea	Supportive/Palliative Care	-1	M1	46,XX[20]	Normal	CD13, CD33, CD38, CD56, CD58, CD117, CD123 and dim MPO positive	Positive	9	Positive	NA	NA	NA	FLT3-ITD (30 bp insertion; MAF 70%)|NPM1 (p.W288fs*12; MAF 45%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2282	aml_ohsu_2022_2282_BA2218	Waves1+2	Yes	6	NA	39	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	40	0	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|HiDAC|ME (Etoposide, Mitoxantrone)|Decitabine	3	Consolidation|Salvage|Induction	Complete Response	Decitabine	Salvage	69	NA	NA	NA	NA	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2547	aml_ohsu_2022_2547_BA2135	Waves1+2	Yes	6	NA	73	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Decitabine	1	Supportive/Palliative Care	NA	Decitabine	Supportive/Palliative Care	-1	NA	46,XX,del(1)(p22),der(15)t(15;?)(q15;?),-17,+mar[19]/46,XX[1]	Loss of RARA gene at 17q21 is detected in 69% of cells Gain of MLL gene at 11q23 is detected in 8% of cells.	blasts 55% of all events; they are positive for cd34, hla-dr, cd117, cd13, cd33, and negative for cd11b, cd14, cd64, tdt and mpo	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 32.6%)	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2547	aml_ohsu_2022_2547_BA3321	Waves3+4	No	6	NA	73	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	73	122	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	1	Decitabine	1	Supportive/Palliative Care	NA	Decitabine	Supportive/Palliative Care	-1	NA	46,XX,del(1)(p22),der(15)t(15;?)(q15:?),-17,+mar[18]/46,XX[2]	Loss of RARA gene at 17q21 is detected in 69% of cells Gain of MLL gene at 11q23 is detected in 8% of cells.	POSITIVE FOR CD34, CD117, HLA-DR, CD13, CD33, CD38, CYCD3 (DIM) AND NEGATIVE FOR TDT AND MPO	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 26.9%)	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2756	aml_ohsu_2022_2756_BA3292	Waves3+4	Yes	1	NA	64	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	AML with maturation	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin) plus Samalizumab|MiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M2	46,XY[20]	Normal	CD13, CD33, CD34, dimCD38, CD71, CD117, dimCD123,  HLA-DR and dim MPO positive	Negative	0	Negative	NA	NA	NA	SRSF2 (p.P95R; MAF 3%)	Acute Myeloid Leukemia	AML	0.066666667	MATCHED
aml_ohsu_2022_2508	aml_ohsu_2022_2508_BA2914	Waves1+2	Yes	1	NA	38	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	38	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	106	M4	46,XX[20]	Normal	CD117, dimCD4,  heterogeneous CD13, CD33, dimCD64 and  MPO positive  (Myeloid Blast Population) | heterogeneous CD13, bright CD33, dimCD4,  dimCD14, bright CD64 positive  (Monocytes/promonocytes Population)	Negative	0	Positive	NA	NA	NA	DNMT3A (p.R882H; MAF 46%)|IDH1 (p.R132H; MAF 25%)|KRAS (p.Q61L; MAF 10%)|NPM1 (p.W288fs*12; MAF 51%)|NRAS (p.G13D; MAF 24%)	Acute Myeloid Leukemia	AML	0.633333333	MATCHED
aml_ohsu_2022_2670	aml_ohsu_2022_2670_BA3272	Waves3+4	Yes	1	NA	51	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	53	0	Post-Chemotherapy|Relapse	Relapse	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	Complete Response	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	M5	46,XX,inv(16)(p13.1q22)[1]/46,XX[19]	CBFB:  12/200 cells (6%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting CBFB rearrangement and previously observed.	CD13, CD33, CD34, CD117, and HLA-DR positive	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.033333333	MATCHED
aml_ohsu_2022_2120	aml_ohsu_2022_2120_BA2500	Waves1+2	Yes	1	NA	59	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	ATRA, Arsenic Trioxide, Idarubicin	1	Induction	Complete Response	ATRA, Arsenic Trioxide, Idarubicin	Induction	-1	M3	46,XX,t(15;17)(q22;q21)[20]	86/100 cells (86%) had the 1r/1g/2f dual fusion signal pattern consistent  with PML/RARA fusion and with t(15;17) as seen on metaphase analysis.	CD13, CD33, CD58, CD64, CD117, CD123, MPO	Negative	0	Negative	NA	NA	NA	ASXL1 (p.M1050V; MAF 51%)|FLT3-ITD (MAF 46%)	Acute Myeloid Leukemia	AML	0.5	MATCHED
aml_ohsu_2022_2315	aml_ohsu_2022_2315_BA2519	Waves1+2	Yes	7	NA	61	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	62	0	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	46,XX[20]	NA	NA	Negative	0	Positive	NA	NA	NA	CUX1 (VAF: 43.9%)|DNMT3A (VAF: 42.8%)|NPM1 (VAF: 44.9%)|WT1 (VAF: 23.2%)	Acute Myeloid Leukemia	AML	0.333333333	UNMATCHED
aml_ohsu_2022_2143	aml_ohsu_2022_2143_BA2406	Waves1+2	Yes	6	NA	64	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	64	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	7+3 (Cytarabine, Idarubicin)	Induction	6	NA	42,XY,-3,-7,der(12)t(12;?)(q24.3;?)-17,der(17)t(17;?)(p13;?),-21,der(22)t(22;?)(p11.2:?)[10]/46,XY[10]	NA	NOT DETECTED for the MLL partial tandem duplication (PTD). NOT DETECTED for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR). NOT DETECTED for the FLT3 TKD Mutation. Pathogenic alterations are DETECTED in the DNMT3A, NF1 and TP53 genes.  (Bone Marrow Immunophenotyping) | positive for CD34, CD117, HLA-DR, CD13, and CD33, negative for monocytic markers CD11b, CD14 and CD64, negative for specific B and T cell markers. (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	TP53 (p.E204*; 52.3%)	DNMT3A (c.2635_2651delAACATGAGCCGCTTGGC; p.N879Efs*36c.2656C>T; pQ886*MAF 43%, 36% )|NF1 (c.2192_2199delTCTTGCCC; p.L731Qfs*3  MAF 38%)|TP53 (c.610G>T;p.E204*MAF 51%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2268	aml_ohsu_2022_2268_BA2830	Waves1+2	Yes	1	NA	72	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	74	0	Relapse	Relapse	Peripheral Blood	1	Dasatinib	1	Experimental	NA	Dasatinib	Experimental	16	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2268	aml_ohsu_2022_2268_BA2353	Both	No	1	NA	72	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	74	33	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	1	Dasatinib	1	Experimental	NA	Dasatinib	Experimental	16	NA	46,XX,inv(16)(p13q22)[18]/46,XX[2]	CBFB:  79/100 cells (79%) reflecting CBFB rearrangement and the inverted chromosome 16 observed in the metaphase karyotype.	CD13, CD33, CD34, variable CD38, CD117,  CD123, and HLA-DR +.	Negative	0	Negative	NA	NA	NA	KIT (p.D816H; MAF 44%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2673	aml_ohsu_2022_2673_BA3108	Waves3+4	Yes	1	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	Vidaza, BI836858 (anti-CD33)|Azacitidine|Enasidenib|Incyte trial (azacitidine and JAK 1 inhibitor)	3	Salvage|Induction|Maintenance	Refractory	Enasidenib	Salvage	28	M2	48,XX,+8,+8,add(9)(q22)[1]/50,idem,+15,+18[5]/46,XX[14] (Six of twenty metaphase cells analyzed comprised two related hyperdiploid clones.)	Results were consistent with tetrasomy 8 (RUNX1T1/CEP8) and trisomy 15 (PML) in approximately 50% of cells scored.  All other probe results were within normal limits with no evidence for rearrangements or deletions.	CD13, CD33, CD34, CD38, moderate-dim  CD45, and CD117+	Negative	0	Negative	NA	NA	NA	IDH2 (p.R140Q; MAF 43%)|U2AF1 (p.Q157P; MAF 17%)	Acute Myeloid Leukemia	AML	0.366666667	MATCHED
aml_ohsu_2022_2475	aml_ohsu_2022_2475_BA2924	Both	No	6	NA	66	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	67	0	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	63	NA	NA	NA	NA	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2475	aml_ohsu_2022_2475_BA3192	Waves3+4	No	6	NA	66	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	67	80	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	63	NA	49,XY,+4,+8,+14[9]/49,sl,del(4)(q21q31.1)[11]	NA	POSITIVE FOR CD117, HLA-DR, CD13, CD33, CD14 AND MPO AND NEGATIVE FOR CD34, CD11B, CD64, CD10 AND TDT. (Bone Marrow Immunophenotype)	Positive	NA	Positive	NA	NA	NA	DNMT3A (c.2645G>A; p.R882H MAF 42%)|FLT3-ITD|KIT (c.2447A>T; p.D816V MAF 81%)|NPM1 ((NPM1) c.860_863dupTCTG; p.W288Cfs*12  MAF 51%)|SETBP1 (c.3209C>T; p.P1070L MAF 46%)|TET2 (c.3638T>G; p.V1213G MAF 87%)	Acute Myeloid Leukemia	AML	0.5	MATCHED
aml_ohsu_2022_2570	aml_ohsu_2022_2570_BA2303	Both	No	3	NA	39	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	39	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Fludarabine, TBI	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Fludarabine, TBI	Allogeneic - Sibling	-1	NA	46,XX[20]	NA	Large pop. of promonocytes/monoblasts representing approx 57% of total leukocytes and increased atypicalCD117 pos, partial CD34 pos myeloblasts (partial CD7 pos) representing approx 6% of leukocytes consistent w/AMLw/monocytic differentiation.	Positive	5.666666667	Positive	NA	NA	NA	DNMT3A (p.Arg882His; MAF 41.8%)|FLT3 (p.Tyr572Cys; MAF 1.2%)|FLT3 (p.Val581_Arg595dup; MAF 22%)|FLT3-ITD|NPM1 (p.Trp288fs; MAF 21.2%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2163	aml_ohsu_2022_2163_BA2647	Waves1+2	Yes	6	NA	44	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	45	0	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Bone Marrow Aspirate	5	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Clofarabine, Cytarabine	5	Consolidation|Salvage|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Refractory	Azacitidine	Salvage	4	NA	NA	NA	POSITIVE for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR) with a signal ratio of 0.045. NOT DETECTED for the FLT3 TKD Mutation.  (Bone Marrow Immunophenotyping) | POSITIVE FOR DIM CD45, CD34, HLADR, CD117, CD13, CD38, NEGATIVE FOR CD33. (Bone Marrow Immunophenotyping (Continued))	Positive	0.515151515	Negative	RUNX1 (p.R107C; 43.8%)|RUNX1 (p.W106*; 36.8%)	NA	NA	FLT3-ITD|IDH2 (c.419G>A; p.R140Q   MAF 39%)|NF1 (c.5225A>G; p.N17425 MAF 10%)|PHF6 (c.901T>G; p.Y301D MAF 29%)|RAD21 (c.482-3T>C; MAF 8%)|RUNX1 (c.318G>A; p.W106* MAF 37%, c.319C>T; p.R107C  MAF 37%)|SMC1A (c.3391G>A; p.G1131R  MAF 29%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2216	aml_ohsu_2022_2216_BA2160	Both	No	3	NA	74	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Supportive/Palliative Care	UNKNOWN	7+3 (Cytarabine, Idarubicin)	Induction	-1	NA	46,XX[20]	Normal	Large population of CD117pos, CD34 neg, HLA-DR neg myeloblasts, representing approx 68% of leukocytes, consistent w/ residual/recurrent AML.	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2131	aml_ohsu_2022_2131_BA2590	Both	No	5	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Enasidenib	3	Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Maintenance	Complete Response	Midostaurin	Maintenance	44	NA	46,XY[19]	Normal	Negative (CD19, CD22, Cyt CD3, CD7, CD56, CD11b, CD13, CD14, CD34, CD64, CD117, TdT) | Positive (CD38, Cyt CD79a, CD15, CD33, MPO) | Dim (CD45, HLA-DR)	Positive	1	Positive	NA	NA	NA	FLT3 (c.1811_1812insl8; p.E604_P605insYDLKWE; MAF 32%)|IDH1 (c.395G>A; p.R132H; 44%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 42%)|SRSF2 (c.284_307del; p.P95_R102del; MAF 45%)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2827	aml_ohsu_2022_2827_BA3195	Waves3+4	Yes	5	NA	77	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	Venetoclax, Idasanutlin|anti-CD123, Decitabine|Enasidenib|cd47mAb	3	Salvage|Induction|Experimental	Refractory	Enasidenib	Salvage	-1	NA	46,XY[19]	Normal	Positive (CD38, CD15, CD34, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD13, CD14, CD33, CD64, TdT) | Dim Positive (CD45, CD117)	Negative	0	Negative	RUNX1 (p.L98Pfs*40; 52.3%)|RUNX1 (p.N434Kfs*166; 32.4%)	NA	NA	DNMT3A (c.2644C>T; p.R882C; MAF 47%)|IDH2 (c.419G>A; p.R140Q; MAF 48%)|JAK2 (c.1849G>T; p.V617F; MAF 50%)|RUNX1 (c.1289_1290insTGCC; p.P430fs; MAF 17%)|RUNX1 (c.1301 1302insA; p.N434Â£s; MAF 21%)|RUNX1 (c.292_293insC; p.L98fs; MAF 45%)|SRSF2 (c.284C>A; p.P95H; MAF 48%)	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2500	aml_ohsu_2022_2500_BA2516	Both	No	1	NA	70	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	70	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	4	Imatinib|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Salvage|Induction|Experimental|Re-induction	Refractory	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	NA	46,XY[20]	Normal	NA	Negative	0	Negative	NA	ASXL1 (p.E635Dfs*22; 42.9%)	NA	BCOR (p.S1024; MAF 5%)|NRAS (p.G13D; MAF 34%)|PTPN11 (p.G60V; MAF 3%)|SRSF2 (p.P95H; MAF 40%)	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2372	aml_ohsu_2022_2372_BA3036	Both	No	2	NA	43	FALSE	FALSE	TRUE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	43	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	7+3 (Cytarabine, Idarubicin)	Induction	6	NA	46,XX[20]	nucish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	NA	Positive	0.492537313	Negative	NA	NA	NA	FLT3-D835	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2086	aml_ohsu_2022_2086_BA2971	Both	No	6	NA	57	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|HiDAC|3+7 (Cytarabine, Daunorubicin)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Matched Unrelated Donor	13	NA	46,XY[20]	NA	THESE ARE POSITIVE FOR CD34, CD117, HLADR, CD13, AND CD33. (Bone Marrow Immunophenotyping)	Negative	0	Negative	RUNX1 (p.D198N; 47.6%)|RUNX1 (p.P113L; 42.7%)	NA	NA	DNMT3A (c.2644C>T; p.R882C MAF 47%)|JAK2 (c.1849G>T; p.V617F MAF 91%)|RUNX1 (c.338C>T; p.P113L  MAF 42% c.592G>A; p.D198N MAF 46%)|SETBP1 (c.883G>A; p.V1295M MAF 47%)|SRSF2 (c.284C>A; p.P95H MAF 47%)	Acute Myeloid Leukemia	AML	0.333333333	UNMATCHED
aml_ohsu_2022_2695	aml_ohsu_2022_2695_BA3410	Waves3+4	Yes	8	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|Decitabine	2	Induction|Supportive/Palliative Care	Refractory	Decitabine	Supportive/Palliative Care	67	NA	43-48,XY,add(2)(q11.2),add(3)(p13),add(3)(q29),del(5)(q15q33),der(7)add(7)(p11.2)add(7)(q22),?hsr(8)(q24),+10,+11, add(12)(p11.2),-13,add(14)(p13),add(15)(p12),add(15)(p13),-16,?hsr(16)(q22),-17,-20,+21,add(21)(q22),idic(21)(q22),-22, add(22)(p12),+mar1-5[cp22]/87-88,idem[cp2]	NA	NA	Negative	0	Negative	NA	NA	TP53 (p.R248Q; 58.8%)	NA	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2709	aml_ohsu_2022_2709_BA3118	Waves3+4	Yes	2	NA	45	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Myeloid sarcoma	45	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	92	NA	46,XX[20]	NA	NA	Negative	0	Negative	NA	NA	NA	MYH11 (CBFB-MYH11 fusion)|NRAS (G12D)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2668	aml_ohsu_2022_2668_BA3206	Waves3+4	Yes	1	NA	35	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	35	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine, Venetoclax	4	Consolidation|Salvage|Induction|Re-induction	Refractory	Decitabine, Venetoclax	Salvage	165	M2	45,X,-X,t(8;21)(q22;q22)[20]	RUNX1T1(8q21.3)/RUNX1(21q22):   64% of cells had an atypical 1r/2g/1f  signal pattern, a fusion pattern consistent with t(8;21) as seen on metaphase analysis.  | All twenty metaphase cells examined were abnormal, with monosomy X and  t(8;21).	CD13, dim CD19, dim CD33, CD34, CD38, CD56, CD58, CD117, dim CD123, HLA-DR and MPO+	Negative	0	Negative	NA	NA	NA	FLT3-ITD (MAF 5%)	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2735	aml_ohsu_2022_2735_BA3432	Waves3+4	Yes	6	NA	70	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	70	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	4	3+7 (Cytarabine, Daunorubicin)|Gemtuzumab|Azacitidine|Decitabine	2	Salvage|Induction	Refractory	Azacitidine	Salvage	-1	NA	44-46,XX,del(1)(p32),del(5)(q31q35),del(7)(q11.2q32),-9,-15,-16,-18,add (21)(q22),-22,-22,+3mar[cp3]/46,XX[7]	Clonal abnormalities including deletions in 1p, 5q and 7q are detected in 3 of 10 metaphase cells analyzed. Deletions in 5q and 7q are common abnormalities in MDS and also in AML as treatment related chromosome changes or in AML with myelodysplasia.  (Cytogenetics) | This is an incomplete analysis due to inadequate number of metaphases cells.  (Cytogenetics (Continued))	NOT DETECTED for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR). NOT DETECTED for the FLT3 TKD Mutation. POSITIVE for the MLL partial tandem duplication (PTD) at 2.61%. Pathogenic alterations are NOT DETECTED. These are positive for CD34, CD117, HLADR, CD33, CD13.  (Bone Marrow Immunophenotyping)	Negative	0	Negative	NA	NA	NA	MLL	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2624	aml_ohsu_2022_2624_BA3217	Waves3+4	Yes	5	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)	2	Allogeneic - Sibling|Induction	Complete Response	Fludarabine, Melphalan	Allogeneic - Sibling	-1	NA	46,XY[20]	Normal	Positive (CD38, CD33, CD34, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD13, CD14, CD15, CD117, TdT) | Dim (CD11b, CD45, CD64)	Positive	0.960784314	Negative	NA	NA	NA	FLT3-ITD (ITD, c.1769_1770ins42; p.Y589_F590insl4 (MAF 38%))|IDH2 (c.419G>A; p.R140Q (MAF 48%))|STAG2 (c.3034delC; p.R1012fs (MAF 92%))	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2701	aml_ohsu_2022_2701_BA3405	Waves3+4	Yes	3	NA	67	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myelomonocytic leukaemia	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Cytarabine	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	M4	NA	NA	NA	Negative	0	Negative	RUNX1 (p.D198G; 94.2%)	ASXL1 (p.G646Wfs*12; 30.1%)	NA	NA	Acute Myeloid Leukemia	AML	0.5	MATCHED
aml_ohsu_2022_2811	aml_ohsu_2022_2811_BA3306	Waves3+4	Yes	5	NA	26	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	26	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI	3	Consolidation|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	NA	NA	Normal	Dim Positive (CD13, MPO) | Dim Partial positive (CD34) | Variable partial positive (CD117)	Positive	19	Positive	NA	NA	NA	FLT3-ITD (ITD, c.l815_1816ins30; p.F605_P606insl0 (MAF 49%))|IDH1 (c.395G>A; p.R132H (MAF 45%))|NPM1 (c.863_864insTCTG; p.W288fs (MAF 43%))	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2809	aml_ohsu_2022_2809_BA3371	Waves3+4	Yes	8	NA	21	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	21	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	4	HiDAC|7+3 (Cytarabine, Idarubicin)|Unknown|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Unknown	Allogeneic - Matched Unrelated Donor	-1	NA	46,XX[20]	Negative for RUNX1/RUNX1T1, KMT2A (MLL), CBFB	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2761	aml_ohsu_2022_2761_BA3179	Waves3+4	Yes	1	NA	72	FALSE	FALSE	TRUE	FALSE	FALSE	Intermediate	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	2	Cytarabine|Azacitidine	2	Salvage|Induction	UNKNOWN	Cytarabine	Induction	42	M2	47,XX,+8[1]/46,XX[19]	5/200 (2.5%) interphase cells scored had three signals for both  probes, consistent with trisomy 8.  One metaphase spread showed three  chromosomes 8, each with a centromere signal and a MYC signal in the long  arm.	CD13, CD33, CD34, CD38, CD117 and HLA-DR+	Negative	0	Negative	NA	NA	NA	BCOR (p.E130*, MAF 17%)|IDH2 (p.R140Q; MAF 4%)|KMT2D (p.P2938L; MAF 54%)|KMT2D (p.P657L; MAF 49%)|NRAS (p.T58I; MAF 6%)|PTPN11 (p.E76D; MAF 7%)|SRSF2 (p.P95H; MAF 31%)|STAG2 (p.R614*; MAF 16%)	Acute Myeloid Leukemia	AML	0.366666667	MATCHED
aml_ohsu_2022_2666	aml_ohsu_2022_2666_BA3413	Waves3+4	Yes	3	bi	31	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with mutated CEBPA	31	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Busulfan, Fludarabine|CLAG (Cladribine, Cytarabine, Filgrastim)|7+3 (Cytarabine, Idarubicin, Dexamethasone)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	NA	46,XX,del(9)(q13q22)[5]/46,sl,del(11)(q13q23)[14]  /46,sdl,t(2;4;7)(q33;q21;p15),add(8)(p11.2)[2]	NA	NA	Negative	0	Negative	NA	NA	NA	CEBPA (p.Ala111fs; MAF 44.5%)|CEBPA (p.Ser319_Asp320del; MAF 32.9%)|CSF3R (p.Thr618Ile; MAF 1.6%)|GATA2 (p.Arg330Gln; MAF 46%)	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2615	aml_ohsu_2022_2615_BA3411	Waves3+4	Yes	1	NA	48	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	48	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	-1	M4	47,XX,+8,del(8)(q11.2q22)[20]	CEP 8:  73/100 cells (73%) had three signals, consistent with the extra chromosome 8 in the metaphase karyotype	CD13, CD33, CD34, CD38, CD56, CD58, variable CD64, CD71, CD117, dim CD123, HLA-DR, MPO  (Myeloid Blasts) | CD11b, CD13, CD15, CD33, CD56, CD64, HLA-DR (Abnormal Monocytes)	Negative	0	Negative	NA	ASXL1 (p.L823*; 45.9%)	NA	ASXL1 (p.L823; MAF 47%)	Acute Myeloid Leukemia	AML	0.366666667	MATCHED
aml_ohsu_2022_2747	aml_ohsu_2022_2747_BA3133	Waves3+4	Yes	1	NA	61	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Vidaza	1	Induction	Unknown	Vidaza	Induction	-1	M2	45,XY,del(5)(q13q33),-7,add(8)(q24.3),add(9)(q34),add(10)(q23),del(17)(p13)  ,add(18)(q23)[3]/47-49,sl,+2-4mar[cp12]/44,sl,-2,add(3)(p21),t(6;11)(p22;q1  4),-add(8)(q24.3),add(8)(p22),-9,add(9)(q33),-10,-13,add(21)(q21),+2mar[8]	TP53 (17p13.1):  83% of cells were missing a signal for TP53, consistent with the 17p deletion seen on metaphase analysis.  | RUNX1 (21q22):  15.5% of cells were missing a signal for RUNX1.  No  evidence for RUNX1/RUNX1T1 fusion.  | MECOM (3q26.2):  33% of cells had six (6) signals for MECOM. On available  metaphases, the extra MECOM signals hybridized to the small marker  chromosomes.  No evidence for MECOM/RPN1 fusion.	CD13, CD33, CD34, CD38, CD58, CD71, CD117,  CD123, HLA-DR +	Negative	0	Negative	RUNX1 (p.X170_splice; 26.1%)	NA	TP53 (p.Q167*; 91.3%)	BCOR (p.Q1658H; MAF 100%)|RUNX1 (Splice Site; MAF 17%)|SF3B1 (p.K666M; MAF 47%)|SRSF2 (p.R180G; MAF 54%)|TP53 (p.Q167; MAF 65%)	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2780	aml_ohsu_2022_2780_BA3451	Waves3+4	Yes	1	NA	47	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	95	M5	46,XX[20]	Normal	CD4, CD11b, CD13, CD33, variable CD14, CD38,  dim CD56, CD58, bright CD64, dim CD123, HLA-DR, and partial MPO +	Negative	0	Positive	NA	NA	NA	KRAS (p.G13D; MAF 36%)|NPM1 (p.W288fs*12; MAF 44%)|TET2 (p.Q897*; MAF 39%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2645	aml_ohsu_2022_2645_BA3286	Waves3+4	Yes	1	NA	45	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML without maturation	45	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Daunorubicin) plus Sorafenib|HIDAC + Sorafenib|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation|Induction|Re-induction	Complete Response	HIDAC + Sorafenib	Consolidation	-1	M1	46,XX[20]	Normal	dimCD7, dimCD13, CD33, CD34, CD38, variable CD64, dimCD117, CD123, HLA-DR, and MPO positive	Positive	0.298701299	Negative	NA	NA	NA	FLT3-ITD (123 bp insertion; MAF 50%)	Acute Myeloid Leukemia	AML	0.1	MATCHED
aml_ohsu_2022_2645	aml_ohsu_2022_2645_BA3221	Waves3+4	No	1	NA	45	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML without maturation	45	29	Post-Chemotherapy	Remission	Peripheral Blood	3	7+3 (Cytarabine, Daunorubicin) plus Sorafenib|HIDAC + Sorafenib|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation|Induction|Re-induction	Complete Response	HIDAC + Sorafenib	Consolidation	-1	M1	46,XX[20]	Normal	NA	Negative	0	Negative	NA	NA	NA	CRLF2 (p.P224L; MAF 49%)|FLT3-ITD (MAF 2%)|KMT2D (p.R863P; MAF 48%)|PTPN11 (p.A72V; MAF 6%)|SETBP1 (p.P1134T, MAF 51%)	Acute Myeloid Leukemia	AML	0.133333333	MATCHED
aml_ohsu_2022_2727	aml_ohsu_2022_2727_BA3212	Waves3+4	Yes	1	NA	0	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with minimal differentiation	0	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide|Etoposide, Cytarabine	5	Consolidation|Induction|Intensification|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Re-induction	4	M0	46,XX,der(1)t(1;9)(p36.1;q22),t(5;17)(p13;q21),der(5;9)(p10;p10),+8[12]/47,  sl,+20[7]64~69<3n>,XXX,+1,der(1)t(1;9)(p36.1;q22)x2,+5,t(5;17)(p13;q21)x2,+  6,-9,-11,+21[cp3]	EGR-1/ D5S23, D5S721: 175/200 cells had a 1 red/ 2 green signal  pattern, indicating a deleted 5q. Five cells had a 2 red/ 4 green signal pattern consistent with the  two normal chromosomes 5 and the two derivative chromosomes (5;9),  resulting in loss of 5q, present in the near-triploid clone. | RUNX1T1/ RUNX1: 155/200 cells had a 3 chromosome 8 signals,  consistent with the trisomy 8 observed in the metaphase karyotype.  Four cells had 4 chromosome 21 signals (in addition to trisomy 8),  consistent with the tetrasomy 21 observed in the near-triploid clone. No evid for RUNX1T1/RUNX1 fusion. | ETV6/ RUNX1:   5/200 cells (2.5%) had a 4 red/ 3 green signal pattern,  consistent with the near-triploid clone with trisomy 8 and tetrasomy 21.  There was no evidence for ETV6/ RUNX1 fusion.	CD4, CD7, partial CD13, CD33, CD71, partial CD117, CD123 and dim HLA-DR-positive	Negative	0	Negative	NA	NA	NA	NRAS (p.G12D; MAF 29%)|NRAS (p.Q61K; MAF 6%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2790	aml_ohsu_2022_2790_BA3103	Waves3+4	Yes	2	NA	49	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	49	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	-1	NA	46,XX,inv(16)(p13.1q22)[18]/46,XX[2]	NA	NA	Negative	0	Negative	NA	NA	NA	KIT|KRAS|MYH11 (CBFB-MYH11 fusion)	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2792	aml_ohsu_2022_2792_BA3271	Waves3+4	Yes	1	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	7+3 (Cytarabine, Idarubicin)	Induction	6	M5	46,XX[20]	Normal	dim CD4, dim CD7, CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and dim partial MPO (Myeloid Blast Population) | CD4, CD11b, CD13, dim CD14, dim CD15, CD16, CD33, CD38, CD58, CD63, CD123, HLA-DR  (Promonocyte/Monocyte Blast Population)	Positive	0.666666667	Positive	NA	NA	NA	FLT3-ITD (ITD; MAF 45%)|IDH2 (p.R140Q; MAF 38%)|NPM1 (p.W288fs*12; MAF 41%)	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2758	aml_ohsu_2022_2758_BA3152	Waves3+4	Yes	1	NA	74	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Azacitidine	1	Supportive/Palliative Care	NA	Azacitidine	Supportive/Palliative Care	3	M5	43~44,XY,der(5)t(5;15)(q22;q11.2),add(6)(p23),-15,-16,-17,add(18)(q21),add(  19)(q13.1),-21,+mar1,+mar2[cp20]	Approximately 95% of cells had abnormal signal patterns consistent with the metaphase karyotype and reflecting deleted 5q, monosomy 16, monosomy 17, and monosomy 21.	partial CD11b, CD13, partial CD14, CD33, CD34, partial CD64, CD117, HLA-DR and dim MPO (+)	Negative	0	Negative	NA	NA	TP53 (p.Y220C; 90.9%)	TP53 (p.Y220C;  MAF 91%)	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2626	aml_ohsu_2022_2626_BA3095	Waves3+4	Yes	1	NA	27	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML without maturation	27	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	7	Ruxolitinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Busulfan, Cyclophosphamide|Ibrutinib	5	Consolidation|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	Refractory	Ruxolitinib	Maintenance	-1	M1	47,XX,+8[19]/46,XX[1]	RUNX1T1 (8q21.3):   93% of cells had three signals for RUNX1T1 (8q21.3)  consistent with trisomy 8 as seen on metaphase analysis.	dim CD7, CD13, CD33, dimCD34, dimCD64, dim CD117, CD123, and dim HLA-DR+	Positive	0.818181818	Negative	NA	NA	NA	FLT3-ITD (MAF 50% )	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2661	aml_ohsu_2022_2661_BA3168	Waves3+4	Yes	1	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine	4	Consolidation|Salvage|Induction|Re-induction	Refractory	Azacitidine	Salvage	63	M0	42,XX,add(1)(q32),-5,-7,add(12)(p13),add(13)(q21.2),-17,-18,add(19)(q13.4)[3]/43,sl,+r[10]/44,sdl1,+8[6]/46,XX[1]	19/20 metaphase cells analyzed comprised three related, complex abnormal clones, all with abnormalities of chromosomes 1q, 12p, 13q and 19q, and monosomies 5, 7, 17, and 18. 16 of these cells had a ring chromosome of unknown origin, 6 of which were also trisomy 8. One cell appeared normal female.	CD13, CD33, CD34, CD71, CD117 and HLA-DR+	Negative	0	Negative	NA	NA	TP53 (p.T155N; 81.0%)	NOTCH1 (p.A2257V; MAF 52%)	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2815	aml_ohsu_2022_2815_BA3251	Waves3+4	Yes	5	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Unknown	Venetoclax (ABT-199), Azacitidine	Induction	4	NA	46,XX[20]	Normal	Positive (CD38, CD13, CD33, CD117, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD14, CD15, CD34, CD64, TdT, Glyc A) | DIM (CD45, CD71)	Positive	0.5625	Negative	NA	NA	NA	FLT3-ITD (c.1829_1830ins51; p.N609_L610ins17; MAF 19%)|IDH2 (c.419G>A; p.R140Q; MAF 48%)|RUNX1 (c.1041G>A; p.M347I; MAF 50%)	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2801	aml_ohsu_2022_2801_BA3201	Waves3+4	No	1	NA	68	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Myelodysplastic Syndromes	67	0	NA	NA	Bone Marrow Aspirate	5	Fludarabine, Melphalan|Dasatinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine, Lenalidomide|Decitabine	5	Salvage|Induction|Allogeneic - Mismatched Unrelated Donor|Experimental|Re-induction	Complete Response	Decitabine	Experimental	-1	NA	45,X,-Y[4]/46,XY[16]	Normal	NA	Negative	0	Negative	NA	NA	NA	IKZF1 (p.C492G; MAF 9%)|KRAS (p.G12V; MAF 11%)|SF3B1 (p.K700E; MAF 13%)	Myelodysplastic Syndromes	MDS	0.233333333	UNMATCHED
aml_ohsu_2022_2801	aml_ohsu_2022_2801_BA3358	Waves3+4	No	1	NA	68	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Myelodysplastic Syndromes	67	120	NA	NA	Bone Marrow Aspirate	5	Fludarabine, Melphalan|Dasatinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine, Lenalidomide|Decitabine	5	Salvage|Induction|Allogeneic - Mismatched Unrelated Donor|Experimental|Re-induction	Complete Response	Decitabine	Experimental	-1	NA	46,XY[14]	Normal	NA	Negative	0	Negative	NA	NA	NA	IKZF1 (p.C492G; MAF 4%)|KRAS (p.G12V; MAF 4%)|SF3B1 (p.K700E; MAF 7%)	Myelodysplastic Syndromes	MDS	0.066666667	UNMATCHED
aml_ohsu_2022_2655	aml_ohsu_2022_2655_BA3362	Waves3+4	Yes	1	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Unknown	3+7 (Cytarabine, Daunorubicin)	Induction	-1	M5	46,XX,der(1)t(1;1)(p36.3;q21),t(8;16)(p11.2;p13.3),add(15)(q24)[20]	In 95/100 cells (95%), three  signals for chromosome 1q25 were observed, and only two signals for 1p36  were observed, consistent with gain of 1q by der(1)t(1;1)	CD4, CD11b, partial CD13, CD33, CD56, bright CD64, partial CD117, CD123, HLA-DR and partial MPO-positive	Negative	0	Negative	NA	NA	TP53 (p.R175H; 55.0%)	FLT3 (p.D835E; MAF 42%)|TP53 (p.R175H; MAF 43%)	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2733	aml_ohsu_2022_2733_BA3135	Waves3+4	Yes	8	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	7+3 (Cytarabine, Idarubicin)	Induction	7	M1	NA	NA	dim CD56 | dim CD15 | dim CD123	Positive	0.315789474	Positive	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2689	aml_ohsu_2022_2689_BA3408	Waves3+4	Yes	8	NA	64	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	64	1	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	4	Ruxolitinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Salvage|Induction|Supportive/Palliative Care	Complete Response	Ruxolitinib	Salvage	6	NA	46,XX,der(2)del(2)(p23)inv(2)(p22q31),add(3)(p?14),der(12)add(12)(p11.2)t(3;12)(p?13;q?15)[12]/46,idem,der(7)t(7;11)(q11.2;q13)[7]/46,XX[1]	NA	NA	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 12.8%)	NA	KMT2A	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2819	aml_ohsu_2022_2819_BA3160	Waves3+4	Yes	1	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M2	54~57,XY,+14,+19,+20,add(21)(q22),+add(21)x3~6,+22[cp19]/46,XY[1]	Nineteen of twenty metaphase cells examined were abnormal, with extra  copies of chromosomes 14, 19, 20 and 22, and several copies, 4-7, of a  structurally-abnormal chromosome 21.  This abnormal karyotype has been reported previously by an outside institution. One cell appeared normal  male.  | D20S108/20p:  90% of cells had three signals for both probes, consistent with the trisomy 20 seen on metaphase analysis. | RUNX1:   87% of cells had 4-7 signals for RUNX1 (21q22) consistent with the add(21) seen on metaphase analysis.  On an abnormal metaphase cell, each of the add(21) chromosomes (and the single normal homologue) had a RUNX1 signal. | BCR:  74% of cells had three signals for BCR (22q11.2), consistent with the trisomy 22 seen on metaphase analysis.	CD10, bright CD13, CD33, CD34, CD56, CD117, partial CD123, dim HLA-DR	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 10.8%)	NA	EZH2 (p.G179C; MAF 48%)|TET2 (p.S460F; MAF 50%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2823	aml_ohsu_2022_2823_BA3187	Waves3+4	Yes	8	NA	76	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	78	0	Relapse	Relapse	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	3	Consolidation|Salvage|Induction	Complete Response	Decitabine	Salvage	81	M4	46,XY,inv(16)(p13.1q22.1) [16]/46,idem,del(7)(q32)[ 4]	POSITIVE for CBFB gene locus rearrangement (separated by chromosome 16 inversion)	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2630	aml_ohsu_2022_2630_BA3098	Waves3+4	Yes	3	NA	44	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	44	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Matched Unrelated Donor	-1	NA	46,XY,der(7)t(7;11)(q22;q13), inv(16)(p13.1q22)[15]/46,XY[5]	7cen (D7Z1), 7q31 (D7S486): deletion present | 11q23 (KMT2A; also known as MLL): gain present | 16q22 (CBFB): rearrangement present	NA	Negative	0	Negative	NA	NA	NA	KIT (p.Tyr418_Arg420delinsArgTrpGly; MAF 10%)	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2613	aml_ohsu_2022_2613_BA3435	Waves3+4	Yes	1	NA	79	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML without maturation	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	Decitabine|Azacitidine, BI 836858 (anti-CD33)	2	Salvage|Induction	Refractory	Decitabine	Salvage	37	M1	47,XY,+8[18]/46,XY[2]	CEP8 and RUNX1T1 (8q21.3): ~90% of cells had an extra signal for chromosome 8 probes, consistent with trisomy 8, as seen on metaphase analysis.	partial CD13, partial CD33, CD34, CD117, CD123, partial HLA-DR, and partial MPO	Positive	0.111111111	Negative	RUNX1 (p.T246Hfs*15; 25.0%)	ASXL1 (p.G646Wfs*12; 30.2%)	NA	FLT3-ITD (MAF 16%)|IDH1 (p.R132C; MAF 46%)|JAK2 (p.V617F; MAF 12%)|RUNX1 (p.T246fs*15; MAF 50%)|U2AF1 (p.Q157P; MAF 48%)	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2633	aml_ohsu_2022_2633_BA3261	Waves3+4	Yes	1	bi	61	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated CEBPA	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M2	45,X,-Y,del(11)(q12)[20]	95/100 cells (95%) had a single signal, consistent with the deleted 11q in the metaphase karyotype. There was no evidence for MLL rearrangement.	CD7, partial CD13, dim CD33, CD34, CD28, CD58, CD71, CD117, HLA-DR and MPO	Negative	0	Negative	NA	ASXL1 (p.A752Lfs*20; 43.9%)	NA	ASXL1 (p.A752fs*20; MAF 46%)|CEBPA (D105Vfs*64; MAF 45%)|CEBPA (H236Rfs*78; MAF 35%)|EP300 (p.R1627W ; MAF 46%)|IDH2 (p.R140Q, MAF 50%)|KMT2D (p.P647Q; MAF 43%)	Acute Myeloid Leukemia	AML	0.566666667	MATCHED
aml_ohsu_2022_2767	aml_ohsu_2022_2767_BA3203	Waves3+4	Yes	6	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Busulfan, Fludarabine|HiDAC|3+7 (Cytarabine, Daunorubicin)	3	Allogeneic - Sibling|Consolidation|Induction	Refractory	Busulfan, Fludarabine	Allogeneic - Sibling	6	NA	NA	The translocations commonly seen in AML are not detected. 3 copies of RUNX1T1 gene at 8q22 are detected in 56% of cells. Loss of RUNX1 and RARA genes at 21q22 and 17q21 are detected in about 58% of cells Gain of MLL gene at 11q23 are detected in 82% of cells. (Cytogenetics)	THESE ARE POSITIVE FOR HLA-DR, CD117, CD34, CD33 AND CD13. POSITIVE FOR HLA-DR, CD117, CD34, CD33 AND CD13. (Bone Marrow Immunnophenotype)	Negative	0	Negative	NA	NA	TP53 (p.P153Afs*28; 75.8%)	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2822	aml_ohsu_2022_2822_BA3082	Waves3+4	Yes	1	NA	58	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Therapy-related myeloid neoplasms	58	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Refractory	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	NA	46,XX,t(9;11)(p22;q23)[10]/46,XX[10]	Ten of twenty metaphase cells examined were abnormal, with a t(9;11)  involving MLL; ten cells appeared normal female. | MLL:  35% of cells had the 1r/1g/1f split signal pattern consistent with rearrangement and with the t(9;11) seen on metaphase analysis.	partial CD11b, partial CD13, CD33, bright CD38, CD58, bright CD64, and partial HLA-DR+	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	MATCHED
aml_ohsu_2022_2652	aml_ohsu_2022_2652_BA3174	Waves3+4	Yes	8	NA	61	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	61	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	4	Vidaza|7+3 (Cytarabine, Idarubicin)|Cytarabine, OXi4503|Velcade	3	Salvage|Induction|Supportive/Palliative Care	Refractory	Velcade	Salvage	41	NA	46,XY,del(5)(q13q33)[1]/4 7,idem,+21[14]/46,idem,id ic(21)(p12)[cp4]/47,idem, +21,idic(21)[1]	POSITIVE for chromosome 5q copy number loss	NA	Negative	0	Negative	RUNX1 (p.R107H; 59.2%)	ASXL1 (p.E635Rfs*15; 24.3%)	NA	NA	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2608	aml_ohsu_2022_2608_BA3299	Waves3+4	Yes	6	NA	47	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Busulfan, Fludarabine|HiDAC|3+7 (Cytarabine, Daunorubicin)	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Busulfan, Fludarabine	Allogeneic - Sibling	11	NA	46,XX[20]	An apparently NORMAL KARYOTYPE was observed in all 20 mitotic cells analyzed. Specifically, there was no significant numerical chromosomal abnormality and no clonal structural aberration of any chromosome detectable within the limits of resolution.  (Cytogenetics)	positive for CD117, HLADR, CD33, CD11b, CD64 and MPO (partial).  (Bone Marrow Immunophenotyping)	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2708	aml_ohsu_2022_2708_BA3347	Waves3+4	Yes	5	NA	68	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Complete Response	Venetoclax (ABT-199), Azacitidine	Induction	-1	M5	46,XX[20]	Normal	Neagtive (CD10, CD19, CD16, CD14, CD34, CD117) | Bright Positive (CD64)	Negative	0	Positive	NA	NA	NA	DNMT3A (c.2311T>C; p.R771X; MAF 40%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 38%)|TET2 (c.2827C>T; p.Q943X; MAF 80%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2686	aml_ohsu_2022_2686_BA3126	Waves3+4	Yes	1	NA	66	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute monoblastic and monocytic leukaemia	66	2	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	M5	46,XY[20]	MLL: 86% of cells had a split signal pattern consistent with MLL rearrangement.	CD11b, CD13, CD14, CD33, bright CD64, HLA-DR and partial MPO-positive	Negative	0	Negative	NA	NA	NA	FLT3 (p.D835Y; MAF 35%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2598	aml_ohsu_2022_2598_BA3372	Waves3+4	No	1	NA	75	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	75	0	Post-Chemotherapy	Remission	Bone Marrow Aspirate	5	3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine, MGB453|MiDAC|Methotrexate	4	Consolidation|Salvage|Induction|Re-induction	Complete Response	Decitabine, MGB453	Salvage	49	NA	46,XY[20]	Normal	NA	Negative	0	Negative	NA	NA	NA	DNMT3A (p.N501S; MAF 52%)	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2678	aml_ohsu_2022_2678_BA3223	Waves3+4	No	6	NA	69	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	69	0	Post-Chemotherapy	Remission	Bone Marrow Aspirate	5	Vidaza|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Decitabine|Fludarabine, Cyclophosphamide, TBI	4	Induction|Frontline|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response i	Fludarabine, Cyclophosphamide, TBI	Allogeneic - Matched Unrelated Donor	18	NA	46,XY[20]	NA	NOT DETECTED for the MLL partial tandem duplication (PTD).  (Bone Marrow Immunophenotype)	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2766	aml_ohsu_2022_2766_BA3380	Waves3+4	Yes	7	NA	21	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	23	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	Normal	NA	NA	Positive	5.666666667	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2631	aml_ohsu_2022_2631_BA3114	Waves3+4	No	8	mono	75	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with mutated NPM1	75	0	Post-Chemotherapy	Remission	Peripheral Blood	1	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	1	Induction	Unknown	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Induction	4	NA	46,XX[20]	Normal (Clonal aberrations were not identified in metaphase cells examined by conventional cytogenetic techniques* or for any loci examined by FISH methods.)	NA	Negative	0	Positive	NA	NA	NA	CEBPA (biallelic)|NPM1|PTPN11|TET2	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2835	aml_ohsu_2022_2835_BA3109	Waves3+4	Yes	2	NA	56	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	63	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	4	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine, Trametinib	3	Consolidation|Salvage|Induction	Complete Response	Azacitidine, Trametinib	Salvage	-1	NA	46,XX,der(22)t(1;22)(q12;p11.2)[1]/46,XX[19]	NA	NA	Negative	0	Positive	RUNX1 (p.S100Lfs*38; 45.6%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2835	aml_ohsu_2022_2835_BA3452	Waves3+4	No	2	NA	56	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	64	455	Relapse	Relapse	Peripheral Blood	4	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine, Trametinib	3	Consolidation|Salvage|Induction	Complete Response	Azacitidine, Trametinib	Salvage	-1	NA	46,XXder(22)t(1;22)(q12;p11.2)[1]/46,XX[19]	NA	NA	Negative	0	Negative	RUNX1 (p.S100Lfs*38; 47.8%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2835	aml_ohsu_2022_2835_BA3343	Waves3+4	No	2	NA	56	unknown	unknown	unknown	FALSE	FALSE	NonInitial	AML with mutated NPM1	66	893	Unknown	Unknown	Peripheral Blood	4	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine, Trametinib	3	Consolidation|Salvage|Induction	Complete Response	Azacitidine, Trametinib	Salvage	-1	NA	46,XXder(22)t(1;22)(q12;p11.2)[1]/46,XX[19]	NA	NA	Negative	0	Negative	RUNX1 (p.S100Lfs*38; 36.8%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.366666667	UNMATCHED
aml_ohsu_2022_2824	aml_ohsu_2022_2824_BA3418	Waves3+4	Yes	8	NA	72	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	7+3 (Cytarabine, Idarubicin)	Induction	7	NA	45-46,X,-Y,t(3;3)(q21;q26 .2),del(4)(q12),-5,del(6) (q21),del(9)(q22),del(11) (p11.2),ins(15;5)(q12;p15 .2p15.2),add(16)(q22),-17,-20,-21,-22,+mar1-5[c p18]/ 46,XY[2]	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2829	aml_ohsu_2022_2829_BA3245	Waves3+4	Yes	5	NA	62	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	62	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	1	Decitabine	1	Supportive/Palliative Care	NA	Decitabine	Supportive/Palliative Care	-1	NA	47,XX,psu dic(5;7)(q13;p10),r(7)(p12q11.2),+8,der(12)del(12)(p11.2p13)add(12)(q24.1)[2]/ 44,sl,add(3)(q12),-r(7)(p12q11.2),-8,-der(12)del(12)(p11.2p13)add(12)(q24.1),idic(22)(p11.2), +der(?)(7qter- > 7q11.2::?- > cen- > ?::12q11- > 12qter)[16]/ 45,sdl1,+der(?)(7qter- > 7q11.2::?- > cen- > ?::12q11- > 12qter)[2]	5p15.2/ 5q31 (EGR1) (ABNORMAL - Loss of 5q31 sequences) | 7 centromere/ 7q31 (ABNORMAL - Loss of 7q31 sequences, see interpretation) | 8 centromere/ 20q12 (ABNORMAL - Gain of chromosome 8 centromere, Normal 20q12) | RUNX1 (21q22.12)/ RUNX1T1(8q22) (Negative rearrangement, ABNORMAL - Gain of 8q22 sequences)	Negative (CD19, CD22, CD56, CD14, CD15, CD64, MPO) | Positive (CD38, CD7, CD13, CD33, CD34, HLA-DR) | Dim (CD11b, CD45, CD117)	Negative	0	Negative	NA	NA	TP53 (p.L257Q; 84.5%)	IDH2 (c.419G>A; p.R140Q; MAF 5%)|NRAS (c.!82A>T; p.Q61L; MAF 26%)|TP53 (c.770T>A; p.L257Q; MAF 92%)	Acute Myeloid Leukemia	AML	0.366666667	MATCHED
aml_ohsu_2022_2785	aml_ohsu_2022_2785_BA3085	Waves3+4	Yes	1	NA	14	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	14	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Cytarabine	2	Induction|Intensification	Complete Response	HiDAC	Intensification	9	NA	45,X,-X,t(8;21)(q22;q22)[20]	RUNX1T1/RUNX1:  92/100 cells (92%) had a 1red/ 1 green/ 2 yellow fusion signal pattern, reflecting RUNX1T1/RUNX1fusion	dim CD13, dim CD19, CD33, CD34, CD38, CD58, CD117,  CD123, HLA-DR and MPO	Negative	0	Negative	NA	NA	NA	NRAS (p.G12D; MAF 6%)	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2596	aml_ohsu_2022_2596_BA3128	Waves3+4	Yes	8	NA	33	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	33	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|CECA (Cyclophosphamide, Etoposide, Carboplatin, Cytosine)|Cytarabine, OXi4503	3	Salvage|Induction|Re-induction	Refractory	Cytarabine, OXi4503	Salvage	-1	NA	Normal	Normal	NA	Positive	NA	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2605	aml_ohsu_2022_2605_BA3423	Waves3+4	Yes	6	NA	49	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	50	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Unknown	HiDAC	Consolidation	114	NA	NA	NA	Positive for CD34, CD117, HLADR, CD33 and CD13.  (Bone Marrow Immunophentyping)	Negative	0	Positive	NA	NA	NA	FLT3-TKD	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2784	aml_ohsu_2022_2784_BA3173	Waves3+4	Yes	6	NA	45	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	46	0	Residual Disease	Residual	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	3	Consolidation|Salvage|Induction	Complete Response	CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	Salvage	4	NA	46,XX,t(8;21)(q22;q22)[15]/46-47,sl,+6,add(13)(p11.2),add(15)(q26),-16,+19,+22[cp5]	NA	NA	Positive	0.075268817	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2719	aml_ohsu_2022_2719_BA3171	Waves3+4	Yes	1	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M4	43,XY,dic(5;12)(q11.2;p13),der(7)t(7;13)(q11.2;q12),i(8)(q10),+9,dup(11)(q2  3q23),-13,-15,-16,der(17)t(15;17)(q22;q23),-21,+mar[20]/46,XY[5]	RUNX1T1/RUNX1:  86/100 cells (86%) reflecting the isochromosome 8q and the monosomy 21.  No evidence for RUNX1T1/RUNX1fusion | EGR-1/ D5S23, D5S721:  89/100 cells (89%) consistent with missing 5q in the dicentric 5;12 | PML/RARA:  Signal patterns were within normal limits with no evidence for  PML/RARA fusion.  One metaphase cell shows the PML (15q22) signal on the derivative 17, consistent with the metaphase karyotype | BCR/ABL/ASS:  72/100 cells (72%) consistent the trisomy 9 in the metaphase karyotype.  No evidence  for BCR/ABL fusion.  | D7S486/ CEP 7:  79/100 cells (79%) consistent with missing 7q in the derivative 7 | DEK/NUP:  79/100 cells (79%) reflecting the trisomy 9 in the metaphase karyotype.  No evidence for  DEK/NUP fusion. | MLL:  61/100 cells (61%) had three intact MLL signals. One metaphase cell  shows two signals on the duplicated 11q.  There was no evidence for MLL rearrangement.	CD11c, CD13, CD33, CD34, CD38, CD56, CD64, CD117, HLA-DR; negative TdT, CD19 and CD10 (from bmbx 5/3/17)	Negative	0	Negative	NA	NA	TP53 (p.X125_splice; 75.0%)	KRAS (p.G12D; MAF 35%)|TP53 (Splice site (5' splice site mutation in intron 4); MAF 69%)	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2818	aml_ohsu_2022_2818_BA3277	Waves3+4	Yes	5	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Complete Response	Venetoclax (ABT-199), Azacitidine	Induction	-1	M4	46,XY[20]	Normal	positive (CD38 dim, CD33 dim, CD45 dim, CD117 var, MPO var) | negative (CD10, CD19, CD20, CD22, CD23, Surf Kappa, Surf Lambda, FMC7, CD3, CD5, CD7, CD56, CD13, CD14, CD15, CD34) | PP (CD11b VAR, CD64 VAR, HLA-DR VAR)	Negative	0	Positive	NA	NA	NA	IDH2 (c. 419G>A; p.R140Q; MAF 47%)|NPM1 (C.863_864insTCTG; p.W288fs; MAF 34%)|SRSF2 (c. 284C>A; p.P95H; MAF 47%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2644	aml_ohsu_2022_2644_BA3210	Waves3+4	Yes	2	NA	74	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	75	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Refractory	3+7 (Cytarabine, Daunorubicin)	Induction	-1	NA	47,XX,+8,del(9)(q13q22),t(12;22)(p13;q13)[12]/46,XX[8]	NA	NA	Negative	0	Negative	RUNX1 (p.L429Pfs*171; 82.9%)	ASXL1 (p.G646Wfs*12; 36.4%)	NA	BCORL1 (K632fs*33)|CSF3R (T6181)|ETV6 (MN1-ETV6 fusion)|IDH2 (R140Q)|IDH2 (p.Arg140Gln)|PHF6|PTPN11 (E69K)|RUNX1 (L429fs*171)	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2614	aml_ohsu_2022_2614_BA3157	Waves3+4	Yes	1	NA	60	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	HiDAC|3+7 (Cytarabine, Daunorubicin)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	M1	46,XY,del(9)(q13q22)[20]	Normal	CD13, CD33, variable CD34, CD38, CD58, CD117,  CD123, HLA-DR, variable MPO	Negative	0	Positive	NA	NA	NA	NPM1 (p.W288fs*12; MAF 41%)|NRAS (p.G13D; MAF 41%)|SF3B1 (p.T663I; MAF 50%)	Acute Myeloid Leukemia	AML	0.433333333	MATCHED
aml_ohsu_2022_2681	aml_ohsu_2022_2681_BA3433	Waves3+4	Yes	5	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin) plus Midostaurin	2	Allogeneic - Sibling|Induction	Complete Response	Fludarabine, Melphalan	Allogeneic - Sibling	-1	M0	46,XY[20]	Normal	negative (CD19, CD22, CD7, CD11b, CD13, CD14, CD15, CD34, CD64, HLA-DR) | Dim (CD38, CD45) | Positive (CD56, CD33, CD117, MPO)	Negative	0	Positive	NA	NA	NA	FLT3 (c.1818_1819ins26; p.P606_R607insCREYEYDLKWEFP; MAF 7%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 45%)|TET2 (C.3379C>t; p.Q1127X; MAF 44%)	Acute Myeloid Leukemia	AML	0.133333333	MATCHED
aml_ohsu_2022_2617	aml_ohsu_2022_2617_BA3374	Waves3+4	Yes	1	NA	21	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute monoblastic and monocytic leukaemia	21	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	6	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate	3	Consolidation|Salvage|Induction	Complete Response	Venetoclax (ABT-199), Azacitidine	Salvage	26	M5	47~49,XY,+8[cp13]/46,XY[7]	RUNX1T1/CEP8: 140/200 cells (70%) reflect the trisomy 8 in the metaphase karyotype; 20 cells (10%) reflect extra centromere signals only. It is possible the G-banded cell with two small markers reflects a small clone containing extra copies of a derivative chromosome 8. | MLL: 88/100 cells (88%) had a variant. A green signal appears on the short arm of a chromosome 10 with a red/small green signal retained on the chromosome 11q. It is unclear whether the material translocated disrupts MLL.	CD4, partial CD11b, CD13, CD33, dim CD22, CD34, variable CD56, variable CD64, CD117, HLA-DR, dim PAX5+	Negative	0	Negative	NA	NA	NA	KRAS (p.G13R; MAF 37%)|U2AF1 (p.S34F; MAF 39%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2617	aml_ohsu_2022_2617_BA3403	Waves3+4	No	1	NA	21	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute monoblastic and monocytic leukaemia	22	99	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	6	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate	3	Consolidation|Salvage|Induction	Complete Response	Venetoclax (ABT-199), Azacitidine	Salvage	26	M5	49,XY,+8,+mar1,+mar1[cp13]/49,idem,del(6)(q13q21)[8]	RUNX1T1/CEP8:  95/100 cells (95%) had an abnormal 3 red/ 3 aqua signal  pattern, reflecting the trisomy 8 in the metaphase karyotype and previously  observed. There was no evidence for RUNX1T1/RUNX1 fusion. | MLL:  93/100 cells (93%) had a variant abnormal 0 red/ 1 green/ 1 yellow  (red/small green)/ 1 yellow (red/green) signal pattern, reflecting MLL rearrangement and previously observed. | MECOM/RPN1:  84/100 cells (84%) had an abnormal 5-6 red/ 2 green signal  pattern, reflecting extra copies of MECOM (3q26.2) and gain of 3q.  Metaphase FISH shows the extra signals to be on the two markers. There was  no evidence for MECOM/RPN1 fusion.	CD4, CD11b, CD13, variable CD14, CD15, CD33, CD34, variable CD38, CD56, CD58, CD64, variable CD117, and HLA-DR	Negative	0	Negative	NA	NA	NA	KRAS (p.G13R; MAF 52%)|U2AF1 (p.S34F; MAF 49%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2617	aml_ohsu_2022_2617_BA3222	Waves3+4	No	1	NA	21	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute monoblastic and monocytic leukaemia	22	267	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	6	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate	3	Consolidation|Salvage|Induction	Complete Response	Venetoclax (ABT-199), Azacitidine	Salvage	26	M5	49,XY,del(4)(q21),add(6)(q27),-17,add(19)(p13.3),+mar1X2,+mar2,+mar3 [cp13]/49,XY,add(4)(q21),-6,+8,+mar1X2,+mar4[cp6]/46,XY[1]	51% had an abnormal signal pattern, reflecting the trisomy 8 in the metaphase karyotype and previously observed.  There was no evidence for RUNX1T1/RUNX1 fusion.  | 61% had a variant abnormal signal pattern, reflecting MLL rearrangement and previously observed.  | 72% had an abnormal signal pattern, reflecting extra copies of MECOM (3q26.2) and gain of 3q, previously observed.  Metaphase FISH shows the extra signals to be on  two markers.  There was no evidence for MECOM/RPN1 fusion.	dim CD4, CD13, CD33, CD34, dim CD56, CD64, HLA-DR+	Negative	0	Negative	NA	NA	NA	KRAS (p.G13R; MAF 24%)|U2AF1 (p.S34F; MAF 24%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2627	aml_ohsu_2022_2627_BA3450	Waves3+4	Yes	7	NA	68	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	46~47,XX,add(3)(p13),del(5)(q13q33),der(14)t(14;17)(q32;q11.2),del(16)(q22),-17,-22,+2~4mar[cp19]/46,XX[1]	NA	positive for CD13, CD33, CD34, CD38, partial HLA-DR, CD117, and a minor population is also positive for MPO	Negative	0	Negative	NA	NA	TP53	JAK2|TP53	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2704	aml_ohsu_2022_2704_BA3167	Waves3+4	Yes	2	NA	38	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with t(9;11)(p22;q23); MLLT3-MLL	38	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	-1	NA	46,XY,t(9;11)(p22;q23),inv(9)(p11q12)	NA	NA	Negative	0	Negative	NA	NA	NA	BCOR (D1006fs*16)|FLT3-D835|MLL (MLL-MLLT3 (AF9) Fusion)	Acute Myeloid Leukemia	AML	0.133333333	MATCHED
aml_ohsu_2022_2622	aml_ohsu_2022_2622_BA3269	Waves3+4	Yes	5	NA	66	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	AG-221|Azacitidine	1	Supportive/Palliative Care	NA	Azacitidine	Supportive/Palliative Care	6	M0	46,XX[19]	Normal	negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD14, CD15, CD34, CD64 TdT) | positive (CD38, CD13, CD33, CD117, MPO, HLA-DR) | dim (CD11b, CD45)	Negative	0	Positive	NA	NA	NA	DNMT3A (c.1903C>G; p.R635G (COSM144550) MAF 44%)|IDH2 (c.419G>A; p.R140Q (COSM41590) MAF 44%)|NPM1 (c.863_864insTCTG; p.W288fs (COSM158604) MAF 37%)	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2732	aml_ohsu_2022_2732_BA3246	Waves3+4	No	1	NA	56	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	56	0	Post-Chemotherapy	Remission	Bone Marrow Aspirate	4	3+4 (Cytarabine, Idarubicin)|HiDAC|MiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	3+4 (Cytarabine, Idarubicin)	Induction	4	NA	 46,XY[20]	NA	NA	Negative	0	Negative	NA	ASXL1 (p.C632*; 20.8%)	NA	ASXL1 (p.C632*; MAF 38%)	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2713	aml_ohsu_2022_2713_BA3110	Waves3+4	Yes	2	NA	51	FALSE	unknown	unknown	FALSE	FALSE	Intermediate	Acute Myeloid Leukemia	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	46,XY[20]	Normal	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2702	aml_ohsu_2022_2702_BA3156	Waves3+4	Yes	8	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute erythroid leukaemia	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	7+3 (Cytarabine, Idarubicin)	Induction	-1	M6	45,XY,del(7)(p13),-9[7]/4 5-47,idem,+13,-15,add(19) (p13.3),+20[cp11]/ 46,XY[2]	POSITIVE for ABL1 gene locus copy number loss | POSITIVE for PML gene locus copy number loss	NA	Negative	0	Negative	NA	NA	TP53 (p.R273C; 67.5%)	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2656	aml_ohsu_2022_2656_BA3151	Waves3+4	Yes	2	NA	53	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with mutated NPM1	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|Decitabine	2	Induction|Maintenance	Refractory	Decitabine	Maintenance	-1	NA	45,XX,del(3)(p13p26),-5[cp3]/48,idem,+8,der(9;12)(q10;q10),+19,+21,idic(21)(p11.2)x2,+mar[cp5]/50,idem,+8,der(9)t(5;9)(p13;p13),+19,+21,+21,idic(21)x2,+mar[cp8]/50,idem,del(9)(p13p22),der(9)t(5;9),+19,+21,+21,idic(21)x2,+mar[cp4]	NA	NA	Positive	0.666666667	Positive	NA	NA	TP53 (p.Y220H; 63.6%)	TP53	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2734	aml_ohsu_2022_2734_BA3226	Waves3+4	Yes	1	NA	75	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Therapy-related myeloid neoplasms	75	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	M2	46,XX[20]	Normal	dim CD11b, CD13, CD33, partial CD34, partial CD38, dim CD45, partial CD64, CD58, partial CD117, CD123 and partial MPO positive	Positive	0.960784314	Positive	NA	NA	NA	FLT3-ITD (MAF 44%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2659	aml_ohsu_2022_2659_BA3421	Waves3+4	Yes	5	NA	52	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	52	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin) plus Midostaurin|Midostaurin|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Maintenance	Complete Response	Midostaurin	Maintenance	13	NA	NA	Normal/Negative Rearrangement	NA	Positive	0.724137931	Positive	NA	NA	NA	DNMT3A (MAF 47%)|FLT3-ITD (2 on separate alleles: p.E604_F605insYDLKWE, MAF 19%; p.L601_K602ins18, MAF 9%)|NPM1 (MAF 44%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2714	aml_ohsu_2022_2714_BA3232	Waves3+4	Yes	1	NA	36	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	36	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	6	Azacitidine, Sorafenib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Busulfan, Cyclophosphamide|Cytarabine, Methotrexate	5	Allogeneic - Sibling|Induction|Experimental|Re-induction|Maintenance	Complete Response	SY-1425 (Tamibarotene) plus Daratumumab	Experimental	28	M4	46,XX[20]	Normal	dim CD7, partial CD11b, variable CD13, CD33, CD64,  CD117, dim CD123, dim HLA-DR and partial MPO positive	Positive	0.265822785	Positive	NA	NA	NA	BCOR (p.V89D; MAF 54%)|DNMT3A (p.R882H; MAF 51%)|FLT3-ITD (MAF 15%)|NPM1 (p.W288fs*12; MAF 48%)|NRAS (p.G12S; MAF 20%)	Acute Myeloid Leukemia	AML	0.3	MATCHED
aml_ohsu_2022_2671	aml_ohsu_2022_2671_BA3365	Waves3+4	Yes	7	NA	29	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with t(9;11)(p22;q23); MLLT3-MLL	30	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	46,XY,t(9;11)(p21;q23)[1]/46,idem,t(5;12)(q33;p13)[19]	NA	Population 1: Immature blasts (80%) expressed dim CD45+, partial CD34+ (68% of total cells), CD117+, HLA DR+, CD13+, CD33++, CD123+, and CD64neg /dim+ | Population 2:  Monoblasts (11%) expressed bright CD33 ++, intermediate SSC, brighter CD45, brCD64++, CD33++, and HLA DR++	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2677	aml_ohsu_2022_2677_BA3289	Waves3+4	Yes	5	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with minimal differentiation	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI	3	Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Supportive/Palliative Care	Complete Response	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	M0	NA	Normal	NA	Positive	0.587301587	Negative	NA	NA	NA	DNMT3A|FLT3-ITD|TET2	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2728	aml_ohsu_2022_2728_BA3430	Waves3+4	Yes	5	NA	60	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Therapy-related myeloid neoplasms	60	1	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	positive for CD11b, CD13, CD14, CD15, CD33, CD38, CD45, CD64, HLA-DR and MPO	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2643	aml_ohsu_2022_2643_BA3399	Waves3+4	No	5	NA	57	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Myelodysplastic/Myeloproliferative Neoplasms	57	1	NA	NA	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	47,XY,+21[19]	NA	positive for CD11b, CD13, CD33, CD34, CD38, dim CD45, CD117 and HLA-DR with aberrant expression of CD56	Negative	NA	Negative	NA	ASXL1 (p.E865*; 39.7%)	NA	NA	Myelodysplastic/Myeloproliferative Neoplasms	MDS/MPN	0.233333333	UNMATCHED
aml_ohsu_2022_2794	aml_ohsu_2022_2794_BA3327	Waves3+4	Yes	7	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	46,XY,del(1),del(5q),der(7)add(7)(p11.1)add(7)(q32),add(11)(q23),del(13)(q22)[12]/46,sl,-del(1),+der(1)del(1)(p13p32)del(1)(q12q25)[8]	negative for MLL and deletion 7	positive for dim CD2 (aberrant), CD11b (aberrant), CD13, CD33, CD34, CD38, CD117, HLA-DR, and dim nTdT (aberrant)	Negative	0	Negative	RUNX1	NA	NA	NRAS|PTPN11|RUNX1|STAG2	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2698	aml_ohsu_2022_2698_BA3428	Waves3+4	Yes	8	NA	64	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	64	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	1	M2	47,XX,+8,inv(16)(p13.1q22.1)[20]	POSITIVE for CBFB gene locus rearrangement | POSITIVE for chromosome RUNX1T1 loci copy number gain	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2690	aml_ohsu_2022_2690_BA3419	Waves3+4	Yes	5	NA	87	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	87	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Entospletinib	1	Supportive/Palliative Care	NA	Entospletinib	Supportive/Palliative Care	-1	NA	NA	NA	positive for dim CD7, CD11b, CD13, CD33, CD34, CD38, CD45, dim CD64, CD117, HLA-DR, and MPO	Positive	0.639344262	Negative	NA	NA	NA	FLT3-ITD	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2736	aml_ohsu_2022_2736_BA3384	Waves3+4	Yes	1	NA	39	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myelomonocytic leukaemia	39	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	7	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Radiation|Busulfan, Cyclophosphamide	5	Consolidation|Unknown|Induction|Maintenance|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M4	47,XX,del(11)(q23),+21[20]	MLL:  97/100 cells (97%) had a 0 red/ 1 green/ 1 yellow signal pattern,  partially deleting the MLL region of 11q23 and consistent with the deleted 11q in the metaphase karyotype. | RUNX1T1/RUNX1:  95/100 cells (95%) had a 2 red/ 3 green signal pattern, consistent with the trisomy 21 in the metaphase karyotype. There was no evidence for RUNX1T1/RUNX1fusion.	partial CD11b, dim CD13, CD33, partial CD34, variable CD64, CD117, CD123, HLA-DR+	Negative	0	Negative	RUNX1 (p.P49T; MAF 69%)	NA	NA	MLL (Possible subclone with partial tandem duplication)|RUNX1 (p.P49T; MAF 69%)	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2807	aml_ohsu_2022_2807_BA3427	Waves3+4	Yes	1	NA	67	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	45,XY,-4,-5,del(6)(p24),add(7)(q21),der(9)t(9;14)(q12;q11.2),-14,-21,+22,ad  d(22)(p11.2)x2,+2mar[20]	EGR1/5p:   77% of cells were missing a signal for both probes, consistent  with monosomy, as seen on metaphase analysis.  | D7S486 (7q31):  73% of cells were missing a signal for D7S486 (7q31),  consistent deletion and with the add(7) seen on metaphase analysis. | NUP214 (9q34):   64% of cells were missing a signal for NUP214 (9q34), consistent with deletion due to the der(9) seen on metaphase analysis.  (Also, deletion of 9q34 was observed using the ABL+ASS probe set on a parallel study, GL17-02579.)  | RUNX1 (21q22):   55% of cells had four signals for RUNX1 (21q22); another  28% of cells had three signals.  One of the four signals was on what  appeared to be a larger submetacentric chromosome, possibly the larger of  the two marker chromosomes observed on metaphase analysis.	CD13, CD33, variable CD34, CD117, partial HLA-DR	Negative	0	Negative	NA	NA	TP53 (p.H179N; 16.9%)|TP53 (p.I195Mfs*13; 9.9%)|TP53 (p.I195Yfs*14; 11.4%)	TP53 (p.H179N; MAF 63%)|TP53 (p.I195fs*52; MAF 39%)	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2609	aml_ohsu_2022_2609_BA3449	Waves3+4	Yes	8	NA	55	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	55	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	2	Vidaza|Decitabine	2	Salvage|Supportive/Palliative Care	NA	Decitabine	Salvage	-1	NA	49,XY,dup(1)(p22.1p32.1), inv(3)(q21.3q26.2),+8,+12 ,+21[20]	POSITIVE for RUNX1T1 and RUNX1 copy number gains	NA	Negative	0	Negative	RUNX1 (p.R76Pfs*62; 66.7%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2638	aml_ohsu_2022_2638_BA3163	Waves3+4	Yes	1	NA	43	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Therapy-related myeloid neoplasms	43	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	2	Azacitidine|Mitoxantrone	2	Induction|Supportive/Palliative Care	Refractory	Mitoxantrone	Supportive/Palliative Care	0	M5	46,XX,t(9;11)(p22;q23)[15]/47,idem,+8[2]/46,XX[3]	MLL:  57/100 cells (57%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting MLL (11q23) rearrangement, consistent with the 9;11  translocation observed in the metaphase karyotype. | RUNX1T1/RUNX1:  6/200 cells (3%) had a 3 red/ 2 green signal pattern,  reflecting an extra RUNX1T1 (8q21.3) signal, consistent with the trisomy 8  clone observed in the metaphase karyotype. | CEP 8:  5/200 cells (2.5%) had three signals, reflecting an extra  chromosome 8 centromere signal, consistent with the trisomy 8 clone observed in the metaphase karyotype.	dim CD4, CD11b, CD13, partial CD14, CD33,  CD38, variable CD56, CD58, CD64, dim CD71, dim CD123, and HLA-DR+	Negative	0	Negative	NA	NA	NA	DNMT3A (Splice site mutation (invariant splice donor at end of exon 14; likely pathogenic); MAF 20%)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2646	aml_ohsu_2022_2646_BA3158	Waves3+4	Yes	3	NA	68	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	Therapy-related myeloid neoplasms	68	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,t(8;21)(q22;q22)[8]46,sl,del(9)(q13q22)[4]/47,sdl,+21[2]/47,sl,+21[4]/46,XY[2]	This analysis showed evidence of t(8;21)(q22;q22) (RUNX1T1-RUNX1 translocation) in 196/200 (98.0 percent) cells scored. Of these cells, 20/200 (10.0 percent) showed the translocation accompanied by an additional copy of the RUNX1 locus.	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2755	aml_ohsu_2022_2755_BA3436	Waves3+4	Yes	1	mono	23	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	23	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|FLAG-IDA, Gemtuzumab|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M1	46,XX[8]	Normal	CD13, CD33, partial CD34, CD38, CD58, dim CD71, CD117,  CD123, and cMPO+	Negative	0	Positive	NA	NA	NA	CEBPA (p.A199fs*114; MAF 50%)|EZH2 (p.R288*; MAF46%)|GATA2 (p.A372T; MAF 31%)|NPM1 (p.W288fs*12; MAF 50%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2768	aml_ohsu_2022_2768_BA3154	Waves3+4	Yes	7	NA	29	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Mixed phenotype acute leukaemia, B/myeloid, NOS	29	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	30~35<1n>,XX,+1,+2,+6,+10,+11,+12,+18,+19,+21,+22[cp6]/46XX[20]	Negative for 9;22 and MLL	positive for dim CD2 (aberrant), CD11b (aberrant), CD13, CD33, CD34, CD38, CD117, HLA-DR, and dim nTdT (aberrant)	Negative	0	Negative	NA	NA	TP53 (p.V122Dfs*26; 87.5%)	CREBBP|NF1|TP53	Acute Leukemias of Ambiguous Lineage	ALAL	0.133333333	UNMATCHED
aml_ohsu_2022_2740	aml_ohsu_2022_2740_BA3162	Waves3+4	Yes	2	NA	20	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	20	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	-1	NA	46,XY,inv(16)(p13.1q22)[20]	Evidence of a CBFB [inv(16)] gene rearrangement in 98% of the cells.	CD2(-), CD4(-), CD5(-), CD7(-), CD8(-),CD10(-), CD11b(dim +), CD13(dim +),CD14(dim +), CD15(dim+CD16(-), CD20(-), CD22(-), CD25(dim +), CD33(dim +), CD34(+), CD38(+), CD36(subset +), CD56(-), CD64(subset +), CD79a +)(-), CD123(dim +), MPO(dim +), TdT(-), and surface kappa lambda light chain(-).,	Negative	0	Positive	NA	NA	NA	KIT (Y418_R420>RW; MAF 10.2%)|NRAS (G12s; MAF45.4%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2616	aml_ohsu_2022_2616_BA3355	Waves3+4	Yes	1	NA	70	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	70	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	2	Azacitidine, Itacitinib|Azacitidine, BI 836858 (anti-CD33)	1	Induction	Refractory	Azacitidine, Itacitinib	Induction	8	NA	45,XX,inv(3)(q21q26),-7[20]	Abnormal (MECOM/RPN1 Fusion: 99% of  cells had a 1r/1g/2f dual-fusion signal pattern, reflecting MECOM/RPN1  fusion)	NA	Negative	0	Positive	NA	ASXL1 (p.G646Wfs*12; 24.8%)	NA	NA	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2705	aml_ohsu_2022_2705_BA3081	Waves3+4	Yes	8	NA	68	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	HiDAC|7+3 (Cytarabine, Idarubicin, Dexamethasone)|Fludarabine, Melphalan, ATG	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	NA	50-55,XX,+X,+6,+8,+10,+12,+13,+14,+21,+22[cp 18]/46,XX[2].	POSITIVE for RUNX1T1 and RUNX1 copy number gains	NA	Negative	0	Negative	RUNX1 (p.R162K; 58.7%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2699	aml_ohsu_2022_2699_BA3352	Waves3+4	Yes	2	NA	73	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	7+3 (Cytarabine, Idarubicin)	Induction	-1	NA	46,XY[20]	Normal	CD34(-), CD13(predominantly -), CD33(+), CD38(partial +), CD45(dim +), CD56(variably +), CD64(partial dim +), CD117(+),HLA-DR(-), MPO(+), TdT(-), other myeloid and lymphoid antigens(predominantly -).	Positive	1.222222222	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.466666667	MATCHED
aml_ohsu_2022_2694	aml_ohsu_2022_2694_BA3084	Waves3+4	Yes	1	NA	22	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myelomonocytic leukaemia	22	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone) + Midostaurin|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M4	46,XY,t(10;11)(p13;q23)[20]	MLL: 88% of cells had a 1g/0r/2f signal pattern, where the lone green signal was small and the green component suggesting a disruption of MLL (11q23) within the green portion of  the probe.  This result is consistent with MLL rearrangement and with the t(10;11) seen on metaphase analysis.	Immunophenotype 1(15% WBCs): dim CD4, variable CD13, CD33, bright  CD34, CD58, CD64, CD117, CD123, variable MPO  | Immunophenotype 2 (79% WBCs): dim CD4, CD11b, variable CD13, CD33, CD38, CD58, CD64, CD117, CD123	Negative	0	Negative	NA	NA	NA	FLT3-D835 (MAF: 31%)|KRAS (p.G12D; MAF 4%)	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2597	aml_ohsu_2022_2597_BA3149	Waves3+4	Yes	5	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Azacitidine, BI 836858 (anti-CD33)	1	Supportive/Palliative Care	NA	Azacitidine, BI 836858 (anti-CD33)	Supportive/Palliative Care	6	NA	NA	Normal	positive for CD13, CD33, CD34, dim CD45, CD38, CD117, HLA-DR and MPO	Negative	0	Negative	RUNX1 (p.M267Ifs*44; 77.6%)	ASXL1 (p.E635Rfs*15; 16.4%)	NA	NA	Acute Myeloid Leukemia	AML	0.633333333	MATCHED
aml_ohsu_2022_2662	aml_ohsu_2022_2662_BA3169	Waves3+4	Yes	5	NA	88	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	88	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	47,XX,+8[4]/47,sl,add(10)(q22)[10]/89~94,sdlx2[cp3]/55,sl,+X,+6,+8,+ 8,+9,+13,+21,+22[2]/46,XX[1]	MLL (KMT2A) rearrangement in 94% of 200 cells | gain of 8q22 sequence in 94% of 200 cells	positive for CD11b, dim CD7, CD13, CD14, CD33, CD38, CD15, CD45, CD56, CD64 and HLA-DR	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2770	aml_ohsu_2022_2770_BA3180	Waves3+4	Yes	5	NA	27	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	27	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Azacitidine	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	NA	NA	NA	NA	Positive	0.886792453	Positive	NA	NA	NA	FLT3-ITD|IDH2	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2725	aml_ohsu_2022_2725_BA3255	Waves3+4	Yes	1	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Decitabine, Sorafenib |Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	Complete Response	Decitabine, Sorafenib	Salvage	61	M0	46,XY[20]	Normal	dim partial CD4, dim partial CD7, dim CD11b, CD13, CD33,  partial CD34, CD38, CD58, dim CD71, CD117, CD123 and HLA-DR+	Positive	3	Positive	NA	NA	NA	DNMT3A (Splice site (start of intron 18; likely pathogenic); MAF 47%)|FLT3-ITD (p.E598delinsDYVDFREYE; MAF 60%)|NPM1 (p.W290fs*10; MAF 45%)|WT1 (p.D464N; MAF 46%)	Acute Myeloid Leukemia	AML	0.6	MATCHED
aml_ohsu_2022_2834	aml_ohsu_2022_2834_BA3438	Waves3+4	Yes	1	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)	2	Induction|Re-induction	Refractory	5+2 (Cytarabine, Idarubicin)	Re-induction	4	M1	47,XY,der(5)t(5;17)(q12;q12),+8,+15,der(15)t(11;15)(q22;q24)dup(11)(q25q22)  ,del(16)(q22q24),-17,der(20;21)(p10;q10),+mar[16]/46,idem,der(10)t(10;11)(q  25;q23)t(5;11)(q12;q25),-mar[3]/46,XY[1]	EGR1:  90% of cells were missing a signal for EGR1 (5q31), consistent with  the der(5) seen on metaphase analysis.  | MLL (11q23):   97% of cells had two normal intact signals and a many other  intact signals per cells, suggesting amplification.  (On available metaphase  cells, there was clustering of amplified fused signals on two chromosomes:  in the first clone, amplified signals clustered on the der(15) and on the  marker chromosome; in the second clone, amplified signals clustered on the  der(15) and on the der(10).) | CBFB (16q22):   94% of cells were missing a signal for CBFB, consistent  with del(16q) as seen on metaphase. | RUNX1/RUNX1T1+CEP8: 92% of cells had three signals for chromosome 8 probes (CEP8 and RUNX1T1) and only one signal for RUNX1 (21q22), consistent with trisomy 8. Results with the RUNX1 probe on chromosome 21 suggest that the interpretation of the chrom results as der(20;21) may be more complicated.	CD4, dim CD20, dim CD11b, CD13, CD33, CD34, CD38, CD58,  variable CD64, partial dim CD117, MPO	Negative	0	Negative	NA	NA	TP53 (p.R248Q; 80.3%)	MLL |TP53 (p.R248Q; MAF 82%)	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2775	aml_ohsu_2022_2775_BA3345	Waves3+4	Yes	8	NA	59	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	7+3 (Cytarabine, Idarubicin)	Induction	4	M5	47,XX,+8[20]	POSITIVE for RUNX1T1 copy number gain	NA	Negative	0	Negative	RUNX1 (p.S100F; 39.6%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2647	aml_ohsu_2022_2647_BA3431	Waves3+4	Yes	7	NA	45	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	45	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	46[XX]	NA	positive for CD11b, CD11c, CD14, CD64, CD33, CD38, HLA-DR and partial for CD13, CD15, cMPO	Negative	0	Positive	NA	NA	NA	FLT3-TKD (MAF 1%)|NPM1 (MAF 39%)|PTPN11 (likely pathogenic)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2667	aml_ohsu_2022_2667_BA3181	Waves3+4	Yes	8	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Myeloid sarcoma	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin, Dexamethasone)	2	Allogeneic - Sibling|Induction	Complete Response	Fludarabine, Melphalan	Allogeneic - Sibling	-1	M5	46,XX[20]	Normal	NA	Negative	0	Negative	NA	ASXL1 (p.R634Kfs*24; 38.6%)	NA	NA	Acute Myeloid Leukemia	AML	0.366666667	UNMATCHED
aml_ohsu_2022_2628	aml_ohsu_2022_2628_BA3341	Waves3+4	Yes	2	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Enasidenib	1	Induction	Refractory	Enasidenib	Induction	-1	NA	46,XX,del(7)(q22q32)[cp4]/46,XX[16]	Evidence of deletion of the BCR (22q11.2) gene in 7% of the cells examined.	NA	Negative	0	Negative	NA	NA	NA	DNMT3A|IDH2 (p.172Arg>Lys)|KMT2A	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2700	aml_ohsu_2022_2700_BA3191	Waves3+4	Yes	1	NA	46	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	46	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	5	5+2 (Cytarabine, Idarubicin)|Azacitidine|Gemtuzumab|MiDAC|Decitabine	5	Consolidation|Salvage|Induction|Re-induction|Maintenance	Refractory	Gemtuzumab	Salvage	-1	M4	NA	Positive for CBFB rearrangement. (96/100 cells (96%) reflected a loss of the distal green portion of one break-apart signal. Presence of an  inverted chromosome 16 was confirmed.  In addition, metaphase FISH showed a  normal chromosome 16 with a yellow (red/green) signal in the long arm and the inverted chromosome 16 with the proximal red signal in the short arm and the green signal missing.)	CD13, dim CD33, CD34, CD38, CD117, CD123, HLA-DR  and dim MPO+. (Blast Immunophenotype) | CD11b, CD13, dim CD14, CD33, CD38, CD64,  HLA-DR, dim CD117, CD123 and dim MPO+ (Monocytic Immunophenotype)	Negative	0	Negative	NA	NA	NA	GATA2 (p.T356A; MAF 41%)|NRAS (p.Q61K; MAF 41%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2738	aml_ohsu_2022_2738_BA3197	Waves3+4	Yes	1	NA	47	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	M1	NA	PML/RARA: Negative	partial CD13, CD33, CD38, partial CD56, CD58, CD117,  CD123, and MPO positive	Positive	0.785714286	Positive	NA	NA	NA	FLT3-ITD (p.F605delinsTGSSDNEYFYVDFREYEYDLKWEF; MAF 46%)|IDH1 (p.R132G; MAF 47%)|NOTCH1 (p.E1555V; MAF 51%)|NPM1 (p.W288fs*12; MAF 50%)	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2675	aml_ohsu_2022_2675_BA3370	Waves3+4	Yes	2	NA	69	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Azacitidine, BI 836858 (anti-CD33)	1	Induction	Refractory	Azacitidine, BI 836858 (anti-CD33)	Induction	-1	NA	47,XY,+8[4]/46,XY[16]	NA	NA	Negative	0	Negative	NA	ASXL1 (p.H631N; 29.3%)|ASXL1 (p.R634Gfs*22; 25.0%)	NA	ASXL1|SRSF2|STAG2|TET2 (M1456fs*2 )	Acute Myeloid Leukemia	AML	0.533333333	MATCHED
aml_ohsu_2022_2752	aml_ohsu_2022_2752_BA3448	Waves3+4	Yes	1	NA	27	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with minimal differentiation	27	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)	Allogeneic - Sibling	-1	M0	46,XX,t(6;11)(q27;q23)[25]	MLL:  92/100 cells (92%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting MLL rearrangement and consistent with the 6;11  translocation observed in a companion bone marrow G-banded chromosome  study. One metaphase cell showed the 6;11 rearrangement.	CD13 , CD33 , partial CD34 , CD38 , CD58 , CD64 , CD71 , CD117 , CD123 and HLA-DR positive	Negative	0	Negative	NA	NA	NA	KRAS (p.G12D; MAF 16%)|MLL (PTD)	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2764	aml_ohsu_2022_2764_BA3453	Waves3+4	Yes	5	NA	76	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Decitabine	1	Supportive/Palliative Care	NA	Decitabine	Supportive/Palliative Care	9	NA	46,XX[20]	NA	A large blastic population, positive for CD13, CD15, CD33, CD38, dim CD45, dim CD64, CD117, HLA-DR, and MPO	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2796	aml_ohsu_2022_2796_BA3406	Waves3+4	Yes	3	NA	33	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	33	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	UNKNOWN	7+3 (Cytarabine, Idarubicin)	Induction	6	NA	46, XY[20]	Normal	NA	Positive	0.492537313	Negative	NA	NA	NA	BCOR (p.G1n1626; MAF 62.2%)|FLT3-ITD (p.Glu598_Tyr599ins9)|WT1 (p.Arg370fs; MAF 27.7%)	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2772	aml_ohsu_2022_2772_BA3308	Waves3+4	Yes	1	NA	78	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	78	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	4	AG-221|Imatinib|Midostaurin|Interferon	3	Salvage|Maintenance|Supportive/Palliative Care	NA	AG-221	Salvage	191	NA	47,XY,del(6)(q13),+8[8]/47,idem,-8,+13[2]/46,XY,del(13)(q14q22),del(20)(q11.2)[6]/46,XY[4]	RUNX1T1:  22/200 cells (11%) had a 3 red/ 2 green signal  pattern, reflecting an extra RUNX1T1 (8q21.3) signal, consistent with the  trisomy 8 clone observed in the metaphase karyotype | RUNX1: 18/200 cells (9%) had a 2  red/ 3 green signal pattern, reflecting an extra RUNX1 (21q22) signal.  The  extra chromosome 21 material was not apparent in the G-banded karyotype.  There was no evidence for RUNX1T1/RUNX1 fusion. | CEP8:  29/200 (14.5%) cells  scored with the CEP 8 probe had three signals, consistent with trisomy 8.  | D20S108/20p subtel:  6/200 cells (3%) had a 1 red/ 2 green signal pattern,  consistent with the deleted 20q in the metaphase karyotype.	NA	Negative	0	Negative	RUNX1 (p.R162S; 84.5%)	ASXL1 (p.G646Wfs*12; 34.3%)	TP53 (p.X187_splice; 9.3%)	IDH2 (p.R140Q; MAF 45%)|KRAS (p.Q61R; MAF 5%)|NOTCH1 (p.P2412L; MAF 57%)|RUNX1 (p.R162S; MAF 74%)|SRSF2 (p.P95H; MAF 54%)|TP53 (Splice site; MAF 9%)	Acute Myeloid Leukemia	AML	0.766666667	MATCHED
aml_ohsu_2022_2601	aml_ohsu_2022_2601_BA3134	Waves3+4	Yes	8	NA	71	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	Vidaza|7+3 (Cytarabine, Idarubicin)|HiDAC|Unknown	3	Consolidation|Induction|Allogeneic - Child	Complete Response	Unknown	Allogeneic - Child	-1	NA	47,XY,+8[1]/47,idem,del(3)(q21q27)[19]	POSITIVE for RUNX1T1 copy number gain	NA	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 16.3%)	NA	NA	Acute Myeloid Leukemia	AML	0.366666667	MATCHED
aml_ohsu_2022_2663	aml_ohsu_2022_2663_BA3248	Waves3+4	Yes	1	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	6	Fludarabine, Melphalan|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MiDAC|7+3 (Cytarabine, Idarubicin) plus CX-01|IDAC	6	Consolidation|Salvage|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	Refractory	IDAC	Salvage	35	M2	46,XX,t(3;21)(q26;q11.2)[1]/45,sl,-7[9]/45,sdl1,del(13)(q12q14)[10]	MECOM/RPN1:  65/100 cells (65%) had a 3 red/ 2 green, consistent with  disruption of MECOM (3q26.2). | D7S486/ CEP 7:  69/100 cells (69%) had a 1 red/ 1 green signal pattern,  indicating monosomy 7, consistent with the metaphase karyotype.	CD13, CD34, CD38, CD117, and HLA-DR positive with  partial dim expression of CD2, CD7, and CD11b	Negative	0	Negative	NA	NA	NA	KRAS (p.G13D;  MAF 20%)|NRAS (p.G13D; MAF 13%)	Acute Myeloid Leukemia	AML	0.233333333	MATCHED
aml_ohsu_2022_2743	aml_ohsu_2022_2743_BA3186	Waves3+4	Yes	1	NA	68	TRUE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	70	0	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Peripheral Blood	3	Fludarabine, Melphalan|Azacitidine|MiDAC	3	Symptom Control|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	NA	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	NA	45,XY,add(3)(p22),-7,t(8;22)(q11.2;q11.2),add(11)(q23),-13,-15,-16,  der(17)t(7;17)(q11.2;p11.2),+3mar[cp3]/44~46,sl+der(8)t(8;21)(q11.2;q11.2),  -18[cp15]/44,sl,-add(3)(p22),+10,+13,+15,-18,-3mar[2]	MLL:  97/100 cells (97%) had the variant abnormal 0 red/ 1 green/1 yellow  signal pattern, reflecting MLL (11q23) rearrangement and previously  observed.  | TP53/CEP 17:  99/100 cells (99%) had a 1 red/ 2 green signal pattern,  reflecting TP53 deletion, previously observed and consistent with the  derivative 17 in the metaphase karyotype. | RUNX1T1/RUNX1:  93/100 cells (93%) had a 2-3 red/ 3-4 green signal pattern,  reflecting an extra copies of RUNX1T1 and RUNX1.  There was no evidence for  RUNX1T1/RUNX1 fusion.  | CBFB:  96/100 cells (96%) had a single intact signal, reflecting CBFB  (16q22) loss and consistent with the monosomy 16 in the metaphase  karyotype.  | D7S486/ CEP 7:  99/100 cells (99%) had a 2 red/ 1 green signal pattern,  indicating loss of a chromosome 7 centromere signal with 7q material  attached to the derivative 17 in the metaphase karyotype.  | CEP 8:  66/100 cells (66%) had three signals, consistent with the clone  having an extra copy of the derivative 8.	dim CD4, dim CD7, dim CD33, CD34, dim CD56, CD58, dim  CD123, CD117 and HLA-DR positive	Negative	0	Negative	NA	NA	TP53 (p.R248W; 71.9%)	JAK2 (p.V617F; MAF 88%)|SF3B1 (p.G740V; MAF 41%)|TET2 (p.E692fs*8; MAF 40%)|TP53 (p.R248W; MAF 78%)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2640	aml_ohsu_2022_2640_BA3334	Waves3+4	Yes	2	NA	76	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Entospletinib	1	Experimental	NA	Entospletinib	Experimental	-1	NA	NA	Normal	NA	Negative	0	Negative	NA	ASXL1 (p.C687Yfs*30; 45.2%)	NA	ASXL1|FLT3 (N841K)|SRSF2|STAG2	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2669	aml_ohsu_2022_2669_BA3447	Waves3+4	Yes	7	NA	67	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML without maturation	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	M1	46XY	NA	positive for CD13, CD33, CD34, CD38, CD117, HLA-DR, cytoplasmic myeloperoxidase (subset), and TdT (subset)	Negative	0	Negative	NA	NA	NA	FLT3-ITD|NRAS|U2AF1	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2810	aml_ohsu_2022_2810_BA3116	Waves3+4	Yes	5	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Azacitidine, BI 836858 (anti-CD33)	1	Induction	Complete Response	Azacitidine, BI 836858 (anti-CD33)	Induction	-1	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	ASXL1|TET2	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2648	aml_ohsu_2022_2648_BA3280	Waves3+4	Yes	5	NA	51	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	7+3 (Cytarabine, Idarubicin)	Induction	-1	NA	46,XY[20]	NA	positive for CD117, CD13, CD33, and HLA-DR. Roughly half of the blasts were positive for CD34, roughly half of the blasts showed aberrant dim expression of CD7, and roughly half of the cells showed aberrant dim expression of CD19.	Positive	0.136363636	Positive	NA	NA	NA	ASXL1|CEBPA|FLT3-ITD|NPM1|NRAS|PTPN11|STAG2	Acute Myeloid Leukemia	AML	0.433333333	MATCHED
aml_ohsu_2022_2769	aml_ohsu_2022_2769_BA3185	Waves3+4	Yes	5	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	Entospletinib, Azacitidine|Entospletinib	2	Induction|Re-induction	Refractory	Entospletinib, Azacitidine	Re-induction	-1	NA	47,XY,+13[20]/47,XY,+8[1]	Low level gain of chromosome 8 sequences (trisomy). Loss of 21q22 sequences (monosomy)	CD13, CD33, HLA-DR, and CD34	Negative	0	Negative	RUNX1 (p.H105Afs*33; 41.2%)|RUNX1 (p.T104R; 53.3%)	ASXL1 (p.G646Wfs*12; 33.3%)	NA	ASXL1|RUNX1|SRSF2|TET2	Acute Myeloid Leukemia	AML	0.433333333	MATCHED
aml_ohsu_2022_2660	aml_ohsu_2022_2660_BA3094	Waves3+4	Yes	1	NA	23	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute monoblastic and monocytic leukaemia	23	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M5	46,XY,der(10)t(10;11)(p13;q23),der(11)t(10;11)(p13;q23)inv(11)(q13q23)[20]	MLL:  60% of cells had a split signal pattern consistent with MLL rearrangement. On available metaphase cells, there was a distal signal on chromosome 10p and the proximal signal was close to the chromosome 11 centromere, consistent with t(10;11) and inv(11), as seen on chromosome analysis.	CD4, variable CD13, CD33, CD38, variable CD56, CD58,  CD64, dim CD71, dim CD117, dim CD123 and HLA-DR+	Negative	0	Negative	NA	NA	NA	NRAS (p.G12A; MAF 4%)|NRAS (p.Q61H; MAF 30%)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2593	aml_ohsu_2022_2593_BA3318	Waves3+4	Yes	2	NA	83	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	83	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	46,XX,-15,+dic(1;15)(p11;p11)[10]/47,idem,+11[10]	67.5% of cells had an extra copy of MLL(11q23)	NA	Negative	0	Negative	NA	NA	NA	IDH2 (p.172Arg>Lys)	Acute Myeloid Leukemia	AML	0.3	MATCHED
aml_ohsu_2022_2632	aml_ohsu_2022_2632_BA3216	Waves3+4	Yes	5	mono	73	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Positive	0.428571429	Negative	NA	NA	NA	FLT3-ITD (suspicious for D835 as well)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2748	aml_ohsu_2022_2748_BA3332	Waves3+4	Yes	7	NA	26	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	26	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin	1	Induction	Complete Response	7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin	Induction	8	NA	46,XX	Normal	CD117(+) myeloid precursors comprise 26% of total events and are positive for dim CD7, CD13, CD33, CD38, CD117, HLA-DR, and cyMPO.  They are negative for CD34.	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2820	aml_ohsu_2022_2820_BA3214	Waves3+4	Yes	7	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	Acute Myeloid Leukemia	51	0	Unknown	Unknown	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.566666667	MATCHED
aml_ohsu_2022_2802	aml_ohsu_2022_2802_BA3204	Waves3+4	Yes	7	NA	58	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	58	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	1	BP1001 plus LDAC	1	Experimental	NA	BP1001 plus LDAC	Experimental	28	NA	44-45,XY,-3,-5,der(7)del(7)(q22)inv(7)(p13q22),del(12)9p11.2),add(19)(q13.1),+mar[cp20]	NA	Myeloid blasts comprise 16% of total events and are positive for CD13, CD33, CD34, CD38 (reduced), CD117, HLA-DR and cyMPO. They are negative for CD11b, CD11c, CD14, CD15, CD56, CD64, TdT, B- and other T-cell markers	Negative	0	Negative	NA	NA	TP53 (p.G266R; 41.8%)|TP53 (p.Y220C; 46.5%)	TP53	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2831	aml_ohsu_2022_2831_BA3141	Waves3+4	Yes	3	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	NA	0	Unknown	Unknown	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2680	aml_ohsu_2022_2680_BA3373	Waves3+4	Yes	1	NA	67	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	M1	45,XX,t(3;3)(q21;q26),del(5)(q22q35),-7[20]	EGR-1/ D5S23, D5S721:  96/100 cells (96%) had a 1 red/ 2 green signal  pattern, reflecting a deleted 5q, consistent with the metaphase karyotype. | D7S522/ CEP 7:  98/100 cells (98%) had a 1 red/ 1 green signal pattern,  reflecting monosomy 7, consistent with the metaphase karyotype. | MECOM/ RPN1:  97/100 cells (97%) had a 1 red/ 1 green/ 2 yellow signal  pattern, reflecting MECOM/RPN1 fusion, consistent with the 3;3  translocation in the metaphase karyotype.	dim CD5, CD7,  partial CD11b, CD13, CD33, CD34, variable  CD38, variable CD56, CD58,  dim CD71, CD117, dim CD123, dim HLA-DR and MPO+	Negative	0	Negative	NA	NA	NA	DNMT3A (p.R882H; MAF 48%)|NRAS (p.Q61R; MAF 29%)|PTPN11 (p.E69K; MAF 9%)	Acute Myeloid Leukemia	AML	0.1	MATCHED
aml_ohsu_2022_2707	aml_ohsu_2022_2707_BA3319	Waves3+4	Yes	1	NA	22	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	22	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	106	M4	46,XY,inv(16)(p13;q22)[20]	CBFB:   39% of cells had a 1r/1g/1f split signal pattern consistent with CBFB disruption and inv916), as seen on metaphase analysis.	Myeloid blast immunophenotype: CD13, CD33, CD34, CD38, CD58, CD117,  CD123, dim HLA-DR and MPO+  | Monocytic blast immunophenotype: CD11b, CD13, CD14, partial CD16, CD33,  dim CD34, CD38, CD58, CD64, CD117, dim CD123, HLA-DR and MPO+	Negative	0	Negative	NA	NA	NA	KIT (p.D816Y; MAF 6%)|NRAS (p.Q61H; MAF 32%)	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2741	aml_ohsu_2022_2741_BA3328	Waves3+4	Yes	1	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Fludarabine, Melphalan|HiDAC|7+3 (Cytarabine, Idarubicin) plus Midostaurin	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M1	46,XX[15]	Normal	dim CD13, CD33, CD38, partial CD56, CD58, CD64, dim CD117, CD123 and MPO+	Positive	0.754385965	Positive	NA	NA	NA	DNMT3A (p.R326L; MAF 47%)|FLT3-ITD (MAF 43%; mutant allelic ratio 0.74)|IDH2 (p.R140Q; MAF 47%)|NPM1 (p.W288fs*12; MAF 48%)	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2711	aml_ohsu_2022_2711_BA3240	Waves3+4	Yes	1	NA	79	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Vyxeos (Daunorubicin, Cytarabine - liposomal)	1	Induction	Unknown	Vyxeos (Daunorubicin, Cytarabine - liposomal)	Induction	-1	M1	51~52,XX,+2,+6,add(7)(q31),+8,+9,+10,+15[cp14]/50~52,idem,del(19)(q11.2)[cp  5]/46,XX[1]	BCR/ABL/ASS: 72/100 cells had a variant abnormal fusion reflecting a single BCR/ABL fusion. The Philadelphia rearrangement was not visible in the metaphase karyotype  and is, thus, likely a cryptic rearrangement involving at least three chromosomes.    (Twenty-one cells (21%) had three signals for ASS and ABL with  no fusion signal.) | RUNX1T1:  89/100 cells (89%) had three signals, consistent with the trisomy  8 in the metaphase karyotype.  There was no evidence for RUNX1T1/RUNX1  fusion.  In addition, 80% of cells had three chromosome 8 centromere  signals, also consistent with trisomy 8. | DEK/NUP21:  96/100 cells (96%) had three signals for both probes,  consistent with trisomies 6 and 9 in the metaphase karyotype.  There was no evidence for DEK/NUP21 fusion | PML:  41/100 cells (41%) had three signals, consistent with the trisomy 15  in the metaphase karyotype.  Fifty-two cells (52%) had four PML signals –  the chromosomal context of the fourth signal was not apparent in the  metaphase karyotype.  There was no evidence for PML/RARA fusion.	CD13, variable CD34, CD38, dim CD58, CD117, CD123, HLA-DR and dim MPO+	Negative	0	Negative	NA	NA	NA	DNMT3A (p.R882C; MAF 64%)|FLT3 (p.D835H; MAF 5%)|IDH1 (p.R132L; MAF 54%)	Acute Myeloid Leukemia	AML	0.566666667	MATCHED
aml_ohsu_2022_2612	aml_ohsu_2022_2612_BA3142	Waves3+4	Yes	1	NA	54	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	54	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|Decitabine, MGB453|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Salvage|Induction|Re-induction	Refractory	Decitabine, MGB453	Salvage	56	M1	43,XY,add(5)(q11.2),add(9)(q12),add(10)(p11.2),-12,idic(12)(p11.2),t(14;14)  (q31;q32),-16,-17,add(17)(q21),add(19)(p13),-20,add(21)(p11.2),+mar[19]/46,  XY[1]	NA	CD13, dim CD33, CD34, CD38, CD117, dim CD123,  HLA-DR positive	Negative	0	Negative	NA	NA	TP53 (p.V216M; 78.5%)	TP53 (p.V216M; MAF 57%)	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2742	aml_ohsu_2022_2742_BA3339	Waves3+4	Yes	3	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	31	0	Unknown	Unknown	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2746	aml_ohsu_2022_2746_BA3333	Waves3+4	Yes	5	NA	NA	FALSE	FALSE	TRUE	FALSE	FALSE	Favorable	AML with mutated NPM1	NA	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	46,XY[20]	Normal	NA	Negative	0	Positive	NA	NA	NA	FLT3-TKD (I836del; VAF 8%)|GATA2 (T358A;16%)|NPM1 (W288Cfs*12; VAF 46%)|SRSF2 (P95L; VAF 41%)|TET2 (A1344E; VAF 52%)|TET2 (R1440Tfs*38; VAF 47%)	Acute Myeloid Leukemia	AML	0.433333333	MATCHED
aml_ohsu_2022_2754	aml_ohsu_2022_2754_BA3381	Waves3+4	Yes	1	NA	51	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	HiDAC + Midostaurin|Fludarabine, TBI|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Decitabine, Venetoclax	5	Consolidation|Induction|Allogeneic - Child|Maintenance|Re-induction	Complete Response	Decitabine, Venetoclax	Re-induction	-1	M4	46,XY[20]	Normal	CD13, CD33, CD34, CD38, CD58, dim CD71, CD117, dim CD123  and HLA-DR+	Negative	0	Negative	RUNX1 (p.F259Sfs*338; 18.3%)	ASXL1 (p.G646Wfs*12; 32.0%)	NA	ASXL1 (p.S1236A; MAF 51% )|CBL (p.R420Q, MAF 3%)|CBL (p.Y368_C372delinsP; MAF 9%)|DNMT3A (p.E616*; MAF 50%)|FLT3 (p.D835V; MAF 37%)|FLT3-ITD (Allelic Ratio = .03)|SF3B1 (p.K666N; MAF 47%)	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2753	aml_ohsu_2022_2753_BA3290	Waves3+4	Yes	1	NA	66	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with maturation	67	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	2	Induction|Supportive/Palliative Care	Refractory	7+3 (Cytarabine, Idarubicin)	Induction	6	M2	46,XY,del(12)(p11.2)[9]/46,XY[11]	Normal	dim partial CD7, CD13, CD33, CD34, dim CD38, CD58,  CD117, dim CD123, HLA-DR and partial TdT+	Negative	0	Negative	RUNX1 (p.D198N; MAF 6%)	ASXL1 (p.G646Wfs*12; 36.6%)	NA	RUNX1 (p.D198N; MAF 6%)|SF3B1 (p.K666N; MAF 45%)|SRSF2 (p.P95H; MAF 46%)	Acute Myeloid Leukemia	AML	0.666666667	MATCHED
aml_ohsu_2022_2641	aml_ohsu_2022_2641_BA3207	Waves3+4	Yes	1	NA	65	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Acute myelomonocytic leukaemia	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	2	7+3 (Cytarabine, Idarubicin)|Methotrexate	1	Induction	Complete Response	Methotrexate	Induction	6	M4	46,XY[20]	Normal	CD11b, variable CD14, CD15, CD33, CD38, variable CD56,  CD58, CD64, CD123, HLA-DR, variable MPO	Negative	0	Negative	RUNX1 (p.F396Vfs*204; 55.4%)	ASXL1 (p.G646Wfs*12; 35.0%)	NA	IDH1 (p.R132H; MAF 46%)|MLL (Partial tandem duplication )|NRAS (p.Q61R; MAF 45%)|RUNX1 (p.F396fs*204; MAF 46%)|SRSF2 (p.P95L; MAF 28%)	Acute Myeloid Leukemia	AML	0.566666667	UNMATCHED
aml_ohsu_2022_2634	aml_ohsu_2022_2634_BA3305	Waves3+4	Yes	5	NA	84	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Acute myeloid leukaemia, NOS	84	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Complete Response	Venetoclax (ABT-199), Azacitidine	Induction	344	NA	47,XY,+8[12]/47,XY,+15[8]/46,XY[5]	Gain of 8q22 and 15q22 sequences	NA	Negative	0	Negative	NA	NA	NA	IDH2 (R140Q; VAF 51%)|NRAS (Q61K; VAF 27%)|SMC1A (E687*; VAF 64%)|SMC1A (R807H; VAF 13%)|SRSF2 (P95R; VAF 38%)	Acute Myeloid Leukemia	AML	0.4	MATCHED
aml_ohsu_2022_2651	aml_ohsu_2022_2651_BA3434	Waves3+4	Yes	1	NA	78	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	78	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|Azacitidine	2	Experimental|Supportive/Palliative Care	NA	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Experimental	0	M2	46,XX,del(9)(q22q22)[20]	With the TP53 probe set, 7/200 cells (3.5%) were missing a TP53  signal, within normal limits, but also this patient's previous abnormal  pattern.	CD13, CD33, CD34, CD38, CD58, CD117, HLA-DR, partial  MPO	Negative	0	Negative	RUNX1 (p.T196Dfs*17; 40.6%)|RUNX1 (p.X20_splice; 49.2%)	NA	NA	DNMT3A (p.A644fs*7; MAF 37%)|ETV6 (p.L205fs*12; MAF 30%)|IKZF1 (p.N159S; MAF 35%)|NRAS (p.Q61H; MAF 31%)|RUNX1 (c.58+2T>C, Donor-splice-site mutation in intron 1; MAF 46%)|RUNX1 (p.T196fs*17; MAF 46%)|SF3B1 (p.K700E; MAF 51%)	Acute Myeloid Leukemia	AML	1.166666667	MATCHED
aml_ohsu_2022_2676	aml_ohsu_2022_2676_BA3189	Waves3+4	Yes	1	NA	20	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with maturation	20	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	5	Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|7+3 (Cytarabine, Daunorubicin) plus Midostaurin|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Induction|Re-induction|Maintenance	Refractory	Sorafenib	Maintenance	317	M2	46,XY,del(2)(q11.2q21)[3]	Normal	CD13, CD33, CD34, CD38, CD58, dim CD64, CD117,  variable MPO	Positive	1	Negative	NA	NA	NA	FLT3-ITD (p.E608delinsDPVDFREYEYDLKWEFPRE; p.E598delinsDLSYVDFREYE;  ratio: ~1.0; Two visible FLT3 ITD insertions, one  of ~ 10 amino acids (predominating, with a high mutant allele ratio) and  one of ~18 amino acids (smaller sub-clone).)	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2603	aml_ohsu_2022_2603_BA3264	Waves3+4	Yes	1	NA	41	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	41	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	ATRA, Arsenic Trioxide, Idarubicin|ATRA, Arsenic Trioxide	2	Consolidation|Induction	Complete Response	ATRA, Arsenic Trioxide	Consolidation	200	M3	46,XY,t(15;17)(q24;q21)[20]	PML/RARA (92% of  cells had the dual fusion signal pattern consistent with PML/RARA fusion and t(15;17).)	partial CD11b, CD13, CD33, CD34, CD38, CD58, variable  CD64, CD117, CD123, partial HLA-DR and bright MPO	Positive	1.127659574	Negative	NA	NA	NA	FLT3-ITD (Mutant Allele Ratio:  0.85)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2715	aml_ohsu_2022_2715_BA3329	Waves3+4	Yes	5	mono	77	FALSE	FALSE	TRUE	FALSE	FALSE	Intermediate	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	2	Venetoclax (ABT-199), Azacitidine|Azacitidine	2	Induction|Maintenance	Refractory	Venetoclax (ABT-199), Azacitidine	Induction	36	NA	46,XY,inv(4)(p14q21)[9]/47,sl,+8[2]/46,XY[10]	Gain of chromosome 8 (trisomy)	NA	Negative	0	Negative	NA	NA	NA	CEBPA (P189dup; VAF 30%)|ETV6 (N228S; VAF 52%)|SRSF2 (P95R; VAF 18%)|STAG2 (VAF 34%)|TET2 (Q745*; VAF 23%)	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2600	aml_ohsu_2022_2600_BA3417	Waves3+4	Yes	3	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	Acute Myeloid Leukemia	50	0	Unknown	Unknown	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2730	aml_ohsu_2022_2730_BA3367	Waves3+4	Yes	3	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	Acute Myeloid Leukemia	34	0	Unknown	Unknown	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2658	aml_ohsu_2022_2658_BA3225	Waves3+4	Yes	1	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	1	7+3 (Cytarabine, Idarubicin)	1	Induction	UNKNOWN	7+3 (Cytarabine, Idarubicin)	Induction	4	M5	NA	Normal	Monocytic blast immunophenotype (75%):  CD11b, CD13, CD14, CD33, CD38, CD58, CD64, dim CD117, CD123, and dim HLA-DR+. | Myeloid blast immunophenotype (13%): dim CD13, CD33, CD38, CD58 dim CD117, dim CD123 and MPO+.           | Monoclonal plasma cell population immunophenotype (approximately10% involvement): CD138 and kappa+.	Negative	0	Positive	NA	NA	NA	GNA13 (p.T365S; MAF 46%)|NPM1 (p.W288fs*12; MAF 43%)|PHF6 (c.730-2A>G, Acceptor-splice-site mutation in intron 6; MAF 89%)|TET2 (c.3594+1G>T, Donor-splice-site mutation in intron 3; MAF 46%)|TET2 (p.D1242fs*11; MAF 42%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2798	aml_ohsu_2022_2798_BA3183	Waves3+4	Yes	1	NA	64	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with mutated NPM1	64	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	5	Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Consolidation|Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	NA	46,XY[20]	Normal	CD13, CD33, CD38, CD58, CD117, CD123, partial MPO+	Negative	0	Positive	NA	NA	NA	ATM (p.H1136R; MAF 45%)|DNMT3A (p.R882H; MAF 46%)|IDH1 (p.R132H; MAF 27%)|IDH2 (p.D314V (Low allele frequency, subclonal), MAF 2%)|IDH2 (p.R140Q; MAF 18%)|KRAS (p.G12A; MAF 3%)|NPM1 (p.W288fs*12; MAF 49%)|U2AF1 (p.D208E; MAF 46%)	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2674	aml_ohsu_2022_2674_BA3397	Waves3+4	Yes	1	NA	79	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	M2	44,XY,-3,-5,dic(10;12)(q26;p13),add(11)(p15),-17,+mar[20]	ETV6 (12p13): 93.5% of cells were missing a signal for ETV6, consistent with 12p deletion resulting from dic(10;12).  | CEP17: 98.5% of cells were missing a signal for CEP17, consistent with monosomy 17.  | PML/RARA: 189/200 cells (94.5%) were missing a signal for RARA (17q21.2).	CD13, CD33, CD34, variable CD38, CD117, CD123, HLA-DR, partial MPO	Negative	0	Negative	NA	NA	TP53 (p.L194R; 86.6%)	TP53 (p.L194R; MAF 80%)	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2720	aml_ohsu_2022_2720_BA3311	Waves3+4	Yes	1	NA	74	FALSE	FALSE	TRUE	FALSE	FALSE	Intermediate	Therapy-related myeloid neoplasms	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Azacitidine	1	Induction	Unknown	Azacitidine	Induction	6	M2	48,XY,+11,+13[17]/46,XY[3]	MLL (11q23):  161/200 cells (80.5%) had three intact signals for MLL, consistent with the trisomy 11 seen on metaphase analysis.	CD13, CD33, CD34, variable CD38, partial CD64, CD117, dim CD123, HLA-DR, partial TdT.	Negative	0	Negative	NA	NA	NA	CBLB (p.V581M; MAF 52%)|DNMT3A (p.V877fs*4; MAF 40%)|MLL (Partial tandem duplication (exon 9/exon 3) )|NRAS (p.G12D; MAF 14%)|U2AF1 (p.S34F; MAF 43%)|WT1 (p.R353fs*15; MAF 26%)|WT1 (p.S364*; MAF 25%)	Acute Myeloid Leukemia	AML	0.333333333	UNMATCHED
aml_ohsu_2022_2783	aml_ohsu_2022_2783_BA3175	Waves3+4	Yes	1	NA	62	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	63	248	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	5	Decitabine, anti-PD1, anti-TIM3|7+3 (Cytarabine, Idarubicin)|JNJ-40346527 (CSF1R inhibitor)|Mitoxantrone|FLAG, Midostaurin	3	Salvage|Induction|Re-induction	Refractory	Mitoxantrone	Salvage	0	NA	46,XY,t(1;3)(p36;q21)[2]/46,sl,-1,+der(1)t(1;3)(p36;q21)[15]/46,sl,add(3)(q12)[2]/46,sl,-1,+t(1;3)(p36;q21),-3[1]	MECOM/RPN1:  171/200 cells (85.5%) had a 2 red/ 3 green signal pattern,  reflecting an extra RPN1 (3q21.3) signal, consistent with RPN1 disruption  due to the 1;3 translocation observed in the metaphase karyotype.  There  was no evidence for MECOM/RPN1 fusion.	CD7, CD13, CD33, CD34, CD117, and HLA-DR positive	Positive	0.234567901	Negative	RUNX1 (p.D198N; 44.9%)	NA	NA	BCL2 (p.A32G; VAF 48%)|FLT3-ITD (p.N609delinsIIPCPEYDLKWEFPREN; VAF 19%, allelic ratio 0.24)|GATA2 (p.S201fs*1; VAF 13%)|NPM1 (p.H30Q; VAF 3%)|NRAS (p.G12D; VAF 72%)|RUNX1 (p.D198N; VAF 44%)|WT1 (p.R380fs*5; VAF 45%)|WT1 (p.V371fs*14; VAF 22%)|ZRSR2 (p.P350R; VAF 5%)	Acute Myeloid Leukemia	AML	0.333333333	UNMATCHED
aml_ohsu_2022_2636	aml_ohsu_2022_2636_BA3422	Waves3+4	Yes	5	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Complete Response	Venetoclax (ABT-199), Azacitidine	Induction	-1	NA	46,XX[20]	Normal	NA	Negative	0	Positive	NA	NA	NA	GATA2 (A372T; VAF 48%)|NPM1 (W288Cfs*12; VAF 39%)|TET2 ( E843*; VAF 47%)|TET2 (T1726Lfs*19; VAF 51%)	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2717	aml_ohsu_2022_2717_BA3228	Waves3+4	Yes	1	NA	68	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	69	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	3	Azacitidine|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Cytarabine, Midostaurin	3	Induction|Re-induction|Supportive/Palliative Care	Refractory	Cytarabine, Midostaurin	Re-induction	-1	NA	46,XX,i(14)(q10)[8]/46,XX[12]	IGH (14q32) breakapart probe set, as listed  below.  4/200 interphase cells had three intact signals, but one abnormal  metaphase was found, which had an IGH signal on either end of the  i(14)(q10).	NA	Positive	NA	Negative	RUNX1 (p.R320*; 49.8%)	NA	NA	NA	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2817	aml_ohsu_2022_2817_BA3213	Waves3+4	Yes	5	NA	50	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	50	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin	1	Induction	Complete Response	7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin	Induction	7	NA	46,XY,inv(16)(p13.1q22)[18]/47,sl,+9[2]	Positive for a CBFB rearrangement	NA	Negative	0	Negative	NA	NA	NA	CBL (L399V; VAF 50%)|KIT (N587_R588ins16; VAF 34%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2637	aml_ohsu_2022_2637_BA3368	Waves3+4	Yes	5	NA	62	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	7+3 (Cytarabine, Idarubicin)	Induction	8	NA	47,XX,+8[4]/46,XX[16]	Positive for gain of centromere 8 sequences	NA	Negative	0	Negative	RUNX1 (p.F416Lfs*185; 24.0%)	ASXL1 (p.G646Wfs*12; 29.2%)	NA	ASXL1 (G645Wfs*12; VAF 34%)|BCOR (Q1371*; 34%)|EZH2 (N673y; 40%)|EZH2 (N699D; VAF 37%)|GATA2 (S201*; VAF 37%)|PHF6 (R129*; VAF 42%)|RUNX1 (F416Lfs*185; VAF 38%)	Acute Myeloid Leukemia	AML	0.433333333	MATCHED
aml_ohsu_2022_2825	aml_ohsu_2022_2825_BA3415	Waves3+4	Yes	1	NA	79	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	M2	49~50,XX,+X,-3,del(5)(q13q33),der(7)t(3;7)(q11.2;q21),+8,-9,  del(17)(p11.2),+18,+21,der(21)t(9;21)(q22;q22)X2,+22,+1~2mar[cp20]	EGR-1/ D5S23, D5S721:  97/100 cells (97%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the metaphase karyotype.  | CEP 8:  179/200 cells (89.5%) had three signals, consistent with the trisomy 8 in the metaphase karyotype.  | RUNX1T1/RUNX1:  92/100 cells (92%) had a 3 red/ 3 green signal pattern, reflecting the extra copies of chromosome 8 and chromosome 21 in the metaphase karyotype.  There was no evidence for RUNX1T1/RUNX1 fusion.  | BCR/ABL:  95/100 cells (95%) had a 3 red/ 2-3 green signal pattern, reflecting the extra copies of chromosome 9q and chromosome 22 in the metaphase karyotype.  There was no evidence for BCR/ABL fusion. | DEK/NUP214:  184/200 cells (92%) had a 3 red/ 2 green signal pattern, reflecting an extra copy of NUP214 (9q34),consistent with the extra chromosome 9q material in the metaphase karyotype.  There was no evidence for DEK/NUP214 fusion.  | TP53/CEP 17:  93/100 cells (93%) had a 1 red/ 2 green signal pattern, reflecting TP53 deletion and consistent with the deleted chromosome 17 short arm in the metaphase karyotype.	partial CD7, CD13, CD33, CD34, CD38, CD56,  CD117, HLA-DR, MPO	Negative	0	Negative	NA	NA	TP53 (p.R196*; 89.6%)	CBL (p.L209V; MAF 92%)|FLT3 (p.L198F; MAF 52%)|TP53 (p.R196*; MAF 80%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2814	aml_ohsu_2022_2814_BA3270	Waves3+4	Yes	1	NA	47	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	100	NA	46,XX[20	Normal	NA	Negative	0	Positive	NA	NA	NA	DNMT3A (p.R882C; MAF 46%)|NPM1 (p.W288fs*12; MAF 48%)|NRAS (p.G12D; MAF 46%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2625	aml_ohsu_2022_2625_BA3324	Waves3+4	Yes	1	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	Decitabine, MGB453|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Induction|Re-induction	Complete Response	Decitabine, MGB453	Re-induction	84	M1	46,XY,del(5)(q13q34),add(7)(q11.2),+11,add(12)(p13),-16, add(17)(p11.2)[cp17]/46,idem,add(4)(q35)[4]	EGR-1/ D5S23, D5S721:  193/200 cells (96.5%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the metaphase karyotype.  | D7S522/ CEP 7:  191/200 cells (95.5%) had a 1 red/ 2 green signal pattern, indicating deleted 7q, consistent with the metaphase karyotype.  | MLL:  150/200 cells (75%) had three intact signals, consistent with the trisomy 11 in the metaphase karyotype. An additional 18 cells (9%) had four intact MLL signals.  There was no evidence for MLL rearrangement.  | CBFB:  195/200 cells (97.5%) had a single intact signal, consistent with the monosomy 16 in the metaphase karyotype.  There was no evidence for CBFB rearrangement.	variable CD4, dim CD7, dim CD11b, CD13, variable CD14, variable CD15, CD33, variable CD34, CD38, dim CD56, partial CD64, CD117, HLA-DR, MPO positive.	Negative	0	Negative	NA	NA	TP53 (p.L194R; 88.3%)	PTPN11 (p.S502P; MAF 34%)|TP53 (p.L194R; MAF 87%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2808	aml_ohsu_2022_2808_BA3401	Waves3+4	Yes	1	NA	58	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	58	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	88	M2	46,XY[4]	NA	variable CD11b, CD33, CD38, CD117, MPO positive	Negative	0	Positive	NA	NA	NA	CEBPA (p.G242S; MAF 57%)|FLT3 (p.A680V; MAF 2%)|IDH1 (p.R132S; MAF 34%)|MPL (p.R102P; MAF 55%)|NPM1 (p.W288fs*12; MAF 35%)|PTPN11 (p.S502L; MAF 28%)|TCF3 (p.Q169K; MAF 50%)	Acute Myeloid Leukemia	AML	0.3	MATCHED
aml_ohsu_2022_2757	aml_ohsu_2022_2757_BA3194	Waves3+4	Yes	3	mono	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	NA	9	Unknown	Unknown	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.533333333	MATCHED
aml_ohsu_2022_2602	aml_ohsu_2022_2602_BA3335	Waves3+4	Yes	5	NA	56	FALSE	TRUE	FALSE	FALSE	FALSE	FavorableOrIntermediate	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Refractory	Venetoclax (ABT-199), Azacitidine	Induction	30	NA	46,XX[22]	Normal	NA	Positive	NA	Positive	NA	NA	NA	DNMT3A (P38SRfs*22; VAF 22%)|FLT3-ITD|GATA2 (T354_T355 insF; VAF 15%)	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2724	aml_ohsu_2022_2724_BA3199	Waves3+4	Yes	5	mono	69	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Acute myeloid leukaemia, NOS	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	7+3 (Cytarabine, Idarubicin)	Induction	7	NA	46,XY[19]	Normal	NA	Negative	0	Negative	RUNX1 (p.X269_splice; 48.1%)	ASXL1 (p.K618_A619ins*; 43.5%)	NA	ASXL1 (A619*; VAF 47%)|CEBPA (H24Afs*84; VAF 44%)|CEBPA (R165Afs*153; VAF 48%)|RUNX1 (VAF 45%)|SRSF2 (P95H; VAF 53%)|TET2 (S1486*; VAF 48%)	Acute Myeloid Leukemia	AML	0.333333333	UNMATCHED
aml_ohsu_2022_2797	aml_ohsu_2022_2797_BA3326	Waves3+4	Yes	5	NA	63	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Refractory	Venetoclax (ABT-199), Azacitidine	Induction	29	NA	47,XY,+6[4]/49,sl,+6,+22[2]/49,sl,+4,+8,i(8)(q10)x2[5]/47,XY,+r[2]/46,XY[7]	Gain of 8q22, 8 centromere and 16q22 sequences	NA	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 36.6%)	NA	ASXL1 (G64Wfs*12; VAF 39%)|NRAS (Q61K; VAF 33%)|TET2 (Q892*; VAF 49%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2657	aml_ohsu_2022_2657_BA3297	Waves3+4	Yes	1	NA	46	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	46	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	102	M2	46,XX[20]	Normal	dim CD13, CD33, CD38, CD117 and MPO+	Negative	0	Positive	NA	NA	NA	IDH2 (p.R140Q; VAF 46%)|NPM1 (p.W288fs*12; VAF 40%)	Acute Myeloid Leukemia	AML	0.066666667	MATCHED
aml_ohsu_2022_2650	aml_ohsu_2022_2650_BA3227	Waves3+4	Yes	1	NA	70	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	70	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	MIDAC, Midostaurin|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Methotrexate|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Allogeneic - Sibling|Consolidation|Induction	Refractory	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	M1	46,XX[20]	Normal	dim CD13, CD33, CD38, CD117, and MPO +	Positive	0.149425287	Positive	NA	NA	NA	ATM (p.K1454N; VAF 49%)|BCL6 (p.A321V; VAF 49%)|FLT3-ITD (Allelic ratio: 0.32)|IDH2 (p.R140Q; VAF 49%)|NOTCH2 (p.P2377L; VAF 48%)|NPM1 (p.W288fs*12; VAF 69%)|NRAS (p.A59T; VAS 3%)	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2653	aml_ohsu_2022_2653_BA3394	Waves3+4	Yes	3	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	Acute Myeloid Leukemia	NA	0	Unknown	Unknown	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2833	aml_ohsu_2022_2833_BA3412	Waves3+4	Yes	1	NA	74	FALSE	FALSE	FALSE	FALSE	FALSE	Intermediate	Therapy-related myeloid neoplasms	74	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	1	Vidaza, BI836858 (anti-CD33)	1	Induction	Refractory	Vidaza, BI836858 (anti-CD33)	Induction	90	M5	46,XX,t(8;16)(p11.2;p13.3)[19] /46,XX[1]	Normal	dim CD4, dim CD11b, CD15, bright CD33, CD38, variable CD56, bright CD64, partial CD117, HLA-DR, MPO, and dim TdT+	Negative	0	Negative	NA	NA	NA	KMT2D (p.R1918C; VAF 50%)|PTPN11 (p.S502P; VAF 41%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2685	aml_ohsu_2022_2685_BA3293	Waves3+4	Yes	1	NA	53	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	55	0	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Leukapheresis	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	M4	46,XX[20]	NA	variable CD11b, CD13, CD33, dim CD123, partial HLA-DR, dim/partial MPO	Positive	11.5	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2718	aml_ohsu_2022_2718_BA3250	Waves3+4	Yes	1	NA	58	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	58	2	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	7+3 (Cytarabine, Idarubicin)	1	Induction	UNKNOWN	7+3 (Cytarabine, Idarubicin)	Induction	6	M4	46,XY,inv(16)(p13q22)[20]	CBFB/MYH11:  165/200 cells (82.5%) had the abnormal 1 red/ 1 green/ 2 yellow signal pattern, reflecting CBFB/MYH11 fusion and consistent with the inverted chromosome 16 observed in the metaphase karyotype.	Myeloid blasts: CD13, CD33, CD34,  CD117, HLA-DR+ | Promonocytic/ monocytic population (56%): variable CD13, variable CD14, partial CD16, CD33, CD64, HLA-DR+	Negative	0	Negative	NA	NA	NA	CARD11 (p.N191S; VAF 45%)|KRAS (p.G12V; VAF 4%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2779	aml_ohsu_2022_2779_BA3205	Waves3+4	Yes	1	NA	49	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	49	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide	4	Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	Refractory	Decitabine	Maintenance	4	NA	 Inv(3)(q21q26.2)	NA	NA	Negative	0	Negative	NA	NA	NA	GATA2 (p.Y322C; VAF 32%)|SF3B1 (p.H662Q; VAF 39%)	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2793	aml_ohsu_2022_2793_BA3177	Waves3+4	Yes	1	NA	66	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	partial CD1a, CD13, variable CD14, CD33, CD34, CD38, dim CD117, HLA-DR and cMPO	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2812	aml_ohsu_2022_2812_BA3315	Waves3+4	Yes	1	NA	57	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	3	Salvage|Consolidation|Induction	Complete Response	Decitabine	Salvage	0	M1	69~82<3n>,X,-X,+4,+8,+8,+8,+8,+8,+8,-9,+10,-12,-15,-17,+18,+20,+21,+22,+1~2mar[cp13]/47~48,X,-X,+4,+6,+8,+8,-9,-16,-17,+mar[cp3]/92,XXXX[2]/46,XX[2]	BCR/ABL: 38% of cells had three signals for BCR and another 18% of cells had three signals for BCR and for ABL/ASS.  | PML/RARA: 6% of cells had three signals for both probes.	MPO, CD33, CD43, CD45, and CD117 positive	Negative	0	Negative	NA	NA	TP53 (p.V143M; 44.0%)	BCL6 (p.R459C; VAF 44%)|IDH2 (p.R172K; VAF 14%)|NRAS (p.Q61K; VAF 12%)|TP53 (p.V143M; VAF 32%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2804	aml_ohsu_2022_2804_BA3182	Waves3+4	Yes	1	NA	30	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	30	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA, Gemtuzumab|Methotrexate	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	38	M2	46,XY,del(7)(q32q36),inv(16)(p13.1q22)[20]	CBFB/MYH11: 90% of cells had a 1r1g2f dual-fusion signal pattern consistent with CBFB/MYH11 fusion and inv(16).	Myeloid blast immunophenotype: CD13, CD33, CD34, CD117, HLA-DR, MPO positive | Aberrant monocytoid population with variable CD14, CD15, and CD64 expression	Negative	0	Negative	NA	NA	NA	No clinically significant variants identified	Acute Myeloid Leukemia	AML	0	UNMATCHED
aml_ohsu_2022_2806	aml_ohsu_2022_2806_BA3260	Waves3+4	No	5	NA	72	FALSE	FALSE	FALSE	TRUE	FALSE	NonAML	Refractory cytopenia with multilineage dysplasia	72	0	NA	NA	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	NA	46,XY[20]	Normal	NA	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 36.2%)	NA	ASXL1 (G646Wfs*12; VAF 41%)|BRAF (G469A; VAF 50%)|ETV6 (VAF 48%)|KRAS (Y64N; VAF 10%)|SRSF2 (P95H; VAF 45%)	Myelodysplastic Syndromes	MDS	0.366666667	MATCHED
aml_ohsu_2022_2621	aml_ohsu_2022_2621_BA3369	Waves3+4	Yes	1	NA	73	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	M4	46,XY,inv(16)(p13.1q22)[cp20]	CBFB/MYH11: 93/100 cells (93%) had the abnormal 1 red/ 1 green/ 2 yellow signal pattern, reflecting CBFB/MYH11 fusion, consistent with the metaphase karyotype and the diagnosis of AML.	Myeloid blasts: CD13, CD33, CD34, dimCD38, CD117, dim HLA-DR, and MPO. | Promonocytes/monocytes: dimCD4, CD11b, bright CD13, variable CD14, bright CD33, CD64, variable HLA-DR positive	Negative	0	Negative	NA	NA	NA	EP300 (p.S1033L; VAF 50%)|FLT3-TKD (p.D835V; VAF 26%)|KRAS (p.G12V; VAF 19%)|WT1 (p.T225M; VAF 50%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2737	aml_ohsu_2022_2737_BA3078	Waves3+4	Yes	1	NA	68	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with minimal differentiation	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	7+3 (Cytarabine, Idarubicin)	Induction	6	M0	46,XY[20]	Normal	dimCD2, partial CD7, dimCD13, CD34, CD38, CD117, HLA-DR	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2654	aml_ohsu_2022_2654_BA3386	Waves3+4	Yes	1	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	5	Fludarabine, Melphalan|Gilteritinib or Placebo|MIDAC, Midostaurin|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Methotrexate	5	Consolidation|Induction|CNS|Maintenance|Allogeneic - Matched Unrelated Donor	Refractory	Gilteritinib or Placebo	Maintenance	734	M1	46,XX[20]	NA	dim CD7, partial CD11b, dim CD13, variable CD25, CD33, partial CD34, CD117, HLA-DR, and MPO positive	Positive	32.33333333	Positive	NA	NA	NA	DNMT3A (p.G543C; VAF 49%)|FLT3-ITD (VAF 76%; VAR 13.3)|NPM1 (p.W288fs*12; VAF 45%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2786	aml_ohsu_2022_2786_BA3445	Waves3+4	Yes	3	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	Acute Myeloid Leukemia	NA	0	Unknown	Unknown	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2765	aml_ohsu_2022_2765_BA3176	Waves3+4	Yes	1	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	HiDAC|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MEC (Cytarabine, Etoposide, Mitoxantrone) plus Midostaurin	3	Consolidation|Salvage|Induction	Complete Response	MEC (Cytarabine, Etoposide, Mitoxantrone) plus Midostaurin	Salvage	-1	M2	47,XX,+4[3]/46,XX[17]	Normal	dim CD7, CD13, CD33, CD38, CD117 and HLA-DR+	Negative	0	Positive	NA	NA	NA	DNMT3A (p.N879D; VAF 37%)|NPM1 (p.W288fs*12; VAF 28%)|PTPN11 (p.A461T; VAF 3%)|RAD21 (p.E534*; VAF 4%)|SMC1A (p.R496H; VAF 31%)	Acute Myeloid Leukemia	AML	0.633333333	MATCHED
aml_ohsu_2022_2739	aml_ohsu_2022_2739_BA3258	Waves3+4	Yes	1	NA	66	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|HiDAC, Mitoxantrone, CPI-613|Methotrexate	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M5	46,XX[20]	Normal	partial CD7 and CD9, CD11b, dim CD13, CD14, CD15, CD33, CD38, partial CD56, CD64, HLA-DR+	Negative	0	Positive	NA	NA	NA	DNMT3A (p.N797D; VAF 46%)|IDH2 (p.R140Q; VAF 46%)|NPM1 (p.W288fs*12; VAF 46%)|NRAS (p.Q61P; VAF 47%)	Acute Myeloid Leukemia	AML	0.466666667	MATCHED
aml_ohsu_2022_2739	aml_ohsu_2022_2739_BA3446	Waves3+4	No	1	NA	66	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with mutated NPM1	67	366	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|HiDAC, Mitoxantrone, CPI-613|Methotrexate	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M5	46,XX,del(14)(q21q31)[20]	Normal	Myeloid blasts: CD13, CD33, CD38, CD117, HLA-DR. | Blasts with monocytic features: CD11b, dim CD13, CD15, CD33, CD38, CD64, HLA-DR	Negative	0	Positive	NA	NA	NA	BCOR (p.E1093K; VAF 48%)|DNMT3A (p.N797D; VAF 46%)|FAT4 (p.D1836N; VAF 41%)|IDH2 (p.R140Q; VAF 47%)|KMT2D (p.P647T; VAF 67%)|NPM1 (p.W288fs*12; VAF 43%)|NRAS (p.Q61P; VAF 46%)|RBBP6 (p.P1416A; VAF 51%)	Acute Myeloid Leukemia	AML	0.366666667	MATCHED
aml_ohsu_2022_2763	aml_ohsu_2022_2763_BA3295	Waves3+4	Yes	1	NA	63	FALSE	FALSE	FALSE	FALSE	FALSE	Favorable	Therapy-related myeloid neoplasms	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin|HiDAC|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|FLAG-Ida-Mylotarg	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M2	46,XY,inv(16)(p13.1q22)[20]	CBFB/MYH11: 91% of cells had the 1r1g2f dual-fusion signal pattern consistent with CBFB/MYH11 fusion and inv(16).	Myeloid blast population, about 25%: CD13, CD33, CD34, CD117, HLA-DR and MPO.   | Atypical monocyte population, about 20%: dim CD4, partial CD9, bright CD11b, CD13, CD14, CD33, CD64, HLA-DR and MPO	Negative	0	Negative	NA	NA	NA	NOTCH1 (p.V1739M; VAF 48%)|NRAS (p.Q61K; VAF 45%)	Acute Myeloid Leukemia	AML	0.3	MATCHED
aml_ohsu_2022_2723	aml_ohsu_2022_2723_BA3283	Waves3+4	Yes	3	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NA	0	Unknown	Unknown	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2744	aml_ohsu_2022_2744_BA3390	Waves3+4	Yes	3	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	AML with mutated NPM1	NA	0	Unknown	Unknown	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2639	aml_ohsu_2022_2639_BA3275	Waves3+4	Yes	3	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	Acute Myeloid Leukemia	NA	0	Unknown	Unknown	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Positive	0.388888889	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2649	aml_ohsu_2022_2649_BA3136	Waves3+4	Yes	1	NA	47	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	Acute monoblastic and monocytic leukaemia	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	133	M5	46,XY,t(10;11)(p12;q23)[8]/45,sl,-Y[12]	86/100 cells (86%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting MLL (11q23) rearrangement and consistent with the 10;11 translocation observed in the metaphase karyotype.	dim CD4, CD9, CD11b, CD15, CD33, CD38, partial CD56, CD64, partial CD117, and partial HLA-DR+	Negative	0	Negative	NA	NA	NA	FLT3 (p.I836del; VAF 3% (in frame deletion in the tyrosine kinase domain))|MLL (Partial tandem duplication (exon 11/3 breakpoint) )	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2726	aml_ohsu_2022_2726_BA3190	Waves3+4	Yes	3	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	Acute Myeloid Leukemia	NA	0	Unknown	Unknown	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	ASXL1 (p.G646Wfs*12; 26.8%)	NA	NA	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2688	aml_ohsu_2022_2688_BA3234	Waves3+4	Yes	1	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Azacitidine	1	Induction	UNKNOWN	Azacitidine	Induction	8	M5	46,XY[20]	Normal	Monocytic population (about 80%) : dim CD4, dim CD9, CD11b, partial CD13,  partial CD14, CD15, subset CD16, CD33, CD38, CD56, CD64, and HLA-DR. | Myeloid blasts phenotype (8%): CD33, CD56, CD117, HLA-DR, and MPO	Negative	0	Positive	NA	NA	NA	NPM1 (p.W288fs*12; VAF 24%)|SRSF2 (p.P95R; VAF 48%)|TET2 (p.R506*; VAF 95%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2693	aml_ohsu_2022_2693_BA3087	Waves3+4	Yes	1	NA	31	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML without maturation	31	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine	4	Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	Refractory	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M1	46,XY,del(5)(q13q33),t(10;11)(p13;q21)[15]/46,XY[5]	93% of cells were missing a signal for both 5q probes (EGR1, 5q31; and 5q33) but had two signals for 5p, consistent with 5q deletion.	partial CD7, CD13, CD33, CD34, dim CD38, CD56, CD117, HLA-DR, partial MPO, and dim TDT.	Negative	0	Negative	NA	ASXL1 (p.D821Efs*15; 26.7%)|ASXL1 (p.D821Wfs*6; 20.1%)	NA	ASXL1 (p.D821fs*12; VAF 28%)|CREBBP (p.N970fs*21; VAF 8%)|JAK1 (p.T114A; VAF 49%)|KMT2D (p.R598H; VAF 49%)|WT1 (p.S165fs*35; VAF 45%)	Acute Myeloid Leukemia	AML	0.466666667	MATCHED
aml_ohsu_2022_2679	aml_ohsu_2022_2679_BA3454	Waves3+4	Yes	1	NA	82	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	82	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	M2	46,XX[20]	Normal	CD13, CD33, CD117, and MPO	Positive	0.960784314	Positive	NA	NA	NA	DNMT3A (p.R882C; VAF 48%)|FLT3-ITD (VAF 44%; Allelic ratio 0.77)|NPM1 (p.W288fs*12; VAF 48%)	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2805	aml_ohsu_2022_2805_BA3302	Waves3+4	Yes	1	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|Pexidartinib|Azacitidine, BI 836858 (anti-CD33)|Ruxolitinib, Venetoclax	2	Induction|Experimental|Re-Induction	Refractory	Ruxolitinib, Venetoclax	Experimental	69	M1	46,XY[20]	Normal	partial CD10, CD13, CD33, CD34, subset CD79a, CD117, HLA-DR, partial MPO, and TDT+	Negative	0	Negative	RUNX1 (p.D198N; 47.7%)	NA	NA	CBL (p.V363_Q365del; VAF 31%)|RUNX1 (p.D198N; VAF 50%)|SF3B1 (p.K666N; VAF 51%)	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2805	aml_ohsu_2022_2805_BA3242	Waves3+4	No	1	NA	65	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	66	316	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|Pexidartinib|Azacitidine, BI 836858 (anti-CD33)|Ruxolitinib, Venetoclax	2	Induction|Experimental	Refractory	Ruxolitinib, Venetoclax	Experimental	69	M1	46,XY[20]	Normal	partial CD10, CD34, CD13, CD117, and HLA-DR	Negative	0	Negative	RUNX1 (p.D198N; 47.3%)	NA	NA	ATG2B (p.L1989V; VAF 51%)|CBL (p.V363_Q365del; VAF 34%)|FLT3-ITD (Allelic Ratio: ~0.013)|MED12 (p.N1049T; VAF 97%)|RTEL1 (p.S925Y; VAF 50%)|RUNX1 (p.D198N; VAF 47%)|SF3B1 (p.K666N; VAF 47%)|SH2B3 (p.S488Y; VAF 49%)	Acute Myeloid Leukemia	AML	0.166666667	MATCHED
aml_ohsu_2022_2629	aml_ohsu_2022_2629_BA3117	Waves3+4	Yes	1	bi	35	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated CEBPA	35	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Fludarabine, Cyclophosphamide, TBI	4	Haploidentical - Parent|Consolidation|Induction|Re-induction	Complete Response	Fludarabine, Cyclophosphamide, TBI	Haploidentical - Parent	-1	M1	47,XY,del(9)(q13q22),+10[3]/46,XY[17]	NA	CD7, CD33, CD34, CD38, CD117, HLA-DR, and MPO positive	Negative	0	Negative	RUNX1 (p.R166Q; VAF 6%)	NA	NA	CEBPA (p.A111fs*56; 35% (likely underestimate VAF))|CEBPA (p.D322delinsETQQKVLELTSDND; VAF 37% (likely underestimate VAF))|GATA2 (p.P304H; VAF 32%)|RUNX1 (p.R166Q; VAF 6%)	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2692	aml_ohsu_2022_2692_BA3083	Waves3+4	Yes	3	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	AML with mutated NPM1	57	0	Unknown	Unknown	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Positive	5.666666667	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.366666667	UNMATCHED
aml_ohsu_2022_2672	aml_ohsu_2022_2672_BA3266	Waves3+4	Yes	1	NA	83	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	83	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	M2	46,XX[20]	NA	dim CD4, CD7, partial CD9, CD13, CD25, CD33, partial CD34, CD38, CD117, CD123, HLA-DR and MPO-positive	Positive	0.587301587	Positive	NA	NA	NA	BRAF (p.S87N; VAF 52%)|DNMT3A (p.R882C; VAF 47%)|FLT3-ITD (Allelic ratio: 0.464; VAF 31.7%)|IDH1 (p.R132H; VAF 32%)|IDH2 (p.R140Q; VAF 3%)|NPM1 (p.W288fs*12; VAF 42%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2773	aml_ohsu_2022_2773_BA3268	Waves3+4	Yes	1	NA	73	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	Azacitidine, Ivosidenib|Ivosidenib	2	Induction|Maintenance	Complete Response	Ivosidenib	Maintenance	-1	M1	46,X,-X,add(5)(q23),del(7)(q22),add(11)(p13),add(21)(q22),+mar1[9]/47,sl,add(3)(q28),+5,-add(5)(q23),+mar2[3]/46,XX[1]	D7S486/ CEP 7:  93/100 cells (90%) had a 1 red/ 2 green signal pattern, consistent with the deleted 7q observed in the metaphase karyotype.  | RUNX1T1/RUNX1:  10/200 cells (5%) had a 2 red/ 3 green signal pattern, suggesting low level presence of an extra copy of RUNX1 (21q22).  There was no evidence for RUNX1T1/RUNX1 fusion.  | EGR-1/ D5S23, D5S721: While this probe set showed a normal numeric signal pattern in interphase cells, metaphase FISH showed an EGR-1 (5q) signal on the add(11p) and a 5q33 signal on the add(21q).  (The G-banded chromosomes were not of adequate band length/morphology to establish specific breakpoints.  Therefore, it is possible that some or all of the apparently missing 5q material is actually accounted for on other chromosomes.  This probe set will not be useful for monitoring the abnormal 5q.)	CD7, dim CD13, CD33, CD34, CD38, CD117, partial HLA-DR, and partial MPO	Negative	0	Negative	NA	NA	NA	DNMT3A (Splice site; VAF 46%)|IDH1 (p.R132S; VAF 44%)|STAG2 (p.F437fs*11; VAf 48%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2619	aml_ohsu_2022_2619_BA3229	Waves3+4	Yes	1	NA	56	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	56	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	5	HAM (Cytarabine, Mitoxantrone)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MBG453 (TIM-3 inhibitor)|Decitabine, Ruxolitinib	4	Salvage|Induction|Maintenance|Re-induction	Refractory	Decitabine, Ruxolitinib	Salvage	-1	NA	49,XY,+10,+13,+21[6]/51,idem,+9,+15[14]	Chromosome 9:  With all chromosome 9 probes (ABL, ASS and NUP214) ~20% of cells had three signals, consistent with trisomy 9.  | PML (15q24): 17% of cells had three signals, consistent with trisomy 15.  | RUNX1 (21q22):  69% of cells had three signals, consistent with trisomy 21.	partial CD11b, CD13, partial CD25, CD33, CD34, CD38, partial CD56, CD117 and HLA-DR positive	Negative	0	Negative	RUNX1 (p.S322*; 49.8%)	ASXL1 (p.G646Wfs*12; 37.6%)	NA	ASXL1 (p.G646fs*12; VAF 36%)|BRAF (p.G469R; VAF 36%)|CREBBP (p.F1703fs*33; VAF 12%)|CSF3R (p.T618I; VAF 5%)|EZH2 (p.F672L; VAF 73%)|FLT3 (p.V491L; VAF 53%)|NRAS (p.G12D; VAF 10%)|RUNX1 (p.G199E; VAF 7%)|RUNX1 (p.S322*; VAF 52%)	Acute Myeloid Leukemia	AML	0.233333333	UNMATCHED
aml_ohsu_2022_2619	aml_ohsu_2022_2619_BA3138	Waves3+4	No	1	NA	56	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	56	48	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	5	HAM (Cytarabine, Mitoxantrone)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MBG453 (TIM-3 inhibitor)|Decitabine, Ruxolitinib	4	Salvage|Induction|Maintenance|Re-induction	Refractory	Decitabine, Ruxolitinib	Salvage	-1	NA	49,XY,+10,+13,+21[1]/51,sl,+9,+15[1]/49,sl,+8,-10[12]/46,XY[6]	Chromosome 9:  With all chromosome 9 probes (ABL, ASS and NUP214) ~20% of cells had three signals, consistent with trisomy 9.  | PML (15q24): 17% of cells had three signals, consistent with trisomy 15.  | RUNX1 (21q22):  69% of cells had three signals, consistent with trisomy 21.	NA	Negative	0	Negative	RUNX1 (p.S322*; 17.2%)	ASXL1 (p.G646Wfs*12; 31.3%)	NA	NA	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2619	aml_ohsu_2022_2619_BA3388	Waves3+4	No	1	NA	56	FALSE	FALSE	TRUE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	56	55	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	5	HAM (Cytarabine, Mitoxantrone)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MBG453 (TIM-3 inhibitor)|Decitabine, Ruxolitinib	4	Salvage|Induction|Maintenance|Re-induction	Refractory	Decitabine, Ruxolitinib	Salvage	-1	NA	49,XY,+10,+13,+21[1]/51,sl,+9,+15[1]/49,sl,+8,-10[12]/46,XY[6]	Chromosome 9:  With all chromosome 9 probes (ABL, ASS and NUP214) ~20% of cells had three signals, consistent with trisomy 9.  | PML (15q24): 17% of cells had three signals, consistent with trisomy 15.  | RUNX1 (21q22):  69% of cells had three signals, consistent with trisomy 21.	NA	Negative	0	Negative	RUNX1 (p.S322*; 17.2%)	ASXL1 (p.G646Wfs*12; 37.2%)	NA	NA	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2696	aml_ohsu_2022_2696_BA3353	Waves3+4	Yes	1	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	Adverse	AML without maturation	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	Venetoclax (ABT-199), Azacitidine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	2	Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	-1	M1	46,XX,del(5)(q13q33)[14]/46,XX[6]	5q:  96% of cells were missing a signal for EGR1 (5q31) and 5q33, consistent with deletion, as seen on metaphase analysis.	CD7, CD13, CD33, dim CD38, CD117, HLA-DR and variable MPO +	Negative	0	Negative	NA	NA	NA	DNMT3A (p.R749H; VAF 42%)|ETV6 (p.R378Q; VAF 52%)|JAK2 (p.V617F; VAF 3%)|KMT2D (Partial tandem duplications (exon 9/exon3))|STAT3 (p.D661Y; VAF 38%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2703	aml_ohsu_2022_2703_BA3312	Waves3+4	Yes	1	bi	43	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated CEBPA	43	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	HiDAC	Consolidation	132	M2	46,XY,t(2;12)(p13;q13)[20]	Normal	CD13, CD33, variable CD34, CD117, and HLA-DR positive (CD7, dim CD15, and MPO expression was noted on the prior flow cytometric analysis and was not tested in the current assay)	Negative	0	Negative	NA	NA	NA	CEBPA (p.G36fs*122; VAF 45%)|CEBPA (p.Q311_Q312linsRKAKQRNVETQ; VAF 45%)|DNMT3A (p.R19P; VAF 48%)|EZH2 (p.K30fs*17 (loss of function); VAF 65%)|GATA2 (p.R362Q; VAF 47%)|NRAS (p.G13D; VAF 43%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2778	aml_ohsu_2022_2778_BA3119	Waves3+4	Yes	1	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	MiDAC	Consolidation	101	M1	46,XX[20]	Normal	CD33, CD38, CD117, MPO positive	Negative	0	Positive	NA	NA	NA	ASXL1 (p.L1395V; VAF 50%)|IDH1 (p.R132H; VAF 45%)|KMT2D (p.R3167W; VAF 48%)|NPM1 (p.W288fs*12; VAF 48%)	Acute Myeloid Leukemia	AML	0.266666667	MATCHED
aml_ohsu_2022_2731	aml_ohsu_2022_2731_BA3219	Waves3+4	Yes	1	NA	73	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	1	Cytarabine	1	Induction	Refractory	Cytarabine	Induction	1	M5	46,XY[15]	Normal	dim CD9, CD11b, variable CD13, partial CD14, dim CD15, dim CD16, CD33, CD38, dim CD56, CD64, CD123, and HLA-DR	Negative	0	Positive	NA	NA	NA	CCND1 (p.R245W; VAF 48%)|DNMT3A (p.P633R; VAF 46%)|NPM1 (p.W288fs*12; VAF 46%)|NRAS (p.G13D; VAF 6%)|PTPN11 (p.T73I; VAF 33%)|TET2 (p.N926fs*28; VAF 16%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2623	aml_ohsu_2022_2623_BA3351	Waves3+4	Yes	1	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	1	ATRA, Arsenic Trioxide	1	Induction	Complete Response	ATRA, Arsenic Trioxide	Induction	-1	M3	46,XX,t(15;17)(q22;q21)[20]	positive for PML/RARA fusion	CD7, CD11b, CD13, CD15, CD16, CD33, CD38, CD56, CD64, CD117, CD123, and MPO positive	Positive	0.03092784	Negative	NA	NA	NA	FLT3-ITD (allelic ratio 0.03; VAF 3.09%)|NRAS (p.A146T; VAF 19%)	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2788	aml_ohsu_2022_2788_BA3357	Waves3+4	Yes	1	mono	75	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with maturation	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|Gilteritinib, Decitabine|PIM kinase inhibitor	3	Salvage|Induction|Re-induction	Refractory	PIM kinase inhibitor	Salvage	21	M2	47,XY,+21[2]/46,XY[18]	RUNX1 (21q22): 19/200 cells (9.5%) had three signals for RUNX1, consistent with trisomy 21.	dimCD7, dimCD11b, dimCD13, CD33, varibleCD34, CD38, CD117, partial HLA-DR, and MPO positive	Positive	0.162790698	Negative	NA	NA	NA	CEBPA (p.R300_D301delinsQY; VAF 85%)|FLT3-ITD (VAF 15%; allelic ratio 0.18)|GATA2 (p.G320S; VAF 30%)|NOTCH1 (p.A929D; VAF 52%)|RAD21 (p.E447fs*19; VAF 3%)|RAD21 (p.N462fs*1; VAF 3%)	Acute Myeloid Leukemia	AML	0.1	UNMATCHED
aml_ohsu_2022_2620	aml_ohsu_2022_2620_BA3208	Waves3+4	Yes	1	NA	70	FALSE	FALSE	TRUE	FALSE	FALSE	Intermediate	AML without maturation	70	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	Ruxolitinib, Vyxeos (Daunorubicin, Cytarabine - liposomal)	1	Induction	Refractory	Ruxolitinib, Vyxeos (Daunorubicin, Cytarabine - liposomal)	Induction	43	M1	46,XX[18]	Normal	variable CD11b, CD13, CD33, CD34, variable CD38, dim variable cCD79a, CD117, HLA-DR, cMPO, and cTdT positive	Negative	0	Negative	NA	NA	NA	DNMT3A (p.R882H; VAF 47%)|FLT3-ITD (allelic ratio 0.03; VAF 3%)|KMT2A (PTD, exon 9/3 break)|TET2 (p.H578fs*2; VAF 36%)|TET2 (p.Y1345fs*14; VAF 27%)|WT1 (p.D367_V374delinsWS; VAF 3%)|WT1 (p.R370fs*6; VAF 5%)|WT1 (p.R380fs*5; VAF 2%)|WT1 (p.R380fs*5; VAF 47%)|WT1 (p.T377fs*73; VAF 23%)|ZRSR2 (p.R452C; VAF 48%)	Acute Myeloid Leukemia	AML	0.466666667	MATCHED
aml_ohsu_2022_2716	aml_ohsu_2022_2716_BA3310	Waves3+4	Yes	1	NA	82	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	82	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	M1	46,XY[20]	Normal	dim CD13, CD33, CD117 and MPO	Negative	0	Positive	NA	NA	NA	CBL (p.G838V; VAF 48%)|CREBBP (p.N1615S; VAF 48%)|FLT3 (p.D839G; VAF 6%)|FLT3 (p.N676K; VAF 2%)|FLT3-ITD (Allelic ratio 0.01)|IDH2 (p.R140Q; VAF 46%)|KIT (p.D816V; VAF 4%)|KMT2D (p.F4579S; VAF 49%)|NPM1 (p.W288fs*12; VAF 46%)|SRSF2 (p.P95_R102del; VAF 45%)	Acute Myeloid Leukemia	AML	0.433333333	MATCHED
aml_ohsu_2022_2665	aml_ohsu_2022_2665_BA3200	Waves3+4	Yes	1	NA	76	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	2	SY-1425 (Tamibarotene) plus Azacitidine|Ruxolitinib, Venetoclax	2	Salvage|Induction	Complete Response i	Ruxolitinib, Venetoclax	Salvage	37	M1	46,XX[8]	Normal	CD33, CD38, CD56, CD117, and cMPO positive	Negative	0	Positive	NA	NA	NA	NPM1 (p.W288fs*12; VAF 50%)|PHF6 (p.R274*; VAF 45%)|PRDM1 (p.P467L; VAF 48%)|TET2 (p.H1382R; VAF 50%)|TET2 (p.K1720*; VAF 48%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2782	aml_ohsu_2022_2782_BA3325	Waves3+4	Yes	1	NA	56	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	57	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	6	7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|CSF1R inhibitor|IMGN779 (Immunogen Trial)|Decitabine	4	Salvage|Induction|Experimental|Re-induction	Refractory	Gilteritinib (ASP2215)	Experimental	-1	NA	46,XY[20]	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2776	aml_ohsu_2022_2776_BA3146	Waves3+4	Yes	1	NA	42	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	HIDAC + Gemtuzumab Ozogamicin|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	M2	46,XY[20]	Normal	CD7, CD13, CD25, CD33, partial CD34, CD117, dim CD123, HLA-DR, and MPO.	Positive	0.176470588	Positive	NA	NA	NA	DNMT3A (p.R882H; VAF 45%)|FLT3-ITD (allelic ratio 0.85; VAF 45.9%)|NPM1 (p.W288fs*12; VAF 69%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2697	aml_ohsu_2022_2697_BA3211	Waves3+4	Yes	1	NA	69	FALSE	FALSE	TRUE	FALSE	FALSE	Adverse	AML with myelodysplasia-related changes	69	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	4	Gilteritinib (ASP2215)|Azacitidine|RVD (Bortezomib, Dexamethasone, Lenalidomide)|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin	3	Salvage|Induction|Maintenance	Refractory	Gilteritinib (ASP2215)	Salvage	-1	M0	46,XY,del(20)(q11.2)[cp20]	CEP 3:  16/100 cells (16%) had three signals, reflecting trisomy 3.	CD43+ and dim CD45+ with dim CD13, dim CD33, dim CD38, partial CD11b, variable HLA-DR, and partial, dim CD117	Positive	0.176470588	Negative	RUNX1 (p.R346Pfs*254; 37.7%)|RUNX1 (p.X269_splice; 43.5%)	NA	NA	FLT3-ITD (allelic ratio 0.84; VAF 45.7%)|KMT2A (PTD (exon 11/exon 3))|RUNX1 (splice site; VAF 43%)|U2AF1 (p.S34F; VAF 44%)	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2760	aml_ohsu_2022_2760_BA3237	Waves3+4	Yes	3	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	76	0	Unknown	Unknown	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	ASXL1 (p.C594Mfs*25; 38.2%)	NA	NA	Acute Myeloid Leukemia	AML	0.333333333	UNMATCHED
aml_ohsu_2022_2610	aml_ohsu_2022_2610_BA3130	Waves3+4	Yes	1	NA	61	FALSE	FALSE	TRUE	FALSE	FALSE	Intermediate	AML with myelodysplasia-related changes	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Fludarabine, Melphalan	Allogeneic - Sibling	-1	M2	48,XY,+7,+mar[4]/46,XY[16]	Chromosome 7: 44% of cells had three signals for both chromosome 7 probes, consistent with trisomy 7	CD4, dim CD7, CD11b, CD13, variable CD14, CD16, dim CD33, dim CD 38, dim CD56, CD64.	Negative	0	Negative	NA	NA	NA	BRAF (p.V600E; VAF 36%)|TET2 (p.A1355V; VAF 48%)|TET2 (p.Q803*; VAF 44%)|ZRSR2 (Splice site; VAF 92%)	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2781	aml_ohsu_2022_2781_BA3376	Waves3+4	Yes	1	NA	58	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	58	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	Gilteritinib or Placebo|HiDAC + Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Induction|Maintenance	Complete Response	Gilteritinib or Placebo	Maintenance	-1	M1	46,XX[20]	Normal	CD11b, CD13, CD33, variable CD34, CD38, CD117, CD123, and MPO positive	Positive	1.040816327	Positive	NA	NA	NA	CEBPA (p.G242S; VAF 47%)|FLT3-ITD (allelic ratio 1.03; VAF 51%)|NPM1 (p.W290fs*10; VAF 49%)|SYNE1 (p.A2715G; VAF 50%)	Acute Myeloid Leukemia	AML	0.033333333	UNMATCHED
aml_ohsu_2022_2721	aml_ohsu_2022_2721_BA3196	Waves3+4	Yes	1	NA	76	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	76	0	Residual Disease	Residual	Bone Marrow Aspirate	3	Venetoclax (ABT-199), Azacitidine|Enasidenib|Ruxolitinib, Venetoclax	2	Salvage|Experimental	NA	Enasidenib	Salvage	-1	NA	47,XX,+2[8]/47,XX,+8[1]/46,XX[11]	MYCN (2p24.1)/CEP 2:  70/200 cells (35%) had three signals for both probes, reflecting trisomy 2.  | RUNX1 (8q21.3)/CEP 8:  12/200 cells (6%) had three signals for both probes, reflecting trisomy 8, previously suspected by FISH.  There was no evidence for RUNX1T1/RUNX1	CD13, dim/partial CD33, CD34, CD38, CD117, HLA-DR+	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.5	MATCHED
aml_ohsu_2022_2706	aml_ohsu_2022_2706_BA3125	Waves3+4	Yes	1	NA	59	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	1	7+3 (Cytarabine, Idarubicin) plus Midostaurin	1	Induction	Unknown	7+3 (Cytarabine, Idarubicin) plus Midostaurin	Induction	20	M4	46,XY[20]	NA	Myloid blast population, about 25%: variable CD13, CD33, partial CD34, CD38, CD117, CD123, HLA-DR and dim MPO | Monoblast population, about 50%: Dim CD9, bright CD11b, variable CD13, CD16, CD33, CD38, CD56, CD64, HLA-DR	Positive	0.162790698	Positive	NA	NA	NA	BIRC6 (p.S3135C; VAF 52%)|BRCA2 (p.P59A; VAF 48%)|CDKN2C (p.D64N; VAF 51%)|DNAH5 (p.G2668R; VAF 48%)|DNMT3A (p.R882H; VAF 48%)|EFTUD1 (p.S504Y; VAF 49%)|FLT3-ITD (p.E598delinsDYVDFREYE (24-nucleotide ITD); VAR 0.082; VAF 5.2%)|FLT3-ITD (p.P606delinsPFREYEYDLKWEFP (39-nucleotides ITD); VAR 0.51; VAF 32%)|NPM1 (p.W288fs*12; VAF 49%)|NRAS (p.G13D; VAF 17%)|PCLO (p.P1053S; VAF 47%)|TET2 (p.T1980fs*44; VAF 45%)	Acute Myeloid Leukemia	AML	0.2	UNMATCHED
aml_ohsu_2022_2759	aml_ohsu_2022_2759_BA3137	Waves3+4	Yes	1	NA	39	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	39	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	7	Ruxolitinib|7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|HIDAC + Gemtuzumab Ozogamicin|Busulfan, Cyclophosphamide	6	Consolidation|Salvage|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	Complete Response	Ruxolitinib	Maintenance	-1	M4	46,XY,inv(16)(p13.1q22)[20]	NA	CD13, CD33, CD34, CD38, CD117, HLA-DR, MPO  (the monocytic cells show an aberrant immunophenotype: CD11b, CD13, variable CD14, variable CD15, CD33, CD64, HLA-DR positive)	Negative	0	Negative	NA	NA	NA	CUX1 (p.V88I; VAF 50%)|NRAS (p.G13D; VAF 6%)|NRAS (p.Q61H ((different allele from p.Q61K); VAF 3%)|NRAS (p.Q61K (different allele from p.Q61H); VAF 18%)|PTPN11 (p.G60R; VAF 3%)|USH2A (p.R2557T; VAF 48%)	Acute Myeloid Leukemia	AML	0.066666667	MATCHED
aml_ohsu_2022_2595	aml_ohsu_2022_2595_BA3300	Waves3+4	Yes	1	NA	0	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	Mixed phenotype acute leukaemia, T/myeloid, NOS	0	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	5	Cytarabine|Cytarabine, Mitoxantrone, Gemtuzumab ozogamicin|Cytarabine, Daunorubicin, and Etoposide|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	3	Induction|Intensification|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	NA	46,XY,t(3;12)(q29;p13),ins(12;?)(p13;?)[20]	ETV6 is disrupted by the insertion of unidentified material within the locus.  Any fusion partners with the ETV6 rearrangements were not identified in this study.	cCD3, CD7, CD11b, dim CD13, CD33, CD34, CD56, C117, MPO	Negative	0	Negative	NA	NA	NA	FAT4 (p.S2691L; VAF 50%)	Acute Leukemias of Ambiguous Lineage	ALAL	0	UNMATCHED
aml_ohsu_2022_2749	aml_ohsu_2022_2749_BA3375	Waves3+4	Yes	1	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML with mutated NPM1	63	1	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	3	Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	M1	NA	Normal	dim CD13, CD33, CD117 and MPO-positive	Positive	0.754385965	Positive	NA	NA	NA	CHD2 (p.P1353L; VAF 50%)|CHEK2 (p.T410fs*15; VAF 51%)|FLT3 (p.N676K; VAF 4%)|FLT3-ITD (p.F594delinsLPSDNEYFYVDF (33-nucleotide internal tandem duplication); allelic ratio 0.85; VAF 46%)|IDH1 (p.R132S; VAF 47%)|KMT2A (p.F798L; VAF 49%)|NPM1 (p.W288fs*12; VAF 48%)|PLCG2 (p.Y206F; VAF 50%)	Acute Myeloid Leukemia	AML	0.2	MATCHED
aml_ohsu_2022_2774	aml_ohsu_2022_2774_BA3249	Waves3+4	Yes	3	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	28	0	Unknown	Unknown	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Negative	0	Negative	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2594	aml_ohsu_2022_2594_BA3385	Waves3+4	Yes	1	NA	50	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	50	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	3	HiDAC|7+3 (Cytarabine, Daunorubicin) plus Crenolanib|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	M4	46,XX[20]	Normal	Myeloid blasts immunophenotype:  CD7, partial CD13, CD33, partial CD34, CD117, HLA-DR and MPO | Monoblasts immunophenotype: dim CD4, CD11b, partial CD13, CD14, CD15, bright CD33, CD64, HLA-DR	Positive	0.492537313	Positive	NA	NA	NA	DNMT3A (p.S714C; VAF 43%)|FLT3-ITD (p.E596delinsQVTGSSDNEYFYVDFRE (48-nucleotide internal tandem duplication); VAR 0.79; VAF 44%)|NPM1 (p.W288fs*12; VAF 44%)|WT1 (p.S381fs*4; VAF 43%)	Acute Myeloid Leukemia	AML	0.133333333	UNMATCHED
aml_ohsu_2022_2607	aml_ohsu_2022_2607_BA3416	Waves3+4	Yes	1	mono	54	FALSE	TRUE	FALSE	FALSE	FALSE	Intermediate	AML without maturation	54	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	1	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	1	Induction	Refractory	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Induction	3	M1	46,XY[20]	RUNX1:  17/200 (8.5%) interphase cells had three RUNX1 (21q22) signals. There was no evidence for RUNX1T1/RUNX1 fusion.	Partial immunophenotype: CD33, cCD79a, CD117, HLA-DR, and cMPO	Negative	0	Negative	NA	NA	NA	CBL (p.Q490E; VAF 52%)|CEBPA (p.K304_T318dup; VAF at least 70%)|CHD2 (p.R1354K; VAF 49%)|DOCK8 (p.E766K; VAF 46%)|FAT1 (p.E38K; VAF 49%)|GATA2 (p.R307L; VAF 41%)|RUNX1 (p.I366_G367dup; VAF 46%)	Acute Myeloid Leukemia	AML	0.066666667	MATCHED
aml_ohsu_2022_2604	aml_ohsu_2022_2604_BA3281	Waves3+4	Yes	1	NA	31	TRUE	FALSE	FALSE	FALSE	FALSE	NonInitial	AML with myelodysplasia-related changes	34	0	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Bone Marrow Aspirate	8	Fludarabine, Melphalan|HiDAC|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Busulfan, Cyclophosphamide	6	Consolidation|Salvage|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	NA	37~40,XX,add(2)(p11.2),add(4)(q21),add(5)(q13),-7,-11,-11,add(12)(p11.2),-13,add(13)(q34),-17,-17,-18,-19,-19,del(20)(q22),add(21)(q22),+1~3mar[cp9]//46,XY[11]	35% had one X signal and one Y signal, reflecting the donor sex chromosome complement; 65% had two X signals, reflecting the patient's sex chromosome complement.   | 46.5% reflected extra TP53 signals and was previously observed	partial, dim CD4, CD13, CD33, dim CD34, dim CD56, partial CD64, CD117 and variable HLA-DR	Negative	0	Negative	NA	ASXL1 (p.G1397S; VAF 44%)	NA	ASXL1 (p.G1397S; VAF 44%)|BIRC6 (p.A500_M501insS; VAF 19%)|CREBBP (p.A1666T; VAF 2%)|CTLA4 (p.P21R; VAF 32%)|MAML1 (p.Q546R; VAF 20%)|TET2 (p.H1881R; VAF 47%)	Acute Myeloid Leukemia	AML	0.066666667	UNMATCHED
aml_ohsu_2022_2611	aml_ohsu_2022_2611_BA3123	Waves3+4	Yes	1	NA	69	FALSE	FALSE	FALSE	FALSE	FALSE	Adverse	Therapy-related myeloid neoplasms	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	Busulfan, Fludarabine|Venetoclax (ABT-199), Azacitidine|7+3 (Cytarabine, Daunorubicin) plus Glasdegib/placebo|MiDAC plus Glasdegib/placebo	4	Consolidation|Salvage|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Venetoclax (ABT-199), Azacitidine	Salvage	149	M2	46,XY[20]	NA	variable CD5, CD7, CD11b (partial), CD13, CD33 (dim), CD34, CD38 (dim), CD117, and HLA-DR	Negative	0	Negative	NA	ASXL1 (p.T514Nfs*15; 34.3%)	NA	ASXL1 (p.T514fs*15; VAF 37%)|BLM (p.N936D; VAF 50%)|CSF3R (p.R311C; VAF 50%)|KMT2A (p.D2911N; VAF 50%)|MSH2 (p.V437M; VAF 41%)|PCLO (p.D2885N; VAF 47%)|PRPF40B (p.P751S; VAF 51%)|SRSF2 (p.P95H; VAF 37%)|TCF3 (p.H344R; VAF 49%)|TET2 (p.Q1030*; VAF 43%)|TET2 (p.R1359L; VAF 40%)	Acute Myeloid Leukemia	AML	0.466666667	MATCHED
aml_ohsu_2022_2712	aml_ohsu_2022_2712_BA3088	Waves3+4	Yes	1	bi	60	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated CEBPA	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	5	Ruxolitinib|Azacitidine|7+3 (Cytarabine, Daunorubicin) plus Glasdegib/placebo|MiDAC plus Glasdegib/placebo|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Maintenance|Allogeneic - Matched Unrelated Donor	Complete Response	Ruxolitinib	Maintenance	25	M2	46,XY,del(20)(q11.2q13.3)[19]/46,XY[1]	81% of cells were missing a signal for 20q12 but had two signals for 20q telomere, consistent with interstitial deletion.	CD7, CD11b, CD13, CD33, CD34, CD38, CD117, HLA-DR, partial TdT and MPO+	Negative	0	Negative	RUNX1 (p.L98Sfs*24; 36.0%)	NA	NA	ASXL1 (p.C872*; VAF 1%)|CEBPA (p.F31fs*131; VAF 8%)|CEBPA (p.N321D; VAF 10%)|CEBPA (p.P23fs*137; VAF 39%)|CEBPA (p.T310_Q311insLDPAQ; VAF 33%)|IRF4 (p.H441L; VAF 50%)|RUNX1 (p.L98fs*24; VAF 49%)|SRSF2 (p.P95H; VAF 49%)|STAG2 (Splice site; VAF 90%)	Acute Myeloid Leukemia	AML	0.333333333	MATCHED
aml_ohsu_2022_2795	aml_ohsu_2022_2795_BA3309	Waves3+4	Yes	3	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	AML with mutated NPM1	NA	0	Unknown	Unknown	Leukapheresis	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Positive	0.960784314	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.266666667	UNMATCHED
aml_ohsu_2022_2791	aml_ohsu_2022_2791_BA3129	Waves3+4	Yes	3	NA	NA	unknown	unknown	unknown	FALSE	FALSE	NonInitial	AML with mutated NPM1	NA	0	Unknown	Unknown	Peripheral Blood	0	NA	0	NA	NA	NONE	NONE	NA	NA	NA	NA	NA	Positive	0.204819277	Positive	NA	NA	NA	NA	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2800	aml_ohsu_2022_2800_BA3284	Waves3+4	Yes	1	NA	56	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	0	NA	0	NA	NA	NONE	NONE	NA	M2	46,XY[20]	NA	CD7, CD13, bright CD33, partial CD34, CD38, CD117, dim HLA-DR+, dim MPO	Negative	0	Positive	NA	NA	NA	BLM (p.D1010fs*24; VAF 51%)|FLT3 (p.N676T; VAF 7%)|FLT3 (p.N841I; VAF 5%)|FLT3-D835 (p.D835H; VAF 7%)|FLT3-D835 (p.D835Y; VAF 6%)|NBN (p.L421S; VAF 48%)|NPM1 (p.W288fs*12; VAF 47%)|PTPN11 (p.E76Q; VAF 5%)|STAG2 (p.I1063fs*10; VAF 64%)	Acute Myeloid Leukemia	AML	0.3	UNMATCHED
aml_ohsu_2022_2722	aml_ohsu_2022_2722_BA3111	Waves3+4	Yes	1	NA	4	FALSE	TRUE	FALSE	FALSE	FALSE	MissingKaryo	Myeloid leukaemia associated with Down syndrome	4	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	4	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|COG-AAML0431 (IT/IV Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Thioguanine)	2	Salvage|Induction	Complete Response	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Salvage	4	M0	NA	NA	CD7, CD11b, CD33, CD38, partial CD117 positive	Negative	0	Negative	NA	NA	NA	EFTUD1 (p.P545A; VAF 47%)|FAM47A (p.P545L; VAF 48%)|GATA1 (p.V32fs*7; VAF 39%)|JAK2 (p.V617F; VAF 40%)|MSH6 (p.D217G; VAF 48%)|SUZ12 (Splice site; VAF 38%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED
aml_ohsu_2022_2687	aml_ohsu_2022_2687_BA3209	Waves3+4	Yes	1	NA	68	FALSE	FALSE	FALSE	FALSE	FALSE	NonInitial	Acute myeloid leukaemia, NOS	69	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	4	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Enasidenib, Azacitidine|Enasidenib	4	Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	NA	47,XX,+8[11]/46,XX[9]	NA	CD13, CD33, CD34, CD117, and HLA-DR|CD5, CD19, kappa positive(Small (1%) monoclonal B-cell population)	Negative	0	Negative	NA	ASXL1 (p.T806fs*16; VAF 4%)	NA	ASXL1 (p.T806fs*16; VAF 4%)|ASXL2 (p.M629fs*170; VAF 7%)|CXCR4 (p.E343*; VAF 1%)|DNMT3A (Splice site; VAF 42%)|DNMT3A (p.R899C; VAF 1%)|DNMT3A (p.V897I; VAF 44%)|ID3 (p.Y48N; VAF 1%)|IDH2 (p.R172K; VAF 47%)|IGLL5 (p.D49A; VAF 1%)|KMT2A (partial tandem duplication involving exons 10/11 and exon 3)|NRAS (p.Y64D; VAF 1%)|PCLO (p.L4593R; VAF 1%)|TET2 (p.P1962L; VAF 49% (likely germline))	Acute Myeloid Leukemia	AML	0.433333333	MATCHED
aml_ohsu_2022_2750	aml_ohsu_2022_2750_BA3100	Waves3+4	Yes	1	NA	57	FALSE	TRUE	FALSE	FALSE	FALSE	Favorable	AML with mutated NPM1	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	4	Fludarabine, Melphalan|HiDAC|Venetoclax (ABT-199), Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	Complete Response	Fludarabine, Melphalan	Allogeneic - Sibling	-1	M2	46,XY[20]	Normal	CD13, CD33, CD117, and HLA-DR	Negative	0	Positive	NA	NA	NA	ARID1B (p.G1483S; VAF 51%)|ATM (p.M3011V; VAF 49%)|DNMT1 (p.V1072I; VAF 48%)|DNMT3A (p.R882H; VAF 44%)|KMT2C (p.R3403C; VAF 50%)|MYD88 (p.A6fs*39; VAF 49%)|NBN (p.V210F; VAF 49%)|NPM1 (p.W288fs*12; VAF 62%)|NRAS (p.G12D; VAF 20%)|TET2 (p.R1359C; VAF 43%)	Acute Myeloid Leukemia	AML	0.166666667	UNMATCHED